Supplementary information Natural product inspired antibacterial tetramic acid libraries with dual enzyme inhibition

Yong-Chul Jeong, Muhammad Anwar, and Mark G. Moloney* *Chemistry Research Laboratory, University of Oxford, Mansfield Rd, University of Oxford, OX1 3TA, U.K.* Tel: +44 1865 275656; e-mail: mark.moloney@chem.ox.ac.uk

Zsolt Bikadi, and Eszter Hazai

Virtua Drug, 4C Csalogany Budapest, H-1015 Hungary

Contents

| Figure S1-S6 and Scheme S1 and S2 for synthesis4 |
|---|
| Figure S1. Tetramic acids for enzyme activity and whole cell antibacterial assay4 |
| Figure S2. Bicyclic 3-carboxamides for whole cell antibacterial assay5 |
| Figure S3. Bicyclic 3-acyl derivatives for whole cell antibacterial assay6 |
| Figure S4. NOE correlation of intermediates and tetramic acid templates7 |
| Figure S5. Tautomerisation in 3-carboxamide, 3-acyl and 3-enamine tetramic acids7 |
| Figure S6. HMBC spectra of selected tetramic acids8 |
| Scheme S1. Synthesis of tetramic acid templates9 |
| Scheme S2. Synthesis of carboxylic acid templates10 |
| Table S1-S6 for biological activity 10 |
| Supplementary discussions10 |
| Table S1. In vitro enzyme activity and antibiotic activity of |
| 3-carboxamide tetramic acids shown in Figure S1 |
| Table S2. In vitro enzyme activity and antibiotic activity of |
| 3-acyl and 3-enamine tetramic acids shown in Figure S113 |
| Table S3. In vitro antibiotic activity of 3-carboxamide tetramic acids shown in Figure S214 |
| Table S4. In vitro antibiotic activity of 3-acyltetramic acids shown in Figure S315 |
| Table S5. Pharmacological properties of tetramic acids17 |
| Table S6. In vitro antibiotic activity of 1D and 5C against Gram-negative strains18 |

| Table S7 and Figure S7-S13 for Docking model | 18 |
|--|----|
| Table S7. Summary of docking results | 18 |

| Figure S7. Docking model of 2A, 6C and streptolydigin into RNAP (1ZYR) | 19 |
|--|-----|
| Figure S8. Docking model of 2A in each tautomer into UPPS (1V7U) | ·20 |
| Figure S9. Docking model of 2A in each tautomer into RNAP (1ZYR) | -21 |
| Figure S10. Docking model of 2A in each tautomer into RNAP (3DXJ) | -22 |
| Figure S11. Docking model of 6C in each tautomer into UPPS (1V7U) | -23 |
| Figure S12. Docking model of 6C in each tautomer into RNAP (1ZYR) | -24 |
| Figure S13. Docking model of 6C in each tautomer into RNAP (3DXJ) | -25 |

| Figure S14-S19 for structure-activity relationship study | 26 |
|---|----|
| Figure S14. Plot of ClogD _{7.4} against MSA | 26 |
| Figure S15. Plot of PSA against MSA | 27 |
| Figure S16. Plot of rel-PSA against MSA | 28 |
| Figure S17. Plot of (A) ClogP, (B) ClogD _{7.4} , (C) PSA and (D) rel-PSA against MSA | |
| of the previous analogues | 29 |
| Figure S18. Correlation of blood effect against | |
| (A) MSA, (B), ClogP (C) PSA and (D) rel-PSA | 30 |
| Figure S19. Correlation of blood effect against ClogP and rel-PSA | 30 |
| | |
| | |

| Table S8-S15 for physicochemical property 31 |
|---|
| Table S8. Physical properties of the 3-carboxamide tetramic acids shown in Figure S131 |
| Table S9. Physical properties of the 3-enamine and 3-acyltetramic acids shown in Figure S1-32 |
| Table S10. Physical properties of the 3-carboxamide tetramic acids shown in Figure S233 |
| Table S11. Physical properties of the 3-acyltetramic acids shown in Figure S334 |
| Table S12-S14. Antibiotic activity against S. aureus and physical properties of |
| natural, unnatural 3-carboxamide and 3-acyltetramic acids |
| Table S15. Physical properties of fluoroquinolones40 |

Figure S20 and S21 for chemical structure of reported tetramic acids ------41

| Experimental section | 42 |
|--|----|
| 1. General | 42 |
| 2. Synthesis of tetramic acid templates and carboxylic acids | 46 |
| 3. Synthesis of 3-carboximide tetramic acids | 61 |

| 4. Synthesis of 3-acyltetramic acids | -89 |
|--|-----|
| 5. Synthesis of 3-enamine tetramic acids | 112 |
| | |

| S-References1 | 14 |
|---------------|----|
|---------------|----|



Figure S1. A diverse TA library (69 analogues) used for enzyme inhibition studies and whole cell antibacterial



activity. Analogues 8A, reported by Novartis and natural streptolydigin 8B were used for comparison.

Figure S2. Bicyclic 3-carboxamides (50 analogues) synthesised and used for whole cell antibacterial assay



Figure S3. Bicyclic 3-acyl derivatives (43 analogues) synthesised and used for whole cell antibacterial assay



Figure S4. NOE correlation of intermediates and tetramic acid templates for stereochemical assignment



Figure S5. Tautomerisation in 3-carboxamide, 3-acyl and 3-enamine tetramic acids



Figure S6. HMBC spectra of selected tetramic acids



(a) SOCI₂, ROH; (b) RCOH (1.3 eq), Et₃N (1.1 eq), petrol (40-60), relux; (c) mono-ethyl malonate (1.1 eq), DCC (1.1 eq), DMAP (0.05 eq), CH₂CI₂, r.t; (d) KtBuO (1.1 eq), dry THF, reflux; (e) NaOAc (1.2 eq), trifluoroacetaldehyde ethyl hemiacetal (2.0 eq) for (\pm) -A14 or trifluoroacetone (2.0 eq) for A15, toluene, r.t.-90 i^E then Dean Stark; (f) methyl hydrogen malonate (1.05 eq), DCC (1.05 eq), DMAP (0.03 eq), CH₂CI₂, r.t.; (g) EtLi (5.0 eq) for T17 or *n*-BuLi (5.0 eq) for T18, THF, -78-r.t.; (h) butyl chloroformate (1.2 eq), DMAP (2.2 eq), CH₂CI₂, r.t.





(a) amine (1.1 eq), triethylamine (1.2 eq), CH_2CI_2 , 0 °C-r.t.; (b) LiOH (3.0 eq), H_2O : CH_3OH : THF (2: 1:1), 0 °C-r.t.; (c) acid chloride (1.1 eq), triethylamine (2.2 eq), CH_2CI_2 , 0 °C-r.t.; (d) amine or alcohol (1.1 eq), toluene, reflux;

Scheme S2. Synthesis of carboxylic acid templates

Supplementary discussions for detailed structure-enzyme activity relationships

In SAR of the enzyme inhibition activity of 3-carboxamide TAs, (±)-2A,E, in which the cyclic group was connected to the TA ring directly, and n-alkyl (±)-2I, all showed dual activity, while (±)-2C,D in which the cyclic group was connected to the TA scaffold by a methylene bridge showed only UPPS activity. However, the introduction of a hydroxyl group on the adamantyl pendant ((±)-2A versus (±)-2B) abolished RNAP activity, and polar cyclic (±)-2F and benzyl (±)-2G,H lost both the activities. On the other hand, phenyl (±)-3A had a lower UPPS potency compared with the corresponding monocyclic 1D, which had weak RNAP potency. In the SAR of mono-substituted phenyl derivatives, bulky ((\pm)-3D < (\pm)-3E < (\pm)-3F and (\pm)-3I < (\pm)-3J) and non-polar $((\pm)-3E < (\pm)-3C < (\pm)-3B)$ groups tended to be more active, with diphenyl ether $(\pm)-3F$ showing dual MOA. Disubstituted (±)-3G,H and methylindole (±)-3K showed improved enzyme activities compared with unsubstituted (±)-3A. Of interest is that the morpholinophenyl group of (±)-3L (which was highly effective in monocyclic **1E**) proved to be enzyme inactive, while the piperidinophenyl group $((\pm)-3M)$, which is effective in the Novartis' analogues, possessed only moderate $IC_{50}s$ against both the enzymes, indicating that functionality of the pendant 3-carboxamide is critical. However, the replacement of oxygen by a sulphur atom at the 7-position (4A \Leftrightarrow 4H and 4B \Leftrightarrow 4K) only weakly affected both activities, while the effect of the methyl group at the 5- or 6-position depended on the identity of the functional group in the carboxamide $((\pm)-2A < 4C)$. (\pm) -3A < 4B < 4E, 4A < 4D \leq (\pm) -2C and 4F < (\pm) -3H).

In the SAR of 3-acyl TAs, longer chain 5C-E and 5G-K (n ≥9) were active whereas shorter chain 5A,B and

ent-**5A** ($n \le 6$) were inactive in the RNAP activity of *n*-alkyl derivatives, and stereoisomers **5C** and *ent*-**5C** showed similar efficiency. For substituents at the 5-position, ester derivatives were better than keto derivatives (eg. **5G** versus **5J**) and shorter ester and keto derivatives were better than the longer derivatives (eg. **5J** versus **5K** and **5G** versus **5I**). Furthermore, introduction of a methyl group at the 6-position (**5G** versus **5H**) gave improved activities against not only RNAP (1.6 µM) but also UPPS (3.0 uM), whereas all other *n*-alkylacyl derivatives without the 6-methyl did not show UPPS activity (>10 µM). In the SAR of adamantly (±)-**6A-D**, RNAP activity was high, and only weakly affected by the identity of the substituents R₂ of the adamantly group and at the 5- and 6-positions in the TA scaffold, whereas UPPS activity was found only in **6C**. Interestingly, introduction of a methyl group at the 6-position of the adamantly derivative gave a negative effect on UPPS/RNAP activity (**6C** versus **6D**), while a similar change in the nonyl **5G,H**, gave a similar positive effect as described above. In the SAR of **6E-H**, all inspired by the structure of streptolydigin, the substitution on R₂ was more sensitive (**6G** versus **6H**) than the presence of the methyl group on the 6-position (**6E** versus **6F**) and the chain-length (**6F** versus **6G**) for UPPS activity whereas RNAP activity was only weakly affected.

Table S1. In vitro enzyme activity (IC₅₀, μ M) and antibiotic activity (MIC, μ g/mL) of 3-carboxamide tetramic acids shown in Figure S1^{a-d}

| | RN | UP | S1 | S26 | S4 | S2 | E1 | E2 | P1 | P9 | P9B | HI3 | HI4 |
|----------------|------|------|------|-----|------|------|------|------|------|------|-----------------------|-----|-------|
| 1A | >100 | 0.30 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 1 | 4 | 1 | 0.12 |
| 1B | >100 | 0.50 | 2 | 16 | 16 | 16 | 8 | 0.5 | 4 | 1 | 4 | >64 | ≤0.06 |
| 1C | >100 | 0.10 | 8 | 8 | 8 | 8 | 8 | 8 | 16 | 8 | 8 | 4 | 0.25 |
| 1D | >100 | 1.7 | 1 | 1 | 1 | 2 | 2 | 4 | 4 | 4 | - ^d | 2 | 0.5 |
| 1E | >100 | 0.50 | 4 | 8 | 8 | 8 | 8 | 8 | 16 | 8 | 32 | 16 | 4 |
| (±)- 2A | 17 | 0.38 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| (±)- 2B | >100 | 1.8 | 16 | 16 | 16 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 0.5 |
| (±)-2C | >100 | 0.50 | 2 | 2 | 2 | 1 | 0.25 | 1 | 1 | 1 | 2 | 32 | 4 |
| (±)-2D | >100 | 8.3 | 32 | 64 | 32 | 16 | 16 | 32 | 16 | 16 | 8 | 16 | 8 |
| (±)- 2E | 31 | 0.68 | 4 | 4 | 4 | 2 | 2 | 1 | 2 | 1 | 1 | 4 | 0.12 |
| (±)- 2F | >100 | >10 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 64 |
| (±)- 2G | >100 | >10 | 32 | 32 | 32 | 64 | 16 | 32 | 16 | 16 | 16 | 8 | 2 |
| (±)- 2H | >100 | >10 | 32 | 32 | 32 | 16 | 16 | 32 | 16 | 8 | 16 | 16 | 8 |
| (±)- 2l | 20 | 0.75 | 0.25 | 0.5 | 0.25 | 0.25 | 0.25 | 0.25 | 0.12 | 0.25 | 4 | >64 | 4 |
| (±)- 3A | 64 | >10 | 32 | 32 | 16 | 16 | 8 | 16 | 8 | 8 | 4 | 8 | 8 |
| (±)-3B | 13 | >3.3 | 4 | 8 | 4 | 4 | 2 | 2 | 1 | 1 | 2 | 8 | 4 |
| (±)-3C | 35 | >10 | 8 | 16 | 8 | 8 | 4 | 8 | 4 | 2 | 4 | 8 | _d |

| (±)-3D | >100 | >10 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
|----------------|----------------|------|------|-----|------|------|------|------|------|------|-----|-----|-------|
| (±)-3E | 99 | 6.3 | 32 | 64 | 32 | 32 | 32 | 32 | 16 | 16 | 16 | 32 | 16 |
| (±)-3F | 7.3 | 0.78 | 1 | 4 | 1 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 2 | 1 | 0.5 |
| (±)-3G | 7.4 | 1.3 | 4 | 4 | 2 | 2 | 2 | 1 | 0.5 | 0.5 | 4 | 8 | 2 |
| (±)- 3H | 18 | 0.88 | 4 | 4 | 4 | 2 | 2 | 1 | 2 | 1 | 4 | 16 | 4 |
| (±)-3I | >100 | >10 | 8 | 16 | 16 | 8 | 8 | 8 | 4 | 4 | 4 | 16 | 8 |
| (±)-3J | 20 | 3.1 | 2 | 8 | 4 | 4 | 2 | 4 | 2 | 2 | 2 | 16 | 8 |
| (±)-3K | 48 | 2.3 | 32 | 32 | 32 | 16 | >64 | 32 | >64 | >64 | >64 | >64 | 8 |
| (±)- 3L | >100 | >30 | >64 | >64 | 64 | >64 | 32 | 32 | 32 | 16 | 16 | 32 | 32 |
| (±)-3M | 89 | 4.1 | 32 | >64 | 16 | 16 | 32 | 16 | 8 | 4 | 16 | 16 | 2 |
| 4A | 4.3 | 0.10 | 2 | 4 | 2 | 4 | 2 | 2 | 1 | 0.5 | 2 | 4 | ≤0.06 |
| 4B | >100 | 9.5 | >64 | >64 | >64 | 64 | 64 | 64 | 32 | 16 | 32 | 16 | 8 |
| 4C | 26 | 1.1 | 2 | 4 | 2 | 2 | 2 | 2 | 1 | 4 | 4 | 4 | 4 |
| 4D | >100 | 0.12 | 0.25 | 0.5 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.5 | 2 | ≤0.06 |
| 4E | 88 | 8.4 | 32 | 64 | 16 | 16 | 8 | 16 | 8 | 8 | 8 | 8 | 8 |
| 4F | 34 | >10 | 16 | 16 | 8 | 8 | 8 | 4 | 2 | 2 | 8 | 32 | 8 |
| 4G | 49 | 1.1 | 0.5 | 0.5 | 0.5 | 0.25 | 0.5 | 0.5 | 0.5 | 0.5 | 1 | 1 | ≤0.06 |
| 4H | 5.5 | 0.20 | 0.25 | 0.5 | 0.25 | 0.12 | 0.12 | 0.12 | 0.5 | 0.5 | 1 | 1 | ≤0.06 |
| 41 | 57 | 0.51 | 2 | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ≤0.06 |
| 4J | 16 | 0.17 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 0.5 | 0.5 | 8 | >64 | 1 |
| 4K | 69 | 9.2 | 32 | 64 | 16 | 16 | 16 | 16 | 8 | 8 | 8 | 8 | 4 |
| 4L | 15 | 4.9 | 4 | 4 | 2 | 1 | 1 | 1 | 1 | 0.5 | 4 | 2 | 0.5 |
| 4M | 52 | >10 | 32 | 64 | 16 | 16 | 16 | 32 | 8 | 8 | >64 | 16 | 2 |
| 4N | >100 | >10 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| Line | _ ^d | _d | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0.5 | 0.5 | 16 | 4 |
| Cip | _ ^d | _d | 0.12 | 0.5 | 0.12 | 16 | 1 | 32 | 1 | 1 | 1 | 0.5 | ≤0.06 |

a; abbreviation; **RN**; *In vitro* activity against *E. Coli* RNAP, **UP**; *In vitro* activity against *S. pneumonia* UPPS, **S1**; *S. aureus* 1, ATCC13709 *in vivo* (methicillin sensitive), **S26**; *S. aureus* 26, ATCC25923 (vancomycin susceptible), **S4**; *S. aureus* 4, Oxford, **S2**; *S. aureus* 2 (MRSA *in vivo*), **E1**; *E. faecalis* 1, ATCC29212 VanS (vancomycin susceptible), **E2**; *E. faecium* 1, VanA (vancomycin resistant), **P1**; *S. pneumonia* 1, ATCC49619 (erythromycin susceptible), **P9**; *S. pneumonia* 9, (multi-drug resistant), **P9B**; *S. pneumonia* 9 in presence of 2.5 % horse blood, **H3**; *H. influenzae* 3, ATCC31517 MMSA, **H4**; *H. influenzae* 4, LS2 Efflux ko, **Line**; linezolid, **Cip**; ciprofloxacin; b; All analogues are inactive (MIC > 64 ug/ml) against *E. coli* 1, ATCC25922 (non Pathogenic strain), *E. coli* 50, Ec49 No Efflux and *P. aeruginosa* 1, ATCC27853. c; All analogues are antifungal inactive (MIC > 32 ug/ml) against *Candida albicans*. d; Not determined

| | | | • | | | | | | | | | | |
|----------------|----------------|----------------|---------|----------------|--------|----------------|---------|----------------|---------|--------|----------|----------------|----------------|
| | RN | UP | S1 | S26 | S4 | S2 | E1 | E2 | P1 | P9 | P9B | HI3 | HI4 |
| 5A | >100 | _ ^d | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| ent-5A | >100 | - ^d | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 5B | >100 | >10 | >64 | >64 | >64 | >64 | 64 | >64 | 32 | 32 | 32 | 64 | 8 |
| 5C | 10 | _ ^d | 4 | 8 | 8 | 4 | 4 | 4 | 1 | 0.5 | 4 | 8 | 0.5 |
| ent- 5C | 6.9 | >10 | 4 | 8 | 8 | 8 | 2 | 2 | 1 | 1 | 4 | 8 | 2 |
| 5D | 6.6 | >10 | 0.5 | 1 | 1 | 0.5 | 0.5 | 0.5 | 0.25 | 0.25 | 2 | 4 | 0.5 |
| 5E | 3.3 | >10 | 0.5 | 0.5 | 0.5 | 0.5 | 0.12 | 0.12 | 0.25 | 0.12 | 1 | >64 | 2 |
| 5F | - ^d | - ^d | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 5G | 6.4 | >10 | 4 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 4 | 32 | 4 |
| 5H | 1.6 | 3.0 | 0.5 | 2 | 1 | 1 | 0.5 | 0.5 | 0.12 | 0.25 | 2 | 16 | 0.25 |
| 51 | 30 | >10 | 2 | 4 | 4 | 2 | 2 | 2 | 2 | 1 | 8 | 16 | 4 |
| 5J | 14 | >10 | 2 | 4 | 4 | 2 | 1 | 1 | 0.5 | 0.5 | 1 | 8 | 1 |
| 5K | 98 | >10 | 1 | 4 | 2 | 1 | 0.5 | 1 | 0.5 | 0.5 | 4 | >32 | 2 |
| (±)-5L | - ^d | _ ^d | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 |
| (±)-6A | 4.7 | >10 | 0.5 | 1 | 1 | 1 | 0.5 | 1 | 2 | 1 | 2 | 4 | ≤0.06 |
| 6B | 5.6 | >10 | 8 | 8 | 4 | 8 | 4 | 4 | 2 | 2 | 2 | 32 | 0.5 |
| 6C | 4.0 | 3.2 | 2 | 2 | 2 | 1 | 2 | 1 | 0.5 | 0.5 | 1 | 64 | 0.25 |
| 6D | 6.1 | >10 | 2 | 4 | 2 | 4 | 2 | 4 | 1 | 1 | 4 | >64 | 0.5 |
| 6E | 7.0 | 4.0 | 2 | 2 | 2 | 4 | 1 | 1 | 0.5 | 0.5 | 4 | >64 | 1 |
| 6F | 7.4 | 3.9 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 4 | >64 | 1 |
| 6G | 2.4 | 1.9 | 0.5 | 1 | 1 | 0.5 | 1 | 0.5 | 2 | 1 | 4 | >64 | 2 |
| 6H | 4.4 | >10 | 64 | >64 | >64 | 64 | 32 | 16 | 2 | 4 | >64 | >64 | 4 |
| 61 | >100 | >10 | >64 | >64 | >64 | >64 | >64 | >64 | 64 | 64 | 64 | >64 | 16 |
| (±)-7A | >100 | >10 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 16 |
| 7B | >100 | >10 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 7C | >100 | >10 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 16 |
| 7D | >100 | >10 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 7E | >100 | >10 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 8A | >100 | 0.3 | 0.12 | 0.12 | 1 | 64 | ≤0.06 | ≤0.06 | 2 | 2 | 2 | >64 | 0.5 |
| 8B | 38 | _ ^d | _d | _ ^d | _d | _ ^d | _d | _ ^d | _d | _d | _d | _ ^d | _ ^d |
| a; abbre | eviation; | see foo | ot note | in Table | S1, b; | All analo | ogues a | re inacti | ve (MIC | > 64 u | g/ml) ag | ainst E. | coli 1, |

Table S2. In vitro enzyme activity (IC₅₀, μ M) and antibiotic activity (MIC, μ g/mL) of 3-acyl and 3-enamine tetramic acids shown in Figure S1^{a-d}

ATCC25922 (non Pathogenic strain), *E. coli* 50, Ec49 No Efflux and *P. aeruginosa* 1, ATCC27853. c; All analogues are antifungal inactive (MIC > 32 ug/ml) against *Candida albicans*. d; Not determined

| | S1 | S26 | S4 | S2 | E1 | E2 | P1 | Р9 | P9B | HI3 | HI4 |
|----------------|-----|----------------|-----|-----|------|-----|------|------|-----|-----|----------------|
| 9A | >64 | >64 | >64 | >64 | >64 | >64 | 64 | 64 | 64 | >64 | 8 |
| (±)-9B | 8 | 16 | 8 | 16 | 8 | 4 | 4 | 2 | 4 | 4 | 0.25 |
| 9C | >64 | >64 | >64 | >64 | >64 | >64 | 64 | 64 | 64 | >64 | 64 |
| 9D | 8 | 4 | 8 | 8 | 2 | 4 | 2 | 2 | 2 | 2 | 0.25 |
| 9E | 4 | 8 | 8 | 8 | 2 | 2 | 1 | 1 | 2 | 64 | 1 |
| 9F | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 16 |
| (±)- 9G | 64 | 64 | >64 | 64 | >64 | 32 | 16 | 16 | 16 | 8 | _ ^d |
| 9H | 8 | 8 | 4 | 4 | 4 | 4 | 4 | 2 | 4 | 4 | 0.25 |
| (±)-19I | 1 | 0.5 | 1 | 1 | 0.25 | 0.5 | 0.25 | 0.25 | 2 | 2 | ≤0.06 |
| (±)-9J | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| (±)- 9K | >64 | >64 | >64 | >64 | >64 | >64 | 64 | 64 | 64 | >64 | 16 |
| (±)-9L | 32 | 32 | 32 | 64 | 16 | 32 | 16 | 16 | 16 | 16 | 8 |
| (±)-9M | 64 | >64 | >64 | >64 | 64 | 64 | 32 | 32 | 32 | 16 | 4 |
| (±)-9N | 4 | 4 | 4 | 8 | 4 | 4 | 4 | 4 | 4 | 4 | 0.5 |
| (±)-90 | >64 | _ ^d | >64 | >64 | >64 | >64 | 64 | 64 | 64 | 64 | 16 |
| (±)-9P | 32 | 64 | 32 | 64 | 32 | 32 | 32 | 32 | 16 | 16 | 4 |
| (±)-9Q | 32 | 32 | 32 | 64 | 16 | 16 | 8 | 8 | 8 | 16 | 4 |
| (±)-9R | >64 | >64 | 64 | >64 | >64 | >64 | >64 | 64 | 64 | >64 | 16 |
| (±)-9S | >64 | >64 | 64 | >64 | 64 | 64 | 32 | 32 | 16 | >64 | 64 |
| (±)- 9T | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 64 | 64 | >64 | 8 |
| (±)-9U | >64 | >64 | 64 | 64 | 64 | 32 | 16 | 16 | 8 | >64 | 2 |
| (±)-9V | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 16 |
| (±)- 9W | >64 | >64 | >64 | >64 | >64 | 64 | 32 | 32 | 32 | >64 | 4 |
| (±)- 9X | >64 | >64 | 64 | >64 | >64 | 32 | 64 | 32 | 32 | >64 | 16 |
| 9Y | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 9Z | 16 | 32 | 8 | 16 | 8 | 8 | 8 | 8 | 8 | 16 | 1 |
| 9AA | >64 | >64 | >64 | >64 | >64 | >64 | 64 | 64 | 64 | >64 | 64 |
| (±)-10A | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 32 |
| (±)-10B | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 64 |
| (±)-10C | 64 | >64 | >64 | >64 | >64 | 16 | >64 | >64 | >64 | >64 | 16 |

Table S3. In vitro antibiotic activity (MIC, μ g/mL) of 3-carboxamide tetramic acids shown in Figure S2^{a-d}

| (±)-10D | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
|-----------------|-----------|----------|----------|-----------|---------|------------|-------------------|-------------------|----------|--------|----------------|
| (±)-10E | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 64 | 16 |
| (±)-10F | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 32 |
| (±)-10G | 64 | >64 | >64 | >64 | >64 | 32 | 32 | 32 | >64 | >64 | 64 |
| (±)-10H | 64 | >64 | 64 | 64 | 64 | 64 | 64 | 64 | 64 | >64 | 16 |
| (±)-11A | 8 | 8 | 8 | 16 | 4 | 8 | 4 | 2 | 8 | 4 | 2 |
| (±)-11B | 16 | 32 | 16 | 8 | 8 | 8 | 4 | 4 | 4 | 16 | 4 |
| (±)-11C | 32 | 32 | 32 | 32 | 32 | 8 | 8 | 4 | 8 | 32 | 4 |
| (±)-11D | 4 | 4 | 2 | 4 | 2 | 1 | 1 | 0.5 | 8 | 16 | 0.2 |
| (±)-11E | 64 | 64 | 32 | 32 | 32 | 8 | 8 | 4 | 8 | 64 | 0.2 |
| 11F | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 64 | >64 | >64 | >64 |
| 11G | 32 | 64 | 32 | >64 | 8 | 16 | 8 | 8 | 8 | 8 | 4 |
| 11H | >64 | >64 | >64 | >64 | >64 | >64 | 64 | 64 | 64 | >64 | 64 |
| 111 | >64 | >64 | >64 | >64 | 64 | >64 | >64 | 64 | >64 | >64 | 32 |
| 11J | >64 | >64 | >64 | >64 | 64 | 64 | 32 | 32 | 32 | >64 | 64 |
| 11K | >64 | >64 | >64 | >64 | >64 | 64 | >64 | >64 | >64 | >64 | 4 |
| (±)- 11L | 64 | >64 | >64 | 64 | >64 | >64 | >64 | 64 | 64 | 16 | 64 |
| (±)-11M | >64 | _d | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 64 |
| 11N | >64 | >64 | >64 | >64 | >64 | 64 | >64 | >64 | 64 | >64 | >64 |
| 110 | 16 | 32 | 16 | 16 | 4 | 8 | 2 | 2 | 1 | >64 | 4 |
| a; abbrev | iation; s | see foo | t note i | n Table | S1, b; | All ana | logues | are inac | tive (MI | C > 64 | 4 ug/ml) |
| against E | . coli 1 | , ATCO | 25922 | (non Pa | athogen | iic strair | n), <i>E. c</i> o | o <i>li</i> 50, E | Ec49 No | Efflux | and <i>P</i> . |
| aeruginos | a 1, AT | CC278 | 53. c; A | II analog | gues ar | e antifui | ngal ina | ctive (M | IC > 32 | ug/ml) | against |
| Candida a | lbicans | . d; Not | determ | ined | | | | | | | |

Table S4. In vitro antibiotic activity (MIC, μ g/mL) of 3-acyltetramic acids shown in Figure S3^{a-d}

| | | | | | | - | | | - | | |
|-----|-----|-----|-----|-----|-----|-----|------|------|-----|-----|-----|
| | S1 | S26 | S4 | S2 | E1 | E2 | P1 | Р9 | P9B | HI3 | HI4 |
| 12A | 4 | 16 | 4 | 8 | 4 | 4 | 2 | 2 | 32 | >64 | 64 |
| 12B | 1 | 2 | 1 | 0.5 | 1 | 0.5 | 0.5 | 0.25 | 4 | >64 | 4 |
| 12C | 64 | 64 | 64 | 64 | 64 | 32 | 64 | 64 | 64 | >64 | 16 |
| 12D | 0.5 | 2 | 2 | 1 | 0.5 | 0.5 | 0.12 | 0.25 | 32 | >64 | 1 |
| 12E | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 0.5 | 32 | >64 | 64 |
| 12F | 1 | 8 | 4 | 4 | 2 | 2 | 4 | 2 | 8 | >64 | 8 |
| 12G | 2 | 8 | 4 | 2 | 2 | 2 | 1 | 1 | 4 | 64 | 1 |
| 12H | >64 | >64 | >64 | >64 | >64 | >64 | 1 | 1 | 4 | >64 | 32 |

| | | | | | | | | | | 1 | |
|---------|----------------|-----|-----|------|-----|-----|-----|-----|-----|-----|----------------|
| 121 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 12J | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 12K | >64 | >64 | >64 | .>64 | 4 | 4 | 2 | 2 | 4 | >64 | 4 |
| 12L | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 12M | >64 | >64 | >64 | >64 | >64 | >64 | 2 | 4 | 8 | >64 | >64 |
| 12N | >64 | >64 | >64 | >64 | >64 | >64 | 16 | 4 | 16 | >64 | >64 |
| 120 | >64 | >64 | >64 | >64 | >64 | >64 | 4 | 8 | 16 | >64 | 8 |
| 12P | 16 | 32 | 16 | 16 | 16 | 16 | 8 | 8 | 16 | >64 | 4 |
| 12Q | 32 | 64 | 32 | 32 | 32 | 32 | 32 | 16 | 32 | >64 | 16 |
| 12R | 2 | 4 | 2 | 1 | 1 | 1 | 0.5 | 0.5 | 4 | >64 | 2 |
| 12S | 4 | 32 | 2 | 4 | 1 | 2 | 1 | 1 | 64 | >64 | 2 |
| 12T | >64 | >64 | 16 | >64 | 16 | 8 | 16 | 8 | 32 | >64 | >64 |
| 12U | - ^d | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 32 |
| 12V | 64 | >64 | >64 | >64 | 64 | 64 | 64 | 32 | 32 | >64 | 16 |
| 13A | 8 | 16 | 8 | 8 | 4 | 8 | 4 | 4 | 16 | >64 | 4 |
| 13B | 4 | 8 | 4 | 4 | 2 | 4 | 2 | 2 | 16 | 64 | 4 |
| 13C | >64 | >64 | >64 | >64 | >64 | 64 | 8 | 8 | 64 | >64 | 4 |
| 13D | >64 | >64 | >64 | >64 | 64 | 64 | 32 | 32 | 32 | >64 | 64 |
| 13E | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 13F | - ^d | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| (±)-13G | 64 | 64 | 64 | 64 | 64 | 64 | 32 | 32 | >64 | >64 | _ ^d |
| 13H | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 64 | >64 | 64 | 8 |
| 14A | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 14B | >64 | >64 | >64 | >64 | >64 | >64 | 64 | 64 | 64 | >64 | 16 |
| 14C | 16 | 64 | 64 | 16 | 16 | 16 | 8 | 8 | 16 | >64 | >64 |
| 14D | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 64 |
| 14E | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 64 | 32 | >64 | 8 |
| 14F | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 64 | 32 | >64 | 16 |
| 14G | >64 | >64 | >64 | >64 | >64 | >64 | 16 | 8 | 16 | >64 | 32 |
| 14H | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 141 | >64 | >64 | >64 | .64 | 64 | 32 | 32 | 16 | 16 | >64 | >64 |
| 14J | >64 | >64 | >64 | >64 | 8 | 8 | 4 | 4 | 8 | >64 | 4 |
| 14K | >64 | >64 | >64 | >64 | 32 | 16 | 8 | 4 | 8 | >64 | 32 |
| 14L | >64 | >64 | >64 | >64 | >64 | 64 | 8 | 4 | 16 | >64 | 8 |
| 14M | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | >64 | 8 |

a; abbreviation; see foot note in Table S1, b; All analogues are inactive (MIC > 64 ug/ml) against *E. coli* 1, ATCC25922 (non Pathogenic strain), *E. coli* 50, Ec49 No Efflux and *P. aeruginosa* 1, ATCC27853. c; All analogues are antifungal inactive (MIC > 32 ug/ml) against *Candida albicans.* d; Not determined

| | DEP | RBC | HEK | PMB | SOL | PPB |
|-----------------|-----------------------|-----------------------|-----------------------|-----------------------|----------------|----------------|
| | IC ₅₀ , μΜ | IC ₅₀ , μΜ | LD ₅₀ , µM | LD ₅₀ , μΜ | μM | % |
| 1A | >100 | >100 | >90.9 | >90.9 | _ ^b | _b |
| 1B | >100 | >100 | >90.9 | >90.9 | _ ^b | _b |
| 1C | >100 | >100 | >90.9 | >90.9 | _ ^b | _b |
| 1D | >100 | >100 | >90.9 | >90.9 | >200 | 99.8 |
| 1E | 13.3 | >100 | >90.9 | >90.9 | >300 | 100 |
| (±)-2A | 10.8 | >100 | 30.3 | 30.3 | 75-150 | _b |
| (±)-2C | >100 | >100 | >90.9 | >90.9 | >300 | _b |
| (±)-2E | 84.3 | >100 | 90.9 | 90.9 | >300 | 96.6 |
| (±)- 2 I | >100 | >100 | >90.9 | >90.9 | >300 | _b |
| (±)- 3F | >100 | >100 | 30.3 | 90.9 | 150-300 | - ^c |
| (±)-3G | 21.9 | >100 | 10.1 | 30.3 | _ b | _b |
| (±)-3H | 49.3 | >100 | 30.3 | 30.3 | >300 | _b |
| 4C | 31.3 | >100 | 90.9 | 30.3 | >300 | 99.5 |
| 4D | 39.2 | >100 | >90.9 | 30.3 | 150-300 | р - |
| 4G | >100 | >100 | >90.9 | >90.9 | >300 | <u>ь</u> |
| 4H | >100 | >100 | 10.1 | 90.9 | 150-300 | 99.9 |
| 41 | >100 | >100 | 90.9 | >90.9 | >300 | 99.5 |
| 4J | >100 | >100 | 90.9 | 90.9 | >300 | _b |
| 4L | 68.8 | >100 | 30.3 | 30.3 | >300 | _b |
| 5C | >100 | >100 | 30.3 | 30.3 | >200 | 100 |
| ent- 5C | >100 | >100 | 30.3 | 90.9 | >300 | 100 |
| 5D | 43.4 | >100 | >90.9 | >90.9 | 67-200 | 100 |
| 5E | >100 | >100 | >90.9 | 90.9 | 67-200 | 100 |
| 5G | >100 | >100 | 30.3 | 90.9 | >300 | _b |
| 5H | >100 | >100 | 90.9 | >90.9 | >300 | 100 |
| 51 | >100 | >100 | 90.9 | >90.9 | >300 | _b |
| 5K | >100 | >100 | >90.9 | >90.9 | >300 | _b |
| 6C | >100 | >100 | 90.9 | >90.9 | >300 | 99.8 |

Table S5. Pharmacological properties of tetramic acids^{a,b}

| 6F | >100 | >100 | 10.1 | >90.9 | >300 | _b |
|----|------|------|------|-------|------|----|
| 6G | >100 | >100 | 10.1 | >90.9 | >300 | _b |

a[†]; **DEP**; *In vitro* activity in depolarization of *S. aureus* membrane, **RBC**; *In vitro* mammalian red blood cell membrane lysis activity, **HEK**; *in vitro* toxicities against human embryonic kidney 293 cells, **PMB**; *in vitro* toxicities human peripheral blood cells, **SOL**; aqueous solubility at pH 7.4 (water with 2% DMSO), **PPB**; % ratio of plasma protein binding; b; not determined.

| Strain | E. coli | E. coli TOP10 | K. pneumoniae | K. pneumoniae | K. pneumoniae |
|-----------|---------|---------------|---------------|---------------|---------------|
| | Top10 | ∆TolC | JH1 | JH1 ∆TolC | JH1 ∆AcrB |
| Phenotype | wt | efflux- | wt- | efflux- | efflux- |
| 1D | >64 | 8 | >64 | >64 | >64 |
| 5C | >64 | 8 | >64 | 16 | >64 |

Table S7. Summary of docking results

| | | UPP | S (1V7U) | RNA | P (1ZYR ^a) | RNA | P (3DXJ ^b) |
|------|----------|------------|---------------------|---------|------------------------|------------|------------------------|
| Comp | Tautomer | docking | number of | docking | number of | docking | number of |
| | | energy | nergy conformations | | conformations | energy | conformations |
| | | (kcal/mol) | (kcal/mol) | | | (kcal/mol) | |
| 2A | А | -9.22 | 1 | -6.59 | 2 | -7.11 | 2 |
| | В | -8.88 | 4 | -6.94 | 1 | -7.86 | 2 |
| | С | -9.47 | 2 | -6.53 | 2 | -7.02 | 3 |
| | D | -9.33 | 5 | -7.34 | 2 | -8.10 | 2 |
| 6C | А | -9.92 | 2 | -8.14 | 1 | -7.13 | 3 |
| | В | -10.04 | 2 | -8.23 | 1 | -7.55 | 3 |
| | С | -9.47 | 1 | -7.61 | 2 | -7.27 | 3 |
| | D | -10.25 | 2 | -7.13 | 2 | -7.28 | 4 |

a; active site of streptolydigin, b; active site of myxopyronin.



Figure S7. Docking model of 2A (violet), 6C (light blue) and streptolydigin (yellow) into active site of RNAP (1ZYR)



Figure S8. Docking model of **2A** in each tautomer into active site of UPPS (1V7U); (A) tautomer A, (B) tautomer B, (C) tautomer C and (D) tautomer D.



Figure S9. Docking model of **2A** in each tautomer into active site of RNAP (1ZYR, active site of streptolydigin); (A) tautomer A, (B) tautomer B, (C) tautomer C and (D) tautomer D.



Figure S10. Docking model of **2A** in each tautomer into active site of RNAP (3DXJ, active site of myxopyronin); (A) tautomer A, (B) tautomer B, (C) tautomer C and (D) tautomer D.



Figure S11. Docking model of **6C** in each tautomer into active site of UPPS (1V7U); (A) tautomer A, (B) tautomer B, (C) tautomer C and (D) tautomer D.



Figure S12. Docking model of **6C** in each tautomer into active site of RNAP (1ZYR, active site of streptolydigin); (A) tautomer A, (B) tautomer B, (C) tautomer C and (D) tautomer D.



Figure S13. Docking model of **6C** in each tautomer into active site of RNAP (3DXJ, active site of myxopyronin); (A) tautomer A, (B) tautomer B, (C) tautomer C and (D) tautomer D.



Figure S14. Plot of $ClogD_{7.4}$ against MSA of bicyclic 3-acyl (66 examples) and 3-carboxamide (86 examples) TAs prepared in this work against (A) MRSA, (B) *H. influenzae 3* and (C) efflux-negative *H. influenzae 4*. For comparison, (D) gives MICs against *S. aureus* without consideration of the species of strains of natural (34 analogues) and unnatural (66 analogues) 3-acyl TAs and Novartis' 3-carboxamide TAs (10 analogues) reported in the literatures. "Active", "mild" and "inactive" mean that the values are MIC \leq 4 µg/mL, 4 µg/mL < MIC \leq 32 µg/mL and MIC > 32 µg/mL, respectively. In order to compare with Figure A-C at increased resolution, Figure D has been cut off at 250< MSA <1100. See Figure S17 for the full version.



Figure S15. Plot of PSA against MSA of bicyclic 3-acyl (66 examples) and 3-carboxamide (86 examples) TAs prepared in this work against (A) MRSA, (B) *H. influenzae 3* and (C) efflux-negative *H. influenzae 4*. For comparison, (D) gives MICs against *S. aureus* without consideration of the species of strains of natural (34 analogues) and unnatural (66 analogues) 3-acyl TAs and Novartis' 3-carboxamide TAs (10 analogues) reported in the literatures. "Active", "mild" and "inactive" mean that the values are MIC \leq 4 µg/mL, 4 µg/mL < MIC \leq 32 µg/mL and MIC > 32 µg/mL, respectively. In order to compare with Figure A-C at increased resolution, Figure D has been cut off at 250< MSA <1100. See Figure S17 for the full version.



Figure S16. Plot of rel-PSA against MSA of bicyclic 3-acyl (66 examples) and 3-carboxamide (86 examples) TAs prepared in this work against (A) MRSA, (B) *H. influenzae 3* and (C) efflux-negative *H. influenzae 4*. For comparison, (D) gives MICs against *S. aureus* without consideration of the species of strains of natural (34 analogues) and unnatural (66 analogues) 3-acyl TAs and Novartis' 3-carboxamide TAs (10 analogues) reported in the literatures. "Active", "mild" and "inactive" mean that the values are MIC \leq 4 µg/mL, 4 µg/mL < MIC \leq 32 µg/mL and MIC > 32 µg/mL, respectively. In order to compare with Figure A-C in increased resolution, Figure D has been cut off at 250< MSA <1100. See Figure S17 for the full version.



Figure S17. Plot of (A) ClogP, (B) ClogD_{7.4}, (C) PSA and (D) rel-PSA against MSA of previously reported 3acyl and 3-carboxamide TAs with MICs against *S. aureus* without consideration of the species of strains in the literatures. Active, mild and inactive mean that the values are MIC \leq 4 µg/mL, 4 µg/mL < MIC \leq 32 µg/mL and MIC > 32 µg/mL, respectively.



Figure S18. Correlation of blood effect against (A) MSA, (B) ClogP, (C) PSA and (D) rel-PSA. The MIC difference is defined as MIC with 2.5% blood/ MIC with 0% blood in the assay of *S. pneumonia* 9. 113 analogues were used after removing inactive analogues against any one of the bacterial panels.



Figure S19. Correlation of blood effect against ClogP and rel-PSA. The MIC difference is defined as MIC with 2.5% blood/ MIC with 0% blood in the assay of *S. pneumonia* 9. 113 analogues are used after removing inactive analogues. The green line presents the thresholds for lowered blood effect. For increased resolution, the graph has been cut off at MIC difference >9.

| Entry | Name | Mw | MSA | PSA | %PSA | ClogP | ClogD _{7.4} | HD/ HA | RB |
|-------|--------|-----|-----|------|------|-------|----------------------|--------|----|
| 1 | 1A | 310 | 540 | 69.6 | 12.9 | 1.69 | 0.23 | 2/3 | 11 |
| 2 | 1B | 353 | 632 | 69.6 | 11.0 | 2.88 | 1.42 | 2/3 | 14 |
| 3 | 1C | 308 | 509 | 69.6 | 13.7 | 1.28 | -0.15 | 2/3 | 7 |
| 4 | 1D | 302 | 462 | 69.6 | 15.1 | 1.85 | 0.64 | 2/3 | 7 |
| 5 | 1E | 387 | 599 | 82.1 | 13.7 | 1.77 | 0.41 | 2/5 | 8 |
| 6 | (±)-2A | 389 | 592 | 78.9 | 13.3 | 1.27 | -1.14 | 2/4 | 3 |
| 7 | (±)-2B | 404 | 607 | 99.1 | 16.3 | -0.32 | -2.80 | 3/5 | 3 |
| 8 | (±)-2C | 391 | 629 | 78.9 | 12.5 | 1.98 | -0.36 | 2/4 | 4 |
| 9 | (±)-2D | 336 | 532 | 78.9 | 14.8 | 1.14 | -1.25 | 2/4 | 3 |
| 10 | (±)-2E | 350 | 562 | 78.9 | 14.0 | 1.45 | -0.90 | 2/4 | 4 |
| 11 | (±)-2F | 338 | 519 | 88.1 | 17.0 | -0.21 | -2.72 | 2/5 | 4 |
| 12 | (±)-2G | 344 | 516 | 78.9 | 15.3 | 1.33 | -1.13 | 2/4 | 4 |
| 13 | (±)-2H | 358 | 544 | 78.9 | 14.5 | 1.75 | -0.69 | 2/4 | 4 |
| 14 | (±)-2l | 381 | 655 | 78.9 | 12.0 | 2.74 | 0.32 | 2/4 | 10 |
| 15 | (±)-3A | 330 | 484 | 78.9 | 16.3 | 1.71 | -0.45 | 2/4 | 3 |
| 16 | (±)-3B | 398 | 533 | 78.9 | 14.8 | 2.60 | -0.18 | 2/4 | 4 |
| 17 | (±)-3C | 376 | 540 | 78.9 | 14.6 | 2.37 | 0.03 | 2/4 | 4 |
| 18 | (±)-3D | 346 | 494 | 99.1 | 20.1 | 1.43 | -0.91 | 3/5 | 3 |
| 19 | (±)-3E | 360 | 532 | 88.1 | 16.6 | 1.46 | -0.94 | 2/5 | 4 |
| 20 | (±)-3F | 422 | 607 | 88.1 | 14.5 | 3.14 | 0.70 | 2/4 | 5 |
| 21 | (±)-3G | 399 | 514 | 78.9 | 15.4 | 2.10 | -0.75 | 2/4 | 3 |
| 22 | (±)-3H | 379 | 531 | 78.9 | 14.9 | 2.05 | -0.44 | 2/4 | 3 |
| 23 | (±)-3I | 348 | 490 | 78.9 | 16.1 | 1.85 | -0.69 | 2/4 | 3 |
| 24 | (±)-3J | 388 | 592 | 88.1 | 14.9 | 2.22 | -0.19 | 2/5 | 5 |
| 25 | (±)-3K | 383 | 556 | 94.7 | 17.0 | 1.83 | -0.34 | 3/4 | 3 |
| 26 | (±)-3L | 415 | 618 | 91.3 | 14.8 | 1.64 | -0.64 | 2/6 | 4 |
| 27 | (±)-3M | 414 | 632 | 82.1 | 13.0 | 2.70 | 0.42 | 2/5 | 4 |
| 28 | 4A | 376 | 593 | 78.9 | 13.3 | 1.90 | -0.32 | 2/4 | 4 |
| 29 | 4B | 316 | 449 | 78.9 | 17.6 | 1.64 | -0.41 | 2/4 | 3 |
| 30 | 4C | 389 | 586 | 78.9 | 13.5 | 1.61 | -0.69 | 2/4 | 3 |
| 31 | 4D | 391 | 623 | 78.9 | 12.7 | 2.31 | 0.08 | 2/4 | 4 |
| 32 | 4E | 330 | 477 | 78.9 | 16.5 | 2.05 | 0.00 | 2/4 | 3 |
| 33 | 4F | 379 | 527 | 78.9 | 15.0 | 2.38 | 0.01 | 2/4 | 3 |

Table S8. Physical properties of the 3-carboxamide tetramic acids shown in Figure S1^a

| 34 | 4G | 391 | 562 | 69.6 | 12.4 | 1.73 | -0.26 | 2/3 | 3 |
|----|----|-----|-----|------|------|------|-------|-----|----|
| 35 | 4H | 393 | 597 | 69.6 | 11.7 | 2.43 | 0.52 | 2/3 | 4 |
| 36 | 41 | 352 | 532 | 69.6 | 13.1 | 1.91 | -0.02 | 2/3 | 4 |
| 37 | 4J | 383 | 624 | 69.6 | 11.1 | 3.20 | 1.20 | 2/3 | 10 |
| 38 | 4K | 332 | 454 | 69.6 | 15.3 | 2.17 | 0.43 | 2/3 | 3 |
| 39 | 4L | 381 | 502 | 69.6 | 13.9 | 2.50 | 0.44 | 2/3 | 3 |
| 40 | 4M | 326 | 500 | 69.6 | 13.9 | 1.53 | -0.62 | 2/3 | 9 |
| 41 | 4N | 276 | 329 | 69.6 | 21.2 | 0.50 | -1.42 | 2/3 | 2 |

^a; **Mw**; molecular weight, **MSA**; molecular surface area, **PSA**; polar surface area, **rel-PAS**; relative polar surface area = (PSA/MSA) x 100, **ClogP**; calculated partition coefficient, **ClogD**_{7.4}; calculated distribution coefficient at pH 7.4, **HD**; hydrogen bond donor count, **HA**; hydrogen bond acceptor count, **RB**; rotatable bond count.

Table S9. Physical properties of the 3-enamine and 3-acyltetramic acids shown in Figure S1^a

| Entry | Name | Mw | MSA | PSA | %PSA | ClogP | ClogD _{7.4} | H-D/ H-A | RB |
|-------|--------|-----|-----|------|------|-------|----------------------|----------|----|
| 1 | 5A | 297 | 433 | 93.1 | 21.5 | 0.68 | -0.22 | 1/5 | 3 |
| 2 | 5B | 367 | 587 | 93.1 | 15.9 | 2.73 | 1.84 | 1/5 | 8 |
| 3 | 5C | 410 | 681 | 93.1 | 13.7 | 3.92 | 3.02 | 1/5 | 11 |
| 4 | 5D | 438 | 744 | 93.1 | 12.5 | 4.72 | 3.82 | 1/5 | 13 |
| 5 | 5E | 466 | 805 | 93.1 | 11.6 | 5.51 | 4.61 | 1/5 | 15 |
| 6 | 5F | 311 | 465 | 93.1 | 20.0 | 1.02 | 0.17 | 1/5 | 4 |
| 7 | 5G | 424 | 713 | 93.1 | 13.1 | 4.27 | 3.39 | 1/5 | 12 |
| 8 | 5H | 438 | 743 | 93.1 | 12.5 | 4.68 | 3.83 | 1/5 | 12 |
| 9 | 51 | 482 | 818 | 102 | 12.5 | 4.55 | 3.57 | 1/6 | 16 |
| 10 | 5J | 408 | 694 | 83.9 | 12.1 | 5.07 | 4.27 | 1/5 | 11 |
| 11 | 5K | 436 | 755 | 83.9 | 11.1 | 5.86 | 5.10 | 1/5 | 13 |
| 12 | (±)-5L | 253 | 390 | 66.8 | 17.1 | 1.20 | 0.54 | 1/4 | 1 |
| 13 | (±)-6A | 388 | 604 | 66.8 | 11.1 | 3.50 | 2.68 | 1/4 | 3 |
| 14 | 6B | 446 | 678 | 93.1 | 13.7 | 3.32 | 2.33 | 1/5 | 6 |
| 15 | 6C | 474 | 752 | 93.1 | 12.4 | 4.19 | 3.24 | 1/5 | 6 |
| 16 | 6D | 488 | 779 | 93.1 | 12.0 | 4.60 | 3.68 | 1/5 | 6 |
| 17 | 6E | 560 | 878 | 119 | 13.6 | 4.23 | 3.11 | 1/6 | 11 |
| 18 | 6F | 574 | 908 | 119 | 13.1 | 4.65 | 3.54 | 1/6 | 11 |
| 19 | 6G | 588 | 942 | 119 | 12.6 | 4.90 | 3.74 | 1/6 | 12 |
| 20 | 6H | 559 | 876 | 119 | 13.6 | 4.14 | 3.00 | 1/6 | 12 |

| 21 | 61 | 417 | 618 | 102 | 16.5 | 2.46 | 1.36 | 1/6 | 8 | |
|-----------------------|--|-----|-----|------|------|------|------|-----|----|--|
| 22 | (±)-7A | 387 | 616 | 58.6 | 9.5 | 2.63 | 2.63 | 1/4 | 3 | |
| 23 | 7B | 433 | 694 | 84.9 | 12.2 | 2.82 | 2.82 | 1/5 | 6 | |
| 24 | 7C | 431 | 659 | 84.9 | 12.9 | 2.11 | 2.11 | 1/5 | 5 | |
| 25 | 7D | 423 | 721 | 84.9 | 11.8 | 3.58 | 3.58 | 1/5 | 12 | |
| 26 | 7E | 372 | 550 | 84.9 | 15.4 | 2.22 | 2.22 | 1/5 | 5 | |
| ^a ; see fo | ^a ; see foot note in Table S8 | | | | | | | | | |
| | | | | | | | | | | |

Table S10. Physical properties of the 3-carboxamide tetramic acids shown in Figure S2^a

| Entry | Name | Mw | MSA | PSA | %PSA | ClogP | ClogD _{7.4} | H-D/ | RB |
|-------|--------|-----|-----|------|------|-------|----------------------|------|----|
| | | | | | | | | H-A | |
| 1 | 9A | 390 | 571 | 99.1 | 17.4 | -0.40 | -2.76 | 3/5 | 3 |
| 2 | (±)-9B | 400 | 514 | 78.9 | 15.4 | 0.53 | -2.51 | 2/4 | 3 |
| 3 | (±)-9C | 404 | 601 | 99.1 | 16.5 | 0.02 | -2.36 | 3/5 | 3 |
| 4 | 9D | 400 | 513 | 78.9 | 15.4 | 1.07 | -1.84 | 2/4 | 3 |
| 5 | 9E | 447 | 666 | 105 | 15.8 | 1.10 | -2.45 | 2/5 | 6 |
| 6 | 9F | 402 | 550 | 78.9 | 14.3 | 1.78 | -1.08 | 2/4 | 4 |
| 7 | (±)-9G | 362 | 484 | 78.9 | 16.3 | 0.71 | -2.35 | 2/4 | 4 |
| 8 | 9H | 350 | 557 | 78.9 | 14.2 | 1.79 | -0.46 | 2/4 | 4 |
| 9 | (±)-9I | 403 | 623 | 78.9 | 12.7 | 1.94 | -0.44 | 2/4 | 4 |
| 10 | (±)-9J | 338 | 517 | 88.1 | 17.0 | -0.61 | -3.12 | 2/5 | 3 |
| 11 | (±)-9K | 352 | 547 | 99.1 | 18.1 | -0.26 | -2.74 | 3/5 | 4 |
| 12 | (±)-9L | 362 | 553 | 92.0 | 16.6 | 0.55 | -2.17 | 2/4 | 4 |
| 13 | (±)-9M | 308 | 476 | 78.9 | 16.6 | 0.27 | -2.19 | 2/4 | 4 |
| 14 | (±)-9N | 338 | 563 | 78.9 | 14.0 | 1.56 | -0.87 | 2/4 | 7 |
| 15 | (±)-9O | 354 | 578 | 88.1 | 15.2 | 0.20 | -2.41 | 2/5 | 7 |
| 16 | (±)-9P | 324 | 531 | 78.9 | 14.9 | 1.17 | -1.17 | 2/4 | 5 |
| 17 | (±)-9Q | 374 | 563 | 88.1 | 15.6 | 1.17 | -1.49 | 2/5 | 6 |
| 18 | (±)-9R | 422 | 722 | 82.1 | 11.4 | 1.81 | -1.90 | 2/5 | 6 |
| 19 | (±)-9S | 448 | 747 | 82.1 | 11.0 | 2.39 | -1.32 | 2/5 | 8 |
| 20 | (±)-9T | 456 | 729 | 82.1 | 11.3 | 2.27 | -2.03 | 2/5 | 6 |
| 21 | (±)-9U | 482 | 759 | 82.1 | 10.8 | 2.85 | -1.42 | 2/5 | 8 |
| 22 | (±)-9V | 448 | 676 | 82.1 | 12.1 | 1.55 | -2.28 | 2/5 | 6 |
| 23 | (±)-9W | 454 | 696 | 82.1 | 11.8 | 1.89 | -1.54 | 2/5 | 7 |
| 24 | (±)-9X | 432 | 684 | 82.1 | 12.0 | 1.55 | -1.66 | 2/5 | 7 |

| 25 | 9Y | 312 | 475 | 99.1 | 20.9 | -0.38 | -2.74 | 3/5 | 5 |
|----------------------|-----------------|--------|-----|------|------|-------|-------|-----|---|
| 26 | 9Z | 348 | 533 | 78.9 | 14.8 | 1.26 | -1.04 | 2/4 | 5 |
| 27 | 9AA | 418 | 633 | 97.3 | 15.4 | 1.57 | -1.13 | 2/6 | 6 |
| 28 | (±)-10A | 350 | 565 | 70.1 | 12.4 | 1.39 | -0.99 | 1/4 | 3 |
| 29 | (±)- 10B | 336 | 538 | 70.1 | 13.0 | 0.92 | -1.49 | 1/4 | 2 |
| 30 | (±)- 10C | 376 | 595 | 70.1 | 11.8 | 1.55 | -0.84 | 1/4 | 2 |
| 31 | (±)- 10D | 432 | 687 | 73.3 | 10.7 | 1.77 | -1.31 | 1/5 | 5 |
| 32 | (±)- 10E | 337 | 528 | 82.1 | 15.5 | 0.15 | -2.37 | 2/5 | 3 |
| 33 | (±)- 10F | 416 | 615 | 111 | 18.0 | 0.92 | -1.88 | 3/6 | 5 |
| 34 | (±)- 10G | 379 | 581 | 108 | 18.6 | 1.36 | -1.19 | 3/5 | 6 |
| 35 | (±)- 10H | 384 | 576 | 95.9 | 16.6 | 1.23 | -1.47 | 2/5 | 5 |
| 36 | (±)-11A | 388 | 594 | 88.1 | 14.8 | 2.27 | -0.13 | 2/5 | 6 |
| 37 | (±)-11B | 362 | 522 | 78.9 | 15.1 | 1.67 | -0.81 | 2/4 | 3 |
| 38 | (±)-11C | 391 | 454 | 78.9 | 17.4 | 1.30 | -1.79 | 2/4 | 3 |
| 39 | (±)-11D | 440 | 662 | 82.1 | 12.4 | 3.28 | 1.05 | 2/5 | 6 |
| 40 | (±)-11E | 442 | 647 | 91.3 | 14.1 | 2.21 | -0.02 | 2/6 | 6 |
| 41 | 11F | 359 | 535 | 82.1 | 15.3 | 1.90 | -0.27 | 2/5 | 4 |
| 42 | 11G | 399 | 597 | 82.1 | 13.8 | 2.62 | 0.45 | 2/5 | 4 |
| 43 | 11H | 462 | 592 | 113 | 19.1 | 2.94 | 0.31 | 2/6 | 5 |
| 44 | 111 | 345 | 493 | 105 | 21.3 | 1.27 | -0.76 | 3/5 | 3 |
| 45 | 11J | 438 | 561 | 108 | 19.3 | 2.64 | 0.39 | 3/5 | 4 |
| 46 | 11K | 426 | 602 | 117 | 19.4 | 2.27 | -0.01 | 3/6 | 5 |
| 47 | (±)-11L | 298 | 399 | 69.6 | 17.4 | 1.03 | -0.57 | 2/3 | 2 |
| 48 | (±)-11M | 383 | 534 | 82.1 | 15.4 | 0.95 | -0.77 | 2/5 | 3 |
| 49 | 11N | 414 | 632 | 82.1 | 13.0 | 2.24 | -1.21 | 2/5 | 5 |
| 50 | 110 | 400 | 602 | 95.9 | 15.9 | 3.13 | 0.03 | 2/5 | 7 |
| ^a ; see f | foot note in Ta | ble S8 | | | | | | | |

Table S11. Physical properties of the 3-acyltetramic acids shown in Figure S3^a

| Entry | Name | Mw | MSA | PSA | %PSA | ClogP | ClogD _{7.4} | H-D/ | RB |
|-------|------|-----|-----|------|------|-------|----------------------|------|----|
| | | | | | | | | H-A | |
| 1 | 12A | 454 | 747 | 83.9 | 11.2 | 5.25 | 4.39 | 1/4 | 13 |
| 2 | 12B | 452 | 772 | 93.1 | 12.1 | 5.06 | 4.18 | 1/5 | 14 |
| 3 | 12C | 341 | 512 | 102 | 19.9 | 0.51 | -0.46 | 1/6 | 6 |
| 4 | 12D | 466 | 803 | 93.1 | 11.6 | 5.47 | 4.62 | 1/5 | 14 |

| 5 | 12E | 480 | 834 | 93.1 | 11.2 | 5.87 | 5.02 | 1/5 | 15 |
|----|---------|-----|------|------|------|------|-------|-----|----|
| 6 | 12F | 494 | 867 | 93.1 | 10.7 | 6.26 | 5.41 | 1/5 | 16 |
| 7 | 12G | 408 | 694 | 83.9 | 12.1 | 5.07 | 4.35 | 1/5 | 11 |
| 8 | 12H | 553 | 931 | 131 | 14.1 | 4.51 | 3.61 | 2/6 | 17 |
| 9 | 121 | 453 | 760 | 119 | 15.7 | 3.22 | -0.40 | 2/6 | 14 |
| 10 | 12J | 615 | 1003 | 122 | 12.2 | 5.57 | 4.67 | 2/6 | 16 |
| 11 | 12K | 629 | 728 | 93.1 | 12.8 | 5.79 | 3.38 | 1/5 | 11 |
| 12 | 12L | 523 | 882 | 122 | 13.8 | 4.07 | 3.04 | 2/6 | 17 |
| 13 | 12M | 551 | 933 | 113 | 12.1 | 4.73 | 3.71 | 1/6 | 18 |
| 14 | 12N | 686 | 808 | 122 | 15.1 | 5.16 | 2.23 | 2/6 | 13 |
| 15 | 120 | 509 | 851 | 113 | 13.3 | 3.81 | 1.79 | 1/6 | 15 |
| 16 | 12P | 438 | 741 | 93.1 | 12.6 | 4.61 | 3.84 | 1/5 | 11 |
| 17 | 12Q | 436 | 715 | 93.1 | 13.0 | 4.11 | 3.28 | 1/5 | 9 |
| 18 | 12R | 538 | 907 | 119 | 13.1 | 4.96 | 3.79 | 1/6 | 15 |
| 19 | 12S | 538 | 908 | 119 | 13.1 | 4.95 | 3.86 | 1/6 | 16 |
| 20 | 12T | 566 | 970 | 119 | 12.3 | 5.71 | 4.60 | 1/6 | 16 |
| 21 | 12U | 397 | 638 | 102 | 16.0 | 2.14 | 1.05 | 1/6 | 8 |
| 22 | 12V | 351 | 574 | 83.9 | 14.6 | 3.45 | 2.56 | 1/5 | 5 |
| 23 | 13A | 450 | 742 | 93.1 | 12.5 | 4.50 | 3.70 | 1/5 | 9 |
| 24 | 13B | 438 | 684 | 83.9 | 12.3 | 4.28 | 3.48 | 1/4 | 8 |
| 25 | 13C | 571 | 925 | 113 | 12.2 | 5.18 | 4.21 | 2/6 | 11 |
| 26 | 13D | 494 | 774 | 112 | 14.5 | 3.24 | 2.29 | 1/7 | 12 |
| 27 | 13E | 684 | 1061 | 154 | 14.5 | 4.98 | 3.88 | 1/9 | 10 |
| 28 | 13F | 425 | 649 | 112 | 17.3 | 0.75 | -0.40 | 1/7 | 8 |
| 29 | (±)-13G | 420 | 662 | 101 | 15.3 | 3.55 | 2.62 | 1/6 | 6 |
| 30 | 13H | 307 | 479 | 66.8 | 13.9 | 2.55 | 1.62 | 1/4 | 2 |
| 31 | 14A | 301 | 433 | 66.8 | 15.4 | 2.43 | 1.99 | 1/4 | 2 |
| 32 | 14B | 426 | 615 | 98.1 | 16.0 | 2.71 | 1.34 | 1/5 | 5 |
| 33 | 14C | 458 | 728 | 93.1 | 12.8 | 4.71 | 3.86 | 1/5 | 10 |
| 34 | 14D | 469 | 705 | 109 | 15.5 | 4.02 | 3.17 | 2/5 | 8 |
| 35 | 14E | 544 | 778 | 135 | 17.4 | 4.31 | 3.11 | 2/7 | 9 |
| 36 | 14F | 520 | 792 | 126 | 15.9 | 4.63 | 3.49 | 2/7 | 11 |
| 37 | 14G | 591 | 788 | 131 | 16.6 | 4.74 | 1.68 | 2/8 | 12 |
| 38 | 14H | 635 | 870 | 141 | 16.2 | 4.40 | 2.90 | 2/8 | 13 |
| 39 | 141 | 517 | 721 | 119 | 16.5 | 3.92 | 2.63 | 1/6 | 8 |

| 40 | 14J | 515 | 736 | 110 | 14.9 | 5.10 | 3.90 | 1/6 | 9 | | |
|----------------------|---|-----|-----|-----|------|------|------|-----|----|--|--|
| 41 | 14K | 566 | 779 | 116 | 14.9 | 4.11 | 2.49 | 1/6 | 11 | | |
| 42 | 14L | 651 | 899 | 141 | 15.7 | 4.65 | 1.55 | 1/8 | 10 | | |
| 43 | 14M | 608 | 833 | 110 | 13.2 | 4.42 | 2.71 | 1/6 | 8 | | |
| ^a ; see f | ^a ; see footnote in Table S8 | | | | | | | | | | |

Table S12. In vitro antibiotic activity against S. aureus (MIC, μ g/mL) and physical properties of natural 3-acyltetramic acid analogues^{a,b}

| | Ũ | | | | | | | | | |
|-----------------------|-----------------|------------------|------|------|------|------|-------|----------------------|-------|----|
| Entry | Name | MIC ^c | Mw | MSA | PSA | %PSA | ClogP | ClogD _{7.4} | H-D/ | RB |
| | | | | | | | | | H-A | |
| Active (MIC \leq 4) | | | | | | | | | | |
| 1 | TPU-0037-C | 3.53 | 825 | 1250 | 241 | 19.3 | 2.26 | -1.44 | 10/12 | 19 |
| 2 | Vancoresmycin | 0.04 | 1344 | 2177 | 423 | 19.4 | 0.56 | -1.61 | 17/22 | 43 |
| 3 | Kibdelomycin | 0.5-4 | 940 | 1279 | 259 | 20.3 | 1.90 | 0.42 | 6/12 | 13 |
| 4 | Delaminomycin C | 3.12 | 486 | 749 | 107 | 14.3 | 3.46 | 2.36 | 4/5 | 8 |
| 5 | Equisetin | 1.0 | 373 | 558 | 77.8 | 13.9 | 2.48 | 1.32 | 2/4 | 3 |
| 6 | Vermisporin | 0.5 | 416 | 660 | 70.1 | 10.6 | 3.32 | 2.35 | 1/4 | 3 |
| 7 | Coniosetin | 0.3 | 414 | 619 | 86.6 | 14.0 | 3.34 | 2.23 | 3/4 | 4 |
| 8 | BU-4514N | 3.1 | 475 | 750 | 111 | 14.8 | 2.34 | -1.19 | 3/6 | 5 |
| 9 | 49F233α | 1.0 | 414 | 624 | 77.8 | 12.5 | 3.17 | 2.05 | 2/4 | 4 |
| 10 | Paecilosetin | 4.0 | 373 | 553 | 86.6 | 15.7 | 2.65 | 1.50 | 3/4 | 3 |
| 11 | Reutericyclin | 0.2 | 349 | 574 | 74.7 | 13.0 | 4.05 | 3.34 | 1/4 | 9 |
| 12 | Trichosetin | 2-4 | 359 | 525 | 86.6 | 16.5 | 2.24 | 1.07 | 3/4 | 3 |
| 13 | Cissetin | 2-4 | 388 | 586 | 77.8 | 13.3 | 2.90 | 1.76 | 2/4 | 3 |
| 14 | Ikarugamycin | 1 | 479 | 684 | 95.5 | 14.0 | 3.17 | 2.77 | 3/4 | 1 |
| Mild (4 | l < MIC ≤ 32) | | | | | | | | | |
| 15 | TPU-0037-A | 12.5 | 841 | 1258 | 261 | 20.7 | 1.19 | -2.57 | 11/13 | 19 |
| 16 | TPU-0037-B | 12.5 | 837 | 1256 | 241 | 19.2 | 2.15 | -1.62 | 10/12 | 18 |
| 17 | Lydicamycin | 6.25 | 855 | 1290 | 261 | 20.2 | 1.34 | -2.42 | 11/13 | 19 |
| 18 | TPU-0037-D | 12.5 | 839 | 1283 | 241 | 18.8 | 2.41 | -1.29 | 10/12 | 19 |
| 19 | Virgineone | 16 | 748 | 1202 | 214 | 17.8 | 3.77 | 2.85 | 8/11 | 26 |
| 20 | Delaminomycin B | 6.25 | 516 | 793 | 116 | 14.6 | 3.78 | 2.46 | 4/6 | 9 |
| 21 | Delaminomycin A | 25 | 502 | 754 | 127 | 16.8 | 3.20 | 1.85 | 5/6 | 8 |
| 22 | PF1052 | 10 | 416 | 659 | 70.1 | 10.6 | 3.39 | 2.42 | 1/4 | 4 |
| 23 | Oxasetin | 16 | 359 | 543 | 83.5 | 15.4 | 3.34 | 1.55 | 2/4 | 3 |

| 24 | Ravenic acid | 25 | 259 | 341 | 66.4 | 19.5 | 1.34 | 0.88 | 2/3 | 4 |
|---------|--|-----------|--------|-----------|-------|------|------|-------|-----|----|
| 25 | C12-TA | 25 | 297 | 494 | 86.6 | 17.5 | 1.59 | 0.89 | 3/4 | 10 |
| 26 | Bu-2313 A | 12-25 | 518 | 737 | 129 | 17.5 | 1.80 | 1.91 | 1/8 | 6 |
| 27 | Bu-2313 B | 12-25 | 504 | 705 | 138 | 19.6 | 1.56 | 1.65 | 2/8 | 6 |
| Inactiv | Inactive (MIC > 32) | | | | | | | | | |
| 28 | Methiosetin | 256 | 333 | 492 | 77.8 | 15.8 | 1.53 | 0.51 | 2/4 | 2 |
| 29 | Tirandalydigin | >64 | 401 | 553 | 97.4 | 17.6 | 1.34 | 0.73 | 2/6 | 4 |
| 30 | Streptolygin | >64 | 599 | 885 | 126.9 | 14.3 | 2.96 | 2.39 | 2/8 | 7 |
| 31 | Tirandamycin A | >64 | 433 | 585 | 134.7 | 23.0 | 0.36 | -0.25 | 3/8 | 5 |
| 32 | Ophiosetin | >128 | 389 | 568 | 98.1 | 17.3 | 1.11 | -0.13 | 3/5 | 4 |
| 33 | Ikarugamycin | 100 | 495 | 702 | 108 | 15.4 | 2.30 | 1.83 | 3/5 | 1 |
| | epoxide | | | | | | | | | |
| 34 | Ripromycin | 100 | 525 | 741 | 117 | 15.8 | 1.52 | 1.10 | 3/6 | 2 |
| a; see | a; see foot note in Table S8 for the abbreviation, b; see references S-1; c; MIC values against S. | | | | | | | | | |
| aureus | without consideration | on of the | specie | s of stra | in. | | | | | |

Table S13. *In vitro* antibiotic activity against *S. aureus* (MIC, µg/mL) and physical properties of previously reported unnatural 3-acyltetramic acid analogues^a

| Entry | Name ^b | MIC ^C | Mw | MSA | PSA | %PSA | ClogP | ClogD _{7.4} | H-D/ | R-B |
|---------|-------------------|------------------|-----|-----|------|------|-------|----------------------|------|-----|
| | | | | | | | | | H-A | |
| Active | $(MIC \leq 4)$ | | | | | | | | | |
| 1 | CPB-11 | 1.56 | 295 | 519 | 57.6 | 11.1 | 3.12 | 2.48 | 1/3 | 10 |
| 2 | JMC-B | 0.8 | 337 | 609 | 57.6 | 9.5 | 4.41 | 3.93 | 1/3 | 11 |
| 3 | JMC-I | 0.8 | 323 | 577 | 57.6 | 10.0 | 4.08 | 3.58 | 1/3 | 10 |
| 4 | JMC-K | 0.8 | 363 | 546 | 57.6 | 10.5 | 4.28 | 3.82 | 1/3 | 5 |
| 5 | JMC-L | 1.6 | 331 | 525 | 57.6 | 11.0 | 2.88 | 2.44 | 1/3 | 4 |
| 6 | JMC-M | 0.8 | 335 | 581 | 57.6 | 9.9 | 3.84 | 3.41 | 1/3 | 8 |
| 7 | JMC-N | 0.8 | 372 | 622 | 57.6 | 9.3 | 4.90 | 4.36 | 1/3 | 11 |
| 8 | JMC-T | 3.1 | 319 | 415 | 66.4 | 16.0 | 2.74 | 2.33 | 2/3 | 3 |
| 9 | JMC-U | 3.1 | 333 | 448 | 57.6 | 12.9 | 2.99 | 2.59 | 1/3 | 3 |
| 10 | JMC-V | 1.56 | 319 | 415 | 66.4 | 16.0 | 2.74 | 2.29 | 2/3 | 3 |
| 11 | JMC-W | 1.56 | 333 | 448 | 57.6 | 12.9 | 2.99 | 2.55 | 1/3 | 3 |
| Mild (4 | < MIC ≤ 32) | | | | | | | | | |
| 12 | CPB-9 | 25 | 239 | 397 | 57.6 | 14.5 | 1.54 | 0.96 | 1/3 | 6 |
| 13 | CPB-10 | 6.25 | 267 | 458 | 57.6 | 12.6 | 2.33 | 1.69 | 1/3 | 8 |
| 14 | CPB-13 | 12.5 | 265 | 428 | 57.6 | 13.5 | 2.22 | 1.91 | 1/3 | 7 |
|---------|--------------|------|-----|-----|------|------|-------|-------|-----|----|
| 15 | CPB-15 | 6.25 | 321 | 453 | 57.6 | 12.7 | 2.72 | 1.87 | 1/3 | 4 |
| 16 | CPB-17 | 12.5 | 253 | 426 | 57.6 | 13.5 | 2.08 | 1.51 | 1/3 | 6 |
| 17 | CPB-18 | 6.25 | 281 | 487 | 57.6 | 11.8 | 2.87 | 2.24 | 1/3 | 8 |
| 18 | CPB-19 | 12.5 | 309 | 548 | 57.6 | 10.5 | 3.66 | 3.04 | 1/3 | 10 |
| 19 | CPB-21 | 25 | 273 | 409 | 57.6 | 14.1 | 2.10 | 1.45 | 1/3 | 4 |
| 20 | CPB-22 | 12.5 | 335 | 482 | 57.6 | 12.0 | 3.26 | 2.42 | 1/3 | 4 |
| 21 | CPB-23 | 25 | 259 | 381 | 57.6 | 15.1 | 1.73 | 1.01 | 1/3 | 4 |
| 22 | CPB-24 | 6.25 | 287 | 443 | 57.6 | 13.0 | 2.52 | 1.87 | 1/3 | 6 |
| 23 | CPB-25 | 6.25 | 315 | 504 | 57.6 | 11.4 | 3.31 | 2.71 | 1/3 | 8 |
| 24 | CPB-26 | 12.5 | 343 | 565 | 57.6 | 10.2 | 4.11 | 3.46 | 1/3 | 10 |
| 25 | CPB-28 | 25 | 301 | 472 | 57.6 | 12.2 | 3.06 | 2.42 | 1/3 | 6 |
| 26 | CPB-29 | 6.25 | 329 | 533 | 57.6 | 10.8 | 3.85 | 3.26 | 1/3 | 8 |
| 27 | CPB-31 | 25 | 335 | 485 | 57.6 | 11.9 | 3.70 | 2.96 | 1/3 | 5 |
| 28 | CPB2-14 | 6.25 | 253 | 425 | 66.4 | 15.6 | 2.08 | 1.43 | 2/3 | 8 |
| 29 | CPB2-15 | 6.25 | 267 | 453 | 66.4 | 14.7 | 2.62 | 1.98 | 2/3 | 8 |
| 30 | JMC-A | 6.25 | 287 | 439 | 57.6 | 13.1 | 2.67 | 2.16 | 1/3 | 4 |
| 31 | JMC-C | 25 | 321 | 454 | 57.6 | 12.7 | 3.09 | 2.52 | 1/3 | 4 |
| 32 | JMC-D | 25 | 317 | 487 | 66.8 | 13.7 | 2.34 | 1.64 | 1/4 | 5 |
| 33 | JMC-E | 25 | 305 | 446 | 57.6 | 12.9 | 2.74 | 1.85 | 1/3 | 4 |
| 34 | JMC-J | 6.25 | 253 | 425 | 57.6 | 13.6 | 2.03 | 1.61 | 1/3 | 5 |
| 35 | C14-TA | 6.25 | 325 | 555 | 86.6 | 15.6 | 2.38 | 1.68 | 3/4 | 12 |
| 36 | T-4d | 25 | 431 | 693 | 95.9 | 13.8 | 3.32 | 2.71 | 2/4 | 10 |
| 37 | T-4e | 12.5 | 433 | 679 | 105 | 15.5 | 2.20 | 1.42 | 2/5 | 10 |
| 38 | T-5b | 25 | 346 | 545 | 83.6 | 15.3 | 1.45 | -1.51 | 2/4 | 6 |
| 39 | T-5c | 25 | 353 | 629 | 83.6 | 13.3 | 2.98 | -0.01 | 2/4 | 13 |
| 40 | T-6 | 25 | 381 | 551 | 77.8 | 14.1 | 3.09 | 2.44 | 2/4 | 4 |
| Inactiv | e (MIC > 32) | • | | • | • | | | | • | • |
| 41 | CPB-2 | >64 | 155 | 212 | 57.6 | 27.2 | -0.91 | -1.62 | 1/3 | 0 |
| 42 | CPB-3 | >64 | 169 | 241 | 57.6 | 23.9 | -0.37 | -1.02 | 1/3 | 0 |
| 43 | CPB-4 | >64 | 231 | 320 | 57.6 | 18.0 | 0.86 | 0.24 | 1/3 | 2 |
| 44 | CPB-5 | >64 | 245 | 348 | 57.6 | 16.6 | 1.40 | 0.80 | 1/3 | 2 |
| 45 | CPB-6 | 50 | 307 | 423 | 57.6 | 13.6 | 2.84 | 2.20 | 1/3 | 3 |
| 46 | CPB-12 | >64 | 323 | 580 | 57.6 | 9.9 | 3.92 | 3.28 | 1/3 | 12 |
| 47 | CPB-14 | 50 | 259 | 380 | 57.6 | 15.2 | 1.57 | 0.89 | 1/3 | 4 |
| | | | | | | | | • | | |

| 48 | CPB-16 | 50 | 225 | 364 | 57.6 | 15.8 | 1.28 | 0.66 | 1/3 | 4 |
|--|---------|------|-----|-----|------|------|-------|-------|-----|----|
| 49 | CPB-20 | >64 | 337 | 609 | 57.6 | 9.5 | 4.45 | 3.83 | 1/3 | 12 |
| 50 | CPB-27 | 50 | 273 | 410 | 57.6 | 14.0 | 2.27 | 1.57 | 1/3 | 4 |
| 51 | CPB-30 | 50 | 357 | 594 | 57.6 | 9.7 | 4.64 | 4.01 | 1/3 | 10 |
| 52 | CPB-32 | 50 | 363 | 546 | 57.6 | 10.5 | 4.49 | 3.80 | 1/3 | 7 |
| 53 | CPB2-16 | >64 | 343 | 558 | 66.4 | 11.9 | 4.31 | 3.67 | 2/3 | 10 |
| 54 | CBP2-17 | 50 | 357 | 588 | 66.4 | 11.3 | 4.71 | 4.10 | 2/3 | 10 |
| 55 | JMC-H | >64 | 259 | 378 | 57.6 | 15.2 | 1.65 | 1.10 | 1/3 | 3 |
| 56 | T-4a | 200 | 479 | 738 | 95.9 | 13.0 | 4.14 | 3.63 | 2/4 | 10 |
| 57 | T-4b | >200 | 447 | 716 | 95.9 | 13.4 | 2.74 | 2.29 | 2/4 | 9 |
| 58 | T-4c | 50 | 453 | 798 | 95.9 | 12.0 | 4.26 | 3.74 | 2/4 | 16 |
| 59 | T-5a | 100 | 378 | 566 | 83.6 | 14.8 | 2.85 | -0.13 | 2/4 | 7 |
| 60 | T-5d | >200 | 330 | 522 | 83.6 | 16.0 | 2.03 | -1.03 | 2/4 | 7 |
| 61 | T-5e | 200 | 332 | 508 | 92.9 | 18.3 | 0.92 | -2.26 | 2/5 | 7 |
| 62 | CPB2-3 | >100 | 141 | 180 | 66.4 | 36.9 | -1.16 | -1.94 | 2/3 | 0 |
| 63 | CPB2-4 | >100 | 155 | 209 | 66.4 | 31.8 | -0.62 | -1.32 | 2/3 | 0 |
| 64 | CPB2-5 | >100 | 231 | 314 | 66.4 | 21.1 | 1.06 | 0.46 | 2/3 | 2 |
| 65 | CPB2-6 | >100 | 197 | 300 | 66.4 | 22.1 | 0.65 | 0.12 | 2/3 | 2 |
| 66 | CPB2-7 | >100 | 270 | 354 | 82.2 | 23.2 | 1.17 | 0.58 | 3/3 | 2 |
| a; see foot note in Table S8 for the abbreviation, b; see references S-2; c; MIC values against S. | | | | | | | | | | |
| | | | | | | | | | | |

Table S14. *In vitro* antibiotic activity against *S. aureus* (MIC, μ g/mL) and physical properties of previously reported unnatural 3-carboxamide tetramic acid analogues^a

| Entry | Name | MIC ^b | Mw | MSA | PSA | %PSA | ClogP | ClogD _{7.4} | H-D/ | R-B |
|-----------------------|---------------------|------------------|-----|-----|------|------|-------|----------------------|------|-----|
| | | | | | | | | | H-A | |
| Active (MIC \leq 4) | | | | | | | | | | |
| 1 | BMC-2 | 0.5 | 390 | 568 | 69.6 | 12.3 | 3.51 | 2.03 | 2/3 | 5 |
| 2 | BMC-B | 0.5 | 390 | 561 | 78.4 | 14.0 | 3.58 | 1.93 | 3/3 | 5 |
| 3 | BMC-D | 2 | 376 | 530 | 78.4 | 14.8 | 3.33 | 1.24 | 3/3 | 4 |
| 4 | BMC-E | 4 | 405 | 591 | 78.4 | 13.3 | 3.98 | 2.42 | 3/3 | 6 |
| 5 | BMC-F | 0.5 | 356 | 546 | 78.4 | 14.4 | 3.09 | 1.54 | 3/3 | 5 |
| 6 | BMC-I | 4 | 398 | 545 | 78.4 | 14.4 | 3.78 | 2.34 | 3/3 | 6 |
| 7 | BMC-J | 4 | 405 | 585 | 81.7 | 14.0 | 3.09 | 1.51 | 3/4 | 6 |
| Mild (4 | Mild (4 < MIC ≤ 32) | | | | | | | | | |

| 8 | BMC-G | 16 | 380 | 533 | 96.3 | 18.1 | 1.48 | -0.43 | 3/4 | 4 | |
|---|-------|----|-----|-----|------|------|------|-------|-----|---|--|
| 9 | BMC-K | 16 | 340 | 444 | 78.4 | 17.7 | 2.24 | 0.39 | 3/3 | 5 | |
| 10 | BMC-L | 32 | 328 | 485 | 78.4 | 16.2 | 1.53 | -0.16 | 3/3 | 5 | |
| a; see foot note in Table S8 for the abbreviation, b; see reference S-3; c; MIC values against S. | | | | | | | | | | | |
| aureus without consideration of the species of strain. | | | | | | | | | | | |

Table S15. Physical properties of fluoroquinolones

| Entry | Name | Mw | MSA | PSA | %PSA | ClogP | ClogD _{7.4} | HD/HA | RB |
|-------|----------------|-----|-----|------|------|-------|----------------------|-------|----|
| 1 | Piromidic acid | 288 | 394 | 86.6 | 22.0 | 1.50 | -0.29 | 1/7 | 3 |
| 2 | Pipemidic acid | 303 | 415 | 98.7 | 23.8 | 0.62 | -2.66 | 2/8 | 3 |
| 3 | Rosoxacin | 294 | 388 | 70.5 | 18.2 | 2.04 | 0.77 | 1/5 | 3 |
| 4 | Ciprofloxacin | 331 | 441 | 72.9 | 16.5 | 1.57 | -1.38 | 2/6 | 3 |
| 5 | Enoxacin | 320 | 429 | 85.8 | 20.0 | 1.60 | -1.51 | 2/7 | 3 |
| 6 | Fleroxacin | 369 | 478 | 64.1 | 13.4 | 1.83 | 0.11 | 1/6 | 4 |
| 7 | Lomefloxacin | 365 | 501 | 72.9 | 14.6 | 2.53 | -0.42 | 2/6 | 3 |
| 8 | Nadifloxacin | 360 | 483 | 81.1 | 16.8 | 1.77 | 0.48 | 2/6 | 2 |
| 9 | Norfloxacin | 319 | 436 | 72.9 | 16.7 | 1.51 | -1.42 | 2/6 | 3 |
| 10 | Ofloxacin | 361 | 485 | 73.3 | 15.1 | 1.51 | -0.33 | 1/7 | 2 |
| 11 | Rufloxacin | 363 | 462 | 64.1 | 13.9 | 1.76 | -0.10 | 1/6 | 2 |
| 12 | Pefloxacin | 333 | 468 | 64.1 | 13.7 | 1.87 | 0.20 | 1/6 | 3 |
| 13 | Balofloxacin | 389 | 548 | 82.1 | 15.0 | 1.89 | -1.97 | 2/7 | 5 |
| 14 | Grepafloxacin | 359 | 500 | 72.9 | 14.6 | 2.45 | -0.47 | 2/6 | 3 |
| 15 | Pazufloxacin | 318 | 405 | 92.9 | 22.9 | 0.70 | -2.09 | 2/6 | 2 |
| 16 | Sparfloxacin | 392 | 517 | 98.9 | 19.1 | 2.40 | -0.66 | 3/7 | 3 |
| 17 | Temafloxacin | 417 | 523 | 72.9 | 13.9 | 3.54 | 0.37 | 2/6 | 3 |
| 18 | Tosufloxacin | 404 | 483 | 99.8 | 20.7 | 2.93 | -1.23 | 2/7 | 3 |
| 19 | Clinafloxacin | 365 | 452 | 86.9 | 19.2 | 1.80 | -2.15 | 2/6 | 3 |
| 20 | Gatifloxacin | 375 | 517 | 82.1 | 15.9 | 1.73 | -1.33 | 2/7 | 4 |
| 21 | Gemifloxacin | 389 | 510 | 121 | 23.8 | 2.09 | -1.89 | 2/9 | 5 |
| 22 | Moxifloxacin | 401 | 549 | 82.1 | 15.0 | 1.85 | -1.88 | 2/7 | 4 |
| 23 | Sitafloxacin | 410 | 497 | 86.9 | 17.5 | 2.18 | -1.48 | 2/6 | 3 |
| 24 | Danofloxacin | 357 | 474 | 64.1 | 13.5 | 1.94 | 0.27 | 1/6 | 3 |
| 25 | Garenoxacin | 426 | 543 | 78.9 | 14.5 | 3.68 | 0.26 | 2/6 | 5 |
| 26 | Trovafloxacin | 416 | 487 | 99.8 | 20.5 | 2.69 | -1.32 | 2/7 | 3 |
| 27 | Difloxacin | 399 | 519 | 64.1 | 12.4 | 3.35 | 1.65 | 1/6 | 3 |



Figure S20. Natural 3-acyl tetramic acids reported antibiotic activity against S. aureus.



Figure S21. Unnatural 3-acyl and 3-carboxamide tetramic acids with reported antibiotic activity against *S. aureus*

Experimental Section

1. General

1.1. Synthesis

The ¹H, ¹³C, DEPT, COSY, HSQC and HMBC NMR spectra were obtained using a Bruker AVB500 (500 MHz, 125 MHz respectively) or DPX400 (400 MHz, 100 MHz, respectively) with residual solvent peaks or tetramethylsilane as the internal reference. Mass spectra (MS) and high resolution mass spectra (HRMS) were obtained with Micro Mass LCT and GCT spectrometers under the conditions of electrospray ionization (ESI) and chemical ionization (CI) respectively, and values were reported in Daltons. Optical rotations were read on a Perkin Elmer 241 polarimeter using the sodium D line (589 nm) and [α]_D were given in units of 10⁻¹

deg dm²g⁻¹.

1.2. Calculation

Docking study; Docking calculations were carried out according to the DockingServer methodology.^[S-4a] The MMFF94 force field^[S-4b] was used for energy minimization of ligand molecules 2A and 6C tautomers using DockingServer. PM6 semiempirical charges calcuted by MOPAC2009^[S-4c] were added to the ligand atoms. Non-polar hydrogen atoms were merged and rotatable bonds were defined. Docking calculations were carried out on RNA polymerase of Thermus thermophilus (PDB code: 3DXJ and 1ZYR) and Undecaprenyl Pyrophosphate Synthase (PDB code: 1V7U). Essential hydrogen atoms, Kollman united atom type charges and solvation parameters were added with the aid of AutoDock tools. [S-4d] Affinity (grid) maps of 25×25×25 Å grid points and 0.375 Å spacing were generated using the Autogrid program.^[S-4d] AutoDock parameter setand distance-dependent dielectric functions were used in the calculation of the van der Waals and the electrostatic terms, respectively. Docking simulations were performed using the Lamarckian genetic algorithm (LGA) and the Solis & Wets local search method.^[S-4e] Initial position, orientation and torsions of the ligand molecules were set randomly. Alternative conformations from 100 independent dockings were considered when the frequency of the conformation was above 10% and the docking energy was within 1 kcal/mol as compared to the lowest energy hit. Each docking experiment was derived from 100 different runs that were set to terminate after a maximum of 2500000 energy evaluations. The population size was set to 150. During the search, a translational step of 0.2 Å, and quaternion and torsion steps of 5 were applied.

Calculation of physicochemical properties; Molecular surface area (MSA), polar surface area (PSA), calculated partition coefficient (ClogP), calculated distribution coefficient at pH_{7.4} (ClogD_{7.4}), hydrogen bond donor count, hydrogen bond acceptor count and rotatable bond count were calculated by using MarvinSketch version 5.3.8. (www.chemaxon.org). Van der Waals for MSA and VG method for ClogP and ClogD_{7.4} were selected for the calculations. Sulfur atoms were excluded from the calculation of PSA. rel-PSA were obtained from (PSA/MSA) x 100. In the calculation, the major tautomer only was selected.

Set of previously reported 3-acyl and 3-carboxamide tetramic acids; 34 of natural and 66 of unnatural 3acyltetramic acids and 10 of 3-carboxamide tetramic acids and their reported MIC values against *S. aureus* without consideration of species of strain in the literature were selected in the bins for each family, with activity defined as "active" in which MIC values are $\leq 4 \mu g/ml$, "mild active" in which MIC values are $4 < MIC \leq 32 \mu g/ml$ and "inactive" in which MIC values are $>32 \mu g/ml$.

1.3. Biological tests

RNAP enzyme assay; The activities of the compounds against *Escherichia coli* RNA Polymerase *in vitro* were compared using the Kool NC-45 universal RNAP template (Epicentre, Madison, WI). A dilution series of each compound, starting from 100µM highest concentration, 2/5 dilution, was added to the reaction volume. Data were converted to percent inhibition with respect to positive and negative controls.

UPPS enzyme assay; UPPS from Streptococcus pneumoniae R6 was purified from a recombinant E.coli strain, containing a pQTEV-UPPS(FL) fusion construct with a TEV cleavable N-terminal H₇ tag. The E.coli strain BL21(DE3) was transformed with the pQTEV-UPPS(FL) construct and was grown in Terrific Broth (TB) medium under 200 rpm shaking at 37°C. When OD₆₀₀ reached 0.8, bacteria were induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside and left at 37°C for 3 hours under 200 rpm shaking. Cells were harvested by centrifugation at 6,000 x g and frozen at -20°C before use. Expression yield was determined after lysis using B-PER® Bacterial Protein Extraction Reagent (Thermo Scientific, #78248) as described by the manufacturer, giving 300 mg/ L of soluble protein. A total of 6 g (wet weight) of E.coli BL21(DE3) paste was suspended in 10 volumes of lysis buffer (20 mM Tris pH 8, 10% Glycerol, 1 mM MgSO₄, 150 mM NaCl, 0.1% TritonX-100, 100 mM lysozyme and protease cocktail inhibitor (Roche Diagnostics, # 11873580001)). The pellet was homogenized at 4°C by magnetic stirring for 15 min. Cells were broken by sonication (180 pulses of 5 sec (9.9 sec off) using a 13 mm diameter probe, in icy bath). To hydrolyze DNA and RNA, 25 U/ mL of Benzonase[®] nuclease (Novagen, #70746-3) was added before ultracentrifugation at 142,400 x g for one hour at 4°C. Supernatant was recovered and loaded on a 5 mL Histrap[™] column HP (GE Healthcare, 17-5248-02) preequilibrated in buffer A (20 mM Tris pH 8, 500 mM NaCl, 10% Glycerol, 10 mM Imidazole). The column was washed with buffer A until baseline return to zero. Bound proteins were first eluted with 4 column-volumes of buffer A + 30 mM Imidazole then 4 column-volumes of buffer A + 70 mM Imidazole to remove unspecific binding and finally with a 4-column-volume linear gradient buffer A + 70 mM Imidazole to 100 % buffer B (20 mM Tris pH 8, 500 mM NaCl, 10% Glycerol, 0.5 M Imidazole). Fractions containing UPPS, as determined by SDS-PAGE analysis, were pooled giving 90 mg of 85% pure target protein (yield of affinity chromatography: 225 mg/L). To remove the H7 tag, 20 mg of the pool were then incubated overnight at room temperature with 75 units of AcTev™ protease (Invitrogen, #12575-015) per milligram of UPPS protein. Sample was ultracentrifuged at 142,400 x g for one hour at 4°C before being loaded on a 5 mL Histrap™ column HP (GE Healthcare, 17-5248-02). 20 mg of UPPS were recovered into flow through and wash fractions and concentrated 2.5 times using Amicon®Ultra centrifugal filter 10K (Millipore, UFC 901024) giving 10 mL at 1.9 mg/mL. The solution was ultracentrifuged at 142,400 x g for one hour at 4°C and submitted to size exclusion chromatography on a HRX 16/20 Superdex 200, 184 mL (GE Healthcare) running at 2 mL/ min with GF buffer (Tris HCl pH 8, 250 mM NaCl, 1 mM MgCl₂, 0.01% Triton X-100). Fractions containing UPPS, as determined by SDS-PAGE analysis, were pooled and concentrated using Amicon®Ultra centrifugal filter 10K (Millipore, UFC 901024) giving 10 mg of 95% pure target protein. (Final yield: 50 mg/L). Five µl of a dilution series of compound, starting from 180 µM highest concentration, 1/3 dilution, was added to the wells of a 96 well plate. Purified UPPS enzyme, without tags, was diluted to 0.002µg/ml in a buffer containing 100mM Tris-HCl pH 7.3, 50mM KCl, 1mM MgCl₂, 0,01% Triton-x100 and 20µg/ml BSA and 15µl thereof was added to the compound dilutions. The reaction was started by the addition of 10µl substrate in the same buffer, containing 45µM IPP (Sigma Aldrich, I0503), 1.5µM FPP (Sigma Aldrich, F6892) and 2U/mI E.coli inorganic pyrophosphatase (Sigma Aldrich, I5907). The mixture was incubated at 37°C for 30 minutes and terminated by the addition of 30μ I Biomol Green Reagent (Enzo Life Science). After 60 minutes, the inorganic phosphate generated in the reaction was detected by measurement absorbance at 615 nm. Data were converted to percent inhibition with respect to positive and negative controls and IC₅₀ values calculated using GraphPrismTM software.

Bacterial cell membrane depolarization; To measure the effect of compounds on membrane potential i n *S. aureus* a method based on the cationic dye 3,3'-Diethyloxacarbocyanine iodide, DiOC2(3) was us ed. A rapid microtiter plate assay for measuring the effect of compounds on S. aureus membrane potential.^[S-5a]

Red blood cell lysis; Freshly isolated erythrocytes were resuspended to obtain a 2% erythrocyte suspension (1/50 dilution) in PBS. 2 µl of compound diluted to give the appropriate test concentration was added to 198 µl of the erythrocyte suspension in a V-bottom microtitre plate. This was incubated at 37C for 1 hour with shaking at 200rpm. The plate was then centrifuged at 600 rpm for 10 minutes and the supernatant collected. 100uL was transferred to a flat bottom microtitre plate and the OD read at 415nm. The % haemolysis elicited by the test compound was calculated compared to a positive control using Triton detergent.

MIC determination (bacteria); MICs were determined based on Clinical and Laboratory Standards Institute (CLSI) methodology^[S-5b] by a 2-fold broth dilution technique in Mueller Hinton (pH7.4 Biorad). For *S. pneumoniae*, the medium was supplemented with 2.5% laked horse blood. For *H. influenzae*, the medium was haemophilus test medium (H.T.M.). Overnight cultures were diluted to obtain the final inoculum of 105 cfu/well. Incubation was 37°C overnight in ambient air. The MIC was defined as the lowest concentration which inhibited all visual growth and was expressed in μ g/ml. For each bacterial species, all of the molecules were tested in the same experiment in order to give a head-to-head comparison.

MIC determination (*Candida albicans***)**; MICs were determined for the antifungus by microdilution methods using RPMI 1640 medium buffered with morpholinopropanesulfonic acid (MOPS) and supplemented with L-glutamine as described by CLSI procedures (M27-A method).^[S-5c] After incubation for 24-48 hours at 35°C, the lowest concentration of drug which produced 80% reduction in visible growth compared with control was considered as the MIC.

Cytotoxicity test; Cytotoxicity in Hek293 and PBMC cell cultures, was analysed by ATP content of the cells using ATP-lite (luminescence readout) after 24 hours of incubation of the cells with the compounds. Three concentrations are tested (90.9, 30.3 and 10.1 μ M) and results are expressed as the lowest concentration leading to 50% cell viability (LD₅₀)

Solubility assay; Starting from a 10mM stock solution of compound in DMSO, a dose-response in DMSO was made by using ½ dilutions: 10, 5, 2.5, 1.25 and 0.63 mM. This dose-response in DMSO was further diluted 1/32.5 in 0.1M phosphate buffer pH 7.4 or 0.1M citrate buffer pH 3.0. This was done by adding 4µl of compound to 130µl buffer. Final compound concentrations are 300, 150, 75, 37.5 and 18.75 µM. The final DMSO concentration was 3%. The assay plates were sealed and incubated for 1 hour at 37°C while shaking at 230 rpm. The plates were then scanned under a white light microscope, yielding individual pictures of the precipitate per concentration. The precipitate was analyzed by image analysis software from SISNCOM. The

first concentration at which the compound appears completely dissolved is the concentration reported. Solubility values are reported in μ M and μ g/ml.

Plasma protein binding assay; A 10 mM stock solution of compound in DMSO was diluted with a factor 10 in DMSO. This solution was further diluted in freshly thawed human, rat, mouse or dog plasma (BioReclamation INC) with a final concentration of 5 μM and final DMSO concentration of 0.5%. A Pierce Red Device plate with inserts (ThermoScientific, Cat no. 89809) was filled with 450 μL PBS in the buffer chamber and 300 μL of the spiked plasma in the plasma chamber. The plate was incubated for 4 hours at 37°C while shaking at 100 rpm. After incubation, 120 μL of both chambers was transferred to 480 μL methanol in a 96-well round bottom, deep-well plates (Nunc, Cat no. 278743) and sealed with an aluminum foil lid. The samples were mixed and immediately centrifuged 30 min at 1400 rcf at 4°C and the supernatant was transferred to a 96 v-bottom PP plate (Greiner, 651201) for analysis on LC-MS/MS (API2000 from Applied Biosystems, see appendix). Peak area from the compound in the buffer chamber and the plasma chamber were considered to be 100% compound, thus non-specific binding to plastic was skipped. The percentage bound to plasma proteins was derived from these results. Acebutolol and Nicardipine are included in the assay design as low and high binding controls.

2. Synthesis of tetramic acid templates and carboxylic acids

2.1. Synthesis of tetramic acids via Dieckmann cyclisation



(a) RCOH (1.3 eq), Et₃N (1.1 eq), petrol (40-60), relux; (b) mono-alkyl malonate (1.1 eq), DCC (1.1 eq), DMAP (0.05 eq), CH_2Cl_2 , r.t; (c) KtBuO (1.1 eq), dry THF, reflux.

Synthesis and analytical data of tetramic acid templates *ent*-**15A**, **15A**, (\pm)-**15D**, **15K**, *ent*-**16A**, **16A**,**B**,**I** and (\pm)-**16H** have been reported in previous papers.^[S-6]

General procedure for synthesis of oxazolidine (step (a)): To ester hydrochloride (1.0 eq) in petrol was added triethylamine (1.5 eq) and pivaldehyde (1.2 eq). The mixture was heated at reflux for 20 h with continuous removal of water using Dean Stark head then filtered and washed with ether (20 ml). The combined filtrates were concentrated *in vacuo* to give oxazolidine. (see below for compounds (\pm)-A12, (\pm)-A14 and A15)

General procedure for N-acylation of oxazolidine (step (b)): To a solution of oxaolidine (1.0 eq), DCC (1.1 eq) and DMAP (0.05 eq) in DCM at 0 $^{\circ}$ was added ethyl hydrogen malonate (1.05 eq) in DCM. The mixture was stirred at 0 $^{\circ}$ for 15 min and then at room temperature for 4 h. The reaction mixture was filtered, the residue was washed with DCM. The combined filtrates were evaporated *in vacuo* and purified by flash column chromatography to give N-acyl oxazolidine.

General procedure for Dieckmann cyclisation (step (c)): To a solution of N-acyl oxazolidine (1.0 eq) in dry

THF was added KO^tBu (1.1 eq) and solution was heated at reflux for 3 h, cooled to room temperature and partitioned between ether and water. The aqueous layer was acidified with 2M HCl and extracted with ethyl acetate. The combined ethyl acetate extracts were washed with brine, dried over MgSO₄ and evaporated *in vacuo*. The residue was purified by flash column chromatography giving tetramic acid and 3-ester tetramic acid.

2.1.1. Synthesis of 16C

2.1.1.1. Synthesis of A3 and A5

A3; Yield; 74 % (oil); ¹**H NMR** (400 MHz, CDCl₃); 4.30-4.22 (m, 3H, C2 and C11), 4.09-3.94 (m, 1H, C5), 3.91-3.81 (m, 1H, C4), 3.73-3.62 (m, 1H, C4), 3.55 (t, 2H, J = 4.8 Hz, C12), 3.33 (s, 3H, C13), 2.45 (br s, 1H, NH), 0.95 (s, 9H, C9-C11 *cis* or *trans*), 7 4.8 Hz, C12), 3.33 (s, 3H, C13), 2.45 (br s, 1H, NH), 0.95 (s, 9H, C9-C11 *cis* or *trans*), 0.87 (s, 9H, C9-C11 *cis* or *trans*). ¹³**C NMR** (100 MHz, CDCl₃); 172.6 and 172.5, (C10), 99.9 and 99.2 (C2), 70.2 and 70.1 (C4), 68.9 and 68.3 (C12), 64.3 and 64.1 (C11), 59.5 and 58.9 (C13) 34.6 and 33.1 (C6), 25.2 and 24.8 (C9-C11). **MS** (ES⁺); 232.17 (M+H⁺); **HRMS** (M+Na⁺); calculated for

 $C_{11}H_2NNaO_4$; 254.1363; found; 254.1370.

A5; Yield; 78 % (oil); ¹**H NMR** (400 MHz, CDCl₃, mixture of conformers; major A and minor B); 5.21 (s, 1H, C2 B), 5.18 (s, 1H, C2 A), 4.64 (d, 1H, J = 5.3 Hz, C5 B), 4.41 (d, 1H, J = 8.3 Hz, C5 A), 4.26-4.20 (m, 1H, C4), 4.19-4.12 (m, 2H, C11), 4.11-4.02 (m, 2H, C17), 3.96-3.89 (m, 1H, C4), 3.56-3.39 (m, 4H, C12 and C15), 3.23 (s, 3H, C13), 1.15 (t, 3H, J = 6.7 Hz, C18), 0.85 (s, 9H, C7-C9 B), 0.78 (s, 9H, C7-C9 A). ¹³C NMR (100 MHz, CDCl₃); 169.4 (C=O), 167.5 (C=O), 167.3 (C=O), 96.6 (C2), 69.8 (C12), 67.7 (C11), 64.4 (C4), 61.4 (C17), 58.7 (C13), 42.8 (C15), 37.3 (C6), 25.5 (C7-C9), 13.9 (C18). MS (ES⁺); 346.21 (M+H⁺); HRMS (M+Na⁺); calculated for C₁₆H₂₇NNaO₇; 368.1680; found; 368.1683.

2.1.1.2. Synthesis of 16C



Yield: 47 %; M.P.; 107 °C; ¹H NMR (400 MHz, CDCl₃); 5.04 (s, 1H, C7), 4.75 (d, 1H, J = 8.8 Hz, C6), 4.39-4.25 (m, 2H, C13), 3.72 (d, 1H, J = 21.5 Hz, C3), 3.65 (d, 1H, J = 8.8 Hz, C6), 3.58-3.54 (m, 2H, C14), 3.00 (s, 3H, C15), 3.14 (d, 1H, J = 21.5 Hz, C3), 0.87 (s, 9H, C9-C11). ¹³C NMR (100 MHz, CDCl₃); 198.2 (C4), 172.7 (C2),

166.3 (C12), 98.2 (C7), 80.6 (C5), 69.9 (C6), 67.8 (C14), 65.7 (C13), 58.8 (C15), 44.8 (C3), 35.6 (C8), 24.6 (C9-C11). **MS** (ES⁺); 300.16 (M+H); **HRMS** (M+Na); calculated for C₁₄H₂₁NNaO₆; 322.1261; found; 322.1270.

2.1.2. Synthesis of 15C and 16D

13

2.1.2.1. Synthesis of A4 and A6

A4; Yield; 83 % (oil); ¹H NMR (400 MHz, CDCl₃); 4.33 (d, 1H, J = 7.6 H, C2 *trans*), 4.27-

$$\begin{array}{c}
10 \\
10 \\
7 \\
6 \\
9
\end{array}$$

4.21 (m, 1H, C2 *cis*), 4.16 (q, 2H, *J* = 7.3 Hz, C12), 3.80-3.68 (m, 1H, C4), 3.38 (brs, 1H, C5 *cis*), 3.26 (t, 1H, *J* = 7.7 Hz, C5 *trans*), 2.59 (brs, NH), 1.36-1.17 (m, 6H, C10 and C13), 0.92 (d, 9H, *J* = 7.7 Hz, C7-C9 *cis*), 0.84 (d, 9H, *J* = 7.8 Hz, C7-C9 *trans*); ¹³**C NMR** (400 MHz, CDCl₃); 172.0 (C11 *trans*), 171.4 (C11 *cis*), 98.7 (C2 *trans*), 98.1 (C2 *cis*), 76.7 (C4 *trans*), 76.3 (C4 *cis*), 67.1 (C5 *cis*), 65.7 (C5 *trans*), 61.3 (C12 *cis*), 61.2 (C12 *trans*), 34.7 (C6 *trans*), 33.5 (C6 *cis*), 25.1 (C7-C9 *cis*), 24.7 (C7-C9 *trans*), 19.8 (C13 *cis*), 18.7 (C13 *trans*), 14.1 (C10). **MS** (ES⁺); 216.17 (M+H), 238.15 (M+Na); **HRMS** (M+Na); calculated for C₁₁H₂₁NNaO₃ 238.1414; found 238.1421.



A6; Yield; 72 % (oil); ¹**H NMR** (400 MHz, CDCl₃); 5.42 (s, 1H, C2), 4.29-4.14 (m, 6H, C4, C5, C12 and C17), 3.55 (d, 1H, J = 15.2 Hz, C15), 3.42 (d, 1H, J = 15.2 Hz, C15), 1.36-1.23 (m, 9H, C10, C13 and C18), 0.90 (s, 9H, C7-C9). ¹³C NMR (400 MHz, CDCl₃); 169.4 (C=O), 167.3 (C=O), 167.2 (C=O), 96.2 (C2), 76.2 (C4),

65.5 (C5), 61.6 (C12 and C17), 42.7 (C15), 37.8 (C6), 25.8 (C7-C9), 20.2 (C13 and C18), 14.0 (C10). **MS** (ES^+); 352.18 (M+Na); **HRMS** (M+Na); calculated for C₁₆H₂₇NNaO₆; 352.1731; found 352.1724.

2.1.2.2. Synthesis of **15C** and **16D**



15C; Yield: 23 %; M.P.; 113 °C; ¹H NMR (400 MHz, CDCl₃); 4.82 (s, 1H, C7), 4.37 (q, 2H, J = 7.1 Hz, C14), 3.91-3.86 (m, 1H, C5), 3.64 (dq, 1H, $J_1 = 8.5$ Hz, $J_2 = 6.1$ Hz, C6), 1.45 (d, 3H, J = 6.1, C12), 1.38 (t, 3H, J = 7.1 Hz, C15), 0.95 (s, 9H, C9-C11). ¹³C NMR (125 MHz, CDCl₃); 185.6 (C4), 172.9 (C2), 167.3 (C13), 95.0 (C7), 83.7 (C3), 75.9 (C5), 67.4 (C6), 61.6 (C14), 35.6 (C8), 24.6 (C9-C11), 17.2 (C12), 14.1 (C15). **MS** (ES⁺);

306.16 (M+Na); **HRMS** (M+Na); calculated for C₁₄H₂₁N₂NaO₅; 306.1312; found; 306.1316.



16D; Yield: 56 %; M.P.; 98 °C; ¹H NMR (400 MHz, CDCl₃); 5.10 (s, 1H, C7), 5.06 (q, 1H, J = 6.7 Hz, C6), 4.24 (q, 2H, J = 7.1 Hz, C14), 3.62 (d, 1H, J = 21.7, C3), 3.12 (d, 1H, J = 21.7, C3), 1.28 (t, 3H, J = 7.1 Hz, C15), 1.03 (d, 3H, J = 6.7 Hz, C12), 0.89 (s, 9H, C9-C11). ¹³C NMR (100 MHz, CDCl₃); 199.6 (C4), 172.9 (C2), 166.1 (C13), 95.8 (C7), 83.7

(C5), 74.9 (C6), 63.0 (C14), 45.1 (C3), 35.4 (C8), 24.7 (C9-C11), 15.1 (C12), 13.9 (C15). **MS** (ES⁺); 306.15 (M+Na); **HRMS** (M+Na); calculated for $C_{14}H_{21}N_2NaO_5$; 306.1312; found; 306.1316.

2.1.3. Synthesis of 15B and 16E

2.1.3.1. Synthesis of A8 and A9



A8; Yield; 86 % (oil); ¹**H NMR** (400 MHz, CDCl₃); 4.51 (s, 1H, C2 *trans*), 4.44 (d, 1H, J = 5.9 Hz, C2 cis), 4.12 (*t*, 1H, J = 5.9 Hz, C5 *trans*), 3.78-3.73 (m, 1H, C5 *cis*), 3.76 (s, 3H, C11 *cis*), 3.73 (s, 3H, C11 *trans*), 3.24 (dd, 1H, $J_1 = 10.2$ Hz, $J_2 = 6.7$ Hz, C4 *cis*), 3.10 (dd, 1H, $J_1 = 10.6$ Hz, $J_2 = 6.3$ Hz, C4 *trans*), 3.00 (dd, 1H, $J_1 = 10.6$ Hz, $J_2 = 5.7$ Hz, C4 *trans*), 2.66 (t, 1H, J = 5.9 Hz, C5 Hz, C4 *trans*), 2.66 (t, 1H, J = 5.9 Hz, C4 *trans*), 2.66 (t, 1H, J = 5.9 Hz, C5 Hz, C4 *trans*), 2.66 (t, 1H, J = 5.9 Hz, C5 Hz, C4 *trans*), 2.66 (t, 1H, J = 5.9 Hz, C5 Hz, C4 *trans*), 2.66 (t, 1H, J = 5.9 Hz, C5 Hz, C4 *trans*), 2.66 (t, 1H, J = 5.9 Hz, C5 Hz, C4 *trans*), 2.66 (t, 1H, J = 5.9 Hz, C5 Hz, C4 *trans*), 2.66 (t, 1H, J = 5.9 Hz, C5 Hz, C4 *trans*), 2.66 (t, 1H, J = 5.9 Hz, C4 *trans*), 2.66 (t, 1

10.0 Hz, C4 *cis*), 2.40 (brs, 1H, NH *trans*), 2.18 (t, 1H, J = 12.8 Hz, NH *cis*), 1.05 (s, 9H, C7-C9 *cis*), 0.96 (s, 9H, C7-C9 *trans*). ¹³**C** NMR (100 MHz, CDCl₃); 172.4 (C10 *trans*), 171.8 (C10 *cis*), 81.8 (C2 *cis*), 79.8 (C2 *trans*), 65.4 (C5 *cis*), 65.0 (C5 *trans*), 52.4 (C11), 37.4 (C4 *cis*), 37.0 (C4 *trans*), 35.9 (C6 *trans*), 33.9 (C6 *cis*), 26.9 (C7-C9 *cis*), 26.5 (C7-C9 *trans*). **MS** (ES⁺); 226.10 (M+Na); **HRMS** (M+Na); calculated for C₉H₁₇NNaO₂S; 226.0872; found; 226.0879.

A9; Yield; 83 % (oil); ¹**H NMR** (400 MHz, CDCl₃, 1.5:1 mixture of conformers; major A and minor B); 5.46 (s, 1H, C2), 5.37 (s, 1H, C2 B), 5.04-4.97 (m, 1H, C5 B), 4.92- **A9**; Yield; 83 % (oil); ¹**H NMR** (400 MHz, CDCl₃, 1.5:1 mixture of conformers; major A and minor B); 5.46 (s, 1H, C2), 5.37 (s, 1H, C2 B), 5.04-4.97 (m, 1H, C5 B), 4.92- **A9 A9 A9 A9 A9 A11**, C5 A), 4.12-4.07 (m, 2H, C15), 3.77-3.63 (m, 2H, C13 and C4 B), 3.53-**A9 A11** (m, 1H, C4 A), 3.37-3.18 (m, 1H, C4), 1.21 (t, 3H, J = 7.2 Hz, C16), 0.92 (9H, s, C7-C9 B), 0.91 (9H, s, C7-C9 A). ¹³**C NMR** (100 MHz, CDCl₃); 170.8 (C=O A), 170.5 (C=O B), 166.9 (C=O), 166.7 (C=O), 74.8 (C2 B), 73.1 (C2 A), 65.3 (C5 B), 64.1 (C5 A), 61.5 (C15 A), 61.4 (C15 B), 52.9 (C11 A), 52.4 (C11 B), 42.3 (C13 A), 41.0 (C13 B), 40.0 (C6 B), 39.3 (C6 A), 34.1 (C4 A), 32.8 (C4 B), 27.1 (C7-C9 A), 26.8 (C7-C9 B), 14.0 (C16). **MS** (ES⁺); 318.16 (M+H); **HRMS** (M+Na) calculated for C₁₄H₂₃NNaO₅S 340.1189, found 340.1198.

2.1.3.2. Synthesis of 15B and 16E



15B; Yield: 27 %; M.P.; 117 °C; $[\alpha]_D^{22} = -106$ (c = 0.025 in MeOH); ¹H NMR (400 MHz, CDCl₃); 4.98 (s, 1H, C7), 4.56 (dd, 1H, $J_1 = 9.5$ Hz, $J_2 = 6.4$ Hz, C5), 4.34 (q, 2H, J = 6.9 Hz, C13), 3.86 (s, 1H, C7), 3.14 (dd, 1H, $J_1 = 10.1$ Hz, $J_2 = 6.8$ Hz, C5), 2.69 (t, 1H, J = 10.1 Hz, C4), 1.34 (t, 3H, J = 6.9 Hz, C14), 0.96 (s, 9H, C9-C11). **MS** (ES⁺); 308.11 (M+Na); **HRMS** (M+Na); calculated for C₁₃H₁₉NNaO₄S; 308.0927; found; 308.0932.



16E; Yield: 57 %; M.P.; 109 °C; $[\alpha]_D^{22} = +112$ (c = 0.017 in MeOH); ¹H NMR (400 MHz, CDCl₃); 5.78 (s, 1H, C7), 3.79 (s, 3H, C13), 3.74 (d, 1H, *J* = 11.4 Hz, C6), 3.58 (d, 1H, *J* = 21.5 Hz, C3), 3.12 (d, 1H, *J* = 21.5 Hz, C3), 3.01 (d, 1H, *J* = 11.4 Hz, C6), 0.92 (s, 9H, C9-C11). ¹³C NMR (100 MHz, CDCl₃); 199.4 (C4), 170.7 (C2), 167.1 (C12), 84.9 (C5), 73.6 (C7),

53.8 (C13), 42.8 (C3), 37.1 (C8), 33.7 (C6), 26.4 (C9-C11). **MS** (ES⁺); 272.12 (M+H); **HRMS** (M+H); calculated for $C_{12}H_{18}NO_4S$; 272.0951; found; 272.0954.

2.1.4. Synthesis of (±)-15E and (±)-15E-1

2.1.4.1. Synthesis of (±)-A12 and (±)-A13

(\pm)-**A12;** To α -methyl serine methylester hydrochloride (\pm)-A10 (3.0 g, 17.6 mmol) in toluene (80 ml) was added triethylamine (3.6 ml, 26.4 mmol) and 2,2-dimethyl-4-pentenal (2.96 g, 24.6 mmol). The mixture was heated at reflux, with continuous removal of water using Dean Stark, for 20 h then filtered and washed with ether (25 ml). The combined filtrates were concentrated *in vacuo* and residue was purified by flash column

chromatography to give mixture of the *cis* and *trans* oxazolidine in 3:2 ratio (1.56 g, 39 % yield) as a colourless oil.

¹⁶ ¹⁷ ¹⁷ ¹⁹ ¹⁰ ¹¹ ¹¹



(±)-A13; Yield; 56 % (oil); ¹H NMR (400 MHz, CDCl₃, mixture of rotamers, a; major, b; minor, a: b = 3: 1) 5.88-5.78 (m, 1H, C14), 5.65 (brs, 1H, C2a), 5.29 (brs, 1H, C2b), 5.05-5.01 (m, 2H, C15), 4.42 (d, 1H, J = 8.5 Hz, C4), 4.18 (q, 2H, J = 6.9 Hz, C19), 4.13-4.02 (m, 2H, C4b), 3.84-3.69 (m, 4H, C4a and C9), 3.49 (d, 1H, J = 15.4 Hz, C17a), 3.38 (d, 1H, J = 15.4 Hz, C17a), 3.22 (brs, 2H, C17b), 2.25-2.00 (m, 2H, C13),

1.70 (s, 3H, C6), 1.26 (t, 3H, *J* = 7.2 Hz, C20), 0.93 (brs, 6H, C11 and C12). ¹³**C NMR** (100 MHz, mixture of rotamers, a; major, b; minor) 172.1 (C7), 167.5 (C12), 166.9 (C10), 134.6 (C14), 117.7 (C15), 98.2 (C2a), 97.1 (C2b), 78.7 (C4), 65.9 (C5), 61.5 (C19b), 61.4 (C19a), 53.5 (C9a), 53.0 (C9b), 43.6 (C17a), 43.2 (C17b), 41.8 (C13), 30.6 (C10), 23.6 (C11a), 23.3 (C11b), 22.9 (C6), 21.6 (C12), 14.0 (C20). **MS** (ES⁺); 364.17 (M+Na); **HRMS** (M+Na); calculated for C₁₇H₂₇NNaO₆; 364.1731; found; 364.1722.

2.1.4.2. Synthesis of (\pm)-15E and (\pm)-15E-1



(±)-15E; Yield; 61 %; m.p.; 198 °C; ¹H NMR (400 MHz, CDCl₃) 5.86-5.76 (m, 1H, C13), 5.04-4.98 (m, 2H, C14), 4.68 (s,1 H, C8), 4.32 (q, 2H, J = 6.9 Hz, C16), 3.86 (d, 1H, J = 8.3 Hz, C7), 3.38 (d, 1H, J = 8.3 Hz, C7), 2.09 (d, 2H, J = 7.3 Hz, C12), 1.54 (s, 3H, C6), 1.33 (t, 3H, J = 7.1 Hz, C17), 0.93 (s, 3H, C10), 0.90 (s,

3H, C11). ¹³**C NMR** (100 MHz, CDCl₃): 189.3 (C4), 167.3 (C2 and C15), 134.6 (C13), 117.5 (C14), 97.0 (C8), 72.1 (C7), 61.6 (C16), 42.5 (C12), 37.5 (C9), 22.5 (C10), 22.2 (C11), 20.8 (C6), 14.1 (C17). **MS** (ES⁺); 310.17 (M+H), 332.15 (M+Na); **HRMS** (M+Na); calculated for C₁₆H₂₃NNaO₅; 332.1468; found; 332.1473.



(±)-15E-1; Yield; 10 %; m.p.; 143 °C; ¹H NMR (400 MHz, CDCl₃) 5.92-5.82 (m, 1H, C13), 5.13-5.00 (m, 3H, C8 and C14), 3.86 (d, 1H, J = 8.3 Hz, C7), 3.56 (d, 1H, J = 21.5 Hz, C3), 3.55 (d, 1H, J = 8.3 Hz, C7), 3.14 (d, 1H, J = 21.5 Hz, C3), 2.15-2.12 (m,

2H, C12), 1.58 (s, 3H, C6), 0.99 (s, 3H, C10), 0.96 (s, 3H, C11). ¹³**C NMR** (100 MHz, CDCl₃): 206.1 (C4), 173.0 (C2), 134.3 (C13), 117.9 (C14), 97.9 (C8), 75.1 (C5), 71.4 (C7), 44.7 (C3), 42.6 (C12), 37.8 (C9), 22.7 (CH₃), 22.3 (CH₃), 22.1 (CH₃). **MS** (ES⁺); 238.14 (M+H), 260.13 (M+Na); **HRMS** (M+Na); calculated for C₁₃H₁₉NNaO₃; 260.1257; found; 260.1256.

2.1.5. Synthesis of (\pm)-15F

2.1.5.1. Synthesis of (±)-A14, (±)-A14-1, (±)-A14-2 and (±)-A16

(±)-A14, (±)-A14-1 and (±)-A14-2; To a solution of α -methyl serine methyl ester hydrochloride (±)-A10 (1.0 g, 5.92 mmol) in toluene (10 ml) at 0 °C was added NaOAc (0.58 g, 6.90 mmol) and trifluoroacetaldehyde ethyl hemiacetal (1.37 ml, 11.82 mmol). The resulting mixture was stirred at room temperature for 30 mins and warmed to 90 °C for 2h. Toluene (30 ml) was then added to reaction mixture which was warmed to reflux using a Dean Stark apparatus for 10 h. The reaction mixture was then cooled to 0 °C with an ice bath and filtered and toluene was evaporated. Purification by flash column chromatography gave (±)-A14 (0.15 g, 12 %, oil), (±)-A14-1 (0.23 g, 18 %, oil) and (±)-A14-2 (0.56 g, 34 %, M.P. 132 °O.

(±)-**A14:** ¹**H NMR** (400 MHz, CDCl₃) 4.99 (q, 1H, $J_{H-F} = 5.5$ Hz, C2), 4.28 (dd, 1H, $J_1 = 8.3$ Hz, $J_2 = 1.3$ Hz, C4), 3.80 (dd, 1H, $J_1 = 8.3$ Hz, $J_2 = 0.4$ Hz, C4), 3.76 (s, 3H, C8), 3.60 (brs, 1H, NH), 1.44 (s, 3H, C6). ¹³**C NMR** (100 MHz, CDCl₃): 175.6 (C7), 123.3 (q, $J_{C-F} = 282$ Hz, C9), 87.0 (q, $J_{C-F} = 34.1$ Hz, C2), 75.6 (C4), 65.6 (C5), 53.0 (C8), 22.4 (C6). **MS** (ES⁺); 214.07 (M+H); **HRMS** (M+H); calculated for C₇H₁₁F₃NO₃; 214.0686; found; 214.0689.



(±)-A14-1: ¹H NMR (400 MHz, CDCl₃) 4.97 (q, 1H, $J_{H-F} = 5.1$ Hz, C2), 4.35 (d, 1H, J = 8.3 Hz, C4), 3.77 (s, 3H, C8), 3.70 (d, 1H, J = 8.3 Hz, C4), 1.51 (s, 3H, C6). ¹³C NMR (100 MHz, CDCl₃): 173.6 (C7), 122.9 (q, $J_{C-F} = 281$ Hz, C9), 87.6 (q, $J_{C-F} = 34.1$ Hz, C2), 75.1 (C4), 65.4 (C5), 52.9 (C8), 23.6 (C6). **MS** (ES⁺); 214.07 (M+H); **HRMS** (M+H); calculated for $C_7H_{11}F_3NO_3$; 214.0686; found; 214.0687.



(±)-A14-2: ¹H NMR (400 MHz, CDCl₃) 5.25 (q, 1H, J_{H-F} = 4.6 Hz, C8), 5.03 (q, 1H, J_{H-F} = 5.8 Hz, C2), 4.45 (d, 1H, J = 22.0 Hz, C4), 4.02 (d, 1H, J = 22.0 Hz, C4), 1.60 (s, 3H, C6). ¹³C NMR (100 MHz, CDCl₃): 173.9 (C7), 126.2-119.3 (m, C9 and C10), 96.3 (q, J_{C-F} = 35.7 Hz, C2), 91.0 (q, J_{C-F} = 35.7 Hz, C8), 76.6 (C4), 67.4 (C5), 20.8 (C2). MS (ES⁺); 280.04

(M+H); **HRMS** (M+H); calculated for $C_8H_8F_6NO_3$; 280.0403; found; 280.0407.



(±)-**A16;** Yield; 36 % (oil); ¹**H NMR** (400 MHz, CDCl₃, mixture of rotamers, a; major, b; minor, a: b = 3: 1) 5.62 (brs, 1H, C2a), 4.95 (q, 1H, J_{H-F} = 5.1 Hz, C2b), 4.47-4.27 (m, 1H, C4), 4.18 (q, 2H, J = 7.1 Hz, C14), 4.07 (d, 1H, J = 8.3 Hz, C4), 3.75 (s, 3H, C9), 3.49 (d, 1H, J = 16.0 Hz, C12), 3.38 (d, 1H, J = 16.0 Hz, C12), 1.72 (s, 3H, C6), 1.49 (s, 3H, C6, minor), 1.26 (t, 3H, J = 7.2 Hz, C15). ¹³**C** NMR (100 MHz, CDCl₃): 173.6 (C7), 170.2 (C13), 163.4 (C11), 123.3 (q, $J_{C-F} = 282$ Hz, C10), 87.6 (q, $J_{C-F} = 34.1$ Hz, C2), 75.0 (C4), 65.4 (C5), 61.8 (C14), 52.8 (C9), 42.3 (C12), 23.5 (C6), 13.9 (C15). **MS** (ES⁺); 350.09 (M+H); **HRMS** (M+Na); calculated for C₁₂H₁₆F₃NNaO₆; 350.0822; found; 350.0814.

2.1.5.2. Synthesis of (\pm) -15F



Yield; 65 % (oil); ¹H NMR (400 MHz, CD₃OD); 5.41 (q, 1H, J = 5.4 Hz, C8), 4.31-4.23 (m, 2H, C11), 3.97 (d, 1H, J = 8.3 Hz, C7), 3.77 (d, 1H, J = 8.3 Hz, C7), 1.52 (s, 3H, C6), 1.30 (t, 3H, J = 7.1 Hz, C12). ¹³C NMR (125 MHz, CD₃OD); 193.7 (C4), 178.5 (C2), 166.6 (C10), 123.3 (q, $J_{C-F} = 279$ Hz, C9), 94.0 (C3), 86.5 (q, $J_{C-F} = 36.0$

Hz, C8), 74.5 (C7), 70.5 (C5), 60.9 (C11), 21.4 (C6), 14.8 (C12). **MS** (ES⁺); 296.07 (M+H); **HRMS** (M+Na); calculated for $C_{11}H_{12}F_3NNaO_5$; 318.0560; found; 318.0546.

2.1.6. Synthesis of 15G

2.1.6.1. Synthesis of A15 and A17

A15; To serine ethyl ester salt **A11** (1.0 g, 5.9 mmol) was added NaOAc and toluene (3 ml). Then trifluoroacetone (1.05 ml, 11.8 mmol) was added and resulting mixture was stirred at room temperature for 6h. Then more toluene (40 ml) was added and resulting solution was heated to reflux for 16 h. The mixture was filtered, evaporated and purified by flash column chromatography to give oxazolidine in 32% yield (0.43 g, oil).



¹**H NMR** (400 MHz, CDCl₃); 4.33-4.27 (m, 1H, C4), 4.24 (q, 2H, J = 7.1 Hz, C7), 4.07 (q, 1H, J = 7.1 Hz, C5), 3.92-3.85 (m, 1H, C4), 2.97 (d, 1H, J = 6.3 Hz, NH), 1.58 (s, 3H, C9), 1.29 (t, 3H, J = 7.1 Hz, C12). ¹³**C NMR** (100 MHz, CDCl₃); 171.9 (C6), 124.6 (q, $J_{C-F} = 285$ Hz, C10), 94.7 (q, $J_{C-F} = 30.2$ Hz, C2), 70.3 (C4), 62.1 (C7), 59.7 (C5), 19.8 (C9), 14.1 (C8). **MS** (ES⁺); 250.05 (M+Na); **HRMS** (M+Na); calculated for C₈H₁₂F₃NNaO₃; 250.0661; found;

250.0663.



A17; Yield; 60 % (oil); ¹**H NMR** (400 MHz, CDCl₃, mixture of rotamers, a; major, b; minor, a: b = 5: 1); 4.76 (d, 1H, *J* = 6.6 Hz, C5b), 4.68 (d, 1H, *J* = 6.6 Hz, C5a), 4.43-4.35 (m, 1H, C4a), 4.30-4.16 (m, 4H, C7 and C14 and 1H of C4b), 3.55 (s, 2H, C12b), 3.31 (s, 2H, C12a), 1.90 (s, 3H, C9b), 1.87 (s, 3H, C9a), 1.31 (t, 3H, *J* = 7.1 Hz, CH₃),

1.25 (t, 3H, J = 7.1 Hz, CH₃). ¹³C NMR (100 MHz, CDCl₃,major rotamer): 169.9 (C=O), 166.3 (C=O), 163.9 (C=O), 123.8 (q, $J_{C-F} = 290$ Hz, C10), 94.2 (q, $J_{C-F} = 31.8$ Hz, C2), 69.3 (C5), 62.8 (CH₂), 61.7 (CH₂), 60.1 (CH₂), 43.9 (C2), 18.5 (C9), 14.0 (CH₃), 13.9 (CH₃). **MS** (ES⁺); 342.12 (M+H), 364.10 (M+Na); **HRMS** (M+Na); calculated for C₁₃H₁₈F₃NNaO₆; 364.0978; found; 364.0973.

2.1.6.2. Synthesis of 15G



Yield; 44 % (oil); ¹H NMR (400 MHz, DMSO): 4.64 (t, 1H, J = 7.7 Hz, C6), 4.29 (t, 1H, J = 7.7 Hz, C5), 4.18-4.07 (m, 2H, C11), 3.81-3.72 (m, 1H, C6), 1.68 (s, 3H, C8), 1.20 (t, 3H, J = 7.1 Hz, C12). ¹³C NMR (100 MHz, CDCl₃); 185.5 (C4), 167.4 (C=O), 166.8 (C=O), 123.2 (q, $J_{C-F} = 284$ Hz, C9), 100.0 (C3), 91.8 (q, $J_{C-F} = 32.6$

Hz, C7), 66.3 (C6), 62.3 (C5), 61.9 (C11), 16.2 (C8), 14.0 (C12). **MS** (ES⁺); 296.07 (M+H), 318.06 (M+Na); **HRMS** (M+Na); calculated for $C_{11}H_{12}F_3NNaO_5$; 318.0560; found; 318.0546.

2.1.7. Synthesis of 15H

2.1.7.1. Synthesis of A19



Yield; 71 % (oil); ¹H NMR (400 MHz, CDCl₃, mixture of rotamers, a; major, b; minor, a: b = 2: 1); 5.10 (dd, 1H, J_1 = 6.9 Hz, J_2 = 3.7 Hz, C5a), 4.91 (dd, 1H, J_1 = 6.1 Hz, J_2 = 1.8 Hz, C5b), 4.76 (d, 1H, J = 9.9 Hz, C2b), 4.63 (d, 1H, J = 8.0 Hz, C2a), 4.57 (d, 1H, J = 9.9 Hz, C2b), 4.24-4.09 (m, 2H, C12), 3.77 (s, 3H,

C8b), 3.73 (s, 3H, C8a), 3.49-3.17 (m, 4H, C4 and C10), 1.30-1.21 (m, 3H, C13). ¹³**C NMR** (100 MHz, CDCI₃, mixture of rotamers, a; major, b; minor); 169.9 (C=O a), 169.8 (C=O b), 166.9 (C=O b), 166.6 (C=O a), 164.5 (C=O b), 164.1 (C=O a), 62.3 (C5b), 61.7 (C5a), 61.3 (C12), 53.2 (C8b), 52.8 (C8a), 48.8 (C2a), 48.6 (C2b), 42.8 (C10b), 42.4 (C10a), 34.3 (C4b), 32.8 (C4a), 14.1 (C13). **MS** (ES⁺); 284.06 (M+Na); **HRMS** (M+Na); calcd for $C_{10}H_{15}N_1Na_1O_5S_1$; 284.0563; found; 284.0562.

2.1.4.2. Synthesis of 15H



Yield; 71 % (light yellow solid) $[\alpha]_D^{22} = -126$ (c = 0.027 in MeOH); ¹H NMR (500 MHz, DMSO, mixture of rotamers, a; major, b; minor, a: b = 3: 1);4.70 (d, 1H, *J* = 9.8 Hz, C7b), 4.76 (d, 1H, *J* = 9.8 Hz, C7a), 4.50 (dd, 1H, *J*₁ = 8.2 Hz, *J*₂ = 5.9 Hz, C5a), 4.41 (dd, 1H, *J*₁ = 8.2 Hz, *J*₂ = 5.4 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, *J* = 7.1 Hz, C9a), 4.01 (d, 1H, *J* = 9.8 Hz, C5b), 4.14 (q, 2H, J = 7.1 Hz, C5b), 4.14 (q

9.8 Hz, C7a), 3.97 (d, 1H, J = 9.8 Hz, C7b), 3.44 (q, 2H, J = 7.2 Hz, C9b), 3.28 (dd, $J_1 = 11.4$ Hz, $J_2 = 8.2$ Hz, C6a), 3.22 (dd, $J_1 = 11.2$ Hz, $J_2 = 8.2$ Hz, C6b), 2.92 (dd, $J_1 = 11.2$ Hz, $J_2 = 5.9$ Hz, C6a), 2.85 (dd, $J_1 = 11.2$ Hz, $J_2 = 5.4$ Hz, C6b), 1.21 (t, 3H, J = 7.1 Hz, C10a), 1.06 (t, 3H, J = 7.1 Hz, C10b). ¹³C NMR (125 MHz, DMSO, mixture of rotamers, a; major, b; minor): 182.2 (C4), 177.4 (C2b), 172.0 (C2a), 161.4 (C8), 97.7 (C3a), 93.7 (C3b), 65.7 (C9b), 64.2 (C9a), 59.2 (C5a), 56.0 (C5b), 46.3 (C7b), 47.0 (C7a), 32.6 (C6a), 31.6 (C6b), 18.5 (C10b), 15.1 (C10a). MS (ES⁻); 228.04 (M-H); HRMS (M+-H); calcd for C₉H₁₀N₁O₄S₁; 228.0336; found; 228.0343.

2.1.8. Synthesis of (\pm)-15I, (\pm)-15I-1 and (\pm)-15I-2

2.1.8.1. Synthesis of A21



Yield; 75 % (oil); ¹**H NMR** (400 MHz, CDCl₃, mixture of rotamer A (major) and B (minor)); 7.39-7.26 (m, 5H, C12-C16), 5.17 (s, 2H, C10 B), 5.15 (s, 2H, C10 A), 4.66 (dd, 1H, $J_1 = 9.5$ Hz, $J_2 = 5.8$ Hz, C2 A), 4.53 (dd, 1H, $J_1 = 9.7$ Hz, $J_2 = 2.3$ Hz, C2 B), 4.45 (td, 1H, $J_1 = 7.8$ Hz, $J_2 = 4.6$ Hz, C5 B), 4.25 (td, 1H, $J_1 = 8.0$ Hz, $J_2 = 5.4$ Hz, C5 A), 3.72 (s, 3H, C20 A), 3.70 (s, 3H, C20 B), 3.51 (d, 1H, J = 15.3 Hz, C18 A), 3.41 (d,

1H, *J* = 15.3 Hz, C18 A), 3.31 (d, 1H, *J* = 15.1 Hz, C18 B), 3.27 (d, 1H, *J* = 15.1 Hz, C18 B), 2.85-2.73 (m, 1H, C4 A), 2.63-2.56 (m, 1H, C4 B), 2.45-2.32 (m, 1H, C3), 2.17-1.99 (m, 1H, C6), 1.90-1.03 (m, 6H, C3, C6-C8). ¹³**C NMR** (100 MHz, CDCl₃); 172.1 (C9 B), 171.9 (C9 A), 167.9 (C17 B), 167.8 (C17 A), 164.8 (C19 A), 164.7 (C19 B), 135.6 (C11 A), 134.9 (C11 B), 128.7 (tert-ArC), 128.5 (tert-ArC), 128.2 (tert-ArC), 67.6 (C10 B), 66.9 (C10 A), 64.8 (C5 B), 64.4 (C5 A), 60.9 (C2 B), 60.7 (C2 A), 52.4 (C20), 44.1 (C4 A), 42.0 (C4 B), 41.5 (C18 A), 41.4 (C18 B), 34.9 (C3 B), 33.7 (C3 A), 33.6 (C8 A), 33.5 (C8 B), 32.1 (C6 B), 31.4 (C6 A), 25.7 (C7 B), 25.3 (C7 A). **MS** (ES⁺); 346.17 (M+H), 368.16 (M+Na); **HRMS** (M+Na); calculated for C₁₉H₂₃NNaO₅; 368.1468; found; 368.1477.

2.1.8.2. Synthesis of (±)-15I, (±)-15I-1 and (±)-15I-2



(±)-**15I;** Yield: 41 %; ¹**H NMR** (400 MHz, CDCI₃); 4.36-4.23 (m, 2H, C5 and C8), 3.87 (s, 3H, C13), 3.05-2.92 (m, 1H, C7), 2.04-1.96 (m, 1H, C9), 1.88-1.81 (m, 2H, C6 and C11), 1.79-1.71 (m, 1H, C9), 1.66-1.58 (m, 3H, C6 and C10), 1.50-1.41 (m, 1H, C11). **MS** (ES⁺); 238.12 (M+H); **HRMS** (M+Na); calculated for $C_{12}H_{15}NNaO_4$; 260.0893; found; 260.0897.



(±)-**15I-1**; Yield: 28 %; M.P.; 134 °C; ¹H NMR (400 MHz, CDCl₃); 7.40-7.28 (m, 5H, C15-C19), 5.22 (s, 2H, C13), 4.62 (dt, 1H, $J_1 = 7.9$ Hz, $J_2 = 4.8$ Hz, C8), 3.47 (d, 1H, J = 21.0 Hz, C3), 2.97 (d, 1H, J = 21.0 Hz, C3), 2.80 (quin. 1H, J = 7.6 Hz, C7), 2.56 (d, 1H, J = 13.7 Hz, C6), 2.05 (dd, 1H, $J_1 = 13.7$ Hz, $J_2 = 9.6$ Hz, C6), 1.94 (dt, 1H, $J_1 = 13.7$ Hz, $J_2 = 9.6$ Hz, CH₂), 1.82-1.60 (m, 1H, CH₂), 1.56-1.43 (m, 1H, CH₂),

1.41-1.29 (m, 2H, CH₂), 1.28-1.17 (m, 1H, CH₂). ¹³**C NMR** (100 MHz, CDCl₃); 200.8 (C4), 169.5 (C2), 168.0 (C12), 134.5 (C14), 128.8 (Ar-C), 128.7 (Ar-C), 128.5, (Ar-C), 82.6 (C5), 68.6 (C13), 62.0 (C8), 44.4 (C3), 43.5 (C7), 36.1 (CH₂), 33.2 (CH₂), 32.5 (CH₂), 25.9 (C10). **MS** (ES⁺); 336.14 (M+Na); **HRMS** (M+Na⁺); calculated for $C_{18}H_{19}NNaO_4$; 336.1206; found; 336.1202.

(±)-**15I-2;** Yield: 11 %; M.P.; 121 °C, ¹**H NMR** (400 MHz, CDCl₃); 4.51-4.64 (m, 1H, C8), 4.23 (dd, 1H, $J_1 = 10.9$ Hz, $J_2 = 6.8$ Hz, C5), 3.30 (d, 1H, J = 21.5 Hz, C3), 3.00 (d, 1H, J = 21.5 Hz, C3), 2.86 (quin. 1H, J = 7.6 Hz, C7), 2.08-1.84 (m, 3H, CH₂), 1.77 (td, 1H, $J_1 = 11.6$ Hz, $J_2 = 8.8$ Hz, CH₂), 1.68-1.51 (m, 3H, CH₂), 1.40 (dq, 1H, $J_1 = 12.9$ Hz, $J_2 = 6.8$ Hz, CH₂). ¹³C NMR (100 MHz, CDCl₃); 206.3 (C4), 169.3 (C2), 69.4 (C5), 60.7 (C8), 44.5 (C3),

44.4 (C7), 34.2 (CH₂), 34.1 (CH₂), 33.7 (CH₂), 26.4 (C10). **MS** (ES⁺); 180.13 (M+H); **HRMS** (M+H); calculated

for C₁₀H₁₄NO₂; 180.1019; found; 180.1021.

2.2. Synthesis of keto tetramic acids 16F,G

General procedure; To a solution of ester tetramic acid (1.0 eq) in dry THF was slowly added alkyllithium (5.0 eq) at -78 $^{\circ}$ C. The solution was stirred at -78 $^{\circ}$ C to room temperature for 3 hours and the reaction was quenched by the cautious addition of water. The mixture was partitioned between ether and water. The aqueous layer was acidified with 2 M HCl and extracted with ether. The combined ether extracts were dried over MgSO₄ and evaporated *in vacuo*. The residue was purified by flash column chromatography giving keto tetramic acid.



16F; Yield; 84 %; M.P. 185 °C; ¹**H NMR** (400 MHz, CDCl₃); 5.08 (s, 1H, C7), 4.81 (d, 1H, J = 9.2 Hz, C6), 3.67 (d, 1H, J = 9.2 Hz, C6), 3.63 (d, 1H, J = 17.6 Hz, C3), 3.18 (d, 1H, J = 17.6 Hz, C3), 2.95 (dq, 1H, $J_1 = 18.8$ Hz, $J_2 = 7.2$ Hz, C13), 2.45 (dq, 1H, $J_1 = 18.8$ Hz, $J_2 = 7.2$ Hz, C13), 2.45 (dq, 1H, $J_1 = 18.8$ Hz, $J_2 = 7.2$ Hz, C13), 1.11 (t, 3H, J = 7.2 Hz, C14), 0.88 (s, 9H, C9-11). ¹³C NMR (100 MHz, CDCl₃); 201.5 (Carbonyl), 199.4 (Carbonyl), 173.2 (C2), 98.7 (C7), 86.7 (C5), 67.4 (C6), 44.7 (C3),

35.4 (C8), 31.9 (C13), 25.0 (C9-11), 7.3 (C14). **MS** (ES⁻); 252.10 (M-H); MS (ES⁺); 276.14 (M+Na); **HRMS** (M+Na); calcd for $C_{13}H_{19}N_1Na_1O_4$; 276.1206; found; 276.1214.



16G; Yield; 96 %; M.P. 168 °C; ¹H NMR (400 MHz, CDCl₃); 5.09 (s, 1H, C7), 4.80 (d, 1H, J = 8.8 Hz, C6), 3.68 (d, 1H, J = 9.2 Hz, C6), 3.63 (d, 1H, J = 21.2 Hz, C3), 3.18 (d, 1H, J = 21.2 Hz, C3), 2.91-2.82 (m, 1H, C13), 2.50-2.41 (m, 1H, C13), 1.68-1.49 (m, 2H, C14), 1.36-1.27 (m, 2H, C15), 0.93-0.89 (m, 12H, C9-11 and C16). ¹³C NMR (100 MHz, CDCl₃); 201.0 (Carbonyl), 199.4 (Carbonyl), 173.1 (C2), 98.7 (C7), 86.9 (C5),

67.5 (C6), 44.8 (C3), 38.4 (C13), 35.5 (C8), 25.2 (C14), 25.0 (C9-11), 22.0 (C15), 13.8 (C16). **MS** (ES⁻); 280.16 (M-H); **HRMS** (M-H); calcd for $C_{15}H_{22}N_1O_4$; 280.1554; found; 280.1560.

2.3. Synthesis of tetramic acid 15J

To the solution of tetramic acid **16B** (400 mg, 1.49 mmol) and DMAP (400 mg, 3.28 mmol) in dichloromethane (30 ml) was added butyl chloroformate (250 mg, 1.78 mmol) under nitrogen atmosphere. After strring the solution overnight, the mixture was washed with acidic water (2 M HCl). The organic layer were dried over MgSO₄ and evaporated *in vacuo*. The residue was purified by flash column chromatography giving tetramic acid **T10** (140 mg, 0.379 mmol, 25 % yield, oil).



¹H NMR (500 MHz, CDCl₃); 4.84 (d, 1H, *J* = 9.0 Hz, C6), 4.72 (s, 1H, C7), 4.32-4.22 (m, 4H, C13 and C16), 3.47 (d, 1H, *J* = 9.0 Hz, C6), 1.75-1.69 (m, 2H, C17), 1.46-1.39 (m, 2H, C18), 1.27 (t, 3H, *J* = 7.5 Hz, C14), 0.92 (t, 3H, *J* = 7.5 Hz, C19), 0.90 (s, 9H, C9-C11). ¹³**C NMR** (125 MHz, CDCl₃); 184.0 (C4), 171.9 (C2), 167.0 (C15), 166.2 (C12), 99.6 (C3), 97.4 (C7), 73.4 (C5), 68.8 (C6), 65.6 (OCH₂), 62.9 (OCH₂), 35.0 (C8), 30.3 (C17), 24.6 (C9-C11), 18.9 (C18), 13.9 (CH₃), 13.6 (CH₃). **MS** (ES⁻); 368.17 (M-H); **HRMS** (M-H); calcd for C₁₈H₂₆N₁O₇; 368.1715; found; 368.1712.

2.4. Synthesis of carboxylic acids

2.4.1. Synthesis of carboxylic acids C1-C3



(a) amine (1.1 eq), triethylamine (1.2 eq), CH₂Cl₂, 0 [°]C-r.t.; (b) LiOH (3.0 eq), H₂O: CH₃OH: THF (2: 1:1), 0 [°]C-r.t.;

General procedure for synthesis of ester compounds (step (a)); To a stirred solution of the corresponding amine (1.1 eq) and triethylamine (1.2 eq) in dichloromethane was slowly added methyl adipoyl chloride **B1** (1.0 eq) under nitrogen atmosphere at 0 $^{\circ}$ C. The reaction mixture was stirred for 3 hours at room temperature. After completion of the reaction, the organic layer was washed with aques HCI. Concentration in *vacuo* followed by flash column chromatography gave the ester compounds.

General procedure for carboxylic acids (step (b)); Lithium hydroxide (3.0 eq) in water was slowly added to the solution of the ester compound (1.0 eq) obtained above in 1:1 mixture of THF and methanol at 0 °C. Then the mixture was stirred for 3 hours at room temperature. After completion of the reaction, THF and methanol were removed in *vacuo* and extracted with dichloromethane and aques HCI (pH \approx 1~2). The organic layer was dried with MgSO₄ and concentrated *in vacuo* to afford crude product. Further purification by precipitation in ethyl acetate and petroleum ether solution gave desired product.

2.4.1.1. Synthesis of ester of C1 and C1



Ester of C1; Yield; 99 % (oil); ¹H NMR (400 MHz, CDCl₃, mixture of rotamers); 3.58 (s, 3H, C19), 3.20 (t, 2H, *J* = 7.2 Hz, rotamer a of C6 and C12), 3.12 (t, 2H, *J* = 7.6 Hz, rotamer b of C6 and C12), 2.26-2.23 (m, 4H, C14 and C17), 1.59 (brs, 4H, C15 and C16), 1.45-1.42

(m, 4H, C5 and C11), 1.22-1.20 (m, 12H, C2-4 and C8-10), 0.82-0.78 (m, 6H, C1 and C7). ¹³**C NMR** (100 MHz, CDCl₃ mixture of rotamers); 173.69 (quart C), 171.69 (quart C), 51.22 (C19), 47.74 (rotamer a of C6 and C12), 45.72 (rotamer b of C6 and C12), 33.69 (C14), 32.47 (C17), 31.40 (rotamer a of C5 and 11), 31.32 (rotamer b of C5 and 11), 28.91 (<u>CH</u>₂), 27.55 (<u>CH</u>₂), 26.50 (<u>CH</u>₂), 26.37 (<u>CH</u>₂), 24.69 (<u>CH</u>₂), 24.53 (<u>CH</u>₂), 22.37 (<u>CH</u>₂), 13.77 (C1 and C7). **MS** (ES⁺); 328.30 (M+H), 350.27 (M+Na); **HRMS** (M+Na); calcd for C₁₉H₃₇N₁Na₁O₃; 350.2666; found; 350.2665.



C1; Yield; 96 % (Oil); ¹**H NMR** (400 MHz, CDCl₃, mixture of rotamers); 3.27 (t, 2H, *J* = 7.6 Hz, rotamer a of C6 and C12), 3.18 (t, 2H, *J* = 8.0 Hz, rotamer b of C6 and C12), 2.37-2.30 (m, 4H, C14 and C17), 1.71-1.62

(m, 4H, C15 and C16), 1.52-1.46 (m, 4H, C5 and C11), 1.28-1.26 (m, 12H, C2-4 and C8-10), 0.90-0.84 (m, 6H, C1 and C7). ¹³**C NMR** (100 MHz, CDCl₃, mixture of rotamers); 177.91 (C18), 172.50 (C13), 48.06 (rotamer a of C6 and C12), 46.07 (rotamer b of C6 and C12), 33.85 (C14), 32.63 (C17), 31.50 (rotamer a of C5 and 11), 31.42 (rotamer b of C5 and 11), 28.98 (<u>CH</u>₂), 27.59 (<u>CH</u>₂), 26.61 (<u>CH</u>₂), 26.48 (<u>CH</u>₂), 24.75 (<u>CH</u>₂), 24.50 (<u>CH</u>₂), 22.50 (<u>CH</u>₂), 13.94 (rotamer a of C1 and C7), 13.91 (rotamer b of C1 and C7). **MS** (ES⁻); 312.26 (M-H); MS (ES⁺); 314.29 (M+H), 336.26 (M+Na); **HRMS** (M+Na); calcd for C₁₈H₃₅N₁Na₁O₃; 336.2509; found; 336.2510.

2.4.1.2. Synthesis of ester of C2 and C2



Ester of C2; Yield; 46 %; M.P.; 79 °C; ¹H NMR (400 MHz, CDCl₃); 12,22 (brs, 1H, NH), 3.60 (s, 3H, C12), 2.63 (t, 2H, J = 7.2 Hz, C7), 2.32-2.27 (m, 8H, C1, C2 and C10), 1.77-1.70 (m, 2H, C8), 1.67-1.60 (m, 2H, C9). ¹³C NMR (100 MHz, CDCl₃); 173.3 (quart C), 171.1 (quart C), 158.7 (C5), 131.5 (C3), 119.9

(C4), 51.4 (C12), 35.6 (C7), 33.3 (C10), 23.9 (CH₂), 23.6 (CH₂), 11.6 (C1), 10.5 (C2). **MS** (ES⁻); 269.12 (M-H); MS (ES⁺); 271.12 (M+H), 293.11 (M+Na); **HRMS** (M+H); calcd for C₁₂H₁₉N₂O₃S₁; 271.1111; found; 271.1114.



C2; Yield; 80 %; M.P.; 215 °C; ¹H NMR (400 MHz, DMSO); 2.39 (t, 2H, *J* = 7.6 Hz, C7), 2.23-2.20 (m, 5H, C1 and C10), 2.14 (s, 3H, C2), 1.61-1.45 (m, 4H, C8 and C9). ¹³C NMR (100 MHz, DMSO); 174.4 (C=O), 170.8 (C=O), 154.0 (C5), 140.7 (C3), 118.5 (C4), 34.6 (CH₂), 33.4 (CH₂), 24.3 (CH₂), 24.0 (CH₂),

14.1 (C1), 10.4 (C2). **MS** (ES⁻); 255.09 (M-H); MS (ES⁺); 257.10 (M+H), 279.08 (M+Na); **HRMS** (M-H); calcd for C₁₁H₁₅N₂O₃S₁; 255.0809; found; 255.0809.

2.4.1.3.. Synthesis of C3



C3; Yield; 55 %, M.P.; 244 °C; ¹**H NMR** (400 MHz, DMSO); 7.66 (s. 1H, C5), 7.51 (s. 1H, C6), 2.48 (t, 2H, *J* = 7.2 Hz, C11), 2.30 (s, 3H, C2), 2.29 (s, 3H, C1), 2.24 (t, 2H, *J* = 6.8 Hz, C14), 1.66-1.58 (m, 2H, C12), 1.56-1.49 (m, 2H, C13). ¹³**C NMR** (100 MHz, DMSO); 174.36 (C15), 171.92 (C10), 157.03 (C9),

147.02 (C7), 134.75 (C3), 132.32 (C4), 128.78 (C8), 121.45 (C6), 120.84 (C5), 34.87 (C11), 33.40 (C14), 24.19 (C12), 24.06 (C13), 19.76 (C1), 19.59 (C2). **MS** (ES⁻); 305.11 (M-H); MS (ES⁺); 329.09 (M+Na).

2.4.2. Synthesis of carboxylic acids C4 and C5



(a) acid chloride (1.1 eq), triethylamine (2.2 eq), CH_2CI_2 , 0 $^{\circ}C$ -r.t.; (b) LiOH (3.0 eq), H_2O : CH_3OH : THF (2: 1:1), 0 $^{\circ}C$ -r.t.;

General procedure for synthesis of ester compounds; To a stirred solution of the corresponding amine HCI **B2** or **B3** (1.1 eq) and triethylamine (2.2 eq) in dichloromethane was slowly added acid chloride (1.0 eq) under nitrogen atmosphere at 0 $^{\circ}$ C. The reaction mixture was stirred for 3 hours at room temperature. After completion of the reaction, the organic layer was washed with aques HCI. Concentration in *vacuo* followed by flash column chromatography gave the ester compounds.

General procedure for carboxylic acids: Same as synthesis of C1-C3

2.4.2.1. Synthesis of ester of C4 and C4



Ester of C4; Yield; 97 % (oil); ¹H NMR (400 MHz, CDCl₃); 7.41 (brs, 1H, NH), 4.13 (q, 2H, J = 6.8 Hz, C12), 3.42 (q, 2H, J = 6.4 Hz, C8), 2.40 (t, 2H, J = 6.8 Hz, C10), 1.95-1.88 (m, 2H, C9), 1.24 (t, 3H, J = 6.8 Hz, C10), 1.95-1.88 (m, 2H, C9), 1.24 (t, 3H, J = 6.8 Hz, C10), 1.95-1.88 (m, 2H, C9), 1.24 (t, 3H, J = 6.8 Hz, C10), 1.95-1.88 (m, 2H, C9), 1.24 (t, 3H, J = 6.8 Hz, C10), 1.95-1.88 (m, 2H, C9), 1.24 (t, 3H, J = 6.8 Hz, C10), 1.95-1.88 (m, 2H, C9), 1.24 (t, 3H, J = 6.8 Hz, C10), 1.95-1.88 (m, 2H, C9), 1.24 (t, 2H, J = 6.8 Hz, C10), 1.95-1.88 (m, 2H, C9), 1.24 (t, 2H, J = 6.8 Hz, C10), 1.95-1.88 (m, 2H, C9), 1.24 (t, 2H, J = 6.8 Hz, C10), 1.95-1.88 (m, 2H, C9), 1.24 (t, 2H, J = 6.8 Hz, C10), 1.95-1.88 (m, 2H, C9), 1.24 (t, 2H, J = 6.8 Hz, C10), 1.95-1.88 (m, 2H, C9), 1.95-1

6.8 Hz, C13). **MS** (ES⁻); 476.07 (M-H); MS (ES⁺); 500.08 (M+Na); **HRMS** (M+Na); calcd for C₁₃H₁₂F₁₃N₁Na₁O₃; 500.0502; found; 500.0509.



C4; Yield; 74 %; M.P.; 128 °C; ¹H NMR (400 MHz, MeOD); 3.35 (t, 2H, *J* = 6.8 Hz, C8), 2.39-2.32 (m, 2H, C10), 1.89-1.82 (m, 2H, C9). **MS** (ES⁻); 448.02 (M-H); MS (ES⁺); 472.04 (M+Na); HRMS (M-H); calcd for

 $C_{11}H_7F_{13}N_1O_3$; 448.0224; found; 448.0223.

2.4.2.2. Synthesis of ester of C5 and C5



Ester of C5; Yield; 87 %, M.P.; 61 °C; ¹H NMR (400 MHz, CDCl₃); 5.54 (brs, 1H, NH), 3.67 (s, 3H, C17), 3.25 (q, 2H, J = 6.8 Hz, C11), 2.32 (t, 2H, J = 7.6 Hz, C15), 2.15 (t, 2H,

J = 7.2 Hz, C9), 1.68-1.63 (m, 4H, C8, C140), 1.55-1.48 (m, 2H, C12), 1.39-1.26 (m, 14H, C2-C7, C13), 0.88 (t, 3H, J = 7.6 Hz, C1). ¹³**C NMR** (100 MHz, CDCl₃); 174.0 (C=O), 173.1(C=O), 51.5 (C17), 39.1 (CH₂), 36.9 (CH₂), 33.8 (CH₂), 31.8 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.3 (CH₂), 29.3 (CH₂), 26.3 (CH₂), 25.8 (CH₂), 24.4 (CH₂), 22.6 (CH₂), 14.1 (C1). **MS** (ES⁻); 298.25 (M-H); MS (ES⁺); 300.25 (M+H), 322.23 (M+Na); **HRMS** (M+Na); calcd for C₁₇H₃₃N₁Na₁O₃; 322.2353; found; 322.2349.



C5; Yield; 92 %, M.P.; 89 °C; ¹**H NMR** (400 MHz, CDCl₃); 11.10 (brs, 1H, OH), 5.82 (brs, 1H, NH), 3.24 (q, 2H, J = 6.4 Hz, C11),

2.34 (t, 2H, J = 7.2 Hz, C15), 2.17 (t, 2H, J = 7.6 Hz, C9), 1.68-1.57 (m, 4H, C8 and C14), 1.55-1.48 (m, 2H, C12), 1.40-1.34 (m, 2H, C2), 1.26-1.25 (m, 12H, C3-7 and C13), 0.87 (t, 3H, J = 6.8 Hz, C1). ¹³**C** NMR (100 MHz, CDCl₃); 178.4 (C=O), 173.7 (C=O), 39.2 (C11), 36.8 (C9), 33.8 (C15), 31.8 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 26.2 (CH₂), 25.8 (CH₂), 24.2 (CH₂), 22.6 (CH₂), 14.1 (C1). MS (ES⁻); 284.22 (M-H); MS (ES⁺); 286.25 (M+H), 308.21 (M+Na); HRMS (M-H); calcd for C₁₆H₃₀N₁O₃; 284.2231; found; 284.2237.

2.4.3. Synthesis of carboxylic acids C6-C13



General procedure; A mixture of alcohol or amine (1.0 eq) with glutaric anhydride derivative (1.0 eq) in toluene was refluxed for 3 hours. After completion of the reaction, toluene was removed and the residue was purified by flash column chromatography giving carboxylic acid.

2.4.3.1. Synthesis of C6

$$HO = \frac{15}{2} + \frac{14}{10} + \frac{15}{7} + \frac{14}{11} + \frac{14}{13} + \frac{14}{11} + \frac$$

1.09 (m, 6H, C9-C11), 0.90 (d, 3H, J = 6.8 Hz, C15), 0.87 (d, 6H, J = 6.8 Hz, C13 and C14). ¹³**C NMR** (100 MHz, CDCl₃); 179.05 (carbonyl), 172.98 (carbonyl), 63.16 (C6), 39.16, 37.09, 35.47, 33.21, 32.98, 29.82, 27.92, 24.58, 22.66, 22.56, 19.81, 19.48. **MS** (ES⁻); 271.18 (M-H); MS (ES⁺); 295.20 (M+Na); **HRMS** (M-H); calcd for C₁₅H₂₇O₄; 271.1915; found; 271.1908.

2.4.3.2. Synthesis of C7

Yield; 92 % (Oil); ¹H NMR (400 MHz, CDCl₃); 4.15-4.05 (m, 2H, C8), 2.47 (s, 2H, C4), 2.43 (s, 2H, C2), 1.69-1.61 (m, 1H, C10), 1.56-1.48 (m, 2H, C9), 1.46-1.39 (m, 1H, C14), 1.32-1.08 (m, 12H, C5, C6 and C11-C13), 0.89 (d,

3H, J = 6.4 Hz, C17), 0.86 (d, 6H, J = 6.4 Hz, C15 and C16). ¹³**C NMR** (100 MHz, CDCl₃); 177.78 (carbonyl), 172.20 (carbonyl), 62.89 (C8), 45.14 (C4), 45.01 (C2), 39.13 (<u>C</u>H₂), 37.04 (<u>C</u>H₂), 35.50 (<u>C</u>H₂), 32.48 (C3), 29.78 (C14), 27.88 (<u>C</u>H), 27.68 (<u>C</u>H), 24.56 (<u>C</u>H₂), 22.64 (C16), 22.55 (C15), 19.43 (C17). **MS** (ES⁻); 299.19 (M-H); MS (ES⁺); 301.25 (M+H), 323.20 (M+Na); **HRMS** (M+Na); calcd for C₁₇H₃₂Na₁O₄; 323.2193; found; 323.2194.

2.4.3.3. Synthesis of C8

 $\begin{array}{c} \begin{array}{c} & & & \\ & & & \\ & & \\ & & \\ & & & \\ & & \\ & & & \\ & & \\ &$

2.4.3.4. Synthesis of C9

Yield; 75 %; M.P.; 107 °C. ¹H NMR (400 MHz, CDCl₃); 9.08 (brs, 1H, NH), 8.46 $HO = 2^{O} + 1^{O} + 1^{O}$

2.4.3.5. Synthesis of C10



Yield; 87 %; M.P.; 151 °C. ¹H NMR (400 MHz, CDCl₃); 6.61 (brs, 1H, NH), 3.02 (s, 2H, C6 rotamer A), 3.00 (s, 2H, C6 rotamer A), 2.42 (s, 2H, C2 or C4), 2.35 (s, 2H, C2 or C4), 1.99 (brs, 3H, C14-C16), 1.74-1.60 (m, 6H, adamantly CH₂), 1.50 (brs, 6H, adamantly CH₂), 1.12 (s, 6H, C17 and C18). ¹³C NMR (100 MHz,

CDCl₃); 173.76 (C=O), 173.32 (C=O), 51.58 (C6), 47.05 (C2 or C4), 46.95 (C2 or C4), 40.19 (adamantyl CH₂), 36.76 (adamantyl CH₂), 33.65 (quart C), 33.62 (quart C), 29.36 (C17 and C18), 28.07 (C14-C16). **MS** (ES⁻); 306.19 (M-H); MS (ES⁺); 308.25 (M+H), 330.21 (M+Na); **HRMS** (M+Na); calcd for $C_{18}H_{29}N_1Na_1O_3$; 330.2040; found; 330.2040.

2.4.3.6. Synthesis of C11



Yield; 60 %; M.P.; 89 °C. ¹H NMR (400 MHz, CDCl₃); 3.68 (s, 2H, C6), 2.48 (s, 2H, C2 or C4), 2.47 (s, 2H, C2 or C4), 1.99 (brs, 3H, C14-C16), 1.75-1.64 (m, 6H, adamantly CH₂), 1.54 (brs, 6H, adamantly CH₂), 1.15 (s, 6H, C17 and C18). ¹³C NMR (100 MHz, CDCl₃); 176.8 (C=O), 172.7 (C=O), 74.3 (C6), 45.2 (C2 or C4),

45.1 (C2 or C4), 39.3 (adamantyl CH₂), 36.9 (adamantyl CH₂), 33.0 (quart C), 32.6 (quart C), 28.0 (C15-C17), 27.9 (C17 and C18). **MS** (ES⁻); 307.21 (M-H); MS (ES⁺); 331.21 (M+Na); **HRMS** (M-H); calcd for C₁₈H₂₇O₄; 307.1915; found; 307.1911.

2.4.3.7. Synthesis of C12



Yield; 74% (Oil); ¹H NMR (400 MHz, CDCl₃); 4.14 (t, 2H, J = 7.6 Hz, C6), 2.44 (t, 2H, J = 7.2 Hz, C4), 2.38 (t, 2H, J = 7.2 Hz, C2), 1.99-1.92 (m, 5H, C3, C11-C13), 1.72-1.52 (m, 12H, C9, C10, C14-C17), 1.49 (t, 3H, J = 7.6 Hz, C7). ¹³C NMR (100 MHz, CDCl₃); 179.0 (C=O), 173.0 (C=O), 61.0 (C6), 42.4

(CH₂), 42.3 (CH₂), 37.0 (CH₂), 33.3 (C4), 33.0 (C2), 31.7 (CH₂), 28.5 (C11-C13), 19.8 (C3 and C8). **MS** (ES⁻); 293.18 (M-H); MS (ES⁺); 295.22 (M+H), 317.18 (M+Na); **HRMS** (M-H); calcd for $C_{17}H_{25}O_4$; 293.1758; found; 293.1758.

2.4.3.8. Synthesis of C13



Yield; 99 % (Oil); ¹H NMR (400 MHz, CDCl₃); 4.14 (t, 2H, J = 7.6 Hz, C6), 2.48 (s, 2H, C2 or C4), 2.43 (s, 2H, C2 or C4), 1.95 (brs, 3H, C15-C17), 1.72-1.61 (m, 6H, adamantly CH₂), 1.53 (brs, 6H, adamantly CH₂), 1.42 (t, 2H, J = 7.6 Hz, C7), 1.14 (s, 6H, C18 and C19). ¹³C NMR (100 MHz, CDCl₃);

177.2 (C=O), 172.4 (C=O), 60.9 (C6), 45.2 (C2 or C4), 45.0 (C2 or C4), 42.5 (adamantyl CH₂), 42.3 (adamantyl CH₂), 37.0 (CH₂), 32.6 (quart C), 31.7 (quart C), 28.5 (C15-C17), 27.8 (C18 and C19). **MS** (ES⁻); 321.16 (M-H); MS (ES⁺); 323.25 (M+H), 345.21 (M+Na); **HRMS** (M+Na); calcd for $C_{19}H_{30}Na_1O_4$; 345.2036; found; 345.2035.

3. Synthesis of 3-carboximide tetramic acids



General procedure: To the solution of 3-alkoxycarbonyl tetramic acid (1.0 eq) in toluene was added amine (1.1 eq) and the mixture was refluxed for 4 hr. After completion of reaction as checked by TLC, concentration *in vacuo* followed by flash column chromatography gave metal-chelated 3-carboxamide tetramic acid. The compound was dissolved in dichloromethane (50 mL) and washed with aqueous HCI (3< pH <5, 50 mL). The organic layer was dried with MgSO₄ and concentrated *in vacuo* to give the metal free form of 3-carboxamide tetramic acid.

3.1. Synthesis of mono 3-carboximide tetramic acids

3.1.1. Synthesis of 1A



Yield; 41 % (oil); Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 9.14 (brs, 1H, OH), 7.70 (brs, 1H, NH), 3.90 (s, 2H, C5 AB), 3.68 (s, 2H, C5 CD), 3.39-3.16 (m, 4H, C6 and C13), 1.56-1.51 (m, 4H, C7 and C14),

1.37-1.28 (m, 12H, C8-10 and C15-17), 0.87 (t, 6H, J = 6.8 Hz, C11 and C18). ¹³C NMR (125 MHz, CDCl₃);

189.8 (C4 CD), 181.1 (C4 AB), 175.2 (C2 CD), 169.1 (C2 AB), 166.6 (C12 AB), 166.0 (C12 AB), 98.6 (C3 AB), 85.6 (C3 CD), 55.0 (C5 CD), 49.7 (C5 AB), 41.5 (CH₂), 41.2 (CH₂), 39.6 (CH₂), 38.4 (CH₂), 31.4 (CH₂), 31.3 (CH₂), 29.4 (CH₂), 28.4 (CH₂), 28.0 (CH₂), 26.5 (CH₂), 26.4 (CH₂), 22.5 (CH₂), 13.9 (C11 and C18). **MS** (ES⁻); 309.2, **HRMS** (M-H); calcd for C₁₇H₂₉N₂O₃; 309.2184; found; 309.2178.

3.1.2. Synthesis of 1B



Yield; 58 % (oil); Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 9.44 (brs, 1H, OH), 7.70 (brs, 1H, NH), 3.91 (s, 2H, C5 AB), 3.68 (s, 2H, C5 CD), 3.40-3.30 (m, 4H, C6 and C13), 1.59-

1.52 (m, 4H, C7 and C14), 1.35-1.25 (m, 18H, C8-10 and C15-20), 0.89-0.85 (m, 6H, C11 and C21). ¹³**C NMR** (100 MHz, CDCl₃, Only AB tautomer); 181.1 (C4), 169.1 (C2), 166.0 (C12), 98.6 (C3), 49.7 (C5), 41.3 (CH₂), 38.4 (CH₂), 31.8 (CH₂), 31.4 (CH₂), 29.4 (CH₂), 29.4 (CH₂), 29.2 (CH₂), 29.2 (CH₂), 28.4 (CH₂), 26.8 (CH₂), 26.4 (CH₂), 22.6 (CH₂), 22.5 (CH₂),14.1 (CH₃), 14.0 (CH₃). **MS** (ES⁻); 351.3, **HRMS** (M-H); calcd for C₂₀H₃₅N₂O₃; 351.2653; found; 351.2657.

3.1.3. Synthesis of 1C



Yield; 88 % (oil); Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 8.88 (brs, 1H, OH), 7.65 (brs, 1H, NH), 3.90 (s, 2H, C5 AB), 3.85-3.81 (m, 1H, C13), 3.67 (s, 2H, C5 CD), 3.38 (t, 2H, *J* = 7.2 Hz, C6), 1.91-1.88 (m, 2H, CH₂), 1.74-1.71 (m, 2H, CH₂), 1.60-1.52 (m, 3H, CH₂), 1.42-1.17 (m, 11H, CH₂), 0.88 (t, 3H, *J* =

6.4 Hz, C11). ¹³**C NMR** (125 MHz, CDCl₃); 189.8 (C4 CD), 181.4 (C4 AB), 175.2 (C2 CD), 169.1 (C2 AB), 165.7 (C12 CD), 165.1 (C12 AB), 98.4 (C3 AB), 85.4 (C3 CD), 55.0 (C5 CD), 49.8 (C5 AB), 48.9 (C13 CD), 47.3 (C13 AB), 41.5 (C6 CD), 41.3 (C6 AB), 32.8 (CH₂), 32.7 (CH₂), 31.4 (CH₂), 29.6 (CH₂), 28.4 (CH₂), 28.0 (CH₂), 26.4 (CH₂), 26.3 (CH₂), 25.4 (CH₂), 25.1 (CH₂), 24.5 (CH₂), 22.5 (CH₂), 13.9 (C11). **MS** (ES⁻); 307.2 (M-H); **HRMS** (M+Na); calcd for C₁₇H₂₈N₂Na₁O₃; 331.1992; found; 331.1993.

3.1.4. Synthesis of 1D



Yield; 90 %; M.P.; 67 °C; Form AB: CD = 90: 10; ¹H NMR (500 MHz, CDCl₃); 11.10 (s, 1H, NH), 9.70 (s, 1H, OH AB), 9.30 (s, 1H, OH CD), 7.61 (d, 2H, J =8.0 Hz, C14 and C15 AB), 7.51 (d, 2H, J = 7.6 Hz, C14 and C15 CD), 7.34 (dd, 2H, $J_1 =$ 8.0 Hz, $J_2 =$ 7.6 Hz, C16 and C17), 7.34 (dd, 1H, $J_1 =$ 7.6 Hz, $J_2 =$ 7.6

Hz, C18), 3.97 (s, 2H, C5 AB), 3.79 (s, 2H, C5 CD), 3.43 (t, 2H, *J* = 7.2 Hz, C6), 1.58-1.53 (m, 2H, C7), 1.36-1.26 (m, 6H, C8-10), 0.89 (t, 3H, *J* = 6.8 Hz, C11). ¹³**C NMR** (125 MHz, CDCl₃); 188.8 (C4 CD), 180.6 (C4 AB), 175.8 (C2 CD), 168.6 (C2 AB), 165.2 (C12 CD), 164.0 (C12 AB), 136.9 (C13 AB), 136.3 (C13 CD), 129.0 (C16 and C17 CD), 128.9 (C16 and C17 AB), 124.7 (C18 CD), 124.4 (C18 AB), 120.5 (C14 and C15 CD), 120.0 (C14 and C15 AB), 99.7 (C3 AB), 87.2 (C3 CD), 55.4 (C5 CD), 49.4 (C5 AB), 42.2 (C6 CD), 41.3 (C6 AB),

31.3 (C9 AB), 31.2 (C9 CD), 28.3 (C7 AB), 27.9 (C7 CD), 26.3 (C8 AB), 26.2 (C8 CD), 22.4 (C10), 13.9 (C11). **MS** (ES⁻); 301.1, **HRMS** (M+H); calcd for C₁₇H₂₃N₂O₃; 303.1703; found; 303.1700.

3.1.5. Synthesis of 1E



Yield; 66 %; M.P.; 97 °C; Form AB: CD = 90: 10; ¹H NMR (400 MHz, CDCl₃); 9.81 (brs, 1H, NH or OH), 9.55 (brs, 1H, NH or OH AB), 9.25 (brs, 1H, NH or OH AB), 7.51 (d, 2H, J = 8.8 Hz, C14 and C15 AB), 7.39 (d, 2H, J = 8.8 Hz, C14 and C15 CD), 6.91 (d, 2H, J = 8.8 Hz, C16 and

C17), 3.98 (s, 2H, C5 AB), 3.87 (t, 4H, J = 4.8 Hz, C21 and C22), 3.77 (s, 2H, C5 CD), 3.43 (t, 2H, J = 7.2 Hz, C6), 3.13 (t, 4H, J = 4.8 Hz, C19 and C20), 1.59-1.54 (m, 2H, C7), 1.34-1.25 (m, 6H, C8-10), 0.89 (t, 3H, J = 6.8 Hz, C11). ¹³**C NMR** (100 MHz, CDCl₃, Only AB tautomer); 180.5 (C4), 168.8 (C2), 163.7 (C12), 148.2 (C18), 129.7 (C13), 121.4 (C14 and C15), 116.3 (C16 and C17), 99.6 (C3), 66.7 (C21 and C22), 49.7 (C5), 49.5 (C19 and C20), 41.4 (C6), 31.4 (CH₂), 28.4 (CH₂), 26.4 (CH₂), 22.5 (CH₂), 14.0 (C11). **MS** (ES⁻); 386.22, **HRMS** (M-H); calcd for C₂₁H₂₈N₃O₄; 386.2085; found; 386.2092.

3.2. Synthesis of bicyclic 3-carboximide tetramic acid

3.2.1. Synthesis of (±)-2A



Yield; 31 % (oil); Form AB: CD = 75: 25; ¹H NMR (400 MHz, CDCl₃); 7.90 (brs, 1H, NH or OH CD), 7.42 (brs, 1H, NH or OH AB), 4.62 (s, 1H, C8), 3.86 (d, 1H, J = 8.3 Hz, C7), 3.41 (d, 1H, J = 8.3 Hz, C7), 2.11 (brs, 3H, C21-C23), 2.05 (brs, 6H, C15-C16 and C19), 1.69 (brs, 6H, C17-C18 and C20), 1.55 (s, 3H, C6 AB),

1.49 (s, 3H, C6 CD), 1.01 (s, 9H, C10-C12). ¹³**C NMR** (100 MHz, CDCl₃, Tautomer AB only); 190.5 (C4), 176.0 (C2), 166.2 (C13), 97.2 (C8), 95.6 (C3), 72.1 (C7), 69.7 (C5), 52.9 (C14), 41.6 (CH₂), 36.1 (CH₂), 34.6 (C9), 29.3 (C21-C23), 25.5 (C10-C12), 20.6 (C6). **MS** (ES⁻); 387.24 (M-H); **HRMS** (M-H); calcd for C₂₂H₃₁N₂O₄; 387.2289; found; 387.2291.

3.2.2. Synthesis of (±)-2B



Yield; 64 %; M.P.; 139 °C; Form AB: CD = 75: 25; ¹H NMR (500 MHz, CDCl₃); 7.46 (brs, 1H, NH or OH), 4.63 (s, 1H, C8 CD), 4.61 (s, 1H, C8 AB), 3.87 (d, 1H, J = 8.2 Hz, C7), 3.41 (d, 1H, J = 8.2 Hz, C7), 2.29 (brs, 2H, C22 and C23), 2.05-1.91 (m, 6H, CH₂), 1.70-1.49 (m, 9H, C6 and CH₂), 1.00 (s, 9H, C10-C12). ¹³C

NMR (125 MHz, CDCl₃, Tautomer AB only); 189.5 (C4), 175.9 (C2), 166.0 (C13), 97.2 (C8), 96.5 (C3), 72.2 (C7), 69.5 (quart C), 69.1 (quart C), 54.8 (C14), 48.9 (CH₂), 43.9 (CH₂), 40.3 (CH₂), 34.7 (CH₂), 34.6 (C9), 30.5 (C22 and C23), 25.5 (C10-C12), 20.5 (C6). **MS** (ES⁻); 403.24 (M-H); **HRMS** (M-H); calcd for C₂₂H₃₁N₂O₅; 403.2238; found; 403.2237.

3.2.3. Synthesis of (±)-2C



Yield; 44 % (oil); Form AB: CD = 80: 20; ¹H NMR (500 MHz, CDCl₃); 9.20 (brs, 1H, NH or OH), 7.62 (brs, 1H, NH or OH), 4.64 (s, 1H, C8), 3.88 (d, 1H, *J* = 8.5 Hz, C7 AB), 3.80 (d, 1H, *J* = 8.5 Hz, C7 CD), 3.43 (d, 1H, *J* = 8.5 Hz, C7), 3.35-3.33 (m, 2H, C14), 2.38-2.41 (m, 1H), 2.28-2.22 (m, 1H), 2.00-1.85 (m, 5H),

1.57 (s, 3H, C6), 1.50 (brs, 1H), 1.19 (s, 3H, C22), 1.04-1.02 (m, 12H, C10-C12 and C23), 0.88 (d, 1H, J = 10.0 Hz). ¹³**C NMR** (125 MHz, CDCl₃, Tautomer AB only); 189.2 (C4), 175.8 (C2), 166.2 (C13), 97.2 (C8), 97.0 (C3), 72.2 (C7), 69.7 (C5), 44.3 and 44.2 (C14), 43.6 and 43.5 (C15), 41.2 (C19 and C20), 38.6 (C21), 34.7 (C9), 33.2 (CH₂), 27.9 (C22), 25.9 (CH₂), 25.5 (C10-C12), 23.1 (C23), 20.6 (C6), 19.7 (CH₂). **MS** (ES⁻); 387.26 (M-H); **HRMS** (M-H); calcd for C₂₂H₃₃N₂O₄; 389.2446; found; 389.2447.

3.2.4. Synthesis of (±)-2D



Yield; 39 % (oil); Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 8.99 (brs, 1H, OH), 7.84 (d, 1H, J = 8.0 Hz, NH CD), 7.48 (d, 1H, J = 8.0 Hz, NH AB), 4.66 (s, 1H, C8 CD), 4.64 (s, 1H, C8 AB), 3.88 (d, 1H, J = 8.3 Hz, C7 AB), 3.84-3.76 (m, 1H, C14 and 1H C7 CD), 3.43 (d, 1H, J = 8.3 Hz, C7), 1.94-1.91 (m, 2H, CH₂), 1.78-

1.72 (m, 2H, CH₂), 1.64-1.59 (m, 1H, CH₂), 1.58 (s, 3H, C6 AB), 1.51 (s, 3H, C6 CD), 1.44-1.16 (m, 5H, CH₂), 1.02 (s, 9H, C10-C12). ¹³**C NMR** (100 MHz, CDCl₃, Tautomer AB only); 189.8 (C4), 175.8 (C2), 165.5 (C13), 97.2 (C8), 95.8 (C3), 72.2 (C7), 69.7 (C5), 47.9 (C14), 34.7 (C9), 32.8 (CH₂), 32.6 (CH₂), 25.5 (C10-C12), 25.3 (CH₂), 24.6 (CH₂), 20.6 (C6). **MS** (ES⁻); 335.21 (M-H); **HRMS** (M-H); calcd for C₁₈H₂₇N₂O₄; 335.1976; found; 335.1967.

3.2.5. Synthesis of (±)-2E



Yield; 39 %; M.P.; 139°C; Form AB: CD = 99: 1; ¹H NMR (400 MHz, acetone- d_6); 6.07 (brs, 2H, NH and OH), 4.58 (s, 1H, C8), 3.95 (d, 1H, J = 8.1 Hz, C7), 3.50 (d, 1H, J = 8.1 Hz, C7), 3.25 (brs, 2H, C14), 1.76-1.65 (m, 6H, C15 and CH₂), 1.54 (s, 3H, C6), 1.32-1.18 (m, 5H, CH₂), 1.00 (s, 9H, C10-C12). ¹³C NMR (125 MHz,

acetone- d_6); 191.0 (C4), 176.1 (C2), 167.2 (C13), 97.8 (C8), 96.9 (C3), 72.8 (C7), 70.3 (C5), 45.2 (C14), 38.8 (C15), 35.2 (C9), 31.4 (CH₂), 27.1 (CH₂), 26.5 (CH₂), 25.9 (C10-C12), 21.1 (C6). **MS** (ES⁻); 349.21 (M-H); **HRMS** (M-H); calcd for C₁₉H₂₉N₂O₄; 349.2133; found; 349.2134.

3.2.6. Synthesis of (±)-2F



Yield; 42 %; M.P.; 81 °C; Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃,); 7.75 (br s, 1H, NH or OH), 4.63 (s, 1H, C8), 4.05-4.00 (m, 1H, C15), 3.90-3.86 (m, 2H, C7 and C18), 3.78-3.73 (m, 1H, C18), 3.60-3.51 (m, 1H, C14), 3.42 (d, J = 8.2 Hz) and 3.40 (d, 1H, J = 8.2 Hz, C7), 3.38-3.30 (m, 1H, C14), 2.04-1.53 (m, 7H, C6, C16 and C17), 1.00 (s, 9H, C10-C12). ¹³**C NMR** (100 MHz, CDCl₃,); 188.5 (C4), 175.4 and 175.3 (C2), 166.3 (C13), 97.1 and 97.2 (C8), 97.0 and 97.1 (C3), 77.0 (C), 72.3 and 72.2 (C7), 69.4 (C5), 68.2 (C18), 42.4 (C14), 34.7 (C9), 28.8 (C16), 25.8 (C17), 25.5 (C10-C12), 20.6 (C6). **MS** (ES⁻); 337.19 (M-H); **HRMS** (M-H); calcd for C₁₇H₂₅N₂O₅; 337.1769; found; 337.1770.

3.2.7. Synthesis of (±)-2G



Yield; 39 % (oil); Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 8.11 (brs, 1H, NH or OH CD), 7.88 (brs, 1H, NH or OH AB), 7.40-7.27 (m, 5H, C16-C20), 4.67 (s, 1H, C8 CD), 4.63 (s, 1H, C8 AB), 4.59 (dd, 2H, J_1 = 10.0 Hz, J_2 = 6.3 Hz, C14 CD), 4.53 (d, 2H, J = 6.3 Hz, C14 AB), 3.91 (d, 1H, J = 8.1 Hz, C7 AB), 3.81

(d, 1H, J = 8.1 Hz, C7 CD), 3.45 (d, 1H, J = 8.1 Hz, C7 AB), 3.42 (d, 1H, J = 8.1 Hz, C7 CD), 1.60 (s, 3H, C6 AB), 1.51 (s, 3H, C6 AB), 1.03 (s, 9H, C10-C12 CD), 1.01 (s, 9H, C10-C12 AB). ¹³**C** NMR (100 MHz, CDCl₃, Tautomer AB only); 188.3 (C4), 175.4 (C2), 165.9 (C13), 137.1 (C15), 128.8 (C18 and C19), 127.8 (C16 and C17), 127.7 (C20), 97.3 (C3), 97.1 (C8), 72.3 (C7), 69.4 (C5), 42.6 (C14), 34.7 (C9), 25.5 (C10-C12), 20.6 (C6). **MS** (ES); 343.17 (M-H); **HRMS** (M-H); calcd for C₁₉H₂₃N₂O₄; 343.1663; found; 343.1667.

3.2.8. Synthesis of (±)-2H



Yield; 40 % (oil); Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃, two set of signals in some case caused by two diastereomers); 7.87 (brs, 1H, NH or OH), 7.42-7.28 (m, 5H, C17-C21), 5.22-5.13 (m, 1H, C14), 4.66 (s) and 4.64 (s, 1H, C8), 3.90 (d, J = 8.2Hz) and 3.88 (d, 1H, J = 8.2 Hz, C7), 3.45 (d, J = 8.2 Hz) and 3.42 (d, 1H, J = 8.2 Hz,

C7), 1.59-1.55 (m, 6H, C6 and C15), 1.03 (s) and 1.02 (s, 9H, C10-C12). ¹³**C NMR** (125 MHz, CDCl₃, two set of signals in some case caused by two diastereomers); 187.7 and 187.6 (C4), 174.6 and 174.5 (C2), 164.3 and 164.2 (C13), 141.5 and 141.4 (C16), 127.8 and 127.7 (C19 and C20), 126.6 (C21), 125.0 and 124.9 (C17 and C18), 96.2 and 96.1 (C8), 96.0 and 95.9 (C3), 71.2 and 71.1 (C7), 68.5 and 68.4 (C5), 47.5 and 47.4 (C14), 33.7 (C9), 24.7 (C10-C12), 21.4 and 21.2 (C15), 19.6 and 19.5 (C6). **MS** (ES⁺); 359.20 (M+H), 381.19 (M+Na); **HRMS** (M+Na); calcd for $C_{20}H_{26}N_2Na_1O_4$; 381.1785; found; 381.1775.

3.2.9. Synthesis of (±)-2I



Yield; 19 %; M.P.;163 °C; Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 8.92 (brs, 1H, NH or OH), 7.55 (brs, 1H, NH or OH CD), 4.66 (s, 1H, C8 CD), 4.64 (s, 1H, C8 AB), 3.89 (d, 1H, J = 8.3 Hz, C7 AB), 3.81 (d, 1H, J

= 8.3 Hz, C7 CD), 3.45-3.32 (m, 3H, C7 and C14), 1.63-1.51 (m, 5H, C6 and C15), 1.30-1.22 (m, 12H, C16-C21), 1.02 (s, 9H, C10-C12), 0.88 (t, 3H, *J* = 6.1 Hz, C22). ¹³**C NMR** (100 MHz, CDCl₃, Tautomer AB only); 189.2 (C4), 175.7 (C2), 166.2 (C13), 97.1 (C8), 96.2 (C3), 72.2 (C7), 69.6 (C5), 38.8 (C14), 34.7 (C9), 31.8 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 26.8 (CH₂), 25.5 (C10-C12), 22.6 (CH₂), 20.6 (C6), 14.1 (C22). **MS**

(ES⁻); 379.26 (M-H), **HRMS** (M-H); calcd for C₂₁H₃₅N₂O₄; 379.2602; found; 379.2607.

3.2.10. Synthesis of (±)-3A



Yield; 31 % (oil); Form AB: CD = 95: 5; ¹H NMR (400 MHz, CDCl₃); 9.42 (brs, 2H, NH & OH), 7.59 (d, 2H, J = 8.3 Hz, C15 and C16), 7.36 (dd, 2H, $J_1 = 8.3$ Hz, $J_2 = 7.7$ Hz, C17 and C18), 7.16 (t, 1H, J = 7.7 Hz, C19), 4.69 (s, 1H, C8), 3.95 (d, 1H, J = 8.3 Hz, C7 AB), 3.87 (d, 1H, J = 8.3 Hz, C7 CD), 3.49 (d, 1H, J = 8.3 Hz, C7),

1.64 (s, 3H, C6 AB), 1.58 (s, 3H, C6 CD),1.06 (s, 9H, C10-C12). ¹³**C NMR** (100 MHz, CDCl₃, Tautomer AB only); 187.8 (C4), 175.4 (C2), 164.1 (C13), 136.5 (C14), 129.1 (C17 and C18), 124.9 (C19), 120.3 (C15 and C16), 98.4 (C3), 97.2 (C8), 72.3 (C7), 69.3 (C5), 34.7 (C9), 25.5 (C10-C12), 20.6 (C6). **MS** (ES⁻); 329.15 (M-H); **HRMS** (M-H); calcd for C₁₈H₂₁N₂O₄; 329.1507; found; 329.1506.

3.2.11. Synthesis of (±)-3B

Yield; 42 %; M.P.; 157 °C; Form AB: CD =99: 1; ¹H NMR (400 MHz, CDCl₃); 9.64 (brs, 1H, NH or OH), 7.73 (d, 2H, J = 8.6 Hz, Ar-H), 7.60 (d, 2H, J = 8.6 Hz, Ar-H), 4.69 (s, 1H, C8), 3.96 (d, 1H, J = 8.3 Hz, C7), 3.49 (d, 1H, J = 8.3

Hz, C7), 1.65 (s, 3H, C6), 1.06 (s, 9H, C10-C12). ¹³**C NMR** (100 MHz, CDCl₃); 187.7 (C4), 175.2 (C2), 164.3 (C13), 139.7 (C14), 126.3 (C17 and C18), 119.9 (C15 and C16), 98.6 (C3), 97.3 (C8), 72.3 (C7), 69.3 (C5), 34.7 (C9), 25.5 (C10-C12), 20.6 (C6). **MS** (ES⁻); 397.14 (M-H); **HRMS** (M-H); calcd for $C_{19}H_{20}F_3N_2O_4$; 397.1381; found; 397.1382.

3.2.12. Synthesis of (±)-3C



Yield; 45 %; M.P.; 132 °C; Form AB: CD = 90: 10; ¹H NMR (400 MHz, CDCl₃); 10.95 (brs, 1H, NH or OH), 9.65 (brs, 1H, NH or OH CD), 9.39 (brs, 1H, NH or OH AB), 7.78 (d, 2H, J = 8.3 Hz, C17 and C18 CD), 7.63 (d, 2H, J = 8.3 Hz, C15 and C16 CD), 7.51 (d, 2H, J = 8.3 Hz, C17 and C18 AB), 7.24 (d, 2H, J =

8.3 Hz, C15 and C16 AB), 4.67 (s, 1H, C8), 3.93 (d, 1H, *J* = 8.3 Hz, C7), 3.47 (d, 1H, *J* = 8.3 Hz, C7), 2.72 (s, 3H, C20 CD), 2.47 (s, 3H, C20 AB), 1.62 (s, 3H, C6), 1.04 (s, 9H, C10-C12). ¹³**C NMR** (125 MHz, CDCl₃, Tautomer AB only); 187.7 (C4), 175.3 (C2), 163.9 (C13), 134.6 (quart Ar-C), 134.0 (quart Ar-C), 127.7 (C17 and C18), 120.8 (C15 and C16), 98.4 (C3), 97.2 (C8), 72.3 (C7), 69.3 (C5), 34.7 (C9), 25.5 (C10-C12), 20.6 (C6), 16.4 (C20). **MS** (ES⁻); 375.14 (M-H); **HRMS** (M-H); calcd for C₁₉H₂₃N₂O₄S₁; 375.1384; found; 375.1374.

3.2.13. Synthesis of (±)-3D



Yield; 43 % (oil); Form AB: CD = 95: 5; ¹H NMR (400 MHz, CDCl₃); 9.27 (brs, 1H, NH or OH CD), 9.27 (brs, 1H, NH or OH AB), 7.39 (d, 2H, J = 8.2 Hz, C15 and C16 AB), 7.30 (d, 2H, J = 8.2 Hz, C15 and C16 CD), 6.98 (brs, 1H, NH or

OH), 6.80 (d, 2H, *J* = 8.2 Hz, C17 and C18), 4.69 (s, 1H, C8), 3.94 (d, 1H, *J* = 8.2 Hz, C7 AB), 3.87 (d, 1H, *J* = 8.2 Hz, C7 AB), 3.48 (d, 1H, *J* = 8.2 Hz, C7), 1.63 (s, 3H, C6 AB), 1.57 (s, 3H, C6 CD), 1.05 (s, 9H, C10-C12). ¹³C NMR (125 MHz, CDCl₃, Tautomer AB only); 187.9 (C4), 175.5 (C2), 163.9 (C13), 153.1 (C19), 129.3 (C14), 122.4 (C15 and C16), 115.8 (C17 and C18), 98.1 (C3), 97.2 (C8), 72.3 (C7), 69.4 (C5), 34.7 (C9), 25.5 (C10-C12), 20.6 (C6). **MS** (ES⁻); 345.16 (M-H); **HRMS** (M-H); calcd for C₁₈H₂₁N₂O₅; 345.1456; found; 345.1444.

3.2.14. Synthesis of (±)-3E



Yield; 38 %; M.P.; 129 °C; Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 9.30 (br s, 1H, NH or OH), 7.49 (d, 2H, J = 8.6 Hz, C17 and C18), 6.89 (d, 2H, J = 8.6 Hz, C15 and C16), 4.68 (s, 1H, C8), 3.94 (d, 1H, J = 8.3 Hz, C7), 3.81 (s, 3H, C20), 3.48 (d, 1H, J = 8.3 Hz, C7), 1.63 (s, 3H, C6), 1.05 (s, 9H, C10-

C12). ¹³**C NMR** (125 MHz, CDCl₃); 187.6 (C4), 175.5 (C2), 163.8 (C13), 156.9 (C19), 129.5 (C14), 121.9 (C15 and C16), 114.3 (C17 and C18), 98.1 (C3), 97.2 (C8), 72.3 (C7), 69.3 (C5), 55.4 (C20), 25.5 (C10-C12), 20.6 (C6). **MS** (ES⁻); 359.16 (M-H); **HRMS** (M-H); calcd for C₁₉H₂₃N₂O₅; 359.1612; found; 359.1617.

3.2.15. Synthesis of (±)-3F



Yield; 51 %; M.P.; 188 °C; Form AB: CD = 90: 10; ¹H NMR (400 MHz, CDCl₃); 9.39 (brs, 1H, NH or OH), 7.55 (d, 2H, J = 8.9 Hz, C15 and C16 AB), 7.44 (d, 2H, J = 8.9 Hz, C15 and C16 CD), 7.34 (t, 2H, J = 7.9 Hz, C23 and

C24), 7.11 (t, 1H, J = 7.4 Hz, C25), 7.05-7.00 (m, 4H, C17, C18, C21 and C22), 4.69 (s, 1H, C8), 3.95 (d, 1H, J = 8.3 Hz, C7 AB), 3.88 (d, 1H, J = 8.3 Hz, C7 CD), 3.49 (d, 1H, J = 8.3 Hz, C7), 1.65 (s, 3H, C6 AB), 1.58 (s, 3H, C6 CD), 1.06 (s, 9H, C10-C12). ¹³**C** NMR (100 MHz, CDCl₃, Tautomer AB only); 187.7 (C4), 175.4 (C2), 163.9 (C13), 157.2 (quart C), 154.2 (quart C), 131.9 (quart C), 129.8 (tert C), 123.3 (C25), 121.9 (tert C), 119.5 (tert C), 118.7 (tert C), 98.3 (C3), 97.2 (C8), 72.3 (C7), 69.3 (C5), 34.7 (C9), 25.5 (C10-C12), 20.6 (C6). **MS** (ES⁻); 421.19 (M-H); **HRMS** (M-H); calcd for C₂₄H₂₅N₂O₅; 421.1769; found; 421.1764.

3.2.16. Synthesis of (±)-3G



Yield; 51 %; M.P.; 184 °C; Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 9.98 (brs, 1H, NH or OH), 9.10 (brs, 1H, NH or OH), 8.34 (d, 1H, J = 8.9 Hz, C15), 7.43 (d, 1H, J = 2.4 Hz, C19), 7.26 (dd, 1H, $J_1 = 8.9$ Hz, $J_2 = 2.4$ Hz, C16), 4.72 (s, 1H, C8), 3.95 (d, 1H, J = 8.3 Hz, C7), 3.49 (d, 1H, J = 8.3 Hz, C7), 1.65

(s, 3H, C6), 1.05 (s, 9H, C10-C12). ¹³**C NMR** (100 MHz, CDCl₃); 187.6 (C4), 174.9 (C2), 164.2 (C13), 132.7 (quart Ar-C), 129.77 (quart Ar-C), 129.2 (C19), 127.7 (C15), 124.41 (quart Ar-C), 122.6 (C16), 98.9 (C3), 97.2 (C8), 72.3 (C7), 69.2 (C5), 34.7 (C9), 25.5 (C10-C12), 20.6 (C6). **MS** (ES⁻); 397.09 (M-H), **HRMS** (M-H); calcd for C₁₈H₁₉Cl₂N₂O₄; 397.0727; found; 397.0731.

3.2.17. Synthesis of (±)-3H



Yield; 56 %; M.P.; 149 °C; Form AB: CD = 99: 1; ¹H NMR (400 MHz, DMSO*d*6): 10.08 (brs, 1H, NH or OH), 8.12 (d, 1H, J = 8.6 Hz, C15), 7.32 (s, 1H, C18), 7.24 (d, 1H, J = 8.6 Hz, C17), 4.60 (s, 1H, C8), 3.92 (d, 1H, J = 8.1 Hz, C7), 3.49 (d, 1H, J = 8.1 Hz, C7), 2.27 (s, 3H, C20), 1.49 (s, 3H, C6), 0.97 (s,

9H, C10-C12). ¹³**C NMR** (125 MHz, DMSO-*d*6): 185.4 (C4), 176.9 (C2), 160.9 (C13), 135.1 (quart Ar-C), 129.8 (C18), 129.7 (quart Ar-C), 127.3 (quart Ar-C), 126.1 (C17), 121.9 (C15), 97.7 (C3), 96.5 (C8), 71.7 (C7), 68.7 (C5), 34.4 (C9), 25.5 (C10-C12), 20.8 (C6), 17.3 (C20). **MS** (ES⁻); 377.14 (M-H), **HRMS** (M-H); calcd for C₁₉H₂₂Cl₁N₂O₄; 377.1274; found; 377.1267.

3.2.18. Synthesis of (±)-3I



Yield; 52 %; M.P.; 161 °C; Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 7.57 (d, 1H, J = 10.0 Hz, C15), 7.31-7.19 (m, 2H, C16 and C18), 7 6.84 (t, 1H, J = 7.7 Hz, C17), 4.68 (s, 1H, C8), 3.94 (d, 1H, J = 8.2 Hz, C7), 3.47 (d, 1H, J = 8.2 Hz, C7), 1.63 (s, 3H, C6), 1.05 (s, 9H, C10-C12). ¹³C NMR (125 MHz, CDCl₃); 187.6

(C4), 175.3 (C2), 164.1 (C13), 162.9 (d, $J_{C-F} = 244$ Hz, C18), 138.1 (d, $J_{C-F} = 10.4$ Hz, C14), 130.2 (d, $J_{C-F} = 8.5$ Hz, C17), 115.5 (C15), 111.7 (d, $J_{C-F} = 21.8$ Hz, C16 or C19), 107.9 (d, $J_{C-F} = 26.7$ Hz, C16 or C19), 98.4 (C3), 97.3 (C8), 72.3 (C7), 69.3 (C5), 34.7 (C9), 25.5 (C10-C12), 20.6 (C6). **MS** (ES⁻); 347.15 (M-H); **HRMS** (M-H); calcd for C₁₈H₂₀F₁N₂O₄; 347.1413; found; 347.1414.

3.2.19. Synthesis of (±)-3J



Yield;58 % (oil); Form AB: CD = 90: 10; ¹H NMR (400 MHz, CDCl₃); 9.38 (brs, 1H, NH or OH), 9.19 (brs, 1H, NH or OH), 7.31-7.16 (m, 2H, C16 and C17), 7.08 (d, 1H, J = 7.6 Hz, C15 AB), 7.00 (d, 1H, J = 7.6 Hz, C15 CD), 6.73 (dd, 2H, $J_1 = 8.4$ Hz, $J_2 = 2.1$ Hz, C19 CD), 6.68 (dd, 2H, $J_1 = 8.4$ Hz, $J_2 = 2.1$ Hz, C19 AB), 4.68 (s,

1H, C8), 4.59-4.50 (m, 1H, C20), 3.94 (d, 1H, *J* = 8.3 Hz, C7 AB), 3.87 (d, 1H, *J* = 8.3 Hz, C7 CD), 3.48 (d, 1H, *J* = 8.3 Hz, C7), 1.63 (s, 3H, C6 AB), 1.57 (s, 3H, C6 CD), 1.34 (d, 6H, *J* = 6.1 Hz, C21 and C22), 1.05 (s, 9H, C10-C12). ¹³**C NMR** (100 MHz, CDCl₃, Tautomer AB only); 187.8 (C4), 175.4 (C2), 164.1 (C13), 158.5 (C18), 137.7 (C14), 129.8 (C17), 112.8 (Ar-C), 112.4 (Ar-C), 107.8 (Ar-C), 98.4 (C3), 97.2 (C8), 72.3 (C7), 70.0 (C20), 69.3 (C5), 34.7 (C9), 25.5 (C10-C12), 22.0 (C21 and C22), 20.6 (C6). **MS** (ES⁻); 387.21 (M-H); **HRMS** (M-H); calcd for C₂₁H₂₇N₂O₅; 387.1925; found; 387.1921.

3.2.20. Synthesis of (±)-3K



Yield; 42 %; M.P.; 141 °C; Form AB: CD = 90: 10; ¹H NMR (400 MHz, CDCl₃); 9.31 (brs, 1H, NH or OH), 7.92-7.86 (m, 1H, Ar-H AB), 7.73-7.70 (m, 1H, Ar-H CD), 7.48 (brs, 1H, C16), 6.98-6.90 (m, 2H, Ar-H), 4.70 (s, 1H, C8 AB), 4.69 (s, 1H, C8 CD), 3.95 (d, 2H, J = 8.3 Hz, C7 AB), 3.88 (d, 2H, J = 8.3 Hz, C7 CD), 3.50 (d, 1H, J = 8.3 Hz, C7), 2.37 (s, 3H, C22 CD), 2.36 (s, 3H, C22 AB), 1.65 (s, 3H, C6 AB), 1.59 (s, 3H, C6 CD), 1.06 (s, 9H, C10-C12). ¹³C NMR (125 MHz, CDCl₃, Tautomer AB only); 187.7 (C4), 175.4 (C2), 164.2 (C13), 131.8 (quart C), 130.6 (quart C), 124.0 (quart C), 123.9 (quart C), 117.3 (tert C), 117.1 (tert C), 113.3 (tert C), 113.1 (tert C), 98.5 (C3), 97.2 (C8), 72.3 (C7), 69.3 (C5), 34.7 (C9), 25.5 (C10-C12), 20.5 (C6), 17.9 (C22). **MS** (ES⁻); 382.19 (M-H), **HRMS** (M-H); calcd for C₂₁H₂₄N₃O₄; 382.1772; found; 382.1777.

3.2.21. Synthesis of (±)-3L



Yield; 21 %; M.P.; 119 °C; Form AB: CD = 99: 1; ¹H NMR (500 MHz, CDCl₃); 9.49 (brs, 1H, NH or OH), 7.64 (2H, d, J = 8.2 Hz, C15 and C16), 7.48 (brs, 2H, C17 and C18), 4.66 (s, 1H, C8), 4.14 (brs, 4H, C22 and C23), 3.93 (d, 1H, J = 8.2 Hz, C7), 3.46 (d, 1H, J = 8.2 Hz, C7), 3.36 (brs,

4H, C20 and C21), 1.62 (s, 3H, C6), 1.03 (s, 9H, C10-C12). ¹³**C NMR** (125 MHz, CDCl₃); 187.8 (C4), 175.3 (C2), 164.0 (C13), 121.6 (C15 and C16), 119.9 (C17 and C18), 98.3 (C3), 97.2 (C8), 72.3 (C7), 69.3 (C5), 64.9 (C22 and C23), 53.0 (C20 and C21), 34.7 (C9), 25.4 (C10-C12), 20.6 (C6). **MS** (ES⁻); 414.21 (M-H), **HRMS** (M-H); calcd for C₂₂H₂₈N₃O₅; 414.2034; found; 414.2033.

3.2.22. Synthesis of (±)-3M



Yield; 33 % (oil); Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 9.62 (br s, 1H, NH or OH), 7.89-7.77 (m, 2H, C15 and C16), 7.69 (d, 2H, J = 8.5 Hz, C7 and C18), 4.66 (s, 1H, C8), 3.93 (d, 1H, J = 8.2 Hz, C7), 3.47-3.41 (m, 5H, C7, C20 and C21), 2.31-1.23 (m, 9H, C6 and C22-C24), 1.03 (s, 9H,

C10-C12). ¹³**C NMR** (125 MHz, CDCl₃); 187.9 (C4), 175.3 (C2), 164.2 (C13), 139.1 (quart Ar-C), 137.9 (quart Ar-C), 122.2 (C15 and C16), 121.3 (C17 and C18), 98.3 (C3), 97.3 (C8), 72.2 (C7), 69.3 (C5), 57.3 (C20 and C21), 34.7 (C9), 25.4 (C10-C12), 23.1 (C22 and C23), 21.8 (C24), 20.6 (C6). **MS** (ES⁻); 412.23 (M-H); **HRMS** (M-H); calcd for C₂₃H₃₀N₃O₄; 412.2242; found; 412.2247.

3.2.23. Synthesis of 4A



Yield; 43 %; M.P.; 144 °C; Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 11.56 (brs, 1H, NH or OH), 7.93 (brs, 1H, NH or OH CD), 7.53 (brs, 2H, NH or OH AB), 4.83 (s, 1H, C7 CD), 4.79 (s, 1H, C7 AB), 4.37 (dd, 1H, J_1 = 9.2 Hz, J_2

= 7.0 Hz, C5 AB), 4.28 (dd, 1H, J_1 = 7.0 Hz, J_2 = 6.8 Hz, C6 AB), 4.23 (dd, 1H, J_1 = 9.0 Hz, J_2 = 7.0 Hz, C5 CD), 4.11 (dd, 1H, J_1 = 7.0 Hz, J_2 = 6.8 Hz, C6 CD), 3.47-3.33 (m, 3H, C6 and C13), 2.39-2.21 (m, 2H), 2.02-1.83 (m, 5H), 1.53-1.45 (m, 1H), 1.19 (s, 3H, C21), 1.03 (s, 3H, C22), 0.96 (s, 9H, C9-C11), 0.93-0.87 (m, 1H). ¹³**C NMR** (100 MHz, CDCl₃, Tautomer AB only); 186.7 (C4), 175.0 (C2), 166.2 (C12), 96.7 (C3), 94.7 (C7), 67.2 (C6), 63.4 (C5), 44.2 (C13), 43.4 (CH), 41.2 (CH), 38.6 (C20), 35.8 (C8), 33.2 (CH₂), 27.9 (C21), 25.8 (CH₂), 24.6 (C9-C11), 23.0 (C22), 19.7 (CH₂). **MS** (ES⁻); 375.24 (M-H); MS (ES⁺); 377.11 (M+H); **HRMS** (M+H); calcd for $C_{21}H_{31}N_2O_4$; 375.2289; found; 375.2285.

3.2.24. Synthesis of 4B



Yield; 80 %; M.P.; 156 °C; Form AB: CD = 90: 10; ¹H NMR (400 MHz, CDCl₃); 10.53 (brs, 1H, NH or OH), 9.53 (brs, 1H, NH or OH CD), 9.36 (brs, 2H, NH or OH AB), 7.59 (d, 2H, J = 8.4 Hz,Ar-H, AB), 7.47 (d, 2H, J = 8.4 Hz,Ar-H, CD), 7.41-

7.14 (m, 3H, Ar-H), 4.87 (s, 1H, C7 CD), 4.85 (s, 1H, C7 AB), 4.49 (dd, 1H, $J_1 = 8.0$ Hz, $J_2 = 7.2$ Hz, C5 AB), 4.36-4.29 (m, 1H, C6 AB and 1H C5 CD), 4.11 (dd, 1H, $J_1 = 8.0$ Hz, $J_2 = 6.8$ Hz, C6 CD), 3.52-3.43 (m, 1H, C6), 1.01 (m, 9H, C9-C11). ¹³**C NMR** (125 MHz, CDCl₃, Tautomer AB only); 184.7 (C4), 174.5 (C2), 163.9 (C12), 136.5 (C13), 129.1 (C16 and C17), 125.0 (C18), 120.3 (C14 and C15), 99.5 (C3), 94.8 (C7), 67.4 (C6), 62.7 (C5), 35.8 (C8), 24.6 (C9-C11). **MS** (ES⁻); 315.16 (M-H), **HRMS** (M-H); calcd for $C_{17}H_{19}N_2O_4$; 315.1350; found; 315.1352.

3.2.25. Synthesis of 4C



Yield; 57 % (oil); Form AB: CD = 80: 20; ¹H NMR (500 MHz, CDCl₃); 7.37 (brs, 1H, NH or OH), 5.57 (brs, 1H, NH or OH), 4.80 (s, 1H, C8 CD), 4.77 (s, 1H, C8 AB), 3.81 (d, 1H, J = 8.8 Hz, C5 AB), 3.67-3.62 (m, 1H, C6), 3.55 (d, 1H, J = 9.1 Hz, C5 CD), 2.14 (brs, 3H, C21-C23 CD), 2.11 (brs, 3H, C21-C23 AB), 2.06 (brs, 6H, C15-

C16 and C19), 1.70 (brs, 6H, C17, C18 and C20), 1.45 (d, 3H, J = 7.3 Hz, C7 AB), 1.454(d, 3H, J = 7.3 Hz, C7 CD), 0.97 (s, 9H, C10-C12). ¹³**C** NMR (125 MHz, CDCl₃, Tautomer AB only); 186.7 (C4), 175.1 (C2), 166.0 (C13), 96.7 (C3), 94.7 (C8), 75.7 (C6), 68.8 (C5), 52.8 (C14), 41.6 (CH₂), 36.1 (CH₂), 29.3 (C21-C23), 24.7 (C10-C12), 17.3 (C7). **MS** (ES⁻); 387.24 (M-H); **HRMS** (M-H); calcd for C₂₂H₃₁N₂O₄; 387.2289; found; 387.2290.

3.2.26. Synthesis of 4D



Yield; 39 % (oil); Form AB: CD = 80: 20; ¹H NMR (500 MHz, CDCl₃); 9.95 (brs, NH or OH), 7.91 (brs, 1H, NH or OH CD), 7.53 (brs, 1H, NH or OH AB), 4.79 (s, 1H, C8 CD), 4.77 (s, 1H, C8 AB), 3.84 (d, 1H, J = 8.8 Hz, C5 AB), 3.66-3.61 (m, 1H, C6), 3.55 (d, 1H, J = 9.1 Hz, C5 CD), 3.46-3.28 (m, 2H, C14), 2.40-2.33

(m, 1H), 2.27-2.21 (m, 1H), 1.98-1.85 (m, 5H), 1.52-1.42 (m, 4H, C7 and CH₂), 1.19 (s, 3H, C22 CD), 1.18 (s, 3H, C22 AB), 1.03 (s, 3H, C23), 0.96 (s, 9H, C10-C12), 0.88 (d, 1H, *J* = 9.5 Hz). ¹³**C NMR** (125 MHz, CDCl₃); 191.0 (C4 CD), 185.4 (C4 AB), 181.0 (C2 CD), 174.8 (C2 AB), 166.8 (C13 CD), 166.0 (C13 AB), 97.2 (C3), 94.7 (C8 CD), 94.5 (C8 AB), 75.6 (C6 AB), 74.8 (C6 CD), 72.4 (C5 CD), 68.6 (C5 AB), 45.2 (C14 CD), 44.2 (C14 AB), 43.4 (C15 AB), 43.2 (C15 CD), 41.2 (C19 and C20 AB), 41.1 (C19 and C20 CD), 38.62 (C21), 35.5 (C9 AB), 35.4 (C9 CD), 33.2 (CH₂ AB), 33.0 (CH₂ CD), 27.9 (C22 AB), 27.8 (C22 CD), 25.9 (CH₂ AB), 25.8

(CH₂CD), 24.7 (C10-C12 CD), 24.6 (C10-C12 AB), 23.1 (C23 AB), 23.0 (C23 CD), 19.7 (CH₂ AB), 19.5 (CH₂ CD), 17.4 (C7 CD), 17.3 (C7 AB). **MS** (ES⁻); 387.26 (M-H); **HRMS** (M-H); calcd for C₂₂H₃₃N₂O₄; 389.2446; found; 389.2439.

3.2.27. Synthesis of 4E



Yield; 20 % (oil); Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 9.37 (brs, 1H, NH or OH), 8.50 (brs, 1H, NH or OH), 7.59 (2H, d, J = 7.8. Hz, C15 and C16), 7.35 (t, 2H, J = 7.8 Hz, C17 and C18), 7.16 (t, 1H, J = 7.8 Hz, C19), 4.84 (s, 1H, C8), 3.97 (d, 1H, J = 8.6 Hz, C5), 3.74-3.67 (m, 1H, C6), 1.49 (d, 3H, J = 5.8 Hz, C7),

1.01 (s, 9H, C10-C12). ¹³**C NMR** (100 MHz, CDCl₃); 183.9 (C4), 174.4 (C2), 163.9 (C13), 136.5 (C14), 129.1 (C17 and C18), 124.9 (C19), 120.3 (C15 and C16), 99.6 (C3), 94.8 (C8), 75.9 (C6), 68.1 (C5), 35.6 (C9), 24.7 (C10-C12), 17.2 (C7). **MS** (ES⁻); 329.15 (M-H); **HRMS** (M-H); calcd for $C_{18}H_{21}N_2O_4$; 329.1507; found; 329.1509.

3.2.28. Synthesis of 4F



Yield; 48 %; M.P.; 119 °C; Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 9.38 (brs, 1H, NH or OH), 8.01 (d, 1H, J = 9.2 Hz, C15), 7.25-7.14 (m, 2H, C17 and C18), 4.85 (s, 1H, C8), 3.98 (d, 1H, J = 8.6 Hz, C5), 3.74-3.68 (m, 1H, C6), 2.35 (s, 3H, C20), 1.50 (d, 3H, J = 6.1 Hz, C7), 1.01 (s, 9H, C10-C12). ¹³C

NMR (125 MHz, CDCl₃); 183.7 (C4), 174.4 (C2), 163.9 (C13), 133.4 (quart Ar-C), 130.4 (C18), 130.2 (quart Ar-C), 130.1 (quart Ar-C), 126.6 (C17), 122.8 (C15), 99.9 (C3), 94.7 (C8), 75.9 (C6), 68.1 (C5), 35.6 (C9), 24.7 (C10-C12), 17.7 (CH₃), 17.3 (CH₃). **MS** (ES⁻); 377.14 (M-H), **HRMS** (M-H); calcd for C₁₉H₂₂Cl₁N₂O₄; 377.1274; found; 377.1267.

3.2.29. Synthesis of 4G



Yield; 31 %; M.P.; 97 °C; Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 7.84 (brs, 1H, NH or OH CD), 7.41 (brs, 1H, NH or OH AB), 5.00 (s, 1H, C7 CD), 4.95 (s, 1H, C7 AB), 4.49 (dd, 1H, J_1 = 9.6 Hz, J_2 = 6.8 Hz, C5 AB), 4.25 (dd, 1H, J_1 = 9.6 Hz, J_2 = 6.8 Hz, C5 AB), 4.25 (dd, 1H, J_1 = 9.6 Hz, J_2 = 6.8 Hz, C5 AB), 2.78-2.72 (m,

1H, C6), 2.10 (brs, 3H, C20-C22), 2.05 (brs, 6H, C14, C15 and C18), 1.69 (brs, 6H, C16, C17 and C19), 1.00 (s, 9H, C9-C11). ¹³**C NMR** (100 MHz, CDCl₃, Tautomer AB only); 187.4 (C4), 172.1 (C2), 166.0 (C12), 94.4 (C3), 69.6 (C7), 67.7 (C5), 52.9 (C13), 41.6 (C14, C15 and C18), 37.4 (C8), 36.1 (C16, C17 and C19), 31.8 (C6), 29.3 (C20-C22), 26.2 (C9-C11). **MS** (ES⁻); 389.17 (M-H); **HRMS** (M-H); calcd for $C_{21}H_{29}N_2O_3S_1$; 389.1904; found; 389.1893.

3.2.30. Synthesis of 4H



Yield; 41 %; M.P.; 143 °C; Form AB: CD = 80: 20; ¹H NMR (500 MHz, CDCl₃); 7.69 (brs, 1H, NH or OH), 7.55 (brs, 1H, NH or OH), 5.02 (s, 1H, C7 CD), 4.97 (s, 1H, C7 AB), 4.55 (dd, 1H, J_1 = 9.6 Hz, J_2 = 6.8 Hz, C5 AB), 4.28 (dd, J_1 = 9.8 Hz, J_2 = 6.8 Hz, C5 CD), 3.44-3.29 (m, 2H, C13), 3.17 (dd, J_1 = 10.7 Hz, J_2

= 6.6 Hz, C6), 2.80-2.73 (m, 1H, C6), 2.40-2.35 (m, 1H), 2.31-2.22 (m, 1H), 2.02-1.84 (m, 5H), 1.54-1.45 (m, 1H), 1.21 (s, 3H, C21 CD), 1.20 (s, 3H, C21 AB), 1.04 (s, 3H, C22), 1.02 (s, 9H, C9-C11), 0.92-0.88 (m, 1H). ¹³C NMR (125 MHz, CDCl₃); 191.3 (C4 CD), 186.2 (C4 AB), 177.7 (C2 CD), 171.8 (C2 AB), 166.6 (C12 CD), 166.2 (C12 AB), 95.0 (C3 AB), 84.1 (C3 CD), 71.5 (C7 CD), 70.4 (C5 CD), 69.5 (C7 AB), 67.5 (C5 AB), 45.3 (C13 CD), 44.3 (C13 AB), 43.5 (C14 AB), 43.2 (C14 CD), 41.2 (C18 and C19 AB), 41.1 (C18 and C19 CD), 38.7 (C20), 37.4 (C8 AB), 37.4 (C8 CD), 33.2 (CH₂ AB), 33.1 (CH₂ CD), 32.1 (C6 AB), 31.8 (C6 CD), 27.9 (C21 AB), 27.9 (C21 CD), 26.2 (C9-C11), 25.9 (CH₂ AB), 25.8 (CH₂ CD), 23.1 (C22 AB), 23.0 (C22 CD), 19.7 (CH₂ AB), 19.5 (CH₂ CD). MS (ES⁻); 391.21 (M-H); HRMS (M-H); calcd for C₂₁H₃₁N₂O₃S₁; 391.2061; found; 391.2063.

3.2.31. Synthesis of 4I



Yield; 38% (oil); Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 10.87 (brs, 1H, NH or OH), 7.92 (brs, 1H, NH or OH CD), 7.58 (brs, 1H, NH or OH AB), 5.00 (s, 1H, C7 CD), 4.95 (s, 1H, C7 AB), 4.54 (dd, 1H, J_1 = 9.6 Hz, J_2 = 6.8 Hz, C5 AB), 4.26 (dd, J_1 = 9.8 Hz, J_2 = 6.8 Hz, C5 CD), 3.25-3.11 (m, 3H, C6 and C13), 2.75 (dd, 1H, J_1 =

10.4 Hz, $J_2 = 10.0$ Hz, C6), 1.75-1.67 (m, 6H, CH₂), 1.58-1.47 (m, 1H, C14), 1.24-1.09 (m, 4H, CH₂), 1.00 (s, 9H, C9-C11). ¹³**C NMR** (125 MHz, CDCl₃, Tautomer AB only); 185.9 (C4), 171.8 (C2), 166.1 (C12), 95.6 (C3), 69.6 (C7), 67.2 (C5), 44.9 (C13), 37.8 (C14), 37.4 (C8), 31.8 (C6), 30.7 (CH₂), 26.2 (C9-C11), 25.7 (CH₂). **MS** (ES⁻); 351.18 (M-H); **HRMS** (M-H); calcd for C₁₈H₂₇N₂O₃S₁; 351.1748; found; 351.1742.

3.2.32. Synthesis of 4J



Yield; 42 %; M.P.; 121 °C; Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 10.13 (brs, 1H, NH or OH), 7.86 (brs, 1H, NH or OH), 7.53 (brs, 1H, NH or OH), 5.01 (s, 1H, C7 CD), 4.96 (s, 1H, C7 AB), 4.55 (dd, 1H, J_1 = 9.6 Hz, J_2 = 6.8 Hz, C5 AB), 4.28 (dd, 1H, J_1 = 9.6 Hz, J_2 = 6.9 Hz, C5

CD), 3.42-3.31 (m, 2H, C13), 3.16 (dd, $J_1 = 10.7$ Hz, $J_2 = 6.6$ Hz, C6), 2.75 (dd, 1H, $J_1 = 10.4$ Hz, $J_2 = 10.0$ Hz, C6), 1.61-1.53 (m, 2H, C14), 1.31-1.26 (m, 12H, C15-C20), 1.00 (s, 9H, C9-C11), 0.88 (t, 3H, J = 6.4 Hz, C21). ¹³C NMR (100 MHz, CDCl₃); 191.3 (C4 CD), 185.8 (C4 AB), 177.7 (C2 CD), 171.8 (C2 AB), 166.6 (C12 CD), 166.0 (C12 AB), 95.2 (C3 AB), 84.1 (C3 CD), 71.5 (C7 CD), 70.4 (C5 CD), 69.4 (C7 AB), 67.4 (C5 AB), 40.0 (C13 CD), 38.8 (C13 AB), 37.4 (C8 AB), 37.3 (C8 CD), 32.1 (C6 CD), 31.8 (C6 AB), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂ AB), 29.1 (CH₂ CD), 26.8 (CH₂ AB), 26.6 (CH₂ CD), 26.2 (C9-C11), 22.6 (CH₂), 14.1 (C21). MS (ES⁻); 381.22 (M-H); HRMS (M-H); calcd for C₂₀H₃₃N₂O₃S₁; 381.2217; found; 381.2221. Electronic Supplementary Material (ESI) for Chemical Science This journal is © The Royal Society of Chemistry 2013

3.2.33. Synthesis of 4K



Yield; 47 %; M.P.; 109 °C; Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 9.40 (brs, 1H, NH or OH), 7.58 (d, 2H, J = 7.6 Hz, C14 and C15), 7.36 (t, 2H, J = 9.9 Hz, C16 and C17), 7.16 (t, 1H, J = 7.3 Hz, C18), 5.01 (s, 1H, C7), 4.66 (brs, 1H, C5),

3.21 (dd, 1H, $J_1 = 10.4$ Hz, $J_2 = 6.8$ Hz, C6), 2.79 (dd, 1H, $J_1 = 10.4$ Hz, $J_2 = 10.4$ Hz, C6), 1.05 (s, 9H, C9-C11). ¹³**C** NMR (125 MHz, CDCl₃); 183.9 (C4), 171.3 (C2), 163.9 (C12), 136.5 (C13), 129.1 (C17 and C18), 124.9 (C18), 120.3 (C14 and C15), 97.9 (C3), 69.3 (C7), 66.8 (C5), 37.4 (C8), 31.7 (C6), 26.2 (C9-C11). MS (ES⁻); 331.12 (M-H); HRMS (M-H); calcd for C₁₇H₁₉N₂O₃S₁; 331.1122; found; 331.1121.

3.2.34. Synthesis of 4L



Yield; 52 %; M.P.; 118 °C; Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 10.07 (brs, 1H, NH or OH), 9.43 (brs, 1H, NH or OH), 8.00 (d, 1H, J = 8.3 Hz, C14), 7.25-7.15 (m, 2H, C16 and C17), 5.01 (s, 1H, C7), 4.67 (dd, 1H, $J_1 = 9.2$ Hz, $J_2 = 6.8$ Hz, C5), 3.21 (dd, 1H, $J_1 = 10.6$ Hz, $J_2 = 6.8$ Hz, C6), 2.80 (dd, 1H, $J_1 =$

10.6 Hz, $J_2 = 9.2$ Hz, C6), 2.34 (s, 3H, C19), 1.04 (s, 9H, C9-C11). ¹³**C** NMR (125 MHz, CDCl₃); 183.7 (C4), 171.4 (C2), 163.8 (C12), 133.5 (quart Ar-C), 130.3 (C17), 130.1 (quart Ar-C), 129.9 (quart Ar-C), 126.6 (C16), 122.7 (C14), 98.2 (C3), 68.3 (C7), 66.8 (C5), 37.4 (C8), 31.6 (C6), 26.2 (C9-C11), 17.7 (C19). **MS** (ES⁻); 379.10 (M-H); **HRMS** (M-H); calcd for $C_{18}H_{20}Cl_1N_2O_5S_1$; 379.0889; found; 379.0882.

3.2.35. Synthesis of 4M



Yield; 43 % (oil); Form AB: CD = 20: 80; ¹H NMR (500 MHz, CDCl₃); 7.49 (brs, 1H, NH or OH), 4.88 (d, 1H, J = 9.1 Hz, C7), 4.46 (t, 1H, J = 7.9 Hz, C5), 4.10 (d, 1H, J = 9.1 Hz, C7), 3.41-3.29 (m, 2H, C9), 3.21 (dd, 1H, J_1 = 11.4

Hz, $J_2 = 7.9$ Hz, C6), 2.90 (dd, 1H, $J_1 = 11.4$ Hz, $J_2 = 7.9$ Hz, C6), 1.58-1.55 (m, 2H, C10), 1.34-1.24 (m, 12 H, C11-C16), 0.87 (t, 3H, J = 6.8 Hz, C17). ¹³**C NMR** (125 MHz, CDCl₃, Tautomer AB only); 187.4 (C4), 172.9 (C2), 165.9 (C8), 95.7 (C3), 66.3 (C5), 45.3 (C7), 38.9 (C9), 31.8 (CH₂), 31.1 (C6), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 26.7 (CH₂), 22.6 (CH₂), 14.1 (C17). **MS** (ES⁻); 325.16 (M-H); **HRMS** (M-H); calcd for C₁₆H₂₅N₂O₃S₁; 325.1591; found; 325.1597.

3.2.36. Synthesis of 4N

Yield; 23 %; M.P.; 94 °C; Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 9.32 (brs, 1H, NH or OH), 7.58 (d, 2H, J = 7.8 Hz, C10 and C11), 7.37 (t, 2H, J = 7.8 Hz, C12 and C13), 7.17 (t, 1H, J = 7.8 Hz, C14), 6.64 (brs, 1H, NH or OH), 4.92 (d, 1H, J = 9.1

Hz, C7), 4.60 (t, 1H, J = 7.6 Hz, C5), 4.17 (d, 2H, J = 9.1 Hz, C7), 3.27 (dd, 1H, $J_1 = 11.1$ Hz, $J_2 = 7.6$ Hz, C6), 2.95 (dd, 1H, $J_1 = 11.1$ Hz, $J_2 = 7.6$ Hz, C6). ¹³**C** NMR (100 MHz, CDCl₃); 184.9 (C4), 172.3 (C2), 163.8 (C8),
136.4 (C9), 129.1 (C12 and C13), 125.1 (C14), 120.4 (C10 and C11), 98.8 (C3), 65.6 (C5), 45.1 (C7), 30.9 (C6). **MS** (ES⁻); 275.05 (M-H); **HRMS** (M-H); calcd for C₁₃H₁₁N₂O₃S₁; 275.0496; found; 275.0494.

3.2.37. Synthesis of 9A



Yield; 26 %; M.P.; 106 ℃ Form AB: CD = 85: 15; ¹H NMR (500 MHz, CDCl₃); 7.92 (brs, 1H, NH or OH CD), 7.43 (brs, 1H, NH or OH AB), 6.33 (brs, 2H, NH or OH), 4.82 (s, 1H, C7 CD), 4.78 (s, 1H, C7 AB), 4.35 (dd, 1H, J₁ = 9.0 Hz, J₂ = 7.0 Hz, C5 AB), 4.27 (dd, 1H, J₁ = 7.5 Hz, J₂ = 7.0 Hz, C6), 4.23 (dd, 1H, J₁ = 9.0 Hz, $J_2 = 7.0$ Hz, C5 CD), 3.40 (dd, 1H, $J_1 = 9.0$ Hz, $J_2 = 7.0$ Hz, C6), 2.33-2.30 (m, 2H, C20 and C21),

2.06-1.91 (m, 6H, CH₂), 1.71 (brs, 4H, CH₂), 1.60-1.53 (m, 2H, CH₂), 0.96 (s, 9H, C9-C11). ¹³C NMR (125) MHz, CDCl₃); 191.37 (C4 CD), 186.75 (C4 AB), 181.47 (C2 CD), 175.07 (C2 AB), 166.95 (C12 CD), 165.89 (C12 AB), 97.23 (C3 AB), 94.74 (C3 CD), 95.09 (C7 AB), 86.14 (C7 CD), 69.02 (C22 AB), 68.94 (C22 CD), 67.22 (C6 AB), 66.80 (C6 CD), 63.20 (C5 AB), 60.38 (C5 CD), 56.28 (C13 CD), 54.88 (C13 AB), 48.94 (CH₂), 43.87 (CH₂), 43.71 (CH₂ CD), 40.35 (CH₂ CD), 40.29 (CH₂), 35.77 (C8), 34.65 (CH₂), 34.40 (CH₂ CD), 30.48 (C20 and C21), 24.61 (C9-C11). **MS** (ES⁺); 413.29 (M+Na); **HRMS** (M-H); calcd for C₂₁H₂₉N₂O₅; 389.2082; found; 389.2076.

3.2.38. Synthesis of (±)-9B



Yield; 46 % (oil); Form AB: CD = 70: 30; ¹H NMR (400 MHz, CDCl₃); 8.08 (brs, 1H, NH or OH CD), 7.44 (brs, 1H, NH or OH AB), 5.42-5.34 (m, 1H, C8), 3.99 (d, 1H, J = 8.3 Hz, C7 AB), 3.94 (d, 1H, J = 8.3 Hz, C7 CD), 3.78 (d, 1H, J = 8.3 Hz, C7), 2.13 (brs, 3H, C18-C20), 2.06 (brs, 6H, C12, C13 and C16), 1.70 (brs, 6H, C14,

C15 and C17), 1.60 (s, 3H, C6 AB), 1.55 (s, 3H, C6 CD). ¹³C NMR (125 MHz, CDCl₃); 194.5 (C4 AB), 194.1 (C4 CD), 180.8 (C2 CD), 175.1 (C2 AB), 166.7 (C10 CD), 166.4 (C10 AB), 121.8 (q, J_{C-F} = 280 Hz, C9), 91.1 (C3), 84.6 (q, J_{C-F} = 36.5 Hz,C8 CD), 84.5 (q, J_{C-F} = 36.5 Hz,C8 AB), 72.9 (C7 CD), 72.8 (C7 AB), 72.4 (C5 CD), 70.3 (C5 AB), 54.9 (C11 CD), 53.9 (C11 AB), 41.5 (C12, C13 and C16), 36.9 (C14, C15 and C17 AB), 35.8 (C14, C15 and C17 CD), 29.3 (C18-C20), 20.3 (C6 CD), 20.2 (C6 AB). MS (ES); 399.16 (M-H); HRMS (M-H); calcd for C₁₉H₂₂F₃N₂O₄; 399.1537; found; 399.1541.

3.2.39. Synthesis of 9C



Yield; 29 %; M.P.; 143 °C Form AB: CD = 90: 10; ¹H NMR (400 MHz, CDCl₃); 7.89 (brs, 1H, NH or OH CD), 7.40 (brs, 1H, NH or OH AB), 4.77 (s, 1H, C8 CD), 4.75 (s, 1H, C8 AB), 3.82 (d, 1H, J = 8.6 Hz, C5 AB), 3.66-3.59 (m, 1H, C6), 3.24 (d, 1H, J = 8.6 Hz, C5 CD), 2.28 (brs, 2H, C22 and C23), 2.04-1.89 (m, 6H, CH₂), 1.69 (brs,

4H, CH₂), 1.56 (brs, 2H, CH₂), 1.42 (d, 3H, J = 6.7 Hz, C7), 0.95 (s, 9H, C10-C12). ¹³C NMR (100 MHz, CDCl₃, Tautomer AB only); 185.6 (C4), 174.9 (C2), 165.8 (C13), 97.7 (C3), 94.7 (C8), 75.7 (C6), 69.1 (C21), 68.5

(C5), 54.8 (C14), 48.9 (CH₂), 43.8 (CH₂), 40.3 (CH₂), 35.5 (C9), 34.7 (CH₂), 30.5 (C22 and C23), 24.7 (C10-C12), 17.3 (C7). **MS** (ES⁻); 403.23 (M-H); **HRMS** (M-H); calcd for C₂₂H₃₁N₂O₅; 403.2238; found; 403.2239.

3.2.40. Synthesis of 9D



Yield; 39 % (oil); Form AB: CD = 70: 30; ¹H NMR (400 MHz, CDCl₃); 8.04 (brs, 1H, NH or OH CD), 7.49 (brs, 1H, NH or OH AB), 4.61 (t, 1H, J = 8.2 Hz, C5 AB), 4.41 (t, 1H, J = 8.2 Hz, C5 CD), 4.35-4.29 (m, 1H, C6), 3.78-3.73 (m, 1H, C6), 2.13 (brs, 3H, C18-C20), 2.06 (brs, 6H, C12-C14), 1.81 (s, C9), 1.70 (brs, 6H, 15-C17). ¹³C NMR (125 MHz, CDCl₃); 190.5 (C4 CD), 189.1 (C4 AB), 178.4 (C2 CD), 171.8 (C2 AB), 166.8 (C10 CD), 166.2 (C10 AB), 123.3 (q, J_{C-F} = 284 Hz, C8), 94.9 (C3 AB), 92.2-91.1 (m, C7), 86.7 (C3 CD), 67.5 (C5 CD), 66.3 (C6 CD), 66.2 (C6 AB), 64.6 (C5 AB), 54.7 (C11 CD), 53.5 (C11 AB), 41.6 (C12-C14 CD), 41.5 (C12-C14 AB), 36.0 (C15-C17 AB), 35.8 (C15-C17 CD), 29.3 (C18-C20 AB), 29.3 (C18-C20 CD), 16.5 (C9 CD), 16.4 (C9 AB). MS (ES⁻); 399.16 (M-H); **HRMS** (M-H); calcd for C₁₉H₂₂F₃N₂O₄; 399.1537; found; 399.1539.

3.2.41. Synthesis of 9E



Yield; 50 %; M.P. 75 °C; AB: CD = 50: 50; ¹H NMR (500 MHz, CDCl₃); 10.87 (brs, 1H, NH or OH), 7.80 (brs, 1H, NH or OH a), 7.65 (brs, 1H, NH or OH c), 4.82 (d, 1H, J = 8.5 Hz, C6 a), 4.79 (d, 1H, J = 8.5 Hz, C6 c), 4.73 (s, 1H, C7 a), 4.72 (s, 1H, C7 c), 4.30-4.20 (m, 2H, C13), 3.49 (d, 1H, J = 8.5 Hz, C6 a), 3.48

(d, 1H, J = 8.5 Hz, C6 c), 2.13 (brs, 3H, C23-C25), 2.06-2.05 (m, 6H, adamantyl CH₂), 1.70 (brs, 6H, adamantyl CH₂), 1.30 (t, 3H, J = 7.5 Hz, C14), 0.93 (s, 9H, C9-C11). ¹³C NMR (125 MHz, CDCl₃); 189.6 (C4), 187.8 (C4), 182.6 (C2), 176.8 (C2), 167.7 (C13), 167.3 (C13), 166.9 (C15), 166.6 (C15), 97.5 (C7), 97.3 (C7), 90.9 (C3), 84.9 (C3), 78.4 (C5), 76.5 (C5), 68.6 (C6), 68.4 (C6), 62.6 (C13), 62.4 (C13), 54.7 (C16), 54.1 (C16), 41.5 (C17, C18 and C21), 41.4 (C17, C18 and C21), 35.9 (C19, C20 and C22), 35.8 (C19, C20 and C22), 35.1 (C8), 35.0 (C8), 29.2 (C23-C25), 24.7 (C9-C11), 24.6 (C9-C11), 14.1 (C14), 14.0 (C14). MS (ES); 445.23 (M-H); **HRMS** (M-H); calcd for C₂₄H₃₃N₂O₆; 445.2344; found; 445.2349.

3.2.42. Synthesis of 9F



Yield; 48 % (oil); Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 10.41 (brs, 1H, OH), 7.61 (brs, 1H, NH), 4.65 (brs, 1H, C5), 4.34 (t, 1H, J = 7.9 Hz, C6), 3.76 (t, 1H, J = 8.5 Hz, C6), 3.47-3.31 (m, 2H, C11), 2.41-2.36 (m, 1H), 2.29-2.21 (m, 1H), 2.03-1.88 (m, 5H), 1.81 (s, 3H, C9), 1.54-1.45 (m, 1H), 1.20 (s, 3H,

C19), 1.04 (s, 3H, C20), 0.91 (d, 1H, J = 9.9 Hz). ¹³**C NMR** (125 MHz, CDCl₃); 187.9 (C4), 171.6 (C2), 166.3 (C10), 123.3 (q, J_{C-F} = 284 Hz, C8), 95.5 (C3), 91.5 (q, J_{C-F} = 34.1 Hz,C7), 66.2 (C6), 64.5 (C5), 44.5 (C11), 43.3 (C12), 41.1 (C16 and C17), 38.6 (C18), 33.1 (CH₂), 27.8 (C19), 25.8 (CH₂), 23.0 (C20), 19.6 (CH₂), 16.4 (C9). **MS** (ES⁻); 401.18 (M-H); **HRMS** (M-H); calcd for C₁₉H₂₄F₃N₂O₄; 401.1694; found; 401.1695.

3.2.43. Synthesis of (±)-9G



Yield; 32% (oil); Form AB: CD = 70: 30; ¹H NMR (400 MHz, CDCl₃); 8.14 (brs, 1H, NH or OH), 7.70 (brs, 1H, NH or OH), 7.06 (brs, NH or OH), 5.28-5.14 (m, 1H, C8), 3.87 (d, 1H, *J* = 8.0 Hz, C7 AB), 3.81 (d, 1H, *J* = 8.0 Hz, C7 CD), 3.76 (d, 1H, *J* = 8.3 Hz, C7), 3.32-3.25 (m, 1H, C11), 3.18-3.08 (m, 2H, C11 and C12), 1.75-1.62 (m,

5H, CH₂), 1.58 (s, 3H, C6 AB), 1.52 (s, 3H, C6 CD), 1.25-0.88 (m, 5H, CH₂). ¹³**C** NMR (125 MHz, CDCl₃); 192.2 (C4 CD), 189.8 (C4 AB), 175.6 (C2 CD), 169.5 (C2 AB), 167.6 (C10 CD), 166.6 (C10 AB), 121.7 (q, J_{C-F} = 280 Hz, C9), 94.1 (C3 AB), 85.5 (C3 CD), 84.2 (q, J_{C-F} = 36.0 Hz,C8 CD), 84.0 (q, J_{C-F} = 36.0 Hz,C8 AB), 73.8 (C5 CD), 71.1 (C5 AB), 70.7 (C7 AB), 70.6 (C7 CD), 45.8 (C11 CD), 45.3 (C11 AB), 37.7 (C12 CD), 37.6 (C12 AB), 30.7 (CH₂ CD), 30.6 (CH₂ AB), 26.3 (CH₂ CD), 26.1 (CH₂ AB), 25.7 (CH₂ CD), 25.5 (CH₂ AB), 20.4 (C6). **MS** (ES⁻); 361.13 (M-H); **HRMS** (M-H); calcd for C₁₆H₂₀F₃N₂O₄; 361.1381; found; 361.1381.

3.2.44. Synthesis of 9H



C15), 1.44 (d, 3H, J = 6.0 Hz, C7 AB), 1.42 (d, 3H, J = 6.0 Hz, C7 CD), 1.30-1.13 (m, 5H, CH₂), 0.96 (s, 9H, C10-C12). ¹³**C** NMR (125 MHz, CDCl₃); 191.0 (C4 CD), 185.3 (C4 AB), 181.1 (C2 CD), 174.8 (C2 AB), 166.9 (C13 CD), 166.1 (C13 AB), 97.4 (C3), 94.8 (C8 CD), 94.6 (C8 AB), 75.7 (C6 AB), 74.9 (C6 CD), 72.4 (C5 CD), 68.6 (C5 AB), 46.0 (C14 CD), 44.8 (C14 AB), 37.8 (C15), 35.5 (C9 AB), 35.4 (C9 CD), 30.7 (CH₂ AB), 30.5 (CH₂ CD), 26.2 (CH₂ AB), 26.1 (CH₂ CD), 25.7 (CH₂ AB), 25.6 (CH₂ CD), 24.7 (C10-C12 AB), 24.6 (C10-C12 AB), 17.4 (C7 CD), 17.3 (C7 AB). MS (ES⁻); 349.21 (M-H); HRMS (M-H); calcd for C₁₉H₂₉N₂O₄; 349.2133; found; 349.2134.

3.2.45. Synthesis of (±)-9I



Yield; 36 % (oil); Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 8.06 (brs, 1H, NH or OH CD), 7.64 (brs, 1H, NH or OH AB), 4.67 (s, 1H, C8), 3.89 (d, 1H, J = 8.3 Hz, C7 AB), 3.82 (d, 1H, J = 8.1 Hz, C7 CD), 3.45 (d, 1H, J = 8.3 Hz, C7 AB), 3.43 (d, 1H, J = 8.3 Hz, C7 CD), 3.13-2.97 (m, 2H, C14), 1.99 (brs, 3H, C22-C24), 1.73-1.63 (m, 6H, C16, C17 and C21), 1.59 (s, 3H, C6), 1.53 (brs, 6H,

C18, C19 and C20), 1.03 (s, 9H, C10-C12). ¹³**C NMR** (100 MHz, CDCl₃, Tautomer AB only); 189.4 (C4), 175.8 (C2), 166.6 (C13), 97.5 (C3), 97.1 (C8), 72.2 (C7), 69.7 (C5), 50.3 (C14), 40.1 (C16, C17 and C21), 36.8 (C18, C19 and C20), 34.7 (C9), 33.8 (C15), 28.1 (C22-C24), 25.5 (C10-C12), 20.6 (C6). **MS** (ES⁻); 401.26 (M-H); **HRMS** (M-H); calcd for C₂₃H₃₃N₂O₄; 401.2446; found; 401.2447.

3.2.46. Synthesis of (±)-9J



Yield; 35 %; M.P.; 164 °C Form AB: CD = 90: 10; ¹H NMR (500 MHz, CDCl₃); 8.45 (brs, 1H, NH or OH), 7.49 (brs, 1H, NH or OH), 4.65 (s, 1H, C8 CD), 4.64 (s, 1H, C8 AB), 4.11-4.03 (m,1H, C14), 3.97 (dt, 2H J_1 = 11.7 Hz, J_2 = 3.4 Hz, C17 and C18), 3.90 (d, 1H, J = 8.4 Hz, C7 AB), 3.82 (d, 1H, J = 8.4 Hz, C7 CD), 3.49 (dt, 2H

 $J_1 = 11.7$ Hz, $J_2 = 3.4$ Hz, C17 and C18), 3.44 (d, 1H, J = 8.4 Hz, C7 AB), 3.42 (d, 1H, J = 8.4 Hz, C7 CD), 1.97-1.890 (m, 2H, C15 and C16), 1.64-1.51 (m, 5H, C6, C15 and C16), 1.02 (s, 9H, C10-C12). ¹³**C NMR** (125 MHz, CDCl₃); 194.2 (C4 CD), 188.6 (C4 AB), 182.1 (C2 CD), 175.6 (C2 AB), 166.6 (C13 CD), 165.5 (C13 AB), 97.5 (C8 CD), 97.2 (C8 AB), 97.0 (C3), 73.5 (C7 CD), 72.2 (C7 AB), 71.6 (C5 CD), 69.4 (C5 AB), 66.2 (C17 and C18 CD), 66.5 (C17 and C18 AB), 46.6 (C14 CD), 45.2 (C14 AB), 34.7 (C9 AB), 34.6 (C9 CD), 32.8 (CH₂), 32.7 (CH₂), 25.5 (C10-C12), 20.7 (C6 CD), 20.5 (C6 AB). **MS** (ES⁻); 337.19 (M-H); **HRMS** (M-H); calcd for $C_{17}H_{25}N_2O_5$; 337.1769; found; 337.1768.

3.2.47. Synthesis of (±)-9K



Yield; 51% (oil); Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 4.62 (s, 1H, C8), 3.89 (d, 1H, J = 8.3 Hz, C7), 3.68 (s, 2H, C19), 3.43 (d, 1H, J = 8.3 Hz, C7), 1.94-1.65 (m, 8H, C15-C18), 1.57 (s, 3H, C6), 1.00 (s, 9H, C10-C12). ¹³C NMR (125 MHz, CDCl₃); 166.3 (C13), 97.2 (C8), 72.2 (C7), 68.4 (C5), 67.0 (C14), 66.9

(C19), 35.7 (C15 and C18), 34.6 (C9), 25.5 (C10-C12), 23.9 (C16 and C17), 20.6 (C6). **MS** (ES⁻); 351.19 (M-H); **HRMS** (M-H); calcd for C₁₈H₂₇N₂O₅; 351.1925; found; 351.1912.

3.2.48. Synthesis of (±)-9L



Yield; 38 % (oil); Form AB: CD = 80: 20; ¹H NMR (500 MHz, CDCl₃); 7.57 (brs, 1H, NH or OH CD), 7.57 (brs, 1H, NH or OH AB), 5.87 (s, 1H, C16 AB), 5.85 (s, 1H, C16 CD), 4.65 (s, 1H, C8 CD), 4.62 (s, 1H, C8 AB), 4.22 (d, 2H, J = 5.7 Hz, C14 AB), 4.13 (d, 2H, J = 5.7 Hz, C14 CD), 3.89 (d, 1H, J = 8.2 Hz, C7 AB), 3.89 (d, 1H, J = 8.2 Hz, C7 CD), 3.43 (d, 1H, J = 8.2 Hz, C7 AB), 3.41 (d, 1H, J = 8.2 Hz,

C7 CD), 2.24 (s, 3H, CH₃ CD), 2.23 (s, 3H, CH₃ AB), 2.22 (s, 3H, CH₃ CD), 2.21 (s, 3H, CH₃ AB), 1.58 (s, 3H, C6 AB), 1.49 (s, 3H, C6 CD), 1.02 (s, 9H, C10-C12 CD), 1.01 (s, 9H, C10-C12 AB). ¹³**C** NMR (125 MHz, CDCl₃); 194.1 (C4 CD), 188.6 (C4 AB), 182.2 (C2 CD), 175.5 (C2 AB), 166.8 (C13 CD), 165.8 (C13 AB), 150.5 (C18 CD), 150.2 (C18 AB), 147.6 (C17 CD), 147.3 (C17 AB), 115.3 (C15 AB), 114.4 (C15 CD), 106.7 (C16 AB), 106.5 (C16 CD), 97.5 (C8 CD), 97.1 (C8 AB), 96.9 (C3 AB), 96.8 (C3 CD), 73.4 (C7 CD), 72.2 (C7 AB), 71.6 (C5 CD), 69.4 (C5 AB), 35.0 (C9 CD), 34.6 (C9 AB), 34.5 (C14 CD), 33.8 (C14 AB), 25.4 (C10-C12), 20.7 (C6 CD), 20.6 (C6 AB), 13.4 (C20), 11.4 (C19). MS (ES⁻); 361.19 (M-H); HRMS (M-H); calcd for $C_{19}H_{25}N_2O_5$; 361.1769; found; 361.1749.

3.2.49. Synthesis of (±)-9M



Yield; 41% (oil); Form AB: CD = 99: 1; ¹H NMR (500 MHz, CDCl₃); 9.62 (brs, 1H, NH or OH), 7.78 (brs, 1H, NH or OH), 4.63 (s, 1H, C8), 3.87 (d, 1H, J = 8.4 Hz, C7), 3.41 (d, 1H, J = 8.4 Hz, C7), 3.19 (brs, 2H, C14), 1.55 (s, 3H, C6), 1.01 (brs, 10H, C10-C12 and C15), 0.53 (brs, 2H, C16 and C17), 0.22 (brs, 2H, C16 and

C17). ¹³C NMR (100 MHz, CDCl₃); 188.6 (C4), 175.9 (C2), 165.7 (C13), 97.2 (C8), 96.4 (C3), 72.3 (C7), 69.5 (C5), 43.6 (C14), 34.6 (C9), 25.5 (C10-C12), 20.7 (C6), 10.5 (C15), 3.57 (C16 and C17). **MS** (ES⁻); 307.19 (M-H); **HRMS** (M-H); calcd for C₁₆H₂₃N₂O₄; 307.1663; found; 307.1667.

3.2.50. Synthesis of (±)-9N

Yield; 39 % (oil); Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 7.55 (brs, 14, NH or OH), 4.66 (s, 1H, C8 CD), 4.64 (s, 1H, C8 AB), 3.89 (d, 1H, J = 8.3 Hz, C7 AB), 3.81 (d, 1H, J = 8.3 Hz, C7 CD), 3.43 (d, 1H, J = 8.3 Hz, C7), 3.54 (q, 2H, J = 7.6 Hz, C14), 1.63-1.51 (m, 5H, C6 and C15), 1.38-1.26 (m, 6H, C16-C18), 1.02 (s, 9H, C10-C12), 0.93-0.84 (m, 3H, C19). ¹³C NMR (100 MHz, CDCl₃, Tautomer AB only); 189.2 (C4), 175.7 (C2), 166.3 (C13), 97.5 (C3), 97.1 (C8), 72.2 (C7), 69.6 (C5), 38.8 (C14), 34.7 (C9), 31.4 (CH₂), 29.4 (CH₂), 26.5 (CH₂), 25.5 (C10-C12), 22.5 (CH₂), 20.6 (C6), 13.9 (C19). MS (ES⁻); 337.21 (M-H), HRMS (M-H); calcd for C₁₈H₂₉N₂O₄; 337.2133; found; 337.2135.

3.2.51. Synthesis of (±)-90



Yield; 33 % (oil); Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 8.63 (brs, 1H, NH or OH), 8.14 (brs, 1H, NH or OH CD), 7.78 (brs, 1H, NH or OH AB), 4.65 (s, 1H, C8 CD), 4.63 (s, 1H, C8 AB), 3.88 (d, 1H, *J* = 8.1 Hz, C7 AB), 3.81 (d, 1H, *J* 8.3 Hz, C7 CD), 3.61-3.36 (m, 6H, C7, C14, C16 and C17), 1.89-1.77

(m, 2H, C15), 1.57 (s, 3H, C6 AB), 1.50 (s, 3H, C6 CD), 1.17 (d, 3H, J = 6.4 Hz, C18), 1.16 (d, 3H, J = 6.4 Hz, C19), 1.01 (s, 9H, C10-C12). ¹³**C** NMR (100 MHz, CDCl₃, Tautomer AB only); 189.2 (C4), 175.5 (C2), 166.2 (C13), 97.5 (C3), 97.1 (C8), 72.2 (C7), 71.8 (C17), 69.5 (C5), 65.8 (C16), 36.7 (C14), 34.6 (C9), 29.6 (C15), 25.5 (C10-C12), 21.9 (C18 and C19), 20.6 (C6). **MS** (ES⁻); 353.22 (M-H), **HRMS** (M-H); calcd for C₁₈H₂₉N₂O₅; 353.2082; found; 353.2076.

3.2.52. Synthesis of (±)-9P



Yield; 44 %; M.P.; 87 °C Form AB: CD = 80: 20; ¹H NMR (500 MHz, CDCl₃); 9.04 (br s, 1H, NH or OH), 7.60 (br s, 1H, NH or OH), 4.66 (s, 1H, C8 CD), 4.64 (s, 1H, C8 AB), 3.89 (d, 1H, J = 8.3 Hz, C7 AB), 3.81 (d, 1H, J = 8.3 Hz, C7 CD), 3.44 (d, 1H, J = 8.3 Hz, C7 AB), 3.42 (d, 1H, J = 8.3 Hz, C7 CD), 3.37-3.13 (m,

2H, C14), 1.71-1.61 (m, 1H, C15), 1.58 (s, 3H, C6 AB), 1.53 (s, 3H, C6 CD), 1.47-1.40 (m, 1H, C17), 1.24-1.15 (m, 1H, C17), 1.02 (s, 9H, C10-C12), 0.98-0.88 (m, 6H, C16 and C18). ¹³**C NMR** (125 MHz, CDCl₃); 194.3 (C4 CD), 189.2 (C4 AB), 181.8 (C2 CD), 175.8 (C2 AB), 167.3 (C13 CD), 166.4 (C13 AB), 97.5 (C8 CD), 97.1 (C8 AB), 96.2 (C3), 73.3 (C7 CD), 72.2 (C7 AB), 71.1 (C5 CD), 69.6 (C5 AB), 45.4 (C14 CD), 44.3 (C4 AB), 34.84 and 34.84 (C15 AB), 34.80 and 34.77 (C15 CD), 34.7 (C9 AB), 34.6 (C9 CD), 26.88 and 26.84 (C17 AB), 26.70 and 26.65 (C17 CD), 25.5 (C10-C12), 20.8 (C6 CD), 20.6 (C6 AB), 17.1 (C16 AB), 16.9 (C16 CD), 11.22 and 11.20 (C18 AB), 11.14 and 11.10 (C18 CD). **MS** (ES⁻); 323.20 (M-H), **HRMS** (M-H); calcd for $C_{17}H_{27}N_2O_4$; 323.1976; found; 323.1969.

3.2.53. Synthesis of (±)-9Q



Yield; 39 % (oil); Form AB: CD = 80: 20; ¹H NMR (400 MHz, CDCl₃); 8.85 (brs, 1H, NH or OH), 8.13 (brs, 1H, NH or OH CD), 7.89 (brs, 1H, NH or OH AB), 7.34-7.27 (m, 2H, C19 and C20), 6.97 (t, 1H, *J* = 7.6 Hz, C21), 6.91 (d, 2H, *J* =

7.6 Hz, C17 and C18), 4.66 (s, 1H, C8 CD), 4.64 (s, 1H, C8 AB), 4.13 (t, 2H, J = 5.3 Hz, C15 CD), 4.09 (t, 2H, J = 5.3 Hz, C15 AB), 3.90 (d, 1H, J = 8.3 Hz, C7), 3.83-3.81 (m, 2H, C14 CD), 3.76 (q, 2H, J = 5.6 Hz, C14), 3.44 (d, 1H, J = 8.3 Hz, C7 AB), 3.44 (d, 1H, J = 8.3 Hz, C7 CD), 1.59 (s, 3H, C6 AB), 1.52 (s, 3H, C6 CD), 1.02 (s, 9H, C10-C12). ¹³**C** NMR (100 MHz, CDCl₃, Tautomer AB only); 188.1 (C4), 175.3 (C2), 166.4 (C13), 158.4 (C16), 129.5 (C19 and C20), 121.2 (C21), 114.6 (C17 and C18), 97.2 (C3), 97.1 (C8), 72.3 (C7), 69.3 (C5), 66.1 (C15), 38.2 (C14), 34.7 (C9), 25.5 (C10-C12), 20.6 (C6). MS (ES⁻); 373.19 (M-H), HRMS (M-H); calcd for C₂₀H₂₅N₂O₅; 373.1769; found; 373.1767.

3.2.54. Synthesis of (±)-9R



Yield; 21 % (oil); Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 7.78 (brs, 1H, NH or OH), 4.62 (s, 1H, C8), 3.89 (d, 1H, *J* = 8.3 Hz, C7), 3.79 (brs, 2H, C19 and C20), 3.84-3.40 (m, 3H, C7 and C14), 3.07 (brs, 2H, C19 and C20), 2.90 (s, 2H, C16), 2.14-2.06 (m, 2H, CH₂), 1.88-1.57 (m, 6H, CH₂), 1.58 (s,

3H, C6), 1.30 (s, 6H, C17 and C18), 1.00 (s, 9H, C10-C12). ¹³**C** NMR (125 MHz, CDCl₃); 166.7 (C13), 97.2 (C8), 72.1 (C7), 66.2 (C16), 58.5 (CH₂), 47.1 (CH₂), 36.5 (C15), 34.6 (C9), 27.9 (CH₂), 25.4 (C10-C12), 24.1 (C17 and C18), 22.4 (CH₂), 20.6 (C6). **MS** (ES⁺); 444.29 (M+Na); **HRMS** (M+Na); calcd for $C_{23}H_{39}N_3Na_1O_4$; 444.2833; found; 444.2814.

3.2.55. Synthesis of (±)-9S



Yield; 23 %; M.P.; 139 °C Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 7.79 (brs, NH or OH), 7.49 (brs, NH or OH), 5.91-5.80 (m, 1H, C13), 5.07-5.03 (m, 2H, C14), 4.67 (s, 1H, C8), 3.89 (d, 1H, J = 8.3 Hz, C7), 3.79-3.69 (m, 2H, C21 and C22), 3.51-3.36 (m, 3H, C7 and C16), 3.07 (brs, 2H, C21 and C22), 2.90 (s, 2H, C18), 2.18-2.02 (m, 4H, C12 and CH₂), 1.82-1.64 (m, 6H, CH₂), 1.58 (s, 3H, C6), 1.29 (s, 6H, C19 and C20), 0.98 (s, 3H, C10), 0.95 (s, 3H, C11). ¹³**C NMR** (125 MHz, CDCl₃); 166.7 (C15), 134.4 (C13), 117.7 (C14), 96.6 (C8), 72.2 (C7), 66.2 (C20), 58.5 (C21 and C22), 47.1 (C16), 42.5 (C12), 37.5 (C9), 36.6 (C17), 27.9 (C19 and C20), 24.1 (CH₂), 22.5 (C10), 22.2 (CH₂), 22.1 (C11), 20.6 (C6). **MS** (ES⁻); 446.30 (M-H); **HRMS** (M-H); calcd for $C_{25}H_{40}N_3O_4$; 446.3024; found; 446.3027.

3.2.56. Synthesis of (±)-9T



Yield; 42 % (oil); Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 7.90 (d, 1H, J = 7.6 Hz, NH), 7.61 (d, 1H, J = 6.8 Hz, C18), 7.47 (s, 1H, C17), 7.42-7.31 (m, 2H, C16 and C20), 4.58 (s, 1H, C8), 4.52 (d, 2H, J = 5.8 Hz, C14), 4.12 (s, 2H, C21), 3.86 (d, 1H, J = 8.1 Hz, C7), 3.47-3.34 (m,

3H, C7, C22 and C23), 2.62 (t, 2H, J = 12.0 Hz, C22-C23), 1.99-1.86 (m, 2H, C24 and C25), 1.79-1.66 (m, 3H, C24-C26), 1.55 (s, 3H, C6), 0.96-0.93 (m, 12H, C10-C12 and C27). ¹³**C** NMR (125 MHz, CDCl₃); 187.9 (C4), 175.3 (C2), 165.9 (C13), 138.4 (quart C), 130.9 (quart C), 130.7 (tert C), 129.7 (tert C), 129.2 (tert C), 97.5 (C3), 97.0 (C8), 72.1 (C7), 69.3 (C5), 60.4 (C21), 52.4 (C22 and C23), 42.1 (C14), 34.6 (C9), 30.7 (C24 and C25), 29.1 (C26), 25.4 (C10-C12), 20.9 (CH₃), 20.5 (CH₃). **MS** (ES⁺); 478.28 (M+Na); **HRMS** (M+Na); calcd for C₂₆H₃₇N₃Na₁O₄; 478.2676; found; 478.2667.

3.2.57. Synthesis of (±)-9U



Yield; 27 %; M.P.; 129 °C Form AB: CD = not determined; ¹H NMR (400 MHz, CDCl₃); 7.89-7.35 m, 4H, C18-C21), 5.87-5.77 (m, 1H, C13), 5.04-5.00 (m, 2H, C14), 4.64 (s, 1H, C8), 4.53 (brs, 2H, C16), 4.12 (brs, 2H, C23), 3.88 (d, 1H, J = 7.8 Hz, C7), 3.49-3.30 (m, 3H,

C7, C24 and C25), 2.60 (brs, 2H, C24-C25), 2.15-1.95 (m, 5H, C12 and C26-C28), 1.76-1.72 (m, 2H, C26 and C27), 1.57 (brs, 3H, C6), 0.97-0.92 (m, 9H, C10-C11, C29). ¹³**C NMR** (125 MHz, CDCl₃); 188.0 (C4), 175.4 (C2), 165.9 (C15), 138.5 (C22), 134.4 (C13), 130.9 (tert C), 130.8 (tert C), 129.8 (tert C), 129.3 (tert C), 128.8 (C17), 117.7 (C14), 97.5 (C3), 96.5 (C8), 72.2 (C7), 69.3 (C5), 60.6 (C23), 52.5 (C24 and C25), 42.5 (C12), 42.1 (C16), 37.5 (C9), 30.7 (C26 and C27), 29.2 (C28), 22.5 (C10), 22.2 (C11), 20.9 (CH₃), 20.6 (CH₃). **MS** (ES⁺); 481.30 (M+H), 504.28 (M+Na); **HRMS** (M+Na); calcd for C₂₈H₃₉N₃Na₁O₄; 504.2833; found; 504.2837.

3.2.58. Synthesis of (±)-9V



Yield; 39 %; M.P.; 161 °C, Form AB: CD = 99: 1; ¹H NMR (400 MHz, CD₃OD); 7.46 (d, 1H, J = 5.1 Hz, C24), 7.39 (d, 1H, J = 3.4 Hz, C22), 7.16 (d, 1H, $J_1 = 5.1$ Hz, $J_2 = 3.4$ Hz, C23), 4.61 (s, 1H, C8), 4.58 (s, 2H, C20), 3.92 (d, 1H, J = 8.4 Hz, C7), 3.63-3.53 (m, 2H, C18 and 19), 3.45 (d, 1H,

J = 8.4 Hz, C7), 3.31 (m, 1H, C15), 3.11-2.96 (m, 2H, C18 and 19), 2.01-1.98 (m, 2H, C16 and C17), 1.61-

1.51 (m, 5H, C6, C16 and 17), 1.00 (s, 9H, C10-C12). ¹³**C NMR** (125 MHz, CD₃OD); 190.0 (C4), 178.2 (C2), 167.3 (C13), 133.9 (tert C), 130.9 (C21), 130.5 (tert C), 128.9 (tert C), 99.0 (C3), 98.6 (C8), 73.3 (C7), 71.1 (C5), 55.1 (CH₂), 53.0 (CH₂), 43.9 (C14), 35.6 (C9), 35.4 (C15), 28.3 (C16 and C17), 26.1 (C10-C12), 21.4 (C6). **MS** (ES⁻); 446.21 (M-H); **HRMS** (M-H); calcd for C₂₃H₃₂N₃O₄S₁; 446.2119; found; 446.2123.

3.2.59. Synthesis of (±)-9W



Yield; 51 %; M.P.; 179 °C, Form AB: CD = 80: 20; ¹H NMR (400 MHz, CD-₃OD): 7.56-7.52 (m, 5H, C23-C27), 5.92 (brs, 1H, C13), 5.06 (brs, 2H, C14), 4.70 (s, 1H, C8 CD), 4.66 (s, 1H, C8 AB), 4.43 (s, 2H, C21 CD), 4.35 (s, 2H, C21 AB), 4.26 (brs, 1H, C16 CD), 4.11 (brs, 1H, C16 AB),

3.94 (d, 1H, *J* = 6.0 Hz, C7), 3.57-3.55 (m, 2H, C19-C20), 3.44 (d, 1H, *J* = 6.0 Hz, C7), 3.20-3.14 (m, 2H, C19-C20), 2.24-2.16 (m, 4H, C12, C17 and C18), 1.88-1.85 (m, 2H, C17 and C18), 1.57 (s, 3H, C6), 0.98 (s, 3H, C10), 0.96 (s, 3H, C11). ¹³**C NMR** (125 MHz, CD₃OD and CDCl₃, Tautomer AB only): 189.2 (C4), 178.1 (C2), 166.3 (C13), 135.9 (C13), 132.4 (tert C), 131.4 (tert C), 130.5 (tert C), 130.3 (C22), 118.0 (C14), 98.0 (C8), 97.6 (C3), 73.3 (C7), 70.9 (C5), 61.7 (C21), 52.6 (C19 and C20), 45.1 (C16), 43.9 (C12), 38.5 (C9), 30.2 (C17 and C18), 23.2 (C10), 22.9 (C11), 21.4 (C6). **MS** (ES⁻); 452.27 (M-H), **HRMS** (M-H); calcd for C₂₆H₃₄N₃O₄; 452.2555; found; 452.2553.

3.2.60. Synthesis of (±)-9X



Yield; 23 % (oil); Form AB: CD = 99: 1; ¹H NMR (500 MHz, CDCl₃); 8.04 (brs, 1H, NH or OH), 5.89-5.81 (m, 1H, C13), 5.06-5.03 (m, 2H, C14), 4.67 (s, 1H, C8), 4.02-3.80 (m, 2H, C7 and CH₂), 3.70-3.61 (m, 2H), 3.53-3.44 (m, 3H, C7 and CH₂), 3.28-3.26 (m, 1H), 3.01-2.92 (m, 1H), 2.16-2.07 (m,

2H, C12), 1.99-1.84 (m, 4H), 1.71-1.66 (m, 1H), 1.57 (s, 3H, C6), 1.52-1.42 (m, 2H, C24), 1.35-1.26 (m, 1H), 0.96-0.91 (m, 9H, C10, C11 and C25). ¹³**C NMR** (125 MHz, CDCl₃, two set of signals in some case caused by two diastereomers); 166.9 (C15), 134.6 (C13), 117.7 (C14), 96.6 (C8), 72.1 (C7), 57.3 and 57.0 (C17), 48.5 and 48.4 (CH₂), 48.1 and 48.0 (CH₂), 42.5 (CH₂), 38.9 and 38.7 (CH₂), 37.5 (C9), 35.2 (C23), 24.9 (CH₂), 24.7 (C19), 23.9 and 23.8 (CH₂), 22.5 (C10), 22.2 (C11), 20.6 and 20.5 (C6), 11.5 (C25). **MS** (ES⁺); 432.30 (M+H), 454.28 (M+Na); **HRMS** (M+Na); calcd for C₂₄H₃₇N₃Na₁O₄; 454.2676; found; 454.2674.

3.2.61. Synthesis of 9Y



Yield; 43 % (oil); Form AB: CD = 85: 15; ¹H NMR (500 MHz, CDCl₃); 7.89 (brs, 1H, NH or OH CD), 7.58 (brs, 1H, NH or OH AB), 6.72 (brs, 1H, NH or OH CD), 6.59 (brs, 1H, NH or OH AB), 4.80 (s, 1H, C7 AB), 4.79 (s, 1H, C7 CD), 4.40 (t, 1H, *J* = 8.0 Hz, C5), 4.31-4.28 (m, 1H, C6), 3.97-3.92 (m, 1H, C13), 3.74-3.61 (m, 2H, C16),

3.44-4.41 (m, 1H, C6), 1.71-1.53 (m, 2H, C14), 1.00-0.96 (m, 12H, C9-C11 and C15). ¹³C NMR (125 MHz,

CDCl₃, tautomer AB only); 186.77 and 185.60 (C4), 174.85 and 174.79 (C2), 166.53 and 166.48 (C12), 97.78 and 97.65 (C3), 94.77 and 94.72 (C7), 67.24 and 67.21 (C6), 64.93 and 64.80 (C16), 63.02 (C5), 53.16 and 53.02 (C13), 35.76 (C8), 24.59 (C9-C11), 24.13 (C14), 10.44 (C15). **MS** (ES⁻); 311.16 (M-H); **HRMS** (M-H); calcd for $C_{15}H_{23}N_2O_5$; 311.1612; found; 311.1607.

3.2.62. Synthesis of **9Z**

Yield; 41 %; M.P. 127 °C; AB: CD = 75: 25; ¹H NMR (400 MHz, CDCl₃); 10.37 (s, ¹) J_{14} J_{14} J_{14} J_{16} ¹) J_{14} J_{14} J_{16} ¹) J_{16} ¹

3.2.63. Synthesis of 9AA



Yield; 31 % (oil); Form AB: CD = 90: 10; ¹H NMR (400 MHz, CDCl₃); 8.04 (d, 1H, J = 8.2 Hz, NH CD), 7.55 (d, 1H, J = 8.2 Hz, NH AB), 6.90-6.81 (m, 3H, C17-C19), 5.15-5.06 (m, 1H, C14), 4.79 (s, 1H, C8 CD), 4.75 (s, 1H, C8 AB), 3.87-3.84 (m, 5H, C5, C22 and C23), 3.66-3.58 (m, 1H, C6), 1.59 (d, 3H, J = 6.9 Hz, C7 CD),

1.52 (d, 3H, J = 6.9 Hz, C7 AB), 1.42 (d, 3H, J = 6.0 Hz, C15), 0.95 (s, 9H, C10-C12). ¹³C NMR (100 MHz, CDCl₃, Tautomer AB only); 184.7 (C4), 174.6 (C2), 165.0 (C13), 149.1 (C20), 148.5 (C21), 135.0 (C16), 118.0 (tert C), 111.3 (tert C), 109.6 (tert C), 98.2 (C3), 94.6 (C8), 75.8 (C6), 68.4 (C5), 55.93 (CH₃), 55.90 (CH₃), 48.2 (C14), 35.5 (C9), 24.6 (C10-C12), 22.3 (C15), 17.2 (C7). **MS** (ES⁻); 417.21 (M-H); **HRMS** (M-H); calcd for C₂₂H₂₉N₂O₆; 417.2031; found; 417.2033.

3.2.64. Synthesis of (±)-10A



Yield; 39 %; M.P.; 123 °C Form AB: CD = 99: 1; ¹H NMR (500 MHz, CDCl₃); 4.72 (s, 1H, C8), 4.27 (brs, 1H, C15), 3.84 (d, 1H, J = 8.8 Hz, C7), 3.42 (d, 1H, J = 8.8 Hz, C7), 3.11 (brs, 3H, C14), 1.89-1.73 (m, 4H, CH₂), 1.53 (s, 3H, C6), 1.50-1.34 (m, 4H, CH₂), 1.16-1.06 (m, 2H, CH₂), 1.02 (s, 9H, C10-C12). ¹³C NMR (125 MHz, CDCl₃);

167.1 (C13), 97.8 (C8), 72.3 (C7), 34.7 (C9), 29.7 (CH₂), 25.6 (CH₂), 25.4 (C10-C12), 21.4 (C6). **MS** (ES⁻); 349.21 (M-H); **HRMS** (M-H); calcd for $C_{19}H_{29}N_2O_4$; 349.2133; found; 349.2134.

3.2.65. Synthesis of (±)-10B



Yield; 39 % (oil); Form AB: CD = 99: 1; ¹H NMR (500 MHz, CDCl₃); 4.71 (s, 1H, C8), 4.03 (brs, 2H, C14 and C15), 3.83 (d, 1H, J = 8.5 Hz, C7), 3.62 (brs, 2H, C14 and C15), 3.41 (d, 1H, J = 8.5 Hz, C7), 1.80 (brs, 4H, CH₂), 1.59 (brs, 4H, CH₂), 1.52 (s, 3H, C6), 1.01 (s, 9H, C10-C12). ¹³C NMR (125 MHz, CDCl₃); 167.6 (C13), 97.9 (C8),

72.3 (C7), 70.3 (C5), 34.7 (C9), 25.6 (C10-C12), 21.4 (C6). **MS** (ES⁻); 335.21 (M-H); **HRMS** (M-H); calcd for C₁₈H₂₇N₂O₄; 335.1976; found; 335.1967.

3.2.66. Synthesis of (±)-10C



Yield; 72 % (oil); Form AB: CD = not determined; ¹H NMR (400 MHz, CDCl₃); 4.70 (s, 2H, C8 and CH₂), 4.49 (brs, 1H, CH₂), 3.83 (d, 1H, J = 8.3 Hz, C7), 3.41 (d, 1H, J = 8.3 Hz, C7), 2.92 (t, 1H, J = 12.1 Hz, CH₂), 2.52 (d, 1H, J = 10.6 Hz, CH₂), 1.83-1.61 (m, 6H), 1.52 (s, 3H, C6), 1.41-1.12 (m, 6H), 1.01 (s, 9H, C10-C12). ¹³C NMR (125

MHz, CDCl₃, two set of signals in some case are caused by two diastereomers); 193.76 and 193.58 (C4), 179.8 (C2), 165.88 and 165.33 (C13), 87.87 (C3), 97.80 and 97.77 (C8), 72.2 (C7), 70.38 and 70.26 (C5), 42.50 and 42.30 (CH₂), 41.80 and 41.78 (C17 and C18), 34.7 (C9), 33.1 (CH₂), 32.5 (CH₂), 29.8 (CH₂), 26.1 (C21), 26.06 and 26.03 (CH₂), 25.66 and 25.63 (CH₂), 25.5 (C10-C12), 21.38 and 21.34 (C6). **MS** (ES⁻); 375.24 (M-H); **HRMS** (M-H); calcd for $C_{21}H_{31}N_2O_4$; 375.2289; found; 375.2280.

3.2.67. Synthesis of (±)-10D



Yield; 33 % (oil); Form AB: CD = 99: 1; ¹H NMR (400 MHz, CD₃OD); 5.97-5.87 (m, 1H, C13), 5.08-5.03 (m, 2H, C14), 4.70 (s, 1H, C8), 3.93 (d, 1H, J = 8.2 Hz, C7), 3.72-3.58 (m, 4H, CH₂), 3.48 (d, 1H, J = 8.2 Hz, C7), 3.31-3.13 (m, 5H, C20 and CH₂), 2.20-2.11 (m, 4H, C12 and CH₂), 1.98-1.95 (m, 2H, CH₂), 1.76-1.72 (m, 1H, CH₂), 1.58 (s, 3H, C6), 1.56-1.22 (m, 5H, CH₂), 0.99 (s, 3H, C10), 0.98 (s, 3H, CH₂), 0.98 (s, 3H, C10), 0

C11). ¹³**C NMR** (125 MHz, CD₃OD); 178.5 (C2), 164.5 (C15), 136.1 (C13), 117.9 (C14), 99.5 (C3), 98.3 (C8), 73.4 (C7), 71.0 (C5), 67.4 (C20), 46.6 (CH₂), 44.1 (CH₂), 42.3 (C12), 38.6 (C9), 28.1 (CH₂), 26.1 (CH₂), 23.2 (C10), 23.0 (C11), 21.8 (C6). **MS** (ES⁺); 432.29 (M+H), 454.27 (M+Na); **HRMS** (M+Na); calcd for $C_{24}H_{37}N_3Na_1O_4$; 454.2676; found; 454.2674.

3.2.68. Synthesis of (±)-10E



Yield; 52 % (oil); Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 4.64 (s, 1H, C8), 3.89 (d, 1H, J = 8.4 Hz, C7), 3.45 (d, 1H, J = 8.4 Hz, C7), 2.81 (brs, 4H, C14 and C15), 1.80-1.69 (m, 4H, C16-C17), 1.58 (s, 3H, C6), 1.50-1.40 (m, 2H, C18), 1.02 (s, 9H, C10-C12). ¹³C NMR (125 MHz, CDCl₃); 97.2 (C8), 72.2 (C7),

57.1 (C14 and C15), 34.7 (C9), 25.5 (C16 and C17), 24.9 (C10-C12), 23.0 (C18), 20.6 (C6). MS (ES); 336.20

(M-H); **HRMS** (M-H); calcd for $C_{17}H_{26}N_3O_4$; 336.1929; found; 336.1928.

3.2.69. Synthesis of (±)-10F



Yield; 27 %; M.P.; 169 °C, Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 8.53 (brs, 1H, NH or OH), 7.75 (d, 2H, J = 8.3 Hz, C16 and C17), 6.66 (d, 2H, J = 8.3 Hz, C18 and C19), 4.63 (s, 1H, C8), 3.88 (d, 1H, J = 8.1 Hz, C7), 3.44 (d, 1H, J = 8.1 Hz, C7), 3.02 (s, 6H, C21 and

C22), 1.59 (s, 3H, C6), 1.02 (s, 9H, C10-C12). ¹³**C NMR** (125 MHz, CDCl₃); 186.7 (C4), 174.4 (C2), 165.3 (C13), 163.6 (C14), 152.9 (C20), 128.9 (C16 and C17), 117.8 (C15), 111.1 (C18 and C19), 98.1 (C3), 97.2 (C8), 72.2 (C7), 69.5 (C5), 40.1 (C21 and C22), 34.7 (C9), 25.4 (C10-C12), 20.6 (C6). **MS** (ES⁻); 415.21 (M-H); **HRMS** (M-H); calcd for C₂₁H₂₇N₄O₅; 415.1987; found; 415.1985.

3.2.70. Synthesis of (±)-10G



Yield; 23 %; M.P.; 151 °C, Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 7.58 (brs, 1H, NH or OH), 5.93-5.82 (m, 1H, C13), 5.09-5.05 (m, 2H, C14), 4.70 (s, 1H, C8), 3.91 (d, 1H, J = 8.3 Hz, C7), 3.46 (d, 1H, J = 8.3 Hz, C7), 2.14 (d, 2H, J = 7.3 Hz, C12), 1.61 (s, 3H, C6), 1.28 (s, 9H, C18-C20), 0.99 (s, 3H, C10),

0.97 (s, 3H, C11). ¹³**C NMR** (125 MHz, CDCl₃); 186.8 (C4), 176.0 (C16), 174.4 (C2), 163.4 (C15), 134.5 (C13), 117.7 (C14), 97.9 (C3), 96.6 (C8), 72.2 (C7), 69.4 (C5), 42.5 (C12), 38.3 (C17), 37.5 (C9), 27.2 (C18-C20), 22.5 (C10), 22.2 (C11), 20.6 (C6). **MS** (ES⁻); 378.19 (M-H); **HRMS** (M-H); calcd for C₁₉H₂₈N₃O₅; 378.2034; found; 378.2037.

3.2.71. Synthesis of (±)-10H



Yield; 31 %; M.P.; 151 °C Form AB: CD = 99: 1; ¹H NMR (400 MHz, CD₃OD); 5.97-5.87 (m, 1H, C13), 5.08-5.03 (m, 2H, C14), 4.71 (s, 1H, C8), 3.96 (d, 1H, J = 8.3 Hz, C7), 3.50 (d, 1H, J = 8.3 Hz, C7), 2.17 (dd, 2H, J_1 = 7.2 Hz, J_2 = 4.7 Hz, C12), 1.60 (s, 3H, C6), 1.27 (s, 9H, C17-C19), 1.00 (s, 3H, C10), 0.98 (s, 3H, C11). ¹³C NMR (125 MHz, CD₃OD); 134.9 (C13), 116.9 (C14), 97.1 (C8), 72.3

(C7), 69.8 (C5), 63.59 (C16), 42.9 (C12), 37.5 (C9), 26.5 (C17-C19), 22.2 (C10), 21.9 (C11), 20.4 (C6). **MS** (ES⁺); 385.19 (M+H); **HRMS** (M+H); calcd for $C_{18}H_{29}N_2O_5S_1$; 385.1792; found; 385.1789.

3.2.72. Synthesis of (±)-11A



Yield; 46 % (oil); Form AB: CD = 90: 10; ¹H NMR (500 MHz, CDCl₃); 9.44 (brs, 1H, NH or OH CD), 9.29 (brs, 1H, NH or OH AB), 7.47 (d, 2H, J = 8.8 Hz, C15 and C16 AB), 7.36 (d, 2H, J = 8.8 Hz, C15 and C16 CD), 6.88 (d, 1H, J = 8.8 Hz, C17 and C18), 4.68 (s, 1H, C8), 3.97-3.87 (m,

3H, C7 and C20), 3.48 (d, 1H, J = 8.5 Hz, C7), 1.84-1.77 (m, 2H, C21), 1.63 (s, 3H, C6 AB), 1.57 (s, 3H, C6 CD), 1.08-1.02 (m, 12H, C10-C12, C22). ¹³C NMR (125 MHz, CDCl₃); 187.8 (C4), 175.5 (C2), 163.8 (C13), 156.5 (C19), 129.3 (C14), 121.9 (C15 and C16), 114.9 (C17 and C18), 98.1 (C3), 97.2 (C8), 72.3 (C7), 69.7 (C20), 69.3 (C5), 34.7 (C9), 25.5 (C10-C12), 22.5 (C21), 20.6 (C6), 10.5 (C22). **MS** (ES⁻); 387.21 (M-H); **HRMS** (M-H); calcd for C₂₁H₂₇N₂O₅; 387.1925; found; 387.1921.

3.2.73. Synthesis of (±)-11B



Yield; 53 %; M.P.; 142 °C Form AB: CD = 95: 5; ¹H NMR (400 MHz, CDCl₃); 9.40 (brs, 1H, NH or OH CD), 9.31 (brs, 1H, NH or OH AB), 7.89 (dd, 1H, J_1 = 8.5 Hz, J_2 = 5.4 Hz, C17 AB), 7.71 (dd, 1H, J_1 = 8.5 Hz, J_2 = 5.4 Hz, C17 CD), 6.98-6.89 (m, 2H, C15 and C18), 4.70 (s, 1H, C8), 3.95 (d, 1H, J = 8.3 Hz, C7 AB), 3.88 (d,

1H, J = 8.3 Hz, C7 CD), 3.50 (d, 1H, J = 8.3 Hz, C7), 2.36 (s, 3H, C20), 1.65 (s, 3H, C6 AB), 1.59 (s, 3H, C6 CD), 1.06 (s, 9H, C10-C12). ¹³**C** NMR (125 MHz, CDCl₃, Tautomer AB only); 187.6 (C4), 175.4 (C2), 164.2 (C13), 159.9 (d, $J_{C-F} = 244$ Hz, C19), 131.7 (d, $J_{C-F} = 27.6$ Hz, C16), 130.5 (d, $J_{C-F} = 2.88$ Hz, C14), 124.0 (d, $J_{C-F} = 8.63$ Hz, C15), 117.2 (d, $J_{C-F} = 21.8$ Hz, C18), 113.1 (d, $J_{C-F} = 21.8$ Hz, C17), 98.5 (C3), 97.1 (C8), 72.3 (C7), 69.3 (C5), 34.7 (C9), 25.5 (C10-C12), 20.6 (C6), 17.9 (C20). MS (ES⁻); 361.16 (M-H), HRMS (M-H); calcd for C₁₉H₂₂F₁N₂O₄; 361.1569; found; 361.1564.

3.2.74. Synthesis of (±)-11C



Yield; 46 %; M.P.; 172 °C Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 11.37 (s, 1H, NH or OH), 9.21 (brs, 1H, NH or OH), 7.98 (d, 1H, J = 9.4 Hz, C12), 7.25-7.14 (m, 2H, C14 and C15), 5,42 (q, 1H, J = 5.2 Hz, C8), 4.10 (d, 1H, J = 8.6 Hz, C7), 3.87 (d, 1H, J = 8.6 Hz, C7), 2.34 (s, 3H, C17), 1.72 (s, 3H,

C6). ¹³**C NMR** (125 MHz, CDCl₃); 189.6 (C4), 174.5 (C2), 163.5 (C10), 133.0 (quart C), 130.5 (quart C), 130.4 (tert C), 130.2 (quart C), 126.8 (tert C), 122.8 (tert C), 121.8 (q, $J_{C-F} = 280$ Hz, C9), 97.0 (C3), 84.3 (q, $J_{C-F} = 37.0$ Hz,C8), 72.7 (C7), 69.4 (C5), 20.2 (C6), 17.5 (C17). **MS** (ES⁻); 389.06 (M-H); **HRMS** (M-H); calcd for C₁₆H₁₃Cl₁F₃N₂O₄; 389.0521; found; 389.0522.

3.2.75. Synthesis of (±)-11D



Yield; 31 % (oil); Form AB: CD = not determined; ¹H NMR (400 MHz, CDCl₃); 9.62 (brs, 1H, NH or OH), 7.77 (d, 2H, J = 8.6 Hz, C17 and C18), 7.70 (d, 2H, J = 8.6 Hz, C19 and C20), 5.94-5.83 (m, 1H, C13), 5.10-5.06 (m, 2H, C14), 4.73 (s, 1H, C8), 3.95 (d, 1H, J = 8.3 Hz, C7), 3.48 (d,

1H, *J* = 8.3 Hz, C7), 3.44 (brs, 4H, C22 and C23), 2.25 (brs, 4H, C24 and C25), 2.20-2.12 (m, 2H, C12), 1.75 (brs, 2H, C26), 1.64 (s, 3H, C6), 1.02 (s, 3H, C10), 0.99 (s, 3H, C11). ¹³**C NMR** (125 MHz, CDCl3); 164.2 (C15), 139.2 (quart C), 137.7 (quart C), 134.3 (C13), 122.0 (tert C), 121.4 (tert C), 117.9 (C14), 99.4 (C3),

96.7 (C8), 72.2 (C7), 64.9 (C5), 57.3 (C22 and C23), 42.5 (C12), 37.5 (C9), 23.2 (C24 and C25), 22.6 (C10), 22.2 (C11), 21.8 (C26), 20.6 (C6). **MS** (ES⁻); 438.25 (M-H); **HRMS** (M-H); calcd for $C_{25}H_{32}N_3O_4$; 438.2398; found; 438.2391.

3.2.76. Synthesis of (±)-11E



Yield; 38 %; M.P.; 173 °C Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 9.41 (brs, 1H, NH or OH), 7.64 (d, 2H, J = 8.1 Hz, C17 and C18), 7.48 (brs, 2H, C19 and C20), 5.92-5.82 (m, 1H, C13), 5.09-5.05 (m, 2H, C14), 4.72 (s, 1H, C8), 4.04 (brs, 4H, C24 and C25), 3.94 (d, 1H,

J = 8.3 Hz, C7), 3.46 (d, 1H, J = 8.3 Hz, C7), 3.27 (brs, 4H, C22 and C23), 2.21-2.10 (m, 2H, C12), 1.63 (s, 3H, C6), 1.01 (s, 3H, C10), 0.98 (s, 3H, C11). ¹³**C** NMR (125 MHz, CDCI3); 187.8 (C4), 175.3 (C2), 163.8 (C15), 134.4 (C13), 128.9 (Ar-C), 128.1 (Ar-C), 125.2 (Ar-C), 121.5 (Ar-C), 117.8 (C14), 98.1 (C3), 96.6 (C8), 72.2 (C7), 69.3 (C5), 65.6 (C24 and C25), 51.4 (C22 and C23), 42.5 (C12), 37.5 (C9), 22.5 (C10), 22.1 (C11), 20.5 (C6). **MS** (ES⁻); 440.22 (M-H); **HRMS** (M-H); calcd for C₂₄H₃₀N₃O₅; 440.2191; found; 440.2190.

3.2.77. Synthesis of 11F

11E

Yield; 55 %; M.P.; 111 °C Form AB: CD = 99:1; ¹H NMR (500 MHz, CDCl₃); 7.41 (d, 2H, J = 7.0 Hz, C14 and C15), 6.72 (d, 2H, J = 7.0 Hz, C16 and C17), 4.85 (s, 1H, C7), 4.43 (brs, 1H, C5), 4.33 (t, 1H, J = 7.5 Hz, C6), 3.46 (t, 1H, J = 9.0 Hz, C6), 2.95 (s, 6H, C19 and C20), 1.00 (m, 9H, C9-C11). ¹³C NMR (125 MHz,

CDCl₃); 122.00 (C14 and C15), 112.88 (C16 and C17), 94.84 (C7), 67.34 (C6), 40.78 (C19 and C20), 35.81 (C8), 24.64 (C9-C11). **MS** (ES⁻); 358.21 (M-H), **HRMS** (M-H); calcd for C₁₉H₂₄N₃O₄; 358.1772; found; 358.1776.

3.2.78. Synthesis of 11G



Yield; 68 %; M.P.; 249 °C(decomposed); Form AB: CD = 99: 1; ¹H NMR (500 MHz, CDCl₃); 9.65 (brs, 1H, NH), 7.82 (d, 2H, J = 9.0 Hz, C16 and C17), 7.67 (d, 2H, J = 9.0 Hz, C14 and C15), 4.81 (s, 1H, C7), 4.43 (brs, 1H, C5), 4.32 (t, 1H, J = 7.5 Hz, C6), 3.44-3.41 (m, 5H, C6, C19 and C20), 2.24 (brs, 4H, CH₂),

1.74 (brs, 2H, CH₂), 0.96 (s, 9H, C9-C11). ¹³**C NMR** (125 MHz, CDCl₃); 184.10 (C4), 174.97 (C2), 163.92 (C12), 138.82 (quart C), 138.06 (quart C), 122.16 (C14 and C15), 121.13 (C16 and C17), 98.84 (C3), 94.84 (C7), 67.31 (C6), 62.88 (C5), 57.29 (C19 and C20), 35.72 (C8), 24.53 (C9-C11), 23.03 (C21 and C22), 21.61 (C23). **MS** (ES⁻); 398.21 (M-H); **HRMS** (M-H); calcd for C₂₂H₂₈N₃O₄; 398.2085; found; 398.2081.

3.2.79. Synthesis of 11H



Yield; 40 %; M.P.; 196 °C Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃);

9.89 (brs, 1H, NH or OH), 8.01 (d, 2H, J = 8.8 Hz, C15 and C16), 7.92 (d, 2H, J = 8.8 Hz, C17 and C18), 4.84 (s, 1H, C8), 4.02 (d, 1H, J = 8.6 Hz, C5), 3.77-3.69 (m, 1H, C6), 1.51 (d, 3H, J = 6.1 Hz, C7), 1.01 (s, 9H, C10-C12). ¹³**C** NMR (125 MHz, CDCl₃); 184.1 (C4), 173.9 (C2), 164.3 (C13), 144.3 (C14), 132.4 (C17-C18), 125.7 (C19), 120.2 (C15-C16), 99.9 (C3), 94.9 (C8), 75.9 (C6), 68.1 (C5), 35.6 (C9), 24.6 (C10-C12), 17.2 (C7). **MS** (ES⁻); 461.10 (M-H), **HRMS** (M-H); calcd for C₁₉H₂₀F₃N₂O₆S₁; 461.1000; found; 461.1003.

3.2.80. Synthesis of 111



Yield; 32 % (oil); Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 9.89 (brs, 1H, NH or OH), 8.01 (d, 2H, J = 8.8 Hz, C15 and C16), 7.92 (d, 2H, J = 8.8 Hz, C17 and C18), 4.84 (s, 1H, C8), 4.02 (d, 1H, J = 8.6 Hz, C5), 3.75-3.69 (m, 1H, C6), 1.51 (d, 3H, J= 6.1 Hz, C7), 1.01 (s, 9H, C10-C12). ¹³C NMR

(100 MHz, CDCl₃); 184.1 (C4), 173.9 (C2), 164.4 (C13), 144.3 (C19), 132.4 (C15 and C16), 125.8 (C14), 120.2 (C17 and C18), 99.3 (C3), 94.9 (C8), 76.0 (C6), 68.1 (C5), 35.6 (C9), 24.6 (C10-C12), 17.2 (C7). **MS** (ES⁻); 344.17 (M-H), **HRMS** (M-H); calcd for $C_{18}H_{22}N_3O_4$; 344.1616; found; 344.1609.

3.2.81. Synthesis of 11J



Yield; 38 %; M.P.; 135 °C Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 9.58 (brs, 1H, NH or OH), 8.13 (s, 1H, C16), 7.66 (d, 1H, J = 9.2 Hz, C15), 7.34 (dd, 1H, $J_1 = 9.2$ Hz, $J_2 = 1.6$ Hz, C17), 4.84 (s, 1H, C8), 3.98 (d, 1H, J = 8.8 Hz, C5), 3.75-3.68 (m, 1H, C6), 1.49 (d, 3H, J = 6.4

Hz, C7), 1.00 (s, 9H, C10-C12). ¹³**C NMR** (125 MHz, CDCl₃,); 183.7 (C4), 174.3 (C2), 164.0 (C13), 141.3 (q, $J_{C-F} = 39.8$ Hz, C20), 133.7 (Ar-tert C), 118.6 (q, $J_{C-F} = 270$ Hz, C21), 118.3 (Ar-tert C), 99.6 (C3), 94.8 (C8), 76.0 (C6), 68.1 (C5), 35.6 (C9), 24.6 (C10-C12), 17.2 (C7). **MS** (ES⁺); 439.17 (M+H), 461.14 (M+Na); **HRMS** (M+H); calcd for $C_{20}H_{21}F_3N_4Na_1O_4$; 461.1407; found; 461.1409.

3.2.82. Synthesis of 11K



Yield; 34 % (oil); Form AB: CD = 70: 30; ¹H NMR (400 MHz, CDCl₃); 11.67 (s, 1H, NH AB), 11.44 (s, 1H, NH CD), 7.82 (d, 2H, J = 8.3 Hz, C18 and C19 CD), 7.73 (d, 2H, J = 8.3 Hz, C18 and C19 AB), 6.98-6.79 (m, 2H, C20 and C21), 6.05 (s, 1H, C15), 4.85 (s, 1H, C8 CD),

4.83 (s, 1H, C8 AB), 3.85 (s, 3H, C23 CD), 3.82 (s, 3H, C23 AB), 3.71-3.61 (m, 1H, C6), 3.54 (d, 1H, J = 8.8 Hz, C5 AB), 3.49 (d, 1H, J = 8.8 Hz, C5 CD), 1.46 (d, 3H, J = 5.8 Hz, C7), 1.03 (s, 9H, C10-C12 AB), 1.00 (s, 9H, C10-C12 CD). ¹³**C NMR** (100 MHz, CDCl₃, Tautomer AB only); 193.6 (C4), 179.2 (C2), 163.5 (C13), 161.5 (C22), 145.2 (C16), 142.5 (C14), 128.0 (C18 and C19), 118.6 (C17), 114.4 (C20 and C21), 95.1 (C8), 92.3 (C3), 89.1 (C15), 75.3 (C6), 70.9 (C5), 52.3 (C23), 35.8 (C9), 25.1 (C10-C12), 17.8 (C7). **MS** (ES⁻); 425.19 (M-H), **HRMS** (M-H); calcd for C₂₂H₂₅N₄O₅; 425.1830; found; 425.1824.

3.2.83. Synthesis of (±)-11L

Yield; 23 % (oil); Form AB: CD = 99: 1; ¹H NMR (400 MHz, CDCl₃); 9.55 (brs, 1H, NH or OH), 7.58 (d, 2H, J = 7.6 Hz, C14 and C15), 7.34 (t, 2H, J = 7.6 Hz, C16-C17), 7.15 (t, 1H, J = 7.6 Hz, C18), 4.45-4.24 (m, 2H, C5 and C11), 3.13-3.05 (m, 1H, C7), 2.09-2.04 (m, 1H, CH₂), 1.96-1.79 (m, 3H, CH₂), 1.74-1.65 (m, 3H, CH₂), 1.56-1.48 (m, 1H, CH₂). ¹³C NMR (100 MHz, CDCl₃); 185.9 (C4), 172.1 (C2), 164.4 (C12), 136.9 (C13), 129.1 (C16 and C17), 124.6 (C18), 120.2 (C14 and C15), 98.9 (C3), 63.6 (C11), 59.7 (C5), 47.7 (C7), 35.1 (CH₂), 34.1 (CH₂), 30.9 (CH₂), 26.4 (CH₂). MS (ES⁻); 297.13 (M-H); HRMS (M-H); calcd for C₁₇H₁₇N₂O₃; 297.1245; found; 297.1247.

3.2.84. Synthesis of (±)-11M



Yield; 23 % (oil); Form AB: CD = 99: 1; ¹H NMR (500 MHz, CDCl₃); 9.48 (brs, 1H, NH or OH), 7.54 (d, 2H, J = 8.8 Hz, C14 and C15), 7.07 (d, 2H, J = 8.8 Hz, C16 and 17), 6.16 (brs, 1H, NH or OH), 4.38-4.31 (m, 2H, C5 and C7), 3.96 (brs, 4H, C21 and C22), 3.21 (brs, 4H, C19 and C20), 3.11-3.04

(m, 1H, C8), 2.08-2.04 (m, 1H, CH₂), 1.94-1.87 (m, 2H, CH₂), 1.83-1.80 (m, 1H, CH₂), 1.73-1.65 (m, 3H, CH₂), 1.55-1.49 (m, 1H, CH₂). ¹³**C NMR** (125 MHz, CDCI₃); 186.0 (C4), 172.0 (C2), 164.3 (C12), 142.2 (C18), 134.7 (C13), 121.5 (C14 and C15), 119.5 (C16 and C17), 98.8 (C3), 65.2 (C21 and C22), 63.7 (C7), 59.7 (C5), 52.8 (C19 and C20), 47.7 (C8), 35.1 (CH₂), 34.1 (CH₂), 32.4 (CH₂), 26.4 (CH₂). **MS** (ES⁻); 382.19 (M-H); **HRMS** (M-H); calcd for C₂₁H₂₄N₃O₄; 382.1772; found; 382.1776

3.2.85. Synthesis of 11N



Yield; 60 %; M.P. 242 °C; AB: CD = Not determined; ¹H NMR (500 MHz, CDCl₃); 8.77 (s, 1H, C14), 7.31 (t, 1H, J = 8.0 Hz, C17), 7.05 (d, 1H, J = 8.0 Hz, C15), 6.90 (d, 1H, J = 8.0 Hz, C18), 4.90 (s, 1H, C7), 4.43 (s, 2H, C19),

4.27 (t, 1H, J = 7.5 Hz, C6), 4.04 (brs, 1H, C5), 3.68 (brs, 2H, CH₂), 3.46 (t, 1H, J = 9.0 Hz, C6), 2.62 (brs, 2H, CH₂), 1.91 (brs, 2H, CH₂), 1.76-1.70 (m, 3H, CH₂), 1.15-1.10 (m, 1H, CH₂), 0.99 (s, 9H, C9-C11). ¹³**C NMR** (100 MHz, CDCl₃); 193.0 (C4), 181.7 (C2), 165.0 (C12), 141.2 (C13), 129.1 (C17), 127.7 (C18), 124.5 (Ar-C), 123.2 (Ar-C), 120.0 (Ar-C), 95.4 (C3), 92.5 (C7), 68.0 (C6), 66.0 (C19), 60.9 (C5), 51.7 (C20 and C21), 36.0 (C8), 24.9 (C9-C11), 23.4 (C22 and C23), 21.5 (C24). **MS** (ES⁻); 412.23 (M-H); MS (ES⁺); 414.25 (M+H), 436.23 (M+Na); **HRMS** (M-H); calcd for C₂₃H₃₁N₃Na₁O₄; 436.2207; found; 436.2208.

3.3. Synthesis of 110 with phenyl isocyanate

To the solution of tetramic acid **16G** (150 mg, 0.53 mmol) and DMAP (80 mg, 0.64 mmol) in dichloromethane (30 ml) was added phenyl isocyanate (70 mg, 0.59 mmol) under nitrogen atmosphere. After strring the solution overnight, concentration in vacuo followed by flash column chromatography gave metal-chelated 3-

carboxamide tetramic acid. The compound was dissolved in dichloromethane (50 mL) and washed with aqueous HCI (3< pH <5, 50 mL). The organic layer was dried with MgSO₄ and concentrated in vacuo to give free form of 3-carboxamide tetramic acid **110** (100 mg, 0.26 mmol, 46 % yield, M.P. 91 $^{\circ}$; AB: CD = 80: 20).



¹**H NMR** (500 MHz, CDCl₃); 10.73 (brs, 1H, NH or OH), 9.53 (brs, 1H, NH or OH CD), 9.38 (brs, 1H, NH or OH AB), 7.59 (d, 2H, *J* = 8.0 Hz, C19 and C20 AB), 7.47 (d, 2H, *J* = 8.0 Hz, C19 and C20 CD), 7.43-7.37 (m, 2H, C21 and C22), 7.28-7.19 (m, 1H, C23), 5.00 (d, 1H, *J* = 8.5 Hz, C6 AB), 4.94 (d, 1H, *J* = 8.5 Hz, C6 CD), 4.78 (s, 1H, C7 CD), 4.75 (s, 1H, C7 AB), 3.50 (d, 1H, *J* = 8.5 Hz, C6 CD), 3.48 (d,

1H, *J* = 8.5 Hz, C6 AB), 2.89-2.82 (m, 1H, C13), 2.47-2.39 (m, 1H, C13), 1.70-1.61 (m, 1H, C14), 1.57-1.48 (m, 1H, C14), 1.36-1.29 (m, 2H, C15), 0.94 (s, 9H, C9-C11), 0.91 (t, 3H, *J* = 7.5 Hz, C16). ¹³**C NMR** (125 MHz, CDCl₃); 201.6 (C12 CD), 200.7 (C12 AB), 188.7 (C4 CD), 184.8 (C4 AB), 183.9 (C2 CD), 176.7 (C2 AB), 165.7 (C17 CD), 163.7 (C17 AB), 135.9 (C18 AB), 134.5 (C18 CD), 129.5 (C21 and C22 CD), 129.2 (C21 and C22 AB), 126.6 (C23 CD), 125.5 (C23 AB), 121.5 (C19 and C20 CD), 120.5 (C19 and C20 AB), 98.7 (C3 AB), 98.0 (C7 CD), 97.5 (C7 AB), 86.9 (C3 CD), 84.0 (C5 CD), 79.5 (C5 AB), 66.9 (C6 AB), 66.5 (C6 CD), 37.0 (C13 CD), 36.2 (C13 AB), 35.1 (C8 AB), 35.0 (C8 CD), 25.3 (C14 AB), 25.2 (C14 CD), 25.0 (C9-C11), 22.1 (C15 CD), 22.0 (C15 AB), 13.8 (C16 CD), 13.7 (C16 AB). **MS** (ES⁻); 399.19 (M-H); **HRMS** (M-H); calcd for C₂₂H₂₇N₂O₅; 399.1925; found; 399.1924.

4. Synthesis of 3-acyltetramic acids

4.1. Synthesis of 3-acyltetramic acids via direct 3-acyllation



(a) carboxylic acid (1.1 eq), DCC (1.1 eq), DMAP (1.2 eq), CH₂Cl₂, r.t..

General procedure: To a solution of carboxilic acid (1.0 eq) in dichloromethane were added DCC (1.1 eq), tetramic acid (1.0 eq) and DMAP (1.2 eq), and the mixture was stirred overnight at room temperature. The crude reaction mixture was filtered with dichloromethane. Concentration in vacuo followed by flash column chromatography gave metal-chelated tetramic acid. The compound was dissolved in dichloromethane and washed with aqueous HCI (3< pH <5). The organic layer was dried with MgSO₄ and concentrated in vacuo to give free form of 3-acyltetramic acid.

4.1.1. Synthesis of 5A





3.50 (d, 1H, *J* = 9.0 Hz, C6), 2.56 (s, 3H, C15 AB), 2.49 (s, 3H, C15 CD), 0.93 (s, 9H, C9-11 CD), 0.92 (s, 9H, C9-11 AB). ¹³C NMR (125 MHz, CDCl₃); 195.5 (C4 AB), 190.1 (C14 AB), 188.4 (C14 CD), 188.0 (C4 CD), 179.8 (C2 CD), 172.3 (C2 AB), 167.4 (C12 CD), 166.3 (C12 AB), 104.4 (C3 AB), 101.7 (C3 CD), 98.3 (C7 AB), 98.2 (C7 CD), 78.4 (C5 CD), 76.5 (C5 AB), 68.1 (C6 CD), 68.1 (C6 AB), 53.4 (C13 AB), 53.3 (C13 CD), 35.3 (C8 AB), 35.1 (C8 CD), 24.7 (C9-11 AB), 24.6 (C9-11 CD), 19.9 (C15 CD), 19.8 (C15 AB). MS (ES⁻); 296.10 (M-H); HRMS (M-H); calcd for C₁₄H₁₈N₁O₆; 296.1140; found; 296.1138.

4.1.2. Synthesis of 5B



Yield; 78 % (oil); form AB: CD= 20: 80; ¹H NMR (500 MHz, CDCl₃); 4.88 (s, 1H, C7 AB), 4.85 (s, 1H, C7 CD), 4.82 (d, 1H, *J* = 9.5 Hz, C6), 3.80 (s, 3H, C13 AB), 3.78 (s, 3H, C13 CD), 3.49 (d, 1H, *J* = 9.5 Hz, C6), 3.01-2.79 (m, 2H, C15), 1.72-1.63 (m, 2H, C16), 1.40-1.25 (m, 6H, C17-C19), 0.93 (s, 9H, C9-11), 0.88 (t,

3H, J = 7.0 HZ, C20). ¹³**C** NMR (125 MHz, CDCl₃); 195.7 (C4 AB), 194.0 (C14 AB), 192.5 (C14 CD), 187.7 (C4 CD), 180.3 (C2 CD), 172.3 (C2 AB), 167.5 (C12 CD), 167.4 (C12 AB), 103.7 (C3 AB), 101.0 (C3 CD), 98.3 (C7 AB), 98.2 (C7 CD), 78.3 (C5 CD), 76.4 (C5 AB), 68.2 (C6 CD), 68.2 (C6 AB), 53.4 (C13 AB), 53.2 (C13 CD), 35.3 (C8 AB), 35.1 (C8 CD), 33.8 (C15 AB), 33.0 (C15 CD), 31.3 (CH₂ AB), 31.3 (CH₂ CD), 29.0 (CH₂ AB), 28.8 (CH₂ CD),25.8 (CH₂ CD), 25.7 (CH₂ AB), 24.9 (CH₂ AB), 24.7 (C9-11 AB), 24.6 (C9-11 CD), 22.4 (CH₂ CD), 15.2 (C20 AB), 13.9 (C20 CD). **MS** (ES⁻); 366.18 (M-H); MS (ES⁺); 390.20 (M+Na); **HRMS** (M+Na); calcd for C₁₉H₂₉N₁Na₁O₆; 390.1887; found; 390.1883.

4.1.3. Synthesis of 5C



Yield; 45 % (oil); form AB: CD= 20: 80; ¹H NMR (400 MHz, CDCl₃); 4.88
²³ (s, 1H, C7 AB), 4.85 (s, 1H, C7 CD), 4.82 (d, 1H, J = 8.8 Hz, C6), 3.78 (s, 3H, C13), 3.49 (d, 1H, J = 8.8 Hz, C6), 3.01-2.78 (m, 2H, C15), 1.70-1.61

(m, 2H, C16), 1.37-1.25 (m, 12H, C17-C22), 0.92 (s, 9H, C9-11), 0.87 (t, 3H, J = 6.8 HZ, C23). ¹³**C NMR** (100 MHz, CDCl₃, taumer CD only); 192.5 (C14), 187.7 (C4), 180.3 (C2), 167.5 (C12), 101.0 (C3), 98.2 (C7), 78.3 (C5), 68.2 (C6), 53.2 (C13), 35.1 (C8), 33.0 (C15), 31.8 (CH₂), 29.2 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 25.9 (CH₂), 24.6 (C9-11), 22.6 (CH₂), 14.0 (C23). **MS** (ES⁻); 408.2 (M-H); **HRMS** (M+Na); calcd for C₂₂H₃₅N₁Na₁O₆; 432.2357; found; 432.2350.

4.1.4. Synthesis of 5D



Yield; 58 % (oil); form AB: CD= 20: 80; ¹H NMR (400 MHz, CDCl₃); 4.88 (s, 1H, C7 AB), 4.85 (s, 1H, C7 CD), 4.82 (d, 1H, *J* = 8.8 Hz, C6), 3.78 (s, 3H, C13), 3.49 (d, 1H, *J* = 8.8 Hz, C6), 3.01-2.78 (m, 2H, C15), 1.70-

1.61 (m, 2H, C16), 1.38-1.25 (m, 16H, C17-24), 0.93 (s, 9H, C9-11), 0.87 (t, 3H, *J* = 7.2 Hz, C27). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only); 192.5 (C14), 187.7 (C4), 180.3 (C2), 167.5 (C12), 101.0 (C3), 98.2 (C7),

78.3 (C5), 68.2 (C6), 53.2 (C13), 35.1 (C8), 33.0 (C15), 31.9 (CH₂), 29.5 (CH₂), 29.5 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 25.9 (CH₂), 24.6 (C9-11), 22.6 (CH₂), 14.1 (C27). **MS** (ES⁻); 436.3 (M-H); **HRMS** (M-H); calcd for C₂₄H₃₈NO₆; 436.2705; found; 436.2696.

4.1.5. Synthesis of 5E



CDCl₃); 4.88 (s, 1H, C7 AB), 4.85 (s, 1H, C7 CD), 4.83-4.81 (m, 1H, C6), 3.80 (s, 3H, C13 AB), 3.79 (s, 3H, C13 CD), 3.50 (d, 1H, J = 8.8 Hz, C6 AB), 3.49 (d, 1H, J = 8.8 Hz, C6 CD), 3.02-2.78 (m, 2H, C15), 1.74-1.63 (m, 2H, C16), 1.38-1.25 (m, 20H, C17-26), 0.93 (s, 9H, C9-11 CD), 0.92 (s, 9H, C9-11 AB), 0.88 (t, 3H, J = 7.2 Hz, C27). ¹³C NMR (100 MHz, CDCl₃); 195.7 (C4 AB), 190.0 (C14 AB), 192.5 (C14 CD), 187.7 (C4 CD), 180.3 (C2 CD), 172.3 (C2 AB), 167.5 (C12 CD), 167.3 (C12 AB), 103.7 (C3 AB), 101.0 (C3 CD), 98.3 (C7 AB), 98.2 (C7 CD), 78.3 (C5 CD), 76.4 (C5 AB), 68.2 (C6 CD), 68.2 (C6 AB), 53.4 (C13 AB), 53.2 (C13 CD), 35.3 (C8 AB), 35.1 (C8 CD), 33.0 (C15 CD), 33.0 (C15 AB), 31.9 (CH₂), 29.6 (CH₂), 29.6 (CH₂), 29.5 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 25.9 (CH₂), 25.8 (CH₂), 24.7 (C9-11 AB), 24.6 (C9-11 CD), 22.6 (CH₂), 14.1 (C27). **MS** (ES⁻); 364.3 (M-H); **HRMS** (M-H); calcd for C₂₆H₄₂NO₆; 464.3018; found; 464.3007.

Yield; 49 % (oil); form AB: CD= 20: 80; ¹H NMR (400 MHz,

4.1.6. Synthesis of 5F



Yield; 63 % (oil); Form AB: CD= 20: 80; ¹H NMR (500 MHz, CDCl₃); 4.88 (s, 1H, C7 AB), 4.85 (s, 1H, C7 CD), 4.83-4.82 (m, 1H, C6), 4.28-4.23 (m, 2H, C13), 3.50 (d, 1H, J = 8.5 Hz, C6), 2.57 (s, 3H, C16 AB), 2.49 (s, 3H, C16 CD), 1.29 (t, 3H, J = 7.0 Hz, C14), 0.94 5F (s, 9H, C9-11 CD), 0.93 (s, 9H, C9-11 AB). ¹³C NMR (125 MHz, CDCl₃); 195.7 (C4 AB), 190.0 (C15 AB), 188.2 (C15 CD), 188.2 (C4 CD), 180.0 (C2 CD), 172.4 (C2 AB), 166.9 (C12 CD), 166.8 (C12 AB), 104.4 (C3 AB), 101.7 (C3 CD), 98.3 (C7 AB), 98.2 (C7 CD), 78.5 (C5 CD), 76.5 (C5 AB), 68.2 (C6 CD), 68.1 (C6 AB), 62.9 (C13 AB), 62.7 (C13 CD), 35.3 (C8 AB), 35.1 (C8 CD), 24.8 (C9-11 AB), 24.7 (C9-11 CD), 19.9 (C16 CD), 19.8 (C16 AB), 14.0 (C14). **MS** (ES); 310.11 (M-H); **HRMS** (M-H); calcd for C₁₅H₂₀N₁O₆; 310.1296; found; 310.1297.

4.1.7. Synthesis of 5G



Yield; 65 % (oil); Form AB: CD= 20: 80; ¹H NMR (400 MHz, CDCl₃); 4.87 (s, 1H, C7 AB), 4.84 (s, 1H, C7 CD), 4.81 (d, 1H, J = 8.8 Hz, C6), 4.30-4.18 (m, 2H, C13), 3.48 (d, 1H, J = 8.8 Hz, C6), 3.02-2.77 (m, 2H, C16), 1.72-1.62 (m, 2H, C17), 1.37-1.24 (m, 15H, C14 and C18-C23),

0.93 (s, 9H, C9-11), 0.86 (t, 3H, J = 7.2 Hz, C24). ¹³C NMR (100 MHz, CDCl₃, tautomer CD only); 192.3 (C15), 187.9 (C4), 180.3 (C2), 166.9 (C12), 101.0 (C3), 98.2 (C7), 78.3 (C5), 68.2 (C6), 62.6 (C13), 35.1 (C8), 33.0 (CH₂), 31.8 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 29.1 (CH₂), 25.9 (CH₂), 24.7 (C9-11), 22.6 (CH₂), 14.0 (CH₃), 13.9 (CH₃). **MS** (ES⁻); 422.28 (M-H); **HRMS** (M-H); calcd for C₂₃H₃₆N₁O₆; 422.2548; found; 422.2542.

4.1.8. Synthesis of 5H



Yield: 47 % (oil); Form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 5.14 (q, 1H, *J* = 6.8 Hz, C6), 4.98 (s, 1H, C7 AB), 4.96 (s, 1H, C7 CD), 4.31-4.18 (m, 2H, C14), 2.92-2.78 (m, 2H, C17), 1.74-1.63 (m, 2H, C18), 1.40-1.26 (m, 15H, C15 and C19-C24), 1.05 (d, 3H, *J* = 6.8 Hz, C12), 0.94 (s,

9H, C9-C11), 0.88 (t, 3H, *J* = 6.8 Hz, C25). ¹³**C NMR** (125 MHz, CDCl₃, tautomer CD only): 191.2 (C16), 188.4 (C4), 179.8 (C2), 167.4 (C13), 102.7 (C3), 95.7 (C7), 81.3 (C5), 74.8 (C6), 62.6 (C14), 35.2 (C8), 33.9 (CH₂), 32.8 (CH₂), 31.8 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.2 (CH₂), 29.2 (CH₂), 29.0 (CH₂), 26.1 (CH₂), 24.8 (C9-C11), 22.6 (CH₂), 14.5 (CH₃), 14.1 (CH₃), 13.9 (CH₃). **MS** (ES⁻): 436.29 (M-H); **HRMS** (M-H): calcd for C₂₄H₃₈NO₆ 436.2705, found 436.2708.

4.1.9. Synthesis of 5I



Yield; 43 %; M.P.; 118 °C; Form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 4.89 (s, 1H, C7 AB), 4.86 (s, 1H, C7 CD), 4.84 (d, 1H, *J* = 8.8 Hz, C6), 4.34 (t, 2H, *J* = 4.7 Hz, C13), 3.60-3.57 (m, 2H, C14), 3.52 (d, 1H, *J* = 8.8 Hz, C6 AB), 3.51 (d, 1H, *J* = 8.8

Hz, C6 CD), 3.38 (s, 3H, C15 AB), 3.34 (s, 3H, C15 CD), 3.03-2.78 (m, 2H, C17), 1.73-1.63 (m, 2H, C18), 1.37-1.26 (m, 16H, C19-C26), 0.95 (s, 9H, C9-C11), 0.88 (t, 3H, J = 6.8 Hz, C27). ¹³C NMR (100 MHz, CDCl₃, tautomer CD only): 192.5 (C16), 187.7 (C4), 180.4 (C2), 167.0 (C12), 101.0 (C3), 98.3 (C7), 78.4 (C5), 69.9 (C14), 68.2 (C6), 65.5 (C13), 58.9 (C15), 35.2 (C8), 33.1 (CH₂), 31.9 (CH₂), 29.6 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 25.9 (CH₂), 24.7 (C9-C11), 22.7 (CH₂), 14.1 (C25). **MS** (ES⁻); 480.32 (M-H); **HRMS** (M-H); calculated for C₂₆H₄₂NO₇; 480.2967; found; 480.2968.

4.1.10. Synthesis of 5J



Yield; 55 % (oil); form AB: CD= not determined, major: CD. ¹H NMR (400 MHz, CDCl₃); 4.91-4.84 (m, 2H,C6 and C7), 3.47-3.42 (m, 1H, C6), 2.99-2.78 (m, 3H, C13 and C16), 2.35-2.26 (m, 1H, C13), 1.70-1.58 (m, 2H, C17), 1.36-1.25 (m, 12H, C18-C23), 1.06 (t, 3H, *J* = 7.2 Hz, C14), 0.89-

0.85 (m, 12H, C9-C11 and C24). ¹³**C NMR** (100 MHz, CDCl₃, Tautomer CD only); 201.8 (C12), 192.9 (C15), 188.9 (C4), 181.4 (C2), 101.4 (C3), 98.6 (C7), 83.5 (C5), 66.7 (C6), 35.1 (C8), 33.9 (CH₂), 33.1 (CH₂), 31.8 (CH₂), 30.9 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 26.0 (CH₂), 25.0 (C9-C11), 22.6 (CH₂), 14.0 (C24), 7.3 (C14). **MS** (ES⁻); 406.26 (M-H); MS (ES⁺); 430.29 (M+Na); **HRMS** (M+Na); calcd for C₂₃H₃₇N₁Na₁O₅; 430.2564; found; 430.2558.

4.1.11. Synthesis of 5K



Yield; 43 % (oil); form AB: CD= 20: 80. ¹H NMR (500 MHz, CDCl₃); 4.93 (d, 1H, J = 10.0 Hz, C6 AB), 4.93 (d, 1H, J = 10.0 Hz, C6 CD), 4.87 (s, 1H, C7 AB), 4.85 (s, 1H, C7 AB), 3.46 (d, 1H, J = 10.0 Hz, C6 AB), 3.44 (d, 1H, J = 10.0 Hz, C6 CD), 3.04-2.76 (m, 3H, C13 and

C18), 2.37-2.29 (m, 1H, C13), 1.76-1.47 (m, 4H, C14 and C19), 1.41-1.26 (m, 14H, C15 and C20-C25), 0.91-0.86 (m, 15H, C9-C11, C16 and C26). ¹³**C NMR** (125 MHz, CDCl₃); 201.3 (C12 CD), 201.2 (C12 AB), 196.4 (C4 AB), 195.1 (C17 AB), 192.9 (C17 CD), 188.9 (C4 CD), 181.5 (C2 CD), 173.5 (C2 AB), 104.3 (C3 AB), 101.5 (C3 CD), 98.7 (C7 AB), 98.7 (C7 CD), 83.7 (C5 CD), 81.5 (C5 AB), 66.7 (C6 CD), 66.7 (C6 AB), 37.5 (CH₂ CD), 37.2 (CH₂ AB), 35.3 (C8 AB), 35.1 (C8 CD), 33.5 (CH₂ AB), 33.1 (CH₂), 31.8 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 26.0 (CH₂), 25.6 (CH₂ AB), 25.3 (CH₂), 25.1 (C9-C11 AB), 25.0 (C9-C11 CD), 22.6 (CH₂), 22.3 (CH₂ AB), 22.1 (CH₂), 22.1 (CH₂ AB), 14.1 (C26), 13.8 (C16). **MS** (ES⁻); 434.32 (M-H); **HRMS** (M-H); calcd for C₂₅H₄₀N₁O₅; 434.2912; found; 434.2911.

4.1.12. Synthesis of (±)-5L



Yield; 44 %; M.P.; 131 °C; Form AB: CD = 25: 75; ¹HNMR (400 MHz, CDCl₃): 4.75 (s, 1H, C7), 3.81 (d, 1H, J = 8.3 Hz, C6), 3.41 (d, 1H, J = 8.3 Hz, C6), 2.51 (s, 3H, C14 AB), 2.47 (s, 3H, C14 CD), 1.54 (s, 3H, C12 AB), 1.50 (s, 3H, C12 CD), 1.01 (s, 9H, C9-C11). ¹³C NMR (100 MHz, CDCl₃, tautomer CD only): 194.9 (C13), 187.3 (C4), 179.7 (C2),

102.5 (C3), 98.2 (C7), 73.2 (C5), 71.4 (C6), 34.6 (C8), 25.5 (C9-C11), 21.3 (C12), 19.7 (C14). **MS** (ES⁻); 252.13 (M-H); **HRMS** (M-H); calculated for C₁₃H₁₈NO₄; 252.1241 found; 252.1234.

4.1.13. Synthesis of (±)-6A



Yield; 61 % (oil); Form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 4.79 (s, 1H, C7 AB), 4.78 (s, 1H, C7 CD), 3.85 (d, 1H, J = 8.4 Hz, C6 AB), 3.82 (d, 1H, J = 8.4 Hz, C6 CD), 3.43 (d, 1H, J = 8.4 Hz, C6 AB), 3.40 (d, 1H, J = 8.4 Hz, C6 CD), 2.77-2.58 (m, 2H, C14), 1.96 (brs, 3H, C22-C24), 1.70-1.62 (m, 12H, C16-C21),

1.56 (s, 3H, C12 AB), 1.51 (s, 3H, C12 CD), 1.03 (s, 9H, C9-C11 CD), 1.02 (s, 9H, C9-C11 AB). ¹³**C NMR** (100 MHz, CDCl₃): 201.7 (C4 AB), 194.8 (C13 CD), 192.3 (C13 AB), 189.3 (C4 CD), 180.1 (C2 CD), 172.6 (C2 AB), 106.0 (C3 AB), 103.5 (C3 CD), 98.4 (C7 AB), 98.4 (C7 CD), 73.0 (C5 CD), 71.6 (C6 CD), 71.5 (C6 AB), 70.2 (C5 AB), 46.1 (CH₂ AB), 46.0 (CH₂ CD), 42.6 (CH₂ AB), 42.5 (CH₂ CD), 36.6 (CH₂), 36.2 (C15 CD), 35.9 (C15 AB), 34.8 (C8 AB), 34.6 (C8 CD), 28.8 (C22-C24), 25.7 (C9-C11 AB), 25.6 (C9-C11 CD), 21.3 (C12 CD), 21.2 (C12 AB). **MS** (ES⁻); 386.24 (M-H); **HRMS** (M-H); calculated for C₂₃H₃₂NO₄; 386.2337; found; 386.2327.

4.1.14. Synthesis of 6B



Yield; 45 %; M.P.; 122 °C; form AB: CD= 15: 85; ¹H NMR (400 MHz, CDCl₃);

4.90 (s, 1H, C7 AB), 4.87 (s, 1H, C7 CD), 4.84 (d, 1H, J = 8.8 Hz, C6 AB), 4.82 (d, 1H, J = 8.8 Hz, C6 CD), 4.33-4.14 (m, 2H, C13), 3.51 (d, 1H, J = 8.4 Hz, C6 AB), 3.48 (d, 1H, J = 8.4 Hz, C6 CD), 2.81 (d, 1H, J = 11.6, C16), 2.51 (d, 1H, J = 11.6, C16), 1.96 (brs, 3H, C24-C26), 1.70-1.62 (m, 12H, C18-23), 1.29 (t, 3H, J = 7.2Hz, C14 AB), 1.26 (t, 3H, J = 7.2 Hz, C14 CD), 0.94 (s, 9H, C9-11 CD), 0.93 (s, 9H, C9-11 AB). ¹³C NMR (100 MHz, CDCl₃,Only CD form); 190.2 (C15), 188.3 (C4), 180.3 (C2), 167.0 (C12), 102.9 (C3), 98.2 (C7), 78.3 (C5), 68.1 (C6), 62.5 (C13), 46.3 (C16), 42.4 (<u>C</u>H₂), 36.7 (quart C), 36.5 (<u>C</u>H₂), 35.2 (quart C), 28.8 (C24-C26), 24.7 (C9-11), 13.9 (C14). **MS** (ES⁻); 444.24 (M-H); **HRMS** (M-H); calcd for C₂₅H₃₄N₁O₆; 444.2392; found; 444.2397.

4.1.15. Synthesis of 6C



Yield; 39 %; M.P.; 115 °C; Form AB: CD= 15: 85; ¹H NMR (400 MHz, CDCl₃); 4.90 (s, 1H, C7 AB), 4.87 (s, 1H, C7 CD), 4.84 (d, 1H, J = 8.4 Hz, C6 AB), 4.83 (d, 1H, J = 8.4 Hz, C6 CD), 4.31-4.16 (m, 2H, C13), 3.50 (d, 1H, J = 8.4 Hz, C6 AB), 3.47 (d, 1H, J = 8.4 Hz, C6 CD), 2.86 (d, 1H, J = 11.6, C16), 2.51 (d, 1H, J =

11.6, C16), 2.07-2.02 (m, 1H, C24), 1.48-1.09 (m, 15H, C14, C18-23), 0.94 (s, 9H, C9-11 CD), 0.93 (s, 9H, C9-11 AB), 0.81-0.79 (m, 6H, C27 and C28). ¹³**C NMR** (100 MHz, CDCl₃,Only CD form); 190.1 (C15), 188.3 (C4), 180.3 (C2), 166.9 (C12), 102.8 (C3), 98.2 (C7), 78.3 (C5), 68.1 (C6), 62.6 (C13), 50.7 (<u>C</u>H₂), 48.7 (<u>C</u>H₂), 48.7 (<u>C</u>H₂), 45.6 (C16), 42.8 (<u>C</u>H₂), 40.9 (<u>C</u>H₂), 38.0 (quart C), 35.2 (C8), 31.5 (quart C), 30.4 (C27 and C28), 29.8 (C24), 24.7 (C9-11), 14.0 (C14). **MS** (ES⁻); 472.20 (M-H); MS (ES⁺); 496.35 (M+Na); **HRMS** (M+Na); calcd for $C_{27}H_{39}N_1Na_1O_6$; 496.2670; found; 496.2667.

4.1.16. Synthesis of 6D



Yield; 38 % (oil); Form AB: CD = 15: 85; ¹HNMR (400 MHz, CDCl₃): 5.14 (q, 1H, J = 6.4 Hz, C6), 4.99 (s, 1H, C7 AB), 4.97 (s, 1H, C7 CD), 4.28-4.15 (m, 2H, C14), 2.71 (d, 1H, J = 11.6 Hz, C17), 2.66 (d, 1H, J = 11.6 Hz, C17), 2.05-2.03 (m, 1H, C25), 1.34-1.19 (m, 15H, C19-C24 and C15), 1.05 (d, 3H, J = 6.8 Hz, C12), 0.94

(s, 9H, C9-C11 CD), 0.93 (s, 9H, C9-C11 AB), 0.80 (s, 6H, C28 and C29 AB), 0.78 (s, 6H, C28 and C29 CD). ¹³C NMR (125 MHz, CDCl₃, tautomer CD only): 189.1 (C16), 188.7 (C4), 179.8 (C2), 167.3 (C13), 104.4 (C3), 95.7 (C7), 81.3 (C5), 74.9 (C6), 62.5 (C14), 50.7 (CH₂), 48.8 (CH₂), 48.6 (CH₂), 45.4 (C17), 42.8 (CH₂), 41.1 (CH₂), 38.2 (quart C), 35.2 (C8), 31.5 (quart C), 30.4 (C28 and C29), 29.8 (C25), 24.8 (C9-C11), 14.6 (CH₃), 14.0 (CH₃). **MS** (ES⁻); 486.27 (M-H); **HRMS** (M-H); calculated for C₂₈H₄₀NO₆; 486.2861; found; 486.2864.

4.1.17. Synthesis of 6E



Yield; 35 % (oil); Form AB: CD= 15: 85; ¹HNMR (400 MHz, CDCl₃): 4.88 (s, 1H, C7 AB), 4.86 (s, 1H, C7 CD), 4.82 (d, 1H, *J* = 8.8 Hz, C6), 4.32-4.14 (m, 2H, C13), 3.676(s, 2H, C20), 3.48 (d, 1H, *J* = 8.8 Hz, C6), 3.10

(d, 1H, J = 12.4 Hz, C16), 2.91 (d, 1H, J = 12.4 Hz, C16), 2.46 (s, 2H, C18 AB), 2.41 (s, 2H, C18 CD), 1.98 (brs, 3H, C28-C30), 1.74-1.52 (m, 12H, C22-C27), 1,25 (t, 3H, J = 7.2 Hz, C14), 1.17 (s, 6H, C32 and C33 AB), 1.14 (s, 3H, CH₃ CD), 1.13 (s, 3H, CH₃ CD), 0.94 (s, 9H, C9-C11). ¹³C NMR (100 MHz, CDCl₃, tautomer CD only): 189.8 (C15), 188.2 (C4), 180.1 (C2), 171.7 (C19), 166.3 (C12), 103.0 (C3), 98.2 (C7), 78.3 (C5), 74.1 (C20), 68.0 (C6), 62.6 (C13), 46.2 (CH₂), 42.9 (CH₂), 39.3 (CH₂), 36.9 (CH₂), 35.5 (C8), 35.1 (C21), 32.9 (C17), 28.0 (C31 and C32), 27.4 and 27.3 (C28-C30), 24.7 (C9-C11), 13.9 (C14). MS (ES⁻); 558.25 (M-H); MS (ES⁺); 582.30 (M+Na); HRMS (M-H); calcd for C₃₁H₄₄N₁O₈; 558.3072; found; 558.3078.

4.1.18. Synthesis of 6F



Yield; 39 % (oil); Form AB: CD = 20: 80; ¹HNMR (500 MHz, CDCl₃): 5.14 (q, 1H, *J* = 6.7 Hz, C6), 4.98 (s, 1H, C7 AB), 4.96 (s, 1H, C7 CD), 4.30-4.14 (m, 2H, C14), 3.67 (s, 2H, C21), 3.18-2.97 (m, 2H, C17), 2.46 (s, 2H, C19 AB), 2.41 (s, 2H, C19 CD), 1.98 (brs, 3H, C29-C31), 1.74-

1.53 (m, 12H, C23-C28), 1,25 (t, 3H, J = 7.1 Hz, C15), 1.17 (s, 6H, C32 and C33 AB), 1.13 (s, 6H, C32 and C33 CD), 1.04 (d, 3H, J = 6.7 Hz, C12), 0.93 (s, 9H, C9-C11 CD), 0.92 (s, 9H, C9-C11 AB). ¹³**C** NMR (125 MHz, CDCl₃, tautomer CD only): 188.6 (C16), 188.6 (C4), 177.6 (C2), 171.7 (C20), 167.2 (C13), 104.6 (C3), 95.7 (C7), 81.3 (C5), 74.8 (C6), 62.6 (C14 and C21), 46.3 (CH₂), 42.9 (CH₂), 39.3 (CH₂), 36.9 (CH₂), 35.7 (C8), 35.2 (C22), 33.0 (C18), 28.0 (C32 and C33), 27.3 (C29-C31), 24.7 (C9-C11), 14.6 (CH₃), 13.9 (CH₃). **MS** (ES⁻); 572.34 (M-H); **HRMS** (M-H); calculated for C₃₂H₄₆NO₈; 572.3229; found; 572.3232.

4.1.19. Synthesis of 6G



Yield; 40 % (oil); Form AB: CD = not determined; ¹HNMR (400 MHz, CDCl₃): 5.10 (q, 1H, J = 6.8 Hz, C6), 4.92 (s, 1H, C7), 4.22-4.06 (m, 4H, C14 and C21), 3.71 (d, 1H, J = 12.4 Hz, C17), 2.59 (d, 1H, J = 12.4 Hz, C17), 1.98-1.87 (m, 5H, C19, C30-C32), 1.74-1.51 (m, 12H, C24-C29), 1.40 (t, 2H, J = 7.3 Hz, C22), 1.27 (t, 2H, J = 7.3 Hz,

C15), 1.05 (s, 3H, C33), 1.00 (d, 3H, J = 6.8 Hz, C12), 0.89 (s, 3H, C34), 0.84 (s, 9H, C9-C11). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only): 195.8 (C16), 189.6 (C4), 182.3 (C2), 175.3 (C20), 168.5 (C13), 103.9 (C3), 95.2 (C7), 80.3 (C5), 74.8 (C6), 61.9 (CH₂), 61.3 (CH₂), 44.9 (CH₂), 43.3 (CH₂), 42.5 (CH₂), 42.3 (CH₂), 36.9 (CH₂), 35.2 (C8 and C23), 31.8 (C18), 30.0 (C33 and C34), 28.5 (C30-C32), 25.0 (C9-C11), 14.4 (CH₃), 14.2 (CH₃). **MS** (ES⁻); 585.35 ((M-H); **HRMS** (M-H); calculated for C₃₃H₄₈NO₈; 586.3385; found; 586.3386.

4.1.20. Synthesis of 6H



Yield; 41 % (oil); Form AB: CD = not determined; ¹HNMR (400 MHz, CDCl₃): 5.13 (q, 1H, J = 6.8 Hz, C6), 4.95 (s, 1H, C7), 4.28-4.19 (m, 2H, C14), 4.13 (t, 2H, J = 7.5 Hz, C21), 3.11-2.89 (m, 2H,

C17), 2.43-2.35 (m, 2H, C19), 2.05-1.91 (m, 5H, C18, C30-C32), 1.74-1.51 (m, 12H, C24-C29), 1.43-1.39 (m, 2H, C22), 1.30-1.26 (m, 3H, C15), 1.04 (d, 3H, J = 6.8 Hz, C12), 0.93 (s, 9H, C9-C11). ¹³**C** NMR (100 MHz, CDCl₃, tautomer CD only): 189.4 (C16), 188.4 (C4), 179.5 (C2), 172.6 (C20), 167.2 (C13), 102.9 (C3), 95.6 (C7), 81.3 (C5), 74.8 (C6), 62.6 (CH₂), 61.1 (CH₂), 42.4 (CH₂), 42.3 (CH₂), 36.9 (CH₂), 35.2 (C8), 33.3 (CH₂), 33.2 (CH₂), 31.9 (CH₂), 31.7 (C23), 28.5 (C30-C32), 25.4 (CH₂), 24.7 (C9-C11), 21.0 (CH₂), 14.5 (CH₃), 13.9 (CH₃). **MS** (ES⁺); 560.34 ((M+H); **HRMS** (M+Na); calculated for C₃₁H₄₅NNaO₈; 582.3037; found; 582.3042.

4.1.21. Synthesis of 6I



Yield; 61 % (oil); form AB: CD= 20: 80. ¹H NMR (400 MHz, CDCl₃); 7.27 (dd, 2H, $J_1 = 8.4$ Hz, $J_2 = 8.2$ Hz, C21 and C22), 6.96-6.82 (m, 3H, C19, C20 and C23), 4.82-4.80 (m, 1H, C7 and 1H C6 AB), 4.71 (d, 1H, J = 9.2 Hz, C6 CD), 4.03 (t, 2H, J = 6.0 Hz, C17), 3.79 (s, 3H, C13 AB), 3.74 (s, 3H, C13 CD),

3.41-2.96 (m, 3H, C6 and C15), 2.29-2.12 (m, 2H, C16), 0.93 (s, 9H, C9-11 CD), 0.92 (s, 9H, C9-11 AB). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only); 191.5 (C14), 187.8 (C4), 180.1 (C2), 167.4 (C12), 158.3 (C18), 129.4 (C21 and C22), 120.9 (C23), 114.3 (C19 and C20), 101.3 (C3), 98.1 (C7), 78.2 (C5), 68.0 (C6), 66.5 (C17), 53.2 (C13), 35.1 (C8), 30.1 (C15), 25.6 (C16), 24.6 (C9-C11). **MS** (ES⁻); 416.18 (M-H); **HRMS** (M-H); calcd for C₂₂H₂₆N₁O₇; 416.1715; found; 416.1724.

4.1.22. Synthesis of 12A



Yield; 37 %; M.P.; 107 °C; Form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 5.18 (s, 1H, C7 AB), 5.11 (s, 1H, C7 CD), 3.80-3.76 (m, 4H, C6 and C13), 2.87-2.82 (m, 3H, C6 and C15), 1.71-1.63 (m, 2H, C16), 1.39-1.26 (m, 16H, C17-C24), 0.98 (s, 9H, C9-C11 CD),

0.97 (s, 9H, C9-C11 AB), 0.88 (t, 3H, *J* = 7.2 Hz, C25). ¹³C NMR (125 MHz, CDCl₃, tautomer CD only): 191.61 (C14), 188.51 (C4), 177.70 (C2), 167.54 (C12), 99.51 (C3), 82.85 (C5), 73.51 (C7), 53.31 (C13), 36.68 (C8), 33.66 (C6), 33.30 (CH₂), 32.98 (CH₂), 31.87 (CH₂), 29.56 (CH₂), 29.54 (CH₂), 29.39 (CH₂), 29.29 (CH₂), 29.18 (CH₂), 29.15 (CH₂), 26.43 (C9-C11), 25.91 (CH₂), 25.48 (CH₂), 24.83 (CH₂), 22.65 (CH₂), 14.09 (C25). **MS** (ES⁻); 452.26 (M-H); **HRMS** (M+Na); calculated for C₂₄H₃₉NNaO₅S; 476.2441; found; 476.2448.

4.1.23. Synthesis of 12B



Yield; 52 % (oil); Form AB: CD= 20: 80; ¹H NMR (500 MHz, CDCl₃); 4.88 (s, 1H, C7 AB), 4.85 (s, 1H, C7 CD), 4.82 (d, 1H, *J* = 8.5 Hz, C6), 4.30-4.20 (m, 2H, C13), 3.50 (d, 1H, *J* = 8.5 Hz, C6 AB), 3.49 (d, 1H, *J* = 8.5 Hz, C6 CD), 3.02-2.96 (m, 2H, C16 AB), 2.92-2.79

(m, 2H, C16 CD), 1.74-1.63 (m, 2H, C17), 1.42-1.25 (m, 19H, C14 and C18-C25), 0.94 (s, 9H, C9-11), 0.88 (t, 3H, *J* = 7.5 Hz, C24). ¹³**C NMR** (125 MHz, CDCl₃); 195.9 (C4 AB), 194.0 (C15 AB), 192.3 (C15 CD), 188.0 (C4

CD), 180.4 (C2 CD), 172.4 (C2 AB), 166.8 (C12 AB), 167.0 (C12 CD), 103.8 (C3 AB), 101.1 (C3 CD), 98.3 (C7 AB), 98.2 (C7 CD), 78.4 (C5 CD), 76.5 (C5 AB), 68.2 (C6), 62.8 (C13 AB), 62.6 (C13 CD), 35.3 (C8 AB), 35.1 (C8 CD), 33.0 (CH₂), 31.9 (CH₂), 29.5 (CH₂), 29.5 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.1 (CH₂), 29.1 (CH₂), 25.9 (CH₂ CD), 25.7 (CH₂ AB), 24.8 (C9-11 AB), 24.7 (C9-11 CD), 22.6 (CH₂), 14.1 (CH₃), 14.0 (CH₃). **MS** (ES⁻); 450.30 (M-H); **HRMS** (M-H); calcd for $C_{25}H_{40}N_1O_6$; 450.2861; found; 450.2857.

4.1.24. Synthesis of 12C



Yield; 49 % (oil); form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 4.88 (s, 1H, C7 AB), 4.85 (s, 1H, C7 CD), 4.83 (d, 1H, J = 9.2 Hz, C6), 4.37-4.30 (m, 2H, C13), 3.59 (t, 2H, J = 5.2 Hz, C14), 3.51 (d, 1H, J = 9.2 Hz, C6), 3.34 (s, 3H, C15), 2.56 (s, 3H, C17 AB), 2.48 (s, 3H, C17 AB), 0.94 (s, 9H, C9-C11 CD), 0.90 (s, 9H, C9-C11 AB). ¹³C NMR

(100 MHz, CDCl₃, tautomer CD only): 188.32 (C16), 187.93 (C4), 179.96 (C2), 166.98 (C12), 101.67 (C3), 98.29 (C7), 78.45 (C5), 69.83 (C14), 68.16 (C6), 65.51 (C13), 58.86 (C15), 35.12 (C8), 24.63 (C9-C11), 19.90 (C17). **MS** (ES⁻); 340.15 (M-H); **HRMS** (M-H); calculated for C₁₆H₂₂NO₇; 340.1402; found 340.1402.

4.1.25. Synthesis of 12D



Yield: 42 %; M.P.; 121 °C; Form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 5.14 (q, 1H, J = 6.8 Hz, C6), 4.97 (s, 1H, C7 AB), 4.96 (s, 1H, C7 CD), 4.31-4.17 (m, 2H, C14), 2.92-2.78 (m, 2H, C17), 1.73-1.62 (m, 2H, C18), 1.37-1.25 (m, 19H, C15 and C19-C26), 1.04 (d, 3H, J = 6.8

Hz, C12), 0.93 (s, 9H, C9-C11), 0.88 (t, 3H, *J* = 6.8 Hz, C27). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only): 191.1 (C16), 188.4 (C4), 179.8 (C2), 167.3 (C13), 102.7 (C3), 95.7 (C7), 81.3 (C5), 74.8 (C6), 62.6 (C14), 35.2 (C8), 33.9 (CH₂), 32.8 (CH₂), 31.9 (CH₂), 29.6 (CH₂), 29.5 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.0 (CH₂), 26.1 (CH₂), 25.6 (CH₂), 24.9 (CH₂), 24.8 (C9-C11), 22.7 (CH₂), 14.5 (CH₃), 14.1 (CH₃), 13.9 (CH₃). **MS** (ES⁻): 464.33 (M-H); **HRMS** (M-H): calcd for C₂₄H₃₈NO₆; 464.3018; found; 464.3019.

4.1.26. Synthesis of 12E



Yield: 38 %; M.P.; 117 °C; Form AB: CD = 20: 80; ¹HNMR (500 MHz, CDCl₃): 5.14 (q, 1H, J = 6.5 Hz, C6), 4.98 (s, 1H, C7 AB), 4.96 (s, 1H, C7 CD), 4.30-4.18 (m, 2H, C14), 2.91-2.79 (m, 2H, C17), 1.74-1.65 (m, 2H, C18), 1.41-1.25 (m, 21H, C15 and C19-C27), 1.05 (d,

3H, J = 6.5 Hz, C12), 0.94 (s, 9H, C9-C11 CD), 0.93 (s, 9H, C9-C11 AB), 0.88 (t, 3H, J = 6.5 Hz, C28). ¹³C NMR (125 MHz, CDCl₃, tautomer CD only): 191.2 (C16), 188.4 (C4), 179.8 (C2), 167.4 (C13), 102.7 (C3), 95.7 (C7), 81.3 (C5), 74.8 (C6), 62.6 (C14), 35.2 (C8), 33.6 (CH₂), 32.8 (CH₂), 31.9 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 29.5 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.0 (CH₂), 26.1 (CH₂), 25.5 (CH₂), 24.8 (CH₂), 24.8 (C9-C11), 22.7 (CH₂), 14.5 (CH₃), 14.1 (CH₃), 14.0 (CH₃). **MS** (ES⁻) 478.33 (M-H); **HRMS** (M-H): calcd for

C₂₇H₄₄NO₆; 478.3174; found 478.3177.

4.1.27. Synthesis of 12F



Yield: 35 %; M.P.; 108 °C; Form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 5.14 (q, 1H, J = 6.8 Hz, C6), 4.98 (s, 1H, C7 AB), 4.96 (s, 1H, C7 CD), 4.31-4.19 (m, 2H, C14), 2.92-2.78 (m, 2H, C17), 1.72-1.63 (m, 2H, C18), 1.40-1.26 (m, 23H, C15 and C19-

C28), 1.05 (d, 3H, J = 6.8 Hz, C12), 0.94 (s, 9H, C9-C11), 0.89 (t, 3H, J = 7.2 Hz, C29). ¹³**C** NMR (125 MHz, CDCl₃, tautomer CD only): 191.2 (C16), 188.4 (C4), 179.8 (C2), 167.4 (C13), 102.7 (C3), 95.7 (C7), 81.3 (C5), 74.8 (C6), 62.6 (C14), 35.2 (C8), 33.6 (CH₂), 32.9 (CH₂), 31.9 (CH₂), 29.6 (CH₂), 29.6 (CH₂), 29.5 (CH₂), 29.4 (CH₂), 29.4 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 26.1 (CH₂), 24.8 (CH₂), 24.8 (C9-C11), 22.7 (CH₂), 14.5 (CH₃), 14.1 (CH₃), 14.0 (CH₃). **MS** (ES'): 492.36 (M-H); **HRMS** (M-H): calcd for C₂₈H₄₆NO₆ 492.3331; found 492.3329.

4.1.28. Synthesis of 12G



Yield; 43 % (oil); form AB: CD= 20: 80; ¹H NMR (500 MHz, CDCl₃); 4.93-4.84 (m, 2H, C6 and C7), 3.46 (d, 1H, J = 10.5 Hz, C6 AB), 3.44 (d, 1H, J = 8.5 Hz, C6 CD), 3.03-2.30 (m, 4H, C13 and C18), 1.74-1.58 (m, 4H, C14 and C19), 1.39-1.27 (m, 10H, C15 and C20-C23), 0.91-0.86 (m, 15H, C9-C11, C16 and C24). ¹³C NMR (125 MHz, CDCl₃); 201.3 (C12 CD), 201.2 (C12 AB), 196.3

(C4 AB), 195.2 (C17 AB), 193.0 (C17 CD), 188.9 (C4 CD), 181.5 (C2 CD), 173.6 (C2 AB), 104.3 (C3 AB), 101.5 (C3 CD), 98.7 (C7 AB), 98.7 (C7 CD), 83.7 (C5 CD), 81.5 (C5 AB), 66.7 (C6 CD), 66.7 (C6 AB), 37.4 (CH₂ CD), 37.2 (CH₂ AB), 35.3 (C8 AB), 35.1 (C8 CD), 34.0 (CH₂), 33.5 (CH₂ AB), 33.5 (CH₂ AB), 33.1 (CH₂), 31.6 (CH₂), 29.2 (CH₂ AB), 29.1 (CH₂), 29.0 (CH₂), 28.9 (CH₂), 28.8 (CH₂), 26.0 (CH₂), 25.6 (CH₂ AB), 25.4 (CH₂ AB), 25.1 (C9-C11 AB), 25.0 (C9-C11 CD), 24.7 (CH₂ AB), 24.7 (CH₂), 22.6 (CH₂), 22.5 (CH₂), 22.1 (CH₂), 22.0 (CH₂ AB), 14.0 (C24), 13.8 (C16). **MS** (ES⁻); 406.21 (M-H); **HRMS** (M-H); calcd for C₂₃H₃₆N₁O₅; 406.2599; found; 406.2592.

4.1.29. Synthesis of 12H



Yield; 46 % (oil); Form AB: CD= 20: 80; ¹H NMR (400 MHz, CDCl₃); 4.86 (s, 1H, C7 AB), 4.82 (s, 1H, C7 CD), 4.80 (d, 1H, J = 9.2 Hz, C6), 4.57 (brs, 1H, NH), 3.77 (s, 3H, C13 AB), 3.76 (s, 3H, C13 CD), 3.47 (d, 1H, J = 9.2

Hz, C6), 3.07 (brs, 2H, C25), 2.97-2.86 (m, 2H, C15 AB), 2.84-2.80 (m, 2H, C15 CD), 1.70-1.60 (m, 2H, C16), 1.41 (s, 9H, C28-C30), 1.36-1.24 (m, 16H, C17-C24), 0.90 (s, 9H, C9-C11). ¹³**C** NMR (100 MHz, CDCl₃, tautomer CD only); 192.39 (C14), 187.66 (C4), 180.19 (C2), 167.41 (C12), 155.91 (C26), 100.94 (C3), 98.14

(C7), 79.85 (C27), 78.23 (C5), 68.14 (C6), 53.18 (C13), 40.53 (C25), 35.08 (C8), 32.95 (C15), 29.97 (CH₂), 29.39 (CH₂), 29.35 (CH₂), 29.24 (CH₂), 29.16 (CH₂), 29.08 (CH₂), 29.03 (CH₂), 28.34 (C28-C30), 26.69 (CH₂), 25.79 (CH₂), 24.55 (C9-11). **MS** (ES⁻); 551.30 (M-H); **HRMS** (M-H); calcd for $C_{29}H_{47}N_2O_8$; 551.3338; found; 551.3346.

4.1.30. Synthesis of 12K



Yield; 66 % (oil); Form AB: CD= 20: 80. ¹H NMR (400 MHz, CDCl₃); 4.88-4.84 (m, 2H, C6 and C7), 3.82 (s, 3H, C13 AB), 3.80 (s, 3H, C13 CD), 3.52 (d, 1H, J = 9.2 Hz, C6), 3.44-3.15 (m, 2H, C15), 2.58-2.46 (m, 2H, C16), 0.94 (s, 9H, C9-11). **MS** (ES⁻); 628.03 (M-H); **HRMS** (M-H); calcd

for $C_{21}H_{19}F_{13}N_1O_6$; 628.1010; found; 628.1001.

4.1.31. Synthesis of 12L



Yield; 59 % (oil); Form AB: CD= 20: 80; ¹H NMR (400 MHz, CDCl₃); 5.57 (brs, 1H, NH), 4.86 (s, 1H, C7 AB), 4.84 (s, 1H, C7 CD), 4.81 (d, 1H, *J* = 9.2 Hz, C6), 3.79 (s, 3H, C13 AB), 3.78 (s, 3H, C13 CD), 3.49 (d, 1H, *J* = 9.2 Hz, C6),

3.25-3.20 (m, 2H, C19), 3.01-2.94 (m, 2H, C15 AB), 2.92-2.77 (m, 2H, C15 CD), 2.13 (t, 2H, *J* = 8.0 Hz, C21), 1.75-1.38 (m, 8H, C16, C18, C22 and C28), 1.28-1.24 (m, 12H, C17 and C23-C27), 0.92 (s, 9H, C9-C11), 0.86 (t, 3H, *J* = 7.2 Hz, C29). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only); 191.88 (C14), 187.79 (C4), 180.10 (C2), 173.11 (C20), 167.44 (C12), 101.11 (C3), 98.18 (C7), 78.27 (C5), 68.14 (C6), 53.26 (C13), 39.01 (C19), 36.80 (C21), 35.10 (C8), 32.74 (C15), 31.79 (CH₂), 29.38 (CH₂), 29.30 (CH₂), 29.26 (CH₂), 29.20 (CH₂), 29.15 (CH₂), 26.31 (CH₂), 25.75 (CH₂), 25.38 (CH₂), 24.56 (C9-11), 22.59 (CH₂), 14.04 (C29). **MS** (ES⁻); 521.31 (M-H); **HRMS** (M-H); calcd for C₂₈H₄₅N₂O₇; 521.3232; found; 521.3232.

4.1.32. Synthesis of 12M



Yield; 66 % (oil); Form AB: CD= 20: 80; ¹H NMR (400 MHz, CDCl₃); 4.86 (s, 1H, C7 AB), 4.84 (s, 1H, C7 CD), 4.81 (d, 1H, *J* = 8.8 Hz, C6), 3.79 (s, 3H, C13 AB), 3.78 (s, 3H, C13 CD), 3.49 (d, 1H, *J* = 8.8 Hz, C6), 3.27 (t, 4H, *J* = 8.0 Hz, C20), 3.18 (t, 4H, *J* = 8.0 Hz,

C20'), 3.00-2.88 (m, 2H, C15), 2.33-2.30 (m, 2H, C18), 1.74-1.72 (m, 4H, C16 and C17), 1.56-1.45 (m, 4H, C21 and C21'), 1.34-1.23 (m, 12H, C22-24 and C22'-24'), 0.92-0.85 (m, 15H, C9-11, C25 and C25'). ¹³C NMR (100 MHz, CDCl₃, tautomer CD only); 191.79 (C14), 187.68 (C4), 180.13 (C2), 171.59 (C19), 167.43 (C12), 101.13 (C3), 98.17 (C7), 78.26 (C5), 68.16 (C6), 53.23 (C13), 47.90 (C20'), 45.92 (C20), 35.11 (C8), 32.72 (CH₂), 32.40 (CH₂), 31.56 (CH₂), 31.48 (CH₂), 29.03 (CH₂), 27.69 (CH₂), 26.67 (CH₂), 26.53 (CH₂), 25.41 (CH₂), 24.69 (CH₂), 24.58 (C9-11), 22.54 (CH₂), 13.98 (CH₃), 13.84 (CH₃). **MS** (ES⁻); 549.37 (M-H); **HRMS** (M-

H); calcd for $C_{30}H_{49}N_2O_7$; 549.3545; found; 549.3543.

4.1.33. Synthesis of 12N

3H, C6 and C17), 3.10-2.82 (m, 2H, C15), 2.04-1.92 (m, 2H, C16), 0.94 (s, 9H, C9-11 CD), 0.92 (s, 9H, C9-11 AB). **MS** (ES⁻); 685.03 (M-H); **HRMS** (M-H); calcd for C₂₃H₂₂F₁₃N₂O₇; 685.1225; found; 685.1231.

4.1.34. Synthesis of 120



Yield; 79 % (oil); form AB: CD= 20: 80; ¹H NMR (400 MHz, CDCl₃); 4.78-4.61 (m, 4H, C6, C7 and C15), 3.71 (s, 3H, C13), 3.47 (d, 1H, J = 8.8 Hz, C6), 3.03 (s, 3H, C28 CD), 2.91 (s, 3H, C28 AB), 2.32 (t, 2H, *J* = 6.4 Hz, C17 CD), 2.17 (brs, 2H, C17

AB), 1.57 (brs, 2H, C18), 1.19 (brs, 16H, C19-C26), 0.85 (s, 9H, C9-C11), 0.80 (brs, 3H, C27). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only); 173.87 (C16), 166.92 (C12), 97.91 (C7), 67.93 (C6), 53.12 (C13), 36.75 (C28), 34.92 (C8), 32.72 (C17), 31.67 (C18), 29.38 (CH₂), 29.27 (CH₂), 29.21 (CH₂), 29.10 (CH₂), 24.64 (CH₂), 24.39 (C9-11), 22.44 (CH₂), 13.89 (C27). **MS** (ES⁻); 507.26 (M-H); **HRMS** (M+Na); calcd for C₂₇H₄₄N₂Na₁O₇; 531.3041; found; 531.3041.

4.1.35. Synthesis of 12P



Yield; 39 %; M.P.; 109 °C; Form AB: CD = 20: 80; ¹H NMR (400 MHz, CDCl₃): 5.13 (q, 1H, J = 6.8 Hz, C6), 4.98 (s, 1H, C7 AB), 4.96 (s, 1H, C7 CD), 4.31-4.19 (m, 2H, C14), 2.91-2.77 (m, 2H, C17), 1.73-1.62 (m, 1H, C19), 1.54-1.41 (m, 2H, C18), 1.30-1.26 (m, 11H, C15 and C20-C23), 1.05

(d, 3H, J = 6.8 Hz, C12), 0.93 (s, 9H, C9-C11), 0.91-0.86 (m, 6H, C24 and C25). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only): 191.58 (C16), 188.34 (C4), 179.87 (C2), 167.35 (C13), 102.52 (C3), 95.64 (C7), 81.30 (C5), 74.83 (C6), 62.58 (C14), 36.48 (CH₂), 35.19 (C8), 33.65 (CH₂), 32.97 (CH₂), 32.65 (C19), 32.06 (CH₂), 30.72 (CH₂), 26.54 (CH₂), 24.75 (C9-C11), 22.63 (CH₂), 19.22 (C25), 14.50 (CH₃), 14.05 (CH₃), 13.94 (CH₃). **MS** (ES⁻); 436.29 ((M-H); **HRMS** (M-H); calcd for C₂₄H₃₈NO₆ 436.2705; found 436.2706.

4.1.36. Synthesis of 12Q



Yield; 39 %; M.P.; 131 °C; Form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 5.15-5.04 (m, 2H, C6 and C21), 4.98 (s, 1H, C7 AB), 4.96 (s, 1H, C7 CD), 4.29-4.15 (m, 2H, C14), 2.96-2.71 (m, 2H, C17), 1.04-1.92 (m, 3H, C18 and C19), 1.68 (s, 3H, C23), 1.59 (s, 3H, C24), 1.33-1.24 (m, 5H, C15 and C20),

1.04 (d, 3H, J = 6.0 Hz, C12), 0.96 (d, 3H, J = 6.4 Hz, C25), 0.93 (s, 9H, C9-C11). ¹³C NMR (100 MHz, CDCl₃, tautomer CD only): 190.43 (C16), 188.54 (C4), 179.68 (C2), 167.31 (C13), 131.72 (C22), 123.91 (C21), 103.55 (C3), 95.64 (C7), 81.26 (C5), 74.78 (C6), 62.54 (C14), 39.62 (CH₂), 36.81 (CH₂), 35.20 (C8), 33.75 (CH₂), 31.88 (C18), 25.66 (C23), 24.73 (C9-C11), 19.15 (C25), 17.63 (C24), 14.49 (CH₃), 13.91 (CH₃). **MS** (ES⁺); 436.29 ((M+H); **HRMS** (M+H); calcd for C₂₄H₃₈NO₆ 436.2694; found; 436.2692.

4.1.37. Synthesis of 12R



Yield; 16 % (oil); form AB: CD= 10: 90. ¹H NMR (400 MHz, CDCl₃); 4.88 (s, 1H, C7 AB), 4.86 (s, 1H, C7 CD), 4.82 (d, 1H, J = 8.8 Hz, C6), 4.16-4.05 (m, 2H, C21), 3.80 (s, 3H, C13 AB), 3.77 (s, 3H, C13 CD), 3.48 (d, 1H, J = 8.8 Hz, C6), 3.12-2.94

(m, 2H, C15), 2,43 (s, 2H, C17 AB), 2.38 (s, 2H, C17 CD), 1.69-1.61 (m, 1H, C23), 1.57-1.49 (m, 2H, C22), 1.46-1.38 (m, 1H, C27), 1.32-1.09 (m, 12H, C18, C19 and C24-C26), 0.93 (s, 9H, C9-C11), 0.89 (d, 3H, J = 6.4 Hz, C30), 0.86 (d, 3H, J = 6.4 Hz, C28 and C29). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only); 190.02 (C14), 187.89 (C4), 180.05 (C2), 171.50 (C20), 167.35 (C12), 102.94 (C3), 98.23 (C7), 78.25 (C5), 68.14 (C6), 62.86 (C21), 53.24 (C13), 46.13 (CH₂), 42.89 (CH₂), 39.15 (CH₂), 37.07 (CH₂), 35.53 (CH₂), 35.42 (CH₂), 35.15 (CH₂), 29.80 (C23), 27.90 (C16 and C27), 27.41 (CH₃), 27.33 (CH₃), 24.60 (CH₂), 24.57 (C9-11), 22.65 (CH₃), 22.56 (CH₃), 19.44 (CH₃). **MS** (ES⁻); 536.29 (M-H); **HRMS** (M-H); calcd for C₂₉H₄₆N₁O₈; 536.3229; found; 536.3223.

4.1.38. Synthesis of 12S



Yield; 36 % (oil); Form AB: CD = not determined; ¹H NMR (400 MHz, CDCl₃): 5.13 (q, 1H, J = 6.7 Hz, C6), 4.95 (s, 1H, C7), 4.28-4.19 (m, 2H, C14), 4.13-4.06 (m, 2H, C21), 3.11-2.89 (m, 2H, C17), 2.38 (t, 2H, J = 7.4 Hz, C19), 2.06-1.96 (m, 2H, C18), 1.70-

1.37 (m, 4H, C22, C23 and C27),1.32-1.11(m, 9H, C15 and C24-C26), 1.04 (d, 3H, *J* = 6.7 Hz, C12), 0.93-0.85 (m, 18H, C9-C11 and C28-C30). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only): 189.40 (C16), 188.37 (C4), 179.53 (C2), 172.57 (C20), 167.19 (C13), 102.96 (C3), 95.65 (C7), 81.33 (C5), 74.80 (C6), 63.20 (CH₂), 62.63 (CH₂), 39.16 (CH₂), 37.08 (CH₂), 35.46 (CH₂), 35.19 (C8), 33.60 (CH₂), 33.16 (CH₂), 31.92 (CH₂), 29.80 (C23), 27.90 (C27), 24.73 (C9-C11), 24.56 (CH₂), 22.65 (CH₃), 22.56 (CH₃), 21.00 (C18), 19.46 (CH₃), 14.50 (CH₃), 13.93 (CH₃). **MS** (ES⁻); 536.34 (M-H); **HRMS** (M-H); calculated for C₂₉H₄₆NO₈; 536.3229; found; 536.3230.

4.1.39. Synthesis of 12T



(s, 1H, C7 CD), 4.32-4.06 (m, 4H, C14 and C21), 3.07-2.96 (m, 2H, C17), 2.43 (s, 2H, C19 AB), 2.39 (s, 2H, C19 CD), 1.73-1.40 (m, 4H, C22, C23 and C27),1.31-1.13(m, 15H, C15, C24-C26, C30 and C31), 1.04 (d, 3H, *J* = 6.7 Hz, C12), 0.93-0.85 (m, 18H, C9-C11 and C28-C30). ¹³C NMR (125 MHz, CDCI₃, tautomer CD only): 188.63 (C16), 188.61 (C4), 179.55 (C2), 171.52 (C20), 167.20 (C13), 104.59 (C3), 95.68 (C7), 81.25 (C5), 74.77 (C6), 62.85 (CH₂), 62.55 (CH₂), 46.19 (CH₂), 42.80 (CH₂), 39.16 (CH₂), 37.07 (CH₂), 35.68 (CH₂), 35.53 (CH₂), 35.21 (C8), 33.74 (C18), 29.80 (C23), 27.90 (C27), 27.26 (CH₃), 27.23 (CH₃), 24.73 (C9-C11), 24.58 (CH₂), 22.66 (CH₃), 22.56 (CH₃), 19.44 (CH₃), 14.55 (CH₃), 13.91 (CH₃). MS (ES⁻); 564.36 (M-H); HRMS (M-H); calculated for C₃₁H₅₀NO₈; 564.3542; found; 564.3541.

4.1.40. Synthesis of 12U



Yield; 41 %; M.P.; 98 °C; form AB: CD = Not determined; ¹HNMR (500 MHz, CDCl₃):
4.88 (s, 1H, C7), 4.87 (d, 1H, J = 9.5 Hz, C6), 4.38-4.27 (m, 2H, C13), 3.61-3.54 (m, 2H, C14), 3.50 (d, 1H, J = 9.5 Hz, C6), 3.34 (s, 3H, C15), 2.92 (d, 1H, J = 12.0 Hz, C17), 2.64 (d, 1H, J = 12.0 Hz, C17), 1.06 (s, 9H, C19-C21), 0.95 (s, 9H, C9-C11).

¹³C NMR (125 MHz, CDCl₃, tautomer CD only): 190.94 (C16), 187.98 (C4), 180.40 (C2), 167.05 (C12), 102.59 (C3), 98.33 (C7), 78.30 (C5), 69.86 (C14), 68.18 (C6), 65.42 (C13), 58.87 (C15), 45.17 (C17), 35.18 (C8), 33.92 (C18), 29.75 (C19-C21), 24.66 (C9-C11). MS (ES⁻); 396.21 (M-H); HRMS (M-H); calculated for C₂₀H₃₀NO₇ 396.2028 found 396.2024.

4.1.41. Synthesis of 12V



Yield; 34 %; M.P.; 79 °C; form AB: CD= 20: 80. ¹H NMR (400 MHz, CDCl₃); 4.93 (d, 1H, J = 8.0 Hz, C6 AB), 4.91 (d, 1H, J = 8.0 Hz, C6 CD), 4.87 (s, 1H, C7 AB), 4.85 (s, 1H, C7 CD), 3.44 (d, 1H, J = 8.0 Hz, C6 AB), 3.40 (d, 1H, J = 8.0 Hz, C6 CD), 2.93 (d, 1H, J = 12.0 Hz, C16), 2.89-2.80 (m, 1H, C13), 2.63 (d, 1H, J = 12.0 Hz,

C16), 2.32-2.22 (m, 1H, C13), 1.09-1.03 (m, 12H, C14 and C18-C20), 0.89 (s, 9H, C9-C11 CD), 0.88 (s, 9H, C9-C11 AB). ¹³**C NMR** (100 MHz, CDCl₃, Tautomer CD only); 201.71 (C12), 191.44 (C15), 189.03 (C4), 181.52 (C2), 102.91 (C3), 98.60 (C7), 83.45 (C5), 66.67 (C6), 45.21 (C16), 35.08 (C8), 34.15 (C17), 30.77 (C13), 29.72 (C18-C20), 24.96 (C9-C11), 7.37 (C14). **MS** (ES⁻); 350.19 (M-H); **HRMS** (M-H); calcd for $C_{19}H_{28}N_1O_5$; 350.1973; found; 350.1971.

4.1.42. Synthesis of 13A



Yield; 42 %; M.P.; 152 °C; Form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 5.14 (q, 1H, J = 6.8 Hz, C6), 4.98 (s, 1H, C7 AB), 4.96 (s, 1H, C7 CD), 4.29-4.20 (m, 2H, C14), 2.94-2.78 (m, 2H, C17), 1.73-1.59 (m, 8H, C18, C21 and cyclic CH₂), 1.40-1.26 (m, 7H, C15, C19 and C20), 1.19-1.12 (m, 5H, cyclic

CH₂), 1.05 (d, 3H, J = 6.8 Hz, C12), 0.94 (s, 9H, C9-C11). ¹³C NMR (125 MHz, CDCl₃, tautomer CD only):

191.10 (C16), 188.43 (C4), 179.80 (C2), 167.36 (C13), 102.68 (C3), 95.66 (C7), 81.32 (C5), 74.84 (C6), 62.60 (C14), 37.47 (C21), 36.96 (CH₂), 35.21 (C8), 33.87 (CH₂), 33.32 (CH₂), 33.30 (CH₂), 32.86 (CH₂), 26.65 (CH₂), 26.35 (CH₂), 25.57 (CH₂), 24.91 (CH₂), 24.76 (C9-C11), 14.53 (CH₃), 13.95 (CH₃). **MS** (ES⁻); 448.29 (M-H); **HRMS** (M-H); calcd for C₂₅H₃₈NO₆ 448.2705; found; 448.2702.

4.1.43. Synthesis of 13B



Yield; 36 %; M.P.; 129 °C; Form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 5.18 (s, 1H, C7 AB), 5.11 (s, 1H, C7 CD), 3.80-3.77 (m, 4H, C6 and C13), 2.87-2.82 (m, 3H, C6 and C15), 1.69-1.60 (m, 8H, CH₂), 1.41-1.34 (m, 2H, CH₂), 1.27-1.14 (m, 7H, CH₂ and CH), 0.99 (s, 9H, C9-C11).

¹³C NMR (125 MHz, CDCl₃); 191.61 (C14), 188.50 (C4), 177.70 (C2), 167.54 (C12), 99.52 (C3), 82.86 (C5),
73.52 (C7), 53.32 (C13), 37.48 (C19), 36.93 (CH₂), 36.69 (C8), 33.31 (C6), 32.99 (CH₂), 26.65 (CH₂), 26.47 (CH₂), 26.43 (C9-C11), 26.36 (CH₂), 26.21 (CH₂). MS (ES⁻); 436.23 (M-H); HRMS (M-H); calculated for C₂₃H₃₄NO₅S; 436.2163; found; 436.2162.

4.1.44. Synthesis of 13C



Yield; 33 %; M.P.; 111 °C; form AB: CD= not determined. ¹H NMR (500 MHz, CDCl₃); 4.90 (d, 1H, J = 9.0 Hz, C6), 4.88 (s, 1H, C7), 3.45-3.40 (m, 1H, C6), 3.27-2.96 (m, 4H, C13, C18 and C20), 2.82-2.76 (m, 1H, C22), 2.39-2.25 (m, 3H, C13, C18 and C22), 1.98 (brs, 3H, C30-C32),

1.73-1.48 (m, 14H, C14 and C24-C29), 1.29-1.25 (m, 2H, C15), 1.18-1.14 (m, 6H, C33 and C34), 0.90 (s, 9H, C9-C11), 0.87 (t, 3H, J = 7.5 Hz, C16). ¹³**C NMR** (125 MHz, CDCl₃, tautomer CD only); 103.74 (C3), 98.78 (C7), 83.47 (C5), 66.76 (C6), 51.29 (CH₂), 48.19 (CH₂), 40.26 (CH₂), 37.44 (CH₂), 36.81 (CH₂), 36.18 (quart C), 35.14 (quart C), 33.58 (quart C), 28.10 (C30-C32), 25.32 (CH₂), 25.19 (C33 and C34), 25.07 (C9-C11), 22.10 (CH₂), 13.76 (C16). **MS** (ES⁻); 569.29 (M-H); **HRMS** (M-H); calcd for C₂₂H₄₉N₂O₆; 569.3596; found; 569.3595.

4.1.45. Synthesis of 13D



Yield; 21 % (oil); form AB: CD= 20: 80. ¹H NMR (400 MHz, CDCl₃); 5.61-5.45 (m, 2H, C20 and C21), 4.86 (s, 1H, C7 AB), 4.83 (s, 1H, C7 CD), 4.80 (d, 1H, J = 8.8 Hz, C6), 4.61-4.55 (m, 1H, C23), 4.24-4.02 (m, 2H, C22), 3.88-3.83 (m, 1H, C27), 3.77 (s, 3H, C13),

3.49-3.47 (m, 2H, C6 and C27), 3.00-2.80 (m, 2H, C5), 2.07-1.38 (m, 14H, C16-C19 and C24-C26), 0.91 (s, 9H, C9-C11). ¹³C NMR (100 MHz, CDCl₃, tautomer CD only); 192.2 (C14), 187.7 (C4), 180.2 (C2), 167.4 (C12), 133.1 (C20), 126.1 (C21), 101.0 (C3), 98.1 (C7), 97.8 (C23), 78.2 (C5), 68.1 (C6), 62.6 (CH₂), 62.1 (CH₂), 53.2 (C13), 35.1 (CH₂), 32.9 (CH₂), 30.6 (CH₂), 29.0 (CH₂), 28.6 (CH₂), 27.2 (CH₂), 25.6 (CH₂), 25.4

(CH₂), 24.6 (C9-11), 19.4 (CH₂). **MS** (ES⁻); 492.25 (M-H); **HRMS** (M-H); calcd for C₂₆H₃₈N₁O₈; 492.2603; found; 492.2617.

4.1.46. Synthesis of 13E



Yield; 71 %; M.P.; 138 °C; Form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 4.88 (s, 1H, C7 AB), 4.84 (s, 1H, C7 CD), 4.82 (d, 1H, J = 9.2 Hz, C6), 4.33-4.30 (m, 2H, C13), 3.59-3.56 (m, 2H, C14), 3.50 (d, 1H, J = 9.2 Hz, C6), 3.33 (s, 3H, C15 CD), 3.32 (s,

3H, C15 AB), 2.93-2.76 (m, 5H), 2.37-2.11 (m, 8H), 2.07-1.93 (m, 5H), 1.87-1.77 (m, 2H), 1.65-1.56 (m, 1H), 1.51-1.41 (m, 1H), 1.39 (s, 3H, C26), 1.36-1.26 (m, 3H), 1.06 (s, 3H, C35), 0.93 (s, 9H, C9-C11), 0.89 (d, 3H, J = 6.8 Hz, C20). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only): 211.71 (C=O), 208.99 (C=O), 208.61 (C=O),192.69 (C16), 187.62 (C4), 180.32 (C2), 166.97 (C12), 100.85 (C3), 98.28 (C7), 78.34 (C5), 69.82 (C14), 68.19 (C6), 65.47 (C13), 58.85 (C15), 56.84 (C25), 51.65 (CH), 48.90 (CH), 46.75 (CH), 45.45 (CH), 45.42 (CH), 44.90 (CH₂), 42.71 (CH₂), 38.54 (CH₂), 36.41 (CH₂), 35.94 (C34), 35.19 (CH₂), 35.10 (C8), 31.63 (CH₂), 30.59 (CH₂), 27.53 (CH₂), 25.06 (CH₂), 24.61 (C9-C11), 21.83 (C20), 18.62 (C26), 11.77 (C35). **MS** (ES⁺); 684.39 (M+H); **HRMS** (M+H); calculated for C₃₈H₅₄NO₁₀; 684.3742; found; 684.3747.

4.1.47. Synthesis of 13F



Yield; 52 % (oil); form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 4.89 (s, 1H, C7 AB), 4.85 (s, 1H, C7 CD), 4.83 (d, 1H, J = 9.2 Hz, C6), 4.38-4.28 (m, 2H, C13), 3.96-3.93 (m, 2H, C21 and C22), 3.59-3.56 (m, 2H, C14), 3.50 (d, 1H, J = 9.2 Hz, C6), 3.40-3.37 (m, 2H, C21 and C22), 3.33 (s, 3H, C15), 2.88-2.71 (m,

1H, C17), 2.10-2.00 (m, 1H, C17), 1.66-1.25 (m, 5H, C18-C20), 0.94 (s, 9H, C9-C11 CD), 0.90 (s, 9H, C9-C11 AB). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only): 190.12 (C16), 187.82 (C4), 180.04 (C2), 166.88 (C12), 101.91 (C3), 98.31 (C7), 78.36 (C5), 69.84 (C14), 68.16 (C6), 67.56 (C21 and C22), 65.47 (C13), 58.83 (C15), 39.57 (C17), 35.12 (C8), 33.61 (C18), 32.64 (C19 and C20), 24.61 (C9-C11). **MS** (ES⁻); 424.21 (M-H); **HRMS** (M-H); calculated for C₂₁H₃₀NO₈ 424.1977 found 424.1969.

4.1.48. Synthesis of (\pm) -13G



Yield; 41 % (oil); form AB: CD= 20: 80. ¹H NMR (500 MHz, CDCl₃); 12.28 (brs, 1H, OH), 4.85 (d, 1H, *J* = 9.0 Hz, C6), 4.81 (s, 1H, C7 AB), 4.79 (s, 1H, C7 CD), 3.38 (d, 1H, *J* = 9.0 Hz, C6), 2.99-2.74 (m, 4H, C13, C16 and C20), 2.38-2.21 (m, 2H, C13 and C17), 2.08-2.03 (m, 1H, C18), 1.99 (s, 3H, C24), 1.88-1.83 (m, 1H, C18), 1.27 (s, 3H, C21), 1.03-1.00 (m, 3H, C14), 0.90-0.84 (m, 12H, C9-

C12 and C22). ¹³C NMR (125 MHz, CDCI₃, due to two diastereomers, some peakes are splitted); 206.90 (C 23 AB), 206.80 and 206.77 (C23 CD), 201.58 and 201.53 (C12 CD), 201.47 (C12 AB), 195.78 (C4 AB),

193.85 (C15 AB), 191.36 and 191.32 (C15 CD), 188.70 and 188.64 (C4 CD), 181.16 (C2 CD), 173.16 (C2 AB), 104.28 (C3 AB), 101.33 and 101.30 (C3 CD), 98.44 (C7), 83.40 (C5 CD), 81.09 and 81.05 (C5 AB), 66.58 and 66.55 (C6 CD), 66.46 (C6 AB), 54.05 (C20 AB), 53.95 and 53.93 (C20 CD), 43.81 and 43.77 (C19), 39.20 and 39.05 (C17 CD), 38.66 and 38.62 (C17 AB), 35.11 and 35.09 (C8 AB), 34.93 (C8 CD), 33.96 and 33.87 (C16 AB), 33.45 and 33.39 (C16 CD), 30.83 and 30.75 (C13 CD), 30.56 and 30.51 (C13 AB), 29.90 (C24), 29.82 and 29.75 (C21), 24.92 (C9-C11 AB), 24.83 (C9-C11 CD), 23.22 (C18 AB), 23.06 and 23.05 (C18 CD), 17.46 (C22 AB), 17.38 (C22 CD), 7.24 (C14). **MS** (ES⁻); 418.21 (M-H); MS (ES⁺); 442.23 (M+Na); **HRMS** (M-H); calcd for C₂₃H₃₃N₁Na₁O₆; 442.2200; found; 442.2201.

4.1.49. Synthesis of 14B



Yield; 37 %; M.P.; 85 °C; form AB: CD= 20: 80; ¹H NMR (400 MHz, CDCl₃); 7.76 (d, 1H, J = 8.0 Hz, C20 AB), 7.760 (d, 1H, J = 8.0 Hz, C20 CD), 7.33-7.14 (m, 4H, C17 and C21-C23), 4.97 (s, 1H, C7 AB), 4.97 (d, 1H, J = 8.8 Hz, C6 CD), 4.94 (d, 1H, J = 8.8 Hz, C6 AB), 4.82 (s, 1H, C7 CD), 4.49 (d, 1H, J = 14.4 Hz, C15 AB), 4.33 (d, 1H, J = 14.4 Hz, C15 CD), 4.28 (d, 1H, J = 14.4 Hz, C15 AB), 4.22 (d, 1H, J = 14.4 Hz, C15 CD), 3.83 (s, 3H, C13 CD), 3.79 (s, 3H, C13 AB), 3.79 (s, 3H, C24 AB), 3.77 (s, 3H, C24 CD), 3.51 (d, 1H, J =

8.8 Hz, C6 CD), 3.50 (d, 1H, J = 8.8 Hz, C6 AB), 0.99 (s, 9H, C9-11 AB), 0.93 (s, 9H, C9-11 CD). ¹³C NMR (100 MHz, CDCl₃, tautomer CD only); 192.3 (C14), 187.8 (C4), 180.3 (C2), 167.5 (C12), 136.7 (C19), 128.6 (C17), 127.5 (C18), 121.9 (C23), 119.5 (C22), 119.2 (C20), 109.3 (C21), 105.9 (C16), 100.6 (C3), 98.2 (C7), 78.4 (C5), 68.2 (C6), 53.3 (C13), 35.1 (C8), 32.7 (C24), 29.0, 24.6 (C9-11). MS (ES⁻); 425.18 (M-H); HRMS (M-H); calcd for $C_{23}H_{25}N_2O_6$; 425.1718; found; 425.1712.

4.1.50. Synthesis of 14C



Yield; 41 %; M.P.; 126 °C; Form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 7.30-7.26 (m, 2H, C25 and C26), 7.20-7.15 (m, 3H, C23, C24 and C27), 5.14 (q, 1H, J = 6.8 Hz, C6), 4.98 (s, 1H, C7 AB), 4.96 (s, 1H, C7 CD), 4.31-4.17 (m, 2H, C14), 3.05-2.79 (m, 2H, C17), 2.64-2.58 (m, 2H, C21), 1.78-1.61 (m, 4H, C18 and C20), 1.50-1.38 (m, 2H, C19), 1.28 (t, 3H, J =

7.2 Hz, C15), 1.04 (d, 3H, J = 6.8 Hz, C12), 0.94 (s, 9H, C9-C11). ¹³C NMR (125 MHz, CDCl₃, tautomer CD only): 190.86 (C16), 188.42 (C4), 179.78 (C2), 167.32 (C13), 142.26 (C22), 128.33 (Ar-CH), 128.28 (Ar-CH), 125.71 (C27), 102.70 (C3), 95.66 (C7), 81.32 (C5), 74.83 (C6), 62.61 (C14), 35.62 (CH₂), 35.19 (C8), 32.73 (CH₂), 30.95 (CH₂), 28.62 (CH₂), 25.82 (CH₂), 24.75 (C9-C11), 14.51 (CH₃), 13.95 (CH₃). **MS** (ES⁻); 456.26 (M-H); **HRMS** (M-H); calculated for C₂₆H₃₄NO₆; 456.2392; found; 456.2390.

4.1.51. Synthesis of 14D



Yield; 44%; M.P.; 129 °C; Form AB: CD = 20: 80; ¹HNMR (400 MHz,

CDCl₃): 8.06 (brs, 1H, NH), 7.58 (d, 1H, *J* = 7.8 Hz, C24), 7.36 (d, 1H, *J* = 7.8 Hz, C22), 7.20 (d, 1H, *J* = 7.8 Hz, Ar-H), 7.12 (d, 1H, *J* = 7.8 Hz, Ar-H), 7.02 (d, 1H, *J* = 2.0 Hz, C21), 5.14 (q, 1H, *J* = 6.8 Hz, C6), 4.99 (s, 1H, C7 AB), 4.96 (s, 1H, C7 CD), 4.32-4.19 (m, 2H, C14), 3.08-2.78 (m, 4H, C17 and C19), 2.19-2.06 (m, 2H, C18), 1.28 (t, 3H, *J* = 6.8 Hz, C15), 1.04 (d, 3H, *J* = 6.8 Hz, C12), 0.95 (s, 9H, C9-C11). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only): 190.9 (C16), 188.4 (C4), 179.8 (C2), 167.4 (C13), 136.3 (C23), 127.3 (C22), 122.0 (Ar-CH), 121.6 (Ar-CH), 119.3 (Ar-CH), 118.8 (Ar-CH), 115.2 (C20), 111.1 (C25), 102.7 (C3), 95.7 (C7), 81.4 (C5), 74.9 (C6), 62.7 (C14), 35.2 (C8), 32.8 (CH₂), 26.4 (CH₂), 24.8 (C9-C11), 24.7 (CH₂), 14.5 (CH₃), 14.0 (CH₃). **MS** (ES⁻); 467.24 (M-H); **HRMS** (M-H); calculated for C₂₆H₃₁N₂O₆; 467.2188; found 467.2189.

4.1.52. Synthesis of 14E



Yield; 23 % M.P.; 222 $^{\circ}$ C (decomposed); form AB: CD= 1:99; ¹H NMR (500 MHz, DMSO); 12.21 (brs, 1H, NH), 7.68 (s, 1H, C24), 7.51 (s, 1H, C23), 4.72 (s, 1H, C7), 4.55 (d, 1H, *J* = 8.5 Hz, C6), 3.65 (s, 3H, C13), 3.49 (d, 1H, *J* = 8.5 Hz, C6), 2.84-

2.71 (m, 2H, C15), 2.48-2.46 (m, 2H, C18), 2.31 (s, 3H, CH₃), 2.30 (s, 3H, CH₃), 1.65-1.54 (m, 4H, C16 and C17), 0.81 (s, 9H, C9-11). ¹³**C NMR** (125 MHz, DMSO); 191.03 (C14), 188.14 (C4), 177.50 (C2), 171.83 (C19), 169.01 (C12), 156.94 (C20), 147.08 (C22), 134.67 (quart C), 132.24 (quart C), 128.76 (quart C), 121.40 (tert C), 120.83 (tert C), 100.63 (C3), 97.09 (C7), 76.65 (C5), 67.90 (C6), 52.72 (C13), 34.86 (C8), 33.34 (CH₂), 25.32 (CH₂), 24.82 (CH₂), 24.65 (C9-11), 24.37 (CH₂), 19.70 (CH₃), 19.53 (CH₃). **MS** (ES⁻); 542.15 (M-H); **HRMS** (M-H); calcd for C₂₇H₃₂N₃O₇S₁; 542.1966; found; 542.1967.

4.1.53. Synthesis of 14F



Yield; 20 %; M.P.; 111 °C; form AB: CD= 1: 99. ¹H NMR (500 MHz, CDCl₃); 4.85 (d, 1H, J = 8.5 Hz, C6), 4.83 (s, 1H, C7), 3.42 (d, 1H, J = 8.5 Hz, C6), 2.95-2.80 (m, 3H, C13 and C18), 2.70 (t, 2H, J = 7.0 Hz, C21), 2.38-2.32 (m, 1H, C13), 2.34 (s, 3H, CH₃), 2.30 (s, 3H,

CH₃), 1.86-1.41 (m, 6H, C14, C19 and C20), 1.30-1.22 (m, 2H, C15), 0.88 (s, 9H, C9-C11), 0.85 (t, 3H, J = 7.5 Hz, C16). ¹³**C NMR** (125 MHz, CDCl₃); 171.31 (C22), 158.52 (C23), 132.73 (C25), 119.78 (C24), 98.41 (C7), 66.80 (C6), 36.96 (CH₂), 35.94 (CH₂), 35.16 (C8), 25.30 (CH₂), 25.10 (C9-C11), 24.72 (CH₂), 23.84 (CH₂), 22.04 (CH₂), 13.81 (CH₃), 11.74 (CH₃), 10.66 (CH₃). **MS** (ES⁻); 518.19 (M-H); **HRMS** (M+H); calcd for C₂₆H₃₈N₃O₆S₁; 520.2476; found; 520.2479.

4.1.54. Synthesis of 14G



Yield; 16 % (oil); form AB: CD= not determined. ¹H NMR (500 MHz, CDCl₃); 9.03 (brs, 1H, NH), 8.47 (d, 1H, J = 9.0 Hz, C23), 7.31 (d, 1H, J = 2.5 Hz, C24), 7.18 (dd, 1H, $J_1 = 9.0$ Hz, $J_2 = 2.5$

Hz, C24), 4.99-4.72 (m, 4H, C6, C7 and C19), 4.29 (s, 2H, C18), 3.50-3.48 (m, 1H, C6), 2.83-2.74 (m, 1H, C13), 2.38-2.32 (m, 1H, C13), 1.67-1.46 (m, 2H, C14), 1.32-1.26 (m, 2H, C15), 0.91-0.87 (m, 12H, C9-C11 and C16). ¹³**C NMR** (125 MHz, CDCl₃, tautomer CD only); 201.28 (C12), 188.14 (C17), 186.52 (C4), 181.46 (C2), 166.68 (C20), 144.92 (*quart*-C), 132.78 (*quart*-C), 123.68 (*quart*-C), 122.11 (*tert*-C), 122.08 (*tert*-C), 120.51 (*tert*-C), 100.86 (C3), 98.85 (C7), 83.75 (C5), 71.33 (OCH₂), 69.08 (OCH₂), 66.77 (C6), 37.72 (C13), 35.09 (C8), 25.22 (CH₂), 24.97 (C9-C11), 22.02 (CH₂), 13.77 (C16). **MS** (ES⁻); 589.10 (M-H); **HRMS** (M-H); calcd for C₂₆H₂₉Cl₁F₃N₂O₈; 589.1570; found; 589.1558.

4.1.55. Synthesis of 14H



Yield; 38 %; M.P.; 129 °C; Form AB: CD = 1: 99; ¹HNMR (400 MHz, CDCl₃): 8.52 (brs, 1H, NH), 8.35 (d, 1H, J = 9.1 Hz, C25), 7.27 (d, 1H, J = 2.0 Hz, C26), 7.14 (dd, 1H, $J_1 = 9.1$ Hz, $J_2 = 2.0$ Hz, C27), 4.85 (s, 1H, C7), 4.83 (d, 1H, J = 9.2 Hz, C6), 4.35-

4.32 (m, 2H, C13), 3.59 (t, 2H, J = 5.2 Hz, C14), 3.51 (d, 1H, J = 9.2 Hz, C6), 3.34 (s, 3H, C15), 2.56 (s, 2H, C17), 2.48 (s, 2H, C19), 1.19 (s, 6H, C21 and C22), 0.93 (s, 9H, C9-C11). ¹³**C** NMR (100 MHz, CDCl₃, tautomer CD only): 188.37 (C16), 187.95 (C4), 176.66 (C2), 170.39 (C20), 166.98 (C12), 144.85 (*quart*-C), 133.41 (*quart*-C), 123.94 (*quart*-C), 123.14 (*tert*-C), 122.07 (*tert*-C), 120.29 (*tert*-C), 101.65 (C3), 98.28 (C7), 78.45 (C5), 69.81 (C14), 68.12 (C6), 65.48 (C13), 58.83 (C15), 47.86 (CH₂), 44.69 (CH₂), 35.10 (C8), 33.67 (C18), 28.75 (C21 and C22), 24.60 (C9-C11). **MS** (ES⁻); 633.21 (M-H); **HRMS** (M-H); calculated for $C_{28}H_{33}ClF_3N_2O_9$; 633.1832; found 633.1836.

4.1.56. Synthesis of 14I



Yield: 52 %; M.P.; 89 °C; form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 7.67 (d, 2H, J = 8.3 Hz, C23 and C24), 7.40 (d, 2H, J = 8.3 Hz, C25 and C26), 6.47 (s, 1H, C20 AB), 6.44 (s, 1H, C20 CD), 5.10 (q, 1H, J = 6.8 Hz, C6), 4.94 (s, 1H, C7 CD), 4.93 (s, 1H, C7 AB), 4.20 (q, 2H, J = 7.3 Hz, C14), 3.53-3.04 (m, 4H, C17 and C18), 1.26

(t, 3H, J = 6.8 Hz, C15 AB), 1.25 (t, 3H, J = 6.8 Hz, C15 CD), 0.99 (d, 3H, J = 6.8 Hz, C12 AB), 0.97 (d, 3H, J = 6.8 Hz, C12 CD), 0.92 (s, 9H, C9-C11 CD), 0.91 (s, 9H, C9-C11 AB). ¹³C NMR (125 MHz, CDCl₃, tautomer CD only): 188.4 (C16), 187.8 (C4), 179.4 (C2), 168.9 (C21), 167.1 (C13), 162.2 (C19), 136.2 (C27), 129.3 (C25 and C26), 127.0 (C23 and C24), 125.7 (C22), 103.2 (C3), 99.3 (C20), 95.7 (C7), 81.4 (C5), 74.8 (C6), 62.7 (C14), 35.2 (C8), 31.0 (C17), 24.7 (C9-C11), 21.9 (C18), 14.4 (CH₃), 13.9 (CH₃). **MS** (ES⁺); 517.20 (M+H); **HRMS** (M+H): calculated for C₂₆H₃₀ClN₂O₇ 517.1736; found; 517.1740.

4.1.57. Synthesis of 14J



7.69-7.66 (m, 2H, C24 and C25), 7.43 (d, 2H, J = 8.4 Hz, C26 and C27), 6.47 (s, 1H, C21 AB), 6.44 (s, 1H, C21 CD), 4.92 (d, 1H, J = 8.4 Hz, C6 AB), 4.89 (d, 1H, J = 8.8 Hz, C6 CD), 4.83 (s, 1H, C7 CD), 4.82 (s, 1H, C7 AB), 3.53-3.24 (m, 3H, C6 and C19), 3.18-3.08 (m, 2H, C18), 2.84-2.74 (m, 1H, C13), 2.33-2.25 (m, 1H, C13), 1.63-1.42 (m, 2H, C14), 1.30-1.20 (m, 2H, C15), 0.90-0.84 (m, 12H, C9-C11 and C16). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only); 201.03 (C12), 189.67 (C17), 188.84 (C4), 181.19 (C2), 168.97 (C22), 162.12 (C20), 136.28 (C28), 129.29 (C26 and C27), 126.98 (C24 and C25), 125.67 (C23), 102.07 (C3), 99.32 (C21), 98.71 (C7), 83.74 (C5), 66.66 (C6), 37.47 (CH₂), 35.08 (C8), 31.07 (CH₂), 25.20 (CH₂), 24.99 (C9-C11), 21.99 (CH₂), 21.80 (CH₂), 13.81 (C16). **MS** (ES⁻); 513.15 (M-H); **HRMS** (M-H); calcd for C₂₇H₃₀Cl₁N₂O₆; 513.1798; found; 513.1794.

4.1.58. Synthesis of 14K



Yield; 39 % (oil); Form AB: CD = 20: 80; ¹HNMR (400 MHz, CDCl₃): 7.71 (t, 2H, J = 7.2 Hz, C25 and C26), 7.56 (t, 1H, J = 7.6 Hz, C27), 7.39 (t, 1H, J = 7.7 Hz, C28), 6.60 (d, 1H, J = 3.1 Hz, C22), 6.18 (d, 1H, J = 3.1 Hz, C21), 4.85 (s, 1H, C7 AB), 4.83 (s, 1H, C7 CD), 4.80

(d, 1H, *J* = 8.8 Hz, C6), 4.36-4.29 (m, 2H, C13), 3.60-3.54 (m, 2H, C14), 3.44 (d, 1H, *J* = 8.8 Hz, C6), 3.34-3.21 (m, 5H, C15 and C17), 3.11 (t, 2H, *J* = 7.2 Hz, C18), 0.94 (s, 9H, C9-C11 CD). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only): 189.84 (C16), 187.60 (C4), 180.13 (C2), 166.89 (C12), 153.64 (C19), 149.42 (C20), 131.69 (*tert*-C), 129.52 (*tert*-C), 127.43 (*tert*-C), 126.63 (*quart*-C), 126.57 (*quart*-C), 110.83 (C21), 108.22 (C22), 101.52 (C3), 98.35 (C7), 78.39 (C5), 69.80 (C14), 68.10 (C6), 65.49 (C13), 58.82 (C15), 35.12 (C8), 33.57 (CH₂), 31.53 (CH₂), 24.64 (C9-C11). **MS** (ES⁻); 564.20 (M-H); **HRMS** (M-H); calculated for C₂₈H₂₉F₃NO₈; 564.1851; found; 564.1854.

4.1.59. Synthesis of 14L



Yield; 39 %; M.P.; 102 °C; form AB: CD= 35: 65. ¹H NMR (500 MHz, CDCl₃); 9.16 (brs, 1H, OH), 7.67 (d, 2H, J = 8.5 Hz, C31 and C32), 7.48 (d, 2H, J = 8.5 Hz, C33 and C34), 6.99 (s, 1H, C24 AB), 6.97 (s, 1H, C24 CD), 6.88 (d, 1H, J = 8.5 Hz, C23), 6.68 (dd, 1H, $J_1 = 8.5$ Hz, $J_2 = 2.5$ Hz, C25), 5.30 (s, 2H, C16 AB),

5.23 (s, 2H, C16 CD), 4.97 (d, 1H, *J* = 9.0 Hz, C6 AB), 4.91 (d, 1H, *J* = 9.0 Hz, C6 CD), 4.81 (s, 1H, C7 CD), 4.76 (s, 1H, C7 AB), 3.84 (s, 3H, C27), 3.81 (s, 2H, C18), 3.47 (d, 1H, *J* = 8.0 Hz, C6), 2.98-2.84 (m, 1H, C13), 2.40 (s, 3H, C28), 2.36-2.27 (m, 1H, C13), 1.07 (t, 3H, *J* = 7.0 Hz, C14), 0.90 (s, 9H, C9-C11). ¹³C NMR (125 MHz, CDCl₃); 200.92 (C12 CD), 200.71 (C12 AB), 191.90 (C4 AB), 188.56 (C15 AB), 187.87 (C15 CD), 185.47 (C4 CD), 181.69 (C2 CD), 173.47 (C2 AB), 170.10 (C17), 168.24 (C29), 156.02 (C26), 139.30 (quart C), 136.19 (quart C), 133.77 (quart C), 131.16 (tert-C), 130.75 (quart C), 130.42 (quart C), 129.10 (tert-C), 114.94 (tert-C), 111.68 (tert-C), 105.36 (C3 AB), 101.16 (C24), 100.42 (C3 CD), 98.69 (C7 AB), 97.98 (C7 CD),

83.55 (C5 CD), 79.65 (C5 AB), 66.92 (C6 AB), 66.56 (C6 CD), 64.95 (C16 AB), 61.83 (C16 CD), 55.66 (C27), 35.05 (C8), 31.07 (C18), 29.50 (C13), 24.90 (C9-C11 AB), 13.29 (C28), 7.29 (C14). **MS** (ES⁻); 649.15 (M-H); **HRMS** (M-H); calcd for C₃₄H₃₄Cl₁N₂O₉; 649.1958; found; 649.1955.

4.1.60. Synthesis of 14M



Yield; 84 %; M.P.; 115 °C; Form AB: CD= 20: 80; ¹H NMR (400 MHz, CDCl₃); 7.73 (d, 2H, J = 8.4 Hz, C29 and C30), 7.67 (d, 2H, J = 8.4 Hz, C31 and C32), 7.19 (s, 1H, C27 CD), 7.18 (s, 1H, C27 AB), 7.15 (dd, 1H, $J_{H-H} = 8.8$ Hz, $J_{H-F} = 5.2$ Hz, C23), 6.97 (dd, 1H, $J_{H-F} = 9.2$ Hz, $J_{H-H} = 2.4$ Hz, C22 AB), 6.97 (dd, 1H, $J_{H-F} = 9.2$ Hz, C22

CD), 6.57 (dd, 1H, $J_{H-H} = 8.8$ Hz, $J_{H-H} = 2.4$ Hz, $J_{H-F} = 9.2$ Hz, C25), 4.97 (s, 1H, C7 AB), 4.90 (d, 1H, J = 8.8 Hz, C6 CD), 4.88-4.86 (m, 1H, C7 CD, 1H C6 AB), 4.35-4.23 (m, 3H, C13 and C16), 4.03 (d, 1H, J = 14.8 Hz, C16), 3.56 (d, 1H, J = 8.8 Hz, C6), 2.81 (s, 3H, C34), 2.26 (s, 3H, C26 AB), 2.25 (s, 3H, C26 CD), 1.30 (t, 3H, J = 7.6 Hz, C14), 0.99 (s, 9H, C9-11 AB), 0.94 (s, 9H, C9-11 CD). ¹³**C NMR** (100 MHz, CDCl₃, CD form only); 188.45 (C15), 187.11 (C4), 179.87 (C2), 166.73 (C12), 163.3 (d, $J_{C-F} = 245$ Hz, C24), 146.25 (tert Ar-C), 145.57 (tert Ar-C), 141.42 (tert Ar-C), 139.79 (tert Ar-C), 139.45 (tert Ar-C), 131.47 (tert Ar-C), 130.17 (C29 and C30), 129.29 (C21), 128.79 (C27), 123.81 (C31 and C32), 123.66 (d, $J_{C-F} = 9.5$ Hz, C23), 110.96 (d, $J_{C-F} = 22.3$ Hz, C25), 106.22 (d, $J_{C-F} = 23.8$ Hz, C22), 101.80 (C3), 98.28 (C7), 78.48 (C5), 68.09 (C6), 62.88 (C13), 43.84 (C34), 35.15 (C8), 28.90 (C16), 24.64 (C9-11), 13.93 (C14), 10.83 (C26). **MS** (ES⁻); 606.17 (M-H); **HRMS** (M-H); calcd for C₃₃H₃₃F₁N₁O₇S₁; 606.1967; found; 606.1961.

4.2. Synthesis of 12I and 12J from 12H

In order to prepare HCI solution, acetyl chloride (4.0 ml) was slowly added to methanol (10 ml) under nitrogen atmosphere and at 0 $^{\circ}$ C. Then, the HCI solution made obove was slowly added to the solution of tetramic acid **12H** (200 mg, 0.362 mmol) in methanol (10 ml) under nitrogen atmosphere and at 0 $^{\circ}$ C. After strring for 1 hr at 0 $^{\circ}$ C, monitoring the reaction by TLC, the solvent was evaporated in vacuo and dissoved in dichloromethane. The mixture was washed with acidic water (2 M HCI) and the organic layer was dried over MgSO₄. Tetramic acid **12I** (165 mg, 0.340 mmol, 94 % yield, oil) was obtained after removing the solvent in vacuo.



Form AB: CD= not determined; ¹H NMR (500 MHz, CD₃OD); 4.71-4.66 (m, 2H, C6 and C7), 3.73 (s, 3H, C13), 3.41-3.36 (m, 1H, C6), 2.92 (t, 2H, *J* = 7.5 Hz, C15), 2.79-2.73 (m, 2H, C25), 1.69-1.55 (m, 4H, C16 and C24), 1.40-

1.30 (m, 14H, C17-C23), 1.87 (s, 9H, C9-C11). ¹³**C NMR** (125 MHz, CD₃OD, tautomer CD only); 191.24 (C14), 184.95 (C4), 176.06 (C2), 170.65 (C12), 101.14 (C3), 99.06 (C7), 78.64 (C5), 69.97 (C6), 53.41 (C13), 40.85
(C25), 36.22 (C8), 34.83 (C15), 30.69 (CH₂), 30.55 (CH₂), 30.25 (CH₂), 28.62 (CH₂), 27.49 (CH₂), 26.14 (CH₂), 26.05 (CH₂), 25.49 (C9-11). **MS** (ES⁻); 451.29 (M-H); **HRMS** (M+Na); calcd for $C_{24}H_{40}N_2Na_1O_6$; 475.2779; found; 475.2768.

1-Adamantylcarbonyl chloride (50 mg, 0.245 mmol) was added to the mixture of tetramic acid **12I** (100 mg, 0.204 mmol) and triethylamine (45 mg, 0.450 mmol) in dichloromethane (15 ml), and the mixture was stirred for 2 hr. After completion of reaction, concentration in vacuo followed by flash column chromatography gave metal-chelated product. The compound was dissolved in dichloromethane (20 mL) and washed with aqueous HCI (3< pH <5, 50 mL). The organic layer was dried with MgSO₄ and concentrated in vacuo to give free form of 3-acyltetramic acid **12J** (80 mg, 0.131 mmol, 64 % yield, oil).



Form AB: CD= 20: 80; ¹H NMR (400 MHz, CDCl₃); 5.60 (brs, 1H, NH), 4.87 (s, 1H, C7 AB), 4.84 (s, 1H, C7 CD), 4.81 (d, 1H, *J* = 9.2 Hz, C6), 3.79 (s, 3H, C13 AB), 3.78 (s, 3H, C13 CD), 3.48 (d, 1H, *J* = 9.2 Hz, C6), 3.23-3.18

(m, 2H, C25), 3.01-2.88 (m, 2H, C15 AB), 2.83 (t, 2H, *J* = 8.0 Hz, C15 CD), 2.02 (brs, 3H, C34-C36), 1.91-1.83 (m, 8H, adamantyl CH₂), 1.75-1.62 (m, 6H, C16 and adamantyl CH₂), 1.48-1.25 (m, 16H, C17-C24), 0.92 (s, 9H, C9-C11). ¹³**C NMR** (100 MHz, CDCl₃, tautomer CD only); 192.45 (C14), 187.70 (C4), 180.22 (C2), 177.84 (C26), 167.44 (C12), 100.97 (C3), 98.17 (C7), 78.26 (C5), 68.17 (C6), 53.23 (C13), 40.49 (C27), 39.23 (CH₂), 38.60 (CH₂), 36.48 (CH₂), 36.39 (CH₂), 35.10 (C8), 29.56 (CH₂), 29.38 (CH₂), 29.26 (CH₂), 29.20 (CH₂), 29.11 (CH₂), 29.06 (CH₂), 28.09 (CH), 27.80 (CH), 26.81 (CH₂), 25.81 (CH₂), 24.57 (C9-11). **MS** (ES⁻); 613.31 (M-H); **HRMS** (M+Na); calcd for C₃₅H₅₄N₂Na₁O₇; 637.3823; found; 637.3813.

4.3. Synthesis of 3-acyl tetramic acids via acyl migration



(a) carboxylic acid (1.1 eq), DCC (1.05 eq), DMAP (0.1 eq), CH_2CI_2 , r.t.; (b) $(CH_3)_2C(OH)CN$ (0.5 eq), Et_3N (2.0 eq), CH_3CN , r.t..

General methods for O-acylation: To a mixture of tetramic acid (1 equivalent) and carboxylic acid (1.1 equivalent) in dichloromethane was added DCC (1.1 equivalent) and DMAP (0.1 equivalent). The mixture was stirred 24 hr at r.t. The crude reaction mixture was filtered with dichloromethane. Concentration in *vacuo* followed by flash column chromatography gave the *O*-acyl tetramic acid.

General method for acyl migration: To a mixture of *O*-acyl tetramic acid (1.0 equivalent) and triethyl amine (2.0 equivalents) in acetonitrile was added acetone cyanohydrin (0.5 equivalent) at room temperature. The

reaction mixture was stirred for 12 hr at room temperature. The crude reaction mixture was concentrated in *vacuo*. The crude product was disoved in ether then wash with basic water solution (0.25 N NaOH) and acidic water solution (1N HCl). The organic layer was dried with MgSO₄ and concentrated to afford 3-acyl tetramic acid.

4.3.1. Synthesis of O-13H and 13H



O-13H; Yield; 55 %; ¹**H NMR** (400 MHz, CDCl₃); 5.83 (s, 1H, C3), 4.79 (s, 1H, C7), 4.47 (dd, 1H, $J_1 = 9.2$ Hz, $J_2 = 6.4$ Hz, C5), 4.26 (dd, 1H, $J_1 = 8.0$ Hz, $J_2 = 6.4$ Hz, C6) 3.36 (dd, 1H, $J_1 = 9.2$ Hz, $J_2 = 8.0$ Hz, C6), 2.49-2.42 (m, 1H, C13), 1.96-1.93 (m, 2H, (CH₂)), 1.79-1.75 (m, 2H, CH₂), 1.67-1.64 (m, 1H, CH₂), 1.51-1.42 (m, 2H,

CH₂), 1.35-1.21 (m, 3H, CH₂). ¹³**C NMR** (100 MHz, CDCl₃); 176.06 (quart C), 171.22 (quart C), 165.65 (quart C), 107.88 (C3), 94.31 (C7), 68.95 (C6), 64.17 (C5), 43.06 (C13), 35.81 (C8), 28.63 (CH₂), 28.59 (CH₂), 25.43 (CH₂), 25.10 (CH₂), 24.65 (C9-11).



13H; Yield; 75 % (Oil); Form AB: CD= 30: 70; $[\alpha]_D^{22} = +51.6$ (c = 2.0 in MeOH); ¹H NMR (400 MHz, CDCl₃); 4.93 (s, 1H, C7 AB), 4.90 (s, 1H, C7 CD), 4.25-4.21 (m, 1H, C5, 1H C6 AB), 4.10 (dd, 2H, $J_1 = 9.6$ Hz, $J_2 = 7.2$ Hz, C6 CD), 3.46-3.31 (m, 2H, C6 and C13), 1.80-1.18 (m, 10H, C14-18), 0.94 (s, 9H, C9-11). ¹³C NMR (100

MHz, CDCl₃); 198.63 (C4 AB), 197.47 (C12 AB), 194.23 (C12 CD), 191.35 (C4 CD), 179.77 (C2 CD), 171.91 (C2 AB), 103.88 (C3 AB), 100.89 (C3 CD), 95.84 (C7 AB), 95.75 (C7 CD), 67.08 (C6), 67.08 (C5 CD), 64.38 (C5 AB), 41.42 (C13 AB), 41.01 (C13 CD), 36.01 (C8 AB), 35.90 (C8 CD), 28.97 (CH₂), 28.85 (CH₂), 28.77 (CH₂), 28.53 (CH₂), 28.35 (CH₂), 25.51 (CH₂), 25.45 (CH₂), 25.35 (CH₂), 24.73 (C9-11 AB), 24.67 (C9-11 CD). **MS** (ES⁻); 306.2 (M-H); **HRMS** (M-H); calcd for C₁₇H₂₄N₁O₄; 306.1711; found; 306.1711.

4.3.2. Synthesis of O-14A and 14A



O-14A; Yield; 85 %; ¹**H NMR** (200 MHz, CDCl₃); 8.08 (d, 2H, J = 7.4 Hz, C14, C18), 7.68 (t, 1H, J = 7.4 Hz, C21), 7.51 (t, 2H, J = 7.4 Hz, C19 and C20), 6.01 (s, 1H, C3), 4.86 (s, 1H, C7), 4.68 (dd, 1H, $J_1 = 9.0$ Hz, $J_2 = 6.4$ Hz, C5), 4.39 (dd, 1H, $J_1 = 9.0$ Hz, $J_2 = 6.4$ Hz, C6), 0.98 (s, 1H, C4), 0.98 (s, 0.98 Hz, 0.98

9H, C9-11).



 $J_1 = 9.2$ Hz, $J_2 = 8.8$ Hz, C5), 1.01 (s, 9H, C9-11 CD), 0.99 (s, 9H, C9-11 AB). ¹³C NMR (100 MHz, CDCl₃);

200.56 (C4 AB), 189.72 (C12 CD), 185.10 (C12 AB), 182.02 (C4 CD), 181.37 (C2 CD), 171.08 (C2 AB), 134.33 (C18), 131.22 (C13), 129.95 (C16 and C17), 128.25 (C14 and C15), 104.40 (C3 AB), 101.02 (C3 CD), 96.24 (C7 CD), 96.16 (C7 AB), 67.04 (C6 CD), 66.95 (C6 AB), 66.60 (C5 CD), 64.27 (C5 AB), 36.15 (C8 AB), 35.98 (C8 CD), 24.85 (C9-11 AB), 24.75 (C9-11 CD). MS (ES); 300.1 (M-H), HRMS (M-H); calcd for C₁₇H₁₈N₁O₄; 300.1241; found; 300.1240.

5. Synthesis of 3-enamine tetramic acids



General procedure: To the solution of 3-acetyl tetramic acid (1.0 eq) in toluene was added amine (1.1 eq) and the mixture was reflux for 4 hr. After completion of reaction checking with TLC, flash column chromatography gave 3-enamine tetramic acid.

5.1. Synthesis (±)-7A



Yield; 64% (oil); form AB: CD = 45: 55; ¹H NMR (400 MHz, CDCl₃); 11.26 (br s, 1H, NH B), 10.91 (br s, 1H, NH D), 4.74 (s, 1H, C7 B), 4.70 (s, 1H, C7 D), 3.77 (d, 1H, *J* = 8.3 Hz, C6), 3.36 (d, 1H, *J* = 8.3 Hz, C6), 2.70 (s, 3H, C14 B), 2.69 (s, 3H, C14 D), 2.17 (brs, 3H, C22-C24), 2.09-2.04 (m, 6H, adamantyl CH₂), 1.77-

1.64 (m, 6H, adamantyl CH₂), 1.47 (s, 3H, C12 B), 1.45 (s, 3H, C12 D), 1.01 (s, 9H, C9-C11). ¹³C NMR (100 MHz, CDCl₃); 198.2 (C4 B), 196.1 (C4 D), 180.4 (C2 D), 177.3 (C2 B), 170.1 (C13 B), 169.7 (C13 D), 98.2 (C7 B), 98.1 (C7 D), 96.9 (C3 B), 95.1 (C3 D), 72.3 (C6 B), 72.1 (C6 D), 71.3 (C5 B), 70.2 (C5 D), 55.5 (C15 B), 55.3 (C15 D), 42.5 (adamantyl CH₂), 42.4 (adamantyl CH₂), 35.8 (adamantyl CH₂), 35.7 (adamantyl CH₂), 34.7 (C8 B), 34.6 (C8 D), 29.3 (C22-C24), 25.8 (C9-C11), 21.5 (C12 B), 21.4 (C12 D), 17.3 (C14 B), 16.7 (C14 D). **MS** (ES⁺); 387.29 (M+H); **HRMS** (M+Na); calculated for C₂₃H₃₄N₂NaO₃; 409.2462; found; 409.2458.

5.2. Synthesis of 7B



Yield; 96 %; M.P.; 88 °C; form AB: CD = 45: 55; ¹H NMR (400 MHz, CDCl₃); 10.85 (brs, 1H, NH B), 10.67 (brs, 1H, NH D), 4.84-4.79 (m, 2H, C6 and C7), 3.78 (s, 3H, C13 B), 3.77 (s, 3H, C13 D), 3.47-3.44 (m, 1H, C6), 3.43-3.30 (m, 2H, C16), 2.55 (s, 3H, C15 B), 2.51 (s, 3H, C15 D), 2.45-2.29 (m, 2H, C17 and C19), 2.09-1.69 (m, 5H, C18, C20, C22 and C23), 1.54-1.44 (m, 1H, C18), 1.22 (s, 3H, CH₃ D), 1.21 (s, 3H, CH₃ B), 1.03 (s, 3H, CH₃ B), 1.02 (s, 3H, CH₃ D), 0.94-0.93 (m, 1H, C19), 0.92 (s, 9H, C9-C11). ¹³C

D), 169.0 (C12 B), 169.0 (C12 D), 98.0 (C7 B), 97.9 (C7 D), 95.8 (C3 B), 93.8 (C3 D), 77.6 (C5 D), 76.5 (C5 B), 68.8 (C6 D), 68.7 (C6 B), 53.0 (C13 B), 52.9 (C13 D), 48.9 (C16 B), 48.9 (C16 D), 43.4 (C20 or C22 D), 43.3 (C20 or C22 B), 41.1 (C20 or C22 D), 41.0 (C17), 40.9 (C20 or C22 B), 38.6 (C21), 35.2 (C8 B), 35.2 (C8 D), 33.2 (C19 D), 33.1 (C19 B), 27.8 (C24 or C25), 25.7 (C23 D), 25.7 (C23 B), 24.8 (C9-C11 B), 24.7 (C9-C11 D), 23.1 (C24 or C25), 19.9 (C18 D), 19.8 (C18 B), 14.5 (C15 D), 13.9 (C15 B). **MS** (ES); 431.28 (M-H); MS (ES⁺); 433.31 (M+H), 455.27 (M+Na); **HRMS** (M+Na); calcd for $C_{24}H_{36}N_2Na_1O_5$; 455.2516; found; 455.2508.

5.3. Synthesis of 7C



Yield; 28 %; M.P.; 200 °C; form AB: CD = 45: 55; ¹H NMR (500 MHz, CDCl₃); 10.99 (brs, 1H, NH B), 10.86 (brs, 1H, NH D), 4.84-4.79 (m, 2H, C6 and C7), 3.79 (s, 3H, C13 B), 3.78 (s, 3H, C13 D), 3.47-3.44 (m, 1H, C6), 2.73 (s, 3H, C15 B), 2.68 (s, 3H, C15 D), 2.19 (brs, 3H, C23-C25), 2.07 (brs, 6H, adamantyl CH₂), 1.76-1.69 (m, 6H, adamantyl CH₂), 0.92 (s, 9H, C9-C11). ¹³C NMR (125

MHz, CDCl₃); 191.5 (C4 B), 189.2 (C4 D), 180.7 (C2 D), 177.2 (C2 B), 170.8 (C14 B), 170.3 (C14 D), 169.1 (C12), 98.0 (C7), 96.0 (C3 B), 94.0 (C3 D), 77.3 (C5 D), 76.5 (C5 B), 68.9 (C6 D), 68.8 (C6 B), 56.0 (C16 B), 55.8 (C16 D), 53.0 (C13 B), 52.9 (C13 D), 42.5 (adamantyl CH₂), 42.4 (adamantyl CH₂), 35.7 (adamantyl CH₂), 35.7 (adamantyl CH₂), 35.2 (C8 B), 35.2 (C8 D), 29.3 (C23-C25), 24.8 (C9-C11), 17.5 (C15 D), 16.8 (C15 B). **MS** (ES⁺); 453.25 (M+Na); MS (ES⁻); 429.28 (M-H); **HRMS** (M+Na); calcd for C₂₄H₃₄N₂Na₁O₅; 453.2360; found; 453.2360.

5.4. Synthesis of 7D



Yield; 36 % (oil); form AB: CD = 40: 60. ¹H NMR (500 MHz, CDCl₃); 10.79 (brs, 1H, NH B), 10.65 (brs, 1H, NH D), 4.84-4.80 (m, 2H, C6 and C7), 3.78 (s, 3H, C13 B), 3.77 (s, 3H, C13 D), 3.47-3.44 (m, 1H, C6), 3.41-3.33 (m, 2H, C16), 2.56 (s, 3H, C15 B), 2.52 (s, 3H, C15

D), 1.70-1.64 (m, 2H, C17), 1.41-1.24 (m, 12H, C18-C23), 0.92-0.96 (m, 12H, C9-C11 and C24). ¹³**C NMR** (125 MHz, CDCl₃); 191.9 (C4 B), 188.9 (C4 D), 180.6 (C2 D), 176.8 (C2 B), 170.6 (C14 B), 170.1 (C14 D), 169.0 (C12 B), 169.0 (C12 D), 98.0 (C7 B), 97.9 (C7 D), 95.8 (C3 B), 93.9 (C3 D), 77.6 (C5 D), 76.5 (C5 B), 68.8 (C6 D), 68.7 (C6 B), 53.0 (C13 B), 52.9 (C13 D), 43.5 (C16 B), 43.3 (C16 D), 35.2 (C8 B), 35.2 (C8 D), 31.8 (CH₂), 29.3 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 29.1 (CH₂), 29.0 (CH₂), 26.7 (CH₂), 26.6 (CH₂), 24.8 (C9-C11 B), 24.7 (C9-C11 D), 22.6 (CH₂), 14.3 (C15 D), 14.0 (C24), 13.7 (C15 B). **MS** (ES⁺); 423.2 (M+H), 445.25 (M+Na); MS (ES⁻); 421.27 (M-H); **HRMS** (M-H); calcd for C₂₃H₃₇N₂O₅; 421.2708; found; 421.2709.

5.5. Synthesis of 7E



Yield; 48 %; M.P.; 70 °C; form AB: CD = 35: 65; ¹H NMR (500 MHz, CDCl₃); 12.21

(brs, 1H, NH B), 12.19 (brs, 1H, NH D), 7.47-7.43 (m, 2H, C19 and C20), 7.39-7.35 (m, 1H, C21), 7.19-7.17 (m, 2H, C17 and C18), 4.89 (s, 1H, C7 B), 4.86 (s, 1H, C7 D), 4.85 (d, 1H, *J* = 8.8 Hz, C6 B), 4.84 (d, 1H, *J* = 8.8 Hz, C6 D), 3.80 (s, 3H, C13 B), 3.79 (s, 3H, C13 D), 3.52 (d, 1H, *J* = 8.5 Hz, C6), 2.55 (s, 3H, C15 B), 2.50 (s, 3H, C15 D), 0.94 (s, 9H, C9-C11 D), 0.93 (s, 9H, C9-C11 B). ¹³**C** NMR (125 MHz, CDCl₃); 192.2 (C4 B), 189.2 (C4 D), 179.9 (C2 D), 176.2 (C2 B), 169.7 (C14 B), 169.0 (C14 D), 168.8 (C12 B), 168.7 (C12 D), 135.3 (C16 D), 135.3 (C16 B), 129.7 (Ar-C B), 129.6 (Ar-C D), 128.4 (Ar-C B), 128.2 (Ar-C D), 125.4 (Ar-C B), 125.3 (Ar-C D), 98.1 (C7), 97.2 (C3 B), 95.4 (C3 D), 77.7 (C5 D), 76.7 (C5 B), 68.7 (C6 D), 68.6 (C6 B), 53.1 (C13 B), 53.0 (C13 D), 35.2 (C8 B), 35.2 (C8 D), 24.8 (C9-C11 B), 24.7 (C9-C11 D), 16.2 (C15 D), 15.6 (C15 B). **MS** (ES⁺); 395.17 (M+Na); MS (ES⁻); 371.19 (M+Na); **HRMS** (M-H); calcd for C₂₀H₂₄N₂Na₁O₅; 395.1577; found; 395.1572.

S-References

S-1. References for natural 3-acyltetramic acids; Kibdelomycin; Philips, J. W. et al. Discovery of Kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus. Chem. Biol. 18, 955-965 (2011). Bu-2313 A and B; Tsukiura, H. et al. Bu-2313, a new antibiotic complex active against anaerobes 1. Production, isolation and properties of Bu-2313 A and B. J. Antibiot. 33, 157-165 (1980). BU-4514N; Toda, S. et al. A new neuritogenetic compound BU-4514N produced by Microtetraspora sp.. J. Antibiot. 46, 875-883 (1993). Cissetin and Trichosetin; Boros, C., Dix, A., Katz, B., Vasina, Y. & Pearce, C. Isolation and identification of cissetin-a setin-like antibiotic with a novel cis-octalin ring fusion. J. Antibiot. 56, 862-865 (2003). Coniosetin; Segeth, M. P. et al. Coniosetin, a novel tetramic acid antibiotic from Coniochaeta ellipsoidea DSM 13856. J. Antibiot. 56, 114-122 (2003). C12-TA and C14-TA in the unnatural analogues; Lowery, C. A. et al. Defining the mode of action of tetramic acid antibacterials derived from *Pseudomonas aeruginosa* quorum sensing signals. J. Am. Chem. Soc. 131, 14473-14479 (2009). Delaminomycin A, B and C; Ueno, M. et al. Delaminomycins, novel nonpeptide extracellular matrix receptor antagonist and a new class of potent immunomodulator. J. Antibiot. 46, 719-727 (1993). Equisetin; Rurmeister, H.R., Bennett, G. A., Vesonder, R.F. & Hesseltine, C.W. Antibiotic produced by Fusarium equiseti NRRL 5537. Antimicrob. Agents Chemother. 5, 634-639 (1974). Ikarugamycin, Ikarugamycin epoxides and Ripromycin; Bertasso, M. et al. Ripromycin and other polycyclic macrolactams from Streptomyces sp. Tü 6239: Taxonomy, fermentation, isolation and biological properties. J. Antibiot. 56, 364-371 (2003). Lydicamycin and TPU-0037-A, B, C and D; Furumai, T. et al.TPU-0037-A, B, C and D, novel lydicamycin congeners with anti-MRSA activity from Streptomyces platensis TP-A0598. J. Antibiot. 55, 873-880 (2002). Ophiosetin and Paecilosetin; Putri, S. P., Kinoshita, H., Ihara, F., Igarashi, Y. & Nihira, T. Ophiosetin, a new tetramic acid derivative from the mycopathogenic fungus Elaphocordyceps ophioglossoides. J. Antibiot. 63, 195-198 (2010). Methiosetin; Herath, K. et al. Isolation, structure elucidation, and antibacterial activity of Methiosetin, a tetramic acid from a tropical sooty mold (Capnodium sp.). J. Nat. Prod. 75, 420-424 (2012). Oxasetin; He, H. et al. Oxasetin, a new antibacterial polyketide produced by fungus Vaginatispora aquatica,

HK1821. J. Antibiot. 55, 821-825 (2002). PF1052; Koyama, N. et al. Spylidone, a novel inhibitor of lipid droplet accumulation in mouse macrophages produced by Phoma sp. FKI-1840. J. Antibiot. 58, 338-345 (2005). Ravenic acid; Michael, A. P., Grace, E. J., Kotiw, M. & Barrow, R. A. Ravenic acid, a new tetramic acid isolated from a cultured microfungus, Penicillium sp. J. Nat. Prod. 65, 1360-1362 (2002). Reutericyclin; Gänzle, M. G., Höltzel, A., Walter, J., Jung, G. & Hammes, W. P. Characterization of reutericyclin produced by Lactobacillus reuteri LTH2584. Appl. Environ. Microbiol. 66, 4325-4333 (2000). Streptolygin, Tirandamycin A and Tirandalydigin; Karwowski, J. P. et al. Tirandalydigin, a novel tetramic acid of the tirandamycinstreptolydigin type. 1. Taxonomy of the producing organism, fermentation and biological activity. J. Antibiot. 45, 1125-1132 (1992). Vancoresmycin; Hopmann, C., Kurz, M., Brönstrup, M., Wink, J. & LeBeller, D., Isolation and structure elucidation of vancoresmycin-a new antibiotic from Amycolatopsis sp. ST 101170. Tetrahedron Lett. 43, 435-438 (2002). Vermisporin; Chin, N. X. & Neu, H. C. In vitro antimicrobial activity of the new antibiotic vermisporin. Eur. J. Clin. Microbiol. Infect. Dis. 11, 755-757 (1992). Virgineone; Ondeyka, J. et al. Isolation, structure elucidation, and biological activity of virgineone from Lachnum virgineum using the genome-wide Candida albicans Fitness Test. J. Nat. Prod. 72, 136-141 (2009). 49F233α; Singh, M. P., Zaccardi, J. & Greenstein, M. LL-49F233a, novel antibiotic produced by an unknown fungus: biological and mechanistic activities. J. Antibiot. 51, 1109-1112 (1998).

S-2. References for unnatural 3-acyltetramic acids; CPB-2 - CPB-32; Katsuo, K., Kimura, M., Kinuta, T., Takai, N. & Tanaka, K. Synthesis and antimicrobial activities of 3-acyltetramic acid derivatives. *Chem. Pharm. Bull.* 32, 4197-4204 (1984). CPB2-3 – CPB2-17; Katsuo, K., Kitaguchi, T., Takata, Y. & Tanaka, K. Structure-activity relationships in tetramic acids and their copper (II) complexes. *Chem. Pharm. Bull.* 28, 2494-2502 (1980). JMC-A – TMC-N; Yendapally, R., Hurdle, J. G., Carson, E. I., Lee, R. & Lee, R. E. N-Substituted 3-acetyltetramic acid derivatives as antibacterial agents. *J. Med. Chem.* 51, 1487-1491 (2008). JMC-T – TMC-U; Rosen, T., Fernandes, P. B., Marovich, M. A., Shen, L., Mao, J. & Pernet, A. G. Aromatic dienoyl tetramic acids. Novel antibacterial agents with activity against anaerobes and Staphylococci. *J. Med. Chem.* 32, 1062-1069 (1989). T-4a – T-6; Wilson, J. B. Synthesis and evaluation of tetramic acids as antimicrobial agents. *Master thesis (2008)*; the university of Tennessee.

S-3. Peukert, S. *et al.* Design and structure–activity relationships of potent and selective inhibitors of undecaprenyl pyrophosphate synthase (UPPS): Tetramic, tetronic acids and dihydropyridin-2-ones. *Bioorg. Med. Chem. Lett.* 18, 1840–1844 (2008).

S-4. (a) Bikadi, Z & Hazai, E. Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. *J. Cheminf.* **1**, 15 (2009). (b) Halgren, T. A. Merck molecular force field. 1. Basis, form, scope, parametrization, and performance of MMFF94. *J. Comput. Chem.* **17**, 490-519 (1996). (c) Stewart, J. P. Computer code MOPAC2009, *Stewart Computational Chemistry*, 2009. (d) Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K. & Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *J. Comput. Chem.* **19**, 1639-1662 (1998). (e) Solis, F. J. & Wets, R. J. B. Minimization by random search techniques. *Math. Oper. Res.* **6**, 19-30

(1981).

S-5. (a) Gentry, D. R. et. al. A rapid microtiter plate assay for measuring the effect of compounds on Staphylococcus aureus membrane potential. *J. Microbiol. Methods.* 2010, *83*, 254-256. (b) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard- seventh edition.
2006, M7-A7, CLSI, Wayne PA. (c) Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard - third edition. 2006, M27-A2, CLSI, Wayne PA.

S-6. (a) Andrews, M. D. *et al.* Regioselective Dieckmann cyclisations leading to enantiopure highly functionalised tetramic acid derivatives. *J. Chem. Soc., Perkin Trans. 1,* 223-235 (1998). (b) Jeong, Y.-C. & Moloney, M. G. Tetramic acids as scaffolds: synthesis, tautomeric and antibacterial behavior. *Synlett* 2487-2491 (2009). (c) Jeong, Y.-C., Anwar, M., Nguyen, T. M., Tan, B. S. W., Chai, C. L. L. & Moloney, M. G. Control of chemoselectivity in Dieckmann ring closures leading to tetramic acids. *Org. Biomol. Chem.* **9**, 6663-6669 (2011). (d) Andrews, M. D., Brewster, A. G. & Moloney, M. G. Diastereocontrolled synthesis of hydroxylated lactams. *J. Chem. Soc., Perkin Trans.* **1**, 80-90 (2002).